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IAbstract
'W  ? ? ? ? ? ŝƐ Ă ŚŝŐŚ ĂĨĨŝŶŝƚǇ ɴ ?ďůŽĐŬĞƌ ƚŚĂƚ ĂŶƚĂŐŽŶŝƐĞƐ ĂŐŽŶŝƐƚ ƌĞƐƉŽŶƐĞƐ
ŵĞĚŝĂƚĞĚ ƚŚƌŽƵŐŚ ƚŚĞ ĐĂƚĞĐŚŽůĂŵŝŶĞ ďŝŶĚŝŶŐ ƐŝƚĞ ŽĨ ƚŚĞ ŚƵŵĂŶ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ  ?ɴ1AR). However, CGP 12177 also exerts agonist activity
through a secondary, low affinity CGP 12177 binding site/conformational
ƐƚĂƚĞŽĨƚŚĞɴ1AR. In this thesis, we aimed to further our understanding of the
nature of the secondary CGP 12177 site by investigating ligand-receptor
interactions at this site at the single cell level, using fluorescent derivatives of
CGP 12177 (BODIPY-TMR-CGP, BY-CGP) and propranolol (BODIPY630/650-S-
PEG8-propranolol, BY-PROP) in confocal microscopy studies. Initial studies
ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚďŽƚŚĨůƵŽƌĞƐĐĞŶƚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐĚŝƐƉůĂǇĞĚƐŝŵŝůĂƌ
pharmacology at the human E1AR to their respective parent compounds, and
ƚŚĂƚďŽƚŚůŝŐĂŶĚƐĂůůŽǁĞĚǀŝƐƵĂůŝƐĂƚŝŽŶŽĨɴ1AR expressed in CHO cells. Using
BY-CGP in a live cell fluorescence-based automated screening assay revealed
two-phase antagonist displacement binding curves. In subsequent kinetic
binding studies performed on a confocal perfusion system, we used infinite
dilution conditions to determine dissociation rates of BY-CGP in the absence
and presence of unlabelled ligands at the single cell level. BY-CGP dissociation
rates were enhanced in the presence of unlabelled ligands, thus highlighting
ĂŶ ĂůůŽƐƚĞƌŝĐ ŵĞĐŚĂŶŝƐŵ ŽĨ ĂĐƚŝŽŶ ŽĨ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1AR.
Preliminary data using bimolecular fluorescence complementation suggested
ƚŚĂƚ ƚŚĞƐĞ ĐŽ ?ŽƉĞƌĂƚŝǀĞ ŝŶƚĞƌĂĐƚŝŽŶƐ ďĞƚǁĞĞŶ ƚŚĞ ƚǁŽ ɴ1-adrenoceptor
ďŝŶĚŝŶŐƐŝƚĞƐǁĞƌĞŵĞĚŝĂƚĞĚĂĐƌŽƐƐĂɴ1-adrenoceptor homodimer interface.
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EC50 concentration at which half the system maximal response
occurs
EMAX maximal system response
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G proteins guanine nucleotide-binding regulatory proteins
GPCR G protein-coupled receptor
HBSS HEPES buffered saline solution
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IC50 concentration at which half maximum inhibition occurs
ICI 188,551 (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-
methylethyl)-amino]-2-butanol
IV
KD concentration at which half the receptors are occupied
koff dissociation (off) rate constant
kon association (on) rate constant
konobs observed association rate
PBS phosphate buffered saline
PKA protein kinase A
propranolol (RS)-1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
SPAP secreted placental alkaline phosphatase
TM transmembrane
YFP yellow fluorescent protein
YFPN N-terminal YFP fragment
YFPC C-terminal YFP fragment
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1Chapter 1
Introduction
21.1 The GPCR superfamily
G protein-coupled receptors (GPCRs) are important signalling receptors that
are activated by external stimuli to transmit signals into cellular responses by
coupling to G proteins and activating intracellular effector proteins (Pierce et
al., 2002). GPCRs recognise a great variety of signals, such as light photons,
ions, organic odorants, nucleotides, biogenic amines, lipids, small peptides
and proteins and in turn are responsible for a diverse range of cellular and
physiological responses (Bockaert et al., 1999; Pierce et al., 2002). 1-2 % of
the human genome contains genes that encode at least 1,000 GPCRs
(Fredriksson et al., 2005; Tuteja, 2009). In addition, this receptor class has also
been found in a variety of other species, including vertebrate (Strotmann et
al., 2011) and invertebrate animals (Styer et al., 2008; Yoshiura et al., 2012),
plants (Misra et al., 2007; Tuteja, 2009) and fungi (Xue et al., 2008).
GPCRs are large proteins of circa 300-800 amino acids (Gentles et al., 1999)
ƚŚĂƚ ĨŽůĚ ŝŶƚŽ ƐĞǀĞŶ ɲ ŚĞůŝĐĞƐ ƚŚĂƚ ƐƉĂŶ ƚŚĞ ĞŶƚŝƌĞ ĚĞƉƚŚ ŽĨ ƚŚĞ ƉůĂƐŵĂ
membrane (i.e. transmembrane, TM; Figure 1.1) of a cell, and thus have
lipophilic properties in the transmembrane region and hydrophilic properties
on either sides of the membrane in the extra- and intracellular space. Great
differences in sequence length are seen mainly in a stretch of amino acids at
the beginning and end of a GPCR protein sequence, referred to as the
extracellular N- and intracellular C-terminus, respectively (Tuteja, 2009).
Three intracellular (IL1-3) and three extracellular (EL1-3) loops connect the
seven transmembrane regions (TM1-7), which are arranged in a rough circular
3conformation. Whilst this basic structure is observed for all GPCRs, some
receptors share little or no sequence similarity at all, which resulted in the
classification of GPCRs into 6 different classes (A-F) based on sequence
similarity (Kolakowski, 1994).
Class A (rhodopsin receptor family) constitutes the biggest class of GPCRs,
which bind small-molecule ligands. This class is further subdivided into three
groups based on where the endogenous ligands bind their receptors. Group 1
ĐŽŶƚĂŝŶƐ 'WZƐ ƐƵĐŚ ĂƐ ƌŚŽĚŽƉƐŝŶ ĂŶĚ ƚŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ǁŚŽƐĞ ůŝŐĂŶĚ
binding pocket is in the transmembrane region (Rasmussen et al., 2007).
Group 2 contains receptors (e.g. neuropeptide Y receptors and chemokine
receptors) whose peptide ligands bind the N-terminus, the extracellular loops
and the extracellular parts of the TM regions. Ligands that bind to receptors
of group 3 (e.g. glycoprotein hormone receptors FSHR and TSHR) bind to a
larger N-terminus region and the extracellular loops (Tuteja, 2009). Class B
GPCRs (secretin receptor family) are activated upon binding of their peptide
ligands (e.g. calcitonin peptides) to a large extracellular N-terminus domain
and the extracellular loops (Barwell et al., 2012). Class C GPCRs include
metabotropic glutamate receptors, GABAB and Ca
2+ sensing receptors, which
have a very large N-terminal domain in a very characteristic bi-lobial clam-
shell-like conformation to which the ligands bind (Brauner-Osborne et al.,
2007). The other classes are made up of the fungus pheromone receptor
family (class D; reviewed in Xue et al., 2008), cAMP receptor family (class E;
Tuteja, 2009) and class F frizzled/smoothened receptor family (Malbon, 2004).
4Other classifications of GPCRs have been proposed, such as the family 1-5
system (Bockaert et al., 1999) and the GRAFS system that identified the five
main families glutamate, rhodopsin, adhesion, frizzled/taste2 and secretin
based on phylogenic analysis of human GPCRs (Fredriksson et al., 2003).
5Figure 1.1 Schematic diagram of the characteristic GPCR structure. Seven
transmembrane regions (1-7) are connected by three intracellular loops (IL1-3) and
three extracellular loops (EL1-3) and have an extracellular N-terminal and an
intracellular C-terminal domain.
6 ? ? ?dŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĨĂŵŝůǇ
dŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĨĂŵŝůǇďĞůŽŶŐƐƚŽƚŚĞůĂƐƐ ?ƌŚŽĚŽƉƐŝŶƌĞĐĞƉƚŽƌĨĂŵŝůǇ ?
ŽĨ ƚŚĞ ' ƉƌŽƚĞŝŶ ?ĐŽƵƉůĞĚ ƌĞĐĞƉƚŽƌ ƐƵƉĞƌĨĂŵŝůǇ ? dŚƌĞĞ ƐƵďƚǇƉĞƐ ŽĨ ƚŚĞ ɴ ?
ĂĚƌĞŶŽĐĞƉƚŽƌ ĨĂŵŝůǇŚĂǀĞďĞĞŶ ŝĚĞŶƚŝĨŝĞĚ PƚŚĞɴ1 ? ?ɴ2 ?ĂŶĚɴ3-adrenoceptors
(Emorine et al., 1992; Frielle et al., 1987; Frielle et al., 1988), which are
predominantly (but not exclusively) expressed in the heart (Brodde et al.,
2006), lung and adipose tissues (Mutlu et al., 2008), respectively. In addition,
ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ĂƌĞ ĂůƐŽ ĞǆƉƌĞƐƐĞĚ ŝŶ ǀĂƐĐƵůĂƌ ƐŵŽŽƚŚ ŵƵƐĐůĞ ĐĞůůƐ ĂŶĚ
throughout the central nervous system (Guimaraes et al., 2001; Mantyh et al.,
 ? ? ? ? ? ? dŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ĞŶĚŽŐĞŶŽƵƐ ůŝŐĂŶĚƐ ĂƌĞƚŚĞ ĐĂƚĞĐŚŽůĂŵŝŶĞƐ
adrenaline and noradrenaline, which are synthesised from the amino acid
tyrosine in chromaffin cells of the adrenal medulla in the adrenal gland, and
are then released into the blood stream (Perlman et al., 1977). Noradrenaline
is also synthesised in postganglionic neurons of the sympathetic nervous
ƐǇƐƚĞŵ ?ŝŶĚŝŶŐŽĨƚŚĞĞŶĚŽŐĞŶŽƵƐůŝŐĂŶĚƐƚŽɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐƐƚŝŵƵůĂƚĞƐƚŚĞ
sympathetic nervous system which tightly regulates various body systems
during activity (Iriki et al., 2012) as seen, for example, in the fight-or-flight
ƌĞƐƉŽŶƐĞ ? ǁŚĞƌĞ ƐƚŝŵƵůĂƚĞĚ ɴ1 ? ĂŶĚ ɴ2-adrenoceptors cause cardiac muscle
contraction leading to an increase in the heart rate, and smooth muscle
relaxation resulting in dilation of the airways, respectively (Mutlu et al., 2008).
/Ŷ ĐŽŶƚƌĂƐƚ ? ƚŚĞ ɴ3-adrenoceptor mediates lipolysis and thermogenesis in
adipose tissues upon receptor activation (Collins et al., 2004; Sawa et al.,
2006).
7/Ŷ ƚŚĞ ĐůŝŶŝĐ ? ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ  ?ɴ ?ďůŽĐŬĞƌƐ ? ĂƌĞ ǁŝĚĞůǇ ƵƐĞĚ ƚŽ
decrease cardiac output in a variety of cardiovascular diseases, including
angina pectoris, ischaemic heart disease and myocardial infarction (Baker et
al., 2011b; Poirier et al., 2012; Sanz-Rosa et al. ?  ? ? ? ? ? ?ǇďŝŶĚŝŶŐƚŽ ƚŚĞɴ1-
adrenoceptor they prevent the binding of the endogenous ligands to the
receptor and thus, its activation, which reduces the rate and the force of
cardiac contraction, thereby reducing cardiac output and blood pressure
(Poirier et al., 2012). In ischemic heart disease, the heart muscle becomes
ischemic (oxygen-starved) when the blood flow in the coronary arteries (that
deliver blood to the heart) is not sufficient (e.g. due to obstruction by an
atherosclerotic plaque) to meet the demands of the heart muscle (e.g. during
exercise where the heart muscle increases the cardiac output) which can
ĐĂƵƐĞƐĞǀĞƌĞĐŚĞƐƚƉĂŝŶƐ ?ĂŶŐŝŶĂƉĞĐƚŽƌŝƐ ? ?dŚĞƵƐĞŽĨɴ ?ďůŽĐŬĞƌƐƌĞĚƵĐĞƐƚŚĞ
workload of the heart, which in turn reduces the oxygen demand of the heart
muscle. In myocardial infarction (heart attack), a ruptured atherosclerotic
plaque causes severe obstruction of a coronary artery, which leads to severe
ischemia and oxygen deprivation, resulting in death of the myocardial tissue
supplied by that artery (Sanz-Rosa et al., 2012). It has been shown that the
ůŽŶŐ ?ƚĞƌŵ ƵƐĞ ŽĨ ɴ ?ďůŽĐŬĞƌƐ ƌĞĚƵĐĞƐ ŵŽƌƚĂůŝƚǇ ŽĨ ŵǇŽĐĂƌĚŝĂů ŝŶĨĂƌĐƚŝŽŶ
(Freemantle et al. ?  ? ? ? ? ? ĂŶĚ ƚŚĂƚ ɴ ?ďůŽĐŬĞƌ ƚƌĞĂƚŵĞŶƚ ĚƵƌŝŶŐ ĞĂƌůǇ
myocardial infarction reduces the infarct size (Galcera-Tomas et al., 2001).
/ŶĐŽŶƚƌĂƐƚ ƚŽɴ ?ďůŽĐŬĞƌƐ ?ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŐŽŶŝƐƚƐĂƌĞƵƐĞĚƚŽƐƚŝŵƵůĂƚĞ ƚŚĞ
ɴ2-adrenoceptor in the management of pulmonary diseases including asthma
8(Cazzola et al., 2012). In asthma, the inflammation of the airways leads to
increased contractility of the airway smooth muscles, which causes the
airways to narrow, thus making breathing difficult (Hogg, 1984). The
ĂĐƚŝǀĂƚŝŽŶ ŽĨ ƚŚĞ ɴ2-adrenoceptor expressed in smooth muscle cells in the
lung causes the dilation of the airways (Cazzola et al. ?  ? ? ? ? ? ? dŚĞ ɴ3-
adrenoceptor is subject of investigations as a potential therapeutic target in
ƚŚĞ ƚƌĞĂƚŵĞŶƚ ŽĨ Ă ǀĂƌŝĞƚǇ ŽĨ ĚŝƐĞĂƐĞƐ ŝŶĐůƵĚŝŶŐ ŽďĞƐŝƚǇ ? ĂƐ ƚŚĞ ɴ3-
adrenoceptor has been implicated in the mobilisation of stored fatty acids in
white adipose tissue (Bachman et al., 2002; Collins et al., 2004; Sawa et al.,
 ? ? ? ? ? ? /Ŷ ĂĚĚŝƚŝŽŶ ? ƚŚĞ ɴ3-adrenoceptor agonist mirabegron has been
approved as a treatment of overactive bladder within the last two years
(Chapple et al., 2013; Svalo et al., 2013).
 ? ? ?dŚĞŚƵŵĂŶɴ1-adrenoceptor
1.3.1 Structure
The ADRB1 gene on chromosome 10q25.3 (Ensembl genome database) codes
ĨŽƌƚŚĞŚƵŵĂŶɴ1-adrenoceptor, whose cDNA was isolated and cloned in 1987
to reveal a DNA sequence of 1431 base pairs and a protein sequence of 477
amino acids (Frielle et al. ?  ? ? ? ? ? ? /ŶƚĞƌĞƐƚŝŶŐůǇ ? ƚŚĞ ɴ1 ? ĂŶĚ ɴ2-adrenoceptor
only share a 54 % sequence identity, with the main differences observed in
the intra- and extracellular regions (Frielle et al., 1987). The amino acid
ƐĞƋƵĞŶĐĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor was proposed to fold into a secondary
ƐƚƌƵĐƚƵƌĞ ŽĨ ƐĞǀĞŶ ɲ ŚĞůŝĐĂů ƚƌĂŶƐŵĞŵďƌĂŶĞ ĚŽŵĂŝŶƐ ĂŶĚ ĐŽŶŶĞĐƚŝŶŐ ĞǆƚƌĂ ?
9and intracellular loops based on a hydropathy analysis (Frielle et al., 1987).
The three-dimensional model of bacteriorhodopsin was solved using electron
microscopy in 1975 (Henderson et al., 1975) and provided an insight into how
ƚŚĞ ƚƌĂŶƐŵĞŵďƌĂŶĞ ƌĞŐŝŽŶƐ ŽĨ ƚŚĞ ɴ1-adrenoceptor and other GPCRs would
be arranged in the plasma membrane. In 2000, the crystal structure of
rhodopsin was obtained (Palczewski et al., 2000), which was then used in
homology modelling approaches to not only predict the 3D structure of a
variety of GPCRs but also to better understand ligand binding and receptor
activation process (Ballesteros et al., 2001; Vaidehi et al., 2002). Finally, in
 ? ? ? ? ? ƚŚĞ ĨŝƌƐƚ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ƚƵƌŬĞǇ ɴ1-adrenoceptor was solved
(Warne et al., 2008).
dŚĞE ?ƚĞƌŵŝŶƵƐŽĨƚŚĞɴ1-adrenoceptor has been described to contain an N-
linked glycan on the asparagines residues at position 15 (Frielle et al., 1987;
Hakalahti et al., 2010b), which was reported to play a role in trafficking of the
receptor to the cell surface (He et al., 2002). The second extracellular loop
(EL2) has been demonstrated to play a role in ligand binding to the receptor
as it forms the entrance of the ligand into the transmembrane binding pocket
(Warne et al. ?  ? ? ? ? ? ? /Ŷ ƚŚĞ ƚƌĂŶƐŵĞŵďƌĂŶĞ ƌĞŐŝŽŶ ? ƚŚĞ ɴ1-adrenoceptor
ƐŚĂƌĞƐ ? ?A?ƐĞƋƵĞŶĐĞŝĚĞŶƚŝƚǇǁŝƚŚƚŚĞɴ2-adrenoceptor (Frielle et al., 1987),
and the transmembrane binding site of the two receptors has been shown to
be near identical in recent comparisons of the two crystal structures (Warne
et al., 2008). Subtype selectivity is proposed to be achieved by EL2 where the
electrostatic environment is different in the two receptor subtypes (Warne et
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al., 2008). The three residues aspartic acid (D), arginine (R) and tyrosine (Y) in
the transmembrane domain of GPCRs make up the highly conserved DRY
motif, which is associated with receptor activation, and was also present in
ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ƚƵƌŬĞǇ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?tĂƌŶĞet al., 2008). On the
intracellular side of the plasma membrane, the second intracellular loop is in
fact a short alpha helix (helix 8) that lies parallel to the membrane surface and
binds to the G protein which ultimately relays the signal from the receptor
into the cell by interacting with a variety of effector proteins (Shan et al.,
2010; Warne et al., 2008; Wong et al., 1990). The third intracellular loop (IL3)
is the largest intracellular loop (Frielle et al., 1987) and contains
phosphorylation sites that are targeted by protein kinase A (PKA) and G
protein regulated kinases (GRK) mediating receptor desensitisation
(Freedman et al. ?  ? ? ? ? ? ĂŶĚ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ  ?EŽŽƌet al., 2011), a
scaffolding protein that mediates internalisation and interactions with other
signalling proteins (Hall, 2004; Tilley et al., 2009). IL3 also has a proline-rich
region (Green et al., 1994), which allows interaction with proteins containing
the SH3 domain, such as proteins in the Src-tyrosine kinase family (Sun et al.,
2007). Another example is the SH3 domain-containing proteins endophilin1-3,
ǁŚŝĐŚ ŝŶĐƌĞĂƐĞƐ ĂŐŽŶŝƐƚ ?ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ɴ1-adrenoceptors,
ŚŝŐŚůŝŐŚƚŝŶŐĂƌŽůĞŽĨ ?ƚĞƌŵŝŶĂůŝŶƚĞƌĂĐƚŝŶŐƉƌŽƚĞŝŶƐŝŶƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ1AR
signalling (Tang et al., 1999). The amino acid sequence ESKV in the C-terminus
ŽĨ ƚŚĞ ɴ1-adrenoceptor facilitates the interaction with proteins containing a
PSD-95/Discs-large/ZO-1-homology (PDZ) domain, such as PSD-95 (Hu et al.,
2000), that have a wide range of roles in receptor signalling and trafficking
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(Hall, 2004; Marchese et al., 2008). For example, the PDZ domain-containing
proteins CNRasGEF (a guanine nucleotide exchange protein) and GIPC (GAIP-
interacting protein C) are expressed in the heart, and coimmunoprecipitation
and yeast two-hybrid screen experiments revealed their association with the
ɴ1-adrenoceptor (Hu et al., 2003b; Pak et al. ?  ? ? ? ? ? ? dŚĞ ɴ1-adrenoceptor
activates Ras via CNRasGEF when stimulated with an agonist, and this agonist-
ŝŶĚƵĐĞĚĂĐƚŝǀĂƚŝŽŶŽĨZĂƐǁĂƐĂďŽůŝƐŚĞĚďǇɴ1AR mutants that could no longer
bind CNRasGEF (Pak et al., 2002). The overexpression of GIPC was observed to
ĐĂƵƐĞ Ă ĚĞĐƌĞĂƐĞ ŝŶ ɴ1-adrenoceptor-mediated ERK1/2 activation, thus
ĐŽŶƚƌŝďƵƚŝŶŐƚŽƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ1-adrenoceptor signalling (Hu et al., 2003b).
dǁŽ ƉŽůǇŵŽƌƉŚŝƐŵƐ ŽĨ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor have been described;
Ser49Gly and Arg389Gly in the N- and C-terminal region of the receptor,
respectively (Borjesson et al., 2000; Maqbool et al., 1999; Mason et al., 1999).
The polymorphism at position 49 affects the extent of agonist-induced
receptor downregulation (Levin et al., 2002; Rathz et al., 2002). The C-
terminal polymorphism at position 389 causes an increased response to
agonists (Mason et al., 1999) and, in the clinic, is associated with higher risk of
left ventricular hypertrophy (i.e. increased cardiac mass) in hypertensive
patients (Fu et al., 2008) and following acute myocardial infarction (Hakalahti
et al., 2010a). Crucially however, neither polymorphism has been linked to
causing diseases (Brodde, 2008).
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1.3.2 Ligand binding and receptor activation
dŚĞ ĨŝƌƐƚ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ƚŚĞ ƚƵƌŬĞǇ ɴ1-adrenoceptor was resolved with
antagonist cyanopindolol bound to the receptor, and 15 residues from TM3, 5,
6, 7 and EL2 were identified to make direct contact with the ligand in the
ligand binding pocket (Warne et al., 2008). Since then, the crystal structure of
the receptor bound to full agonists isoprenaline and carmoterol, partial
agonists salbutamol and dobutamine, and biased agonists bucindolol and
carvedilol have been resolved, and a total of 23 residues have been listed to
facilitate ligand binding (Warne et al., 2012; Warne et al., 2011; Warne et al.,
2008). A 1 Å (=0.1 nm) contraction of the ligand binding site was observed in
the presence of agonists, but not the antagonist, which may lead to the
conformational change necessary to activate the receptor (Warne et al.,
2011). The binding of the two full agonists to the receptor was described to
involve hydrogen bonding with two conserved serine residues in TM5,
whereas the two partial agonists only displayed hydrogen bonding to one of
those two serine residues (Warne et al., 2011), which may be a structural
feature contributing to the reduced efficacy partial agonists exhibit compared
to full agonists. Interestingly, the extracellular loop 2 has been identified to
play an important role in ligand binding affinity and, potentially, subtype
ƐĞůĞĐƚŝǀŝƚǇ ? ĨŝƌƐƚůǇ ƚŚƌŽƵŐŚ ŝƚƐ ɲ ?ŚĞůŝĐĂů ƐƚƌƵĐƚƵƌĞ ƚŚĂƚ ĂĐƚƐ ƚŽ ƐƚĂďŝůŝƐĞ ƚŚĞ
entrance to the binding site and secondly, through its electrostatic
ĞŶǀŝƌŽŶŵĞŶƚ ?ƚŚĂƚŝƐǀĞƌǇĚŝĨĨĞƌĞŶƚƚŽƚŚĂƚŝŶƚŚĞɴ2-adrenoceptor (Rasmussen
et al., 2007; Warne et al., 2008). The ligand binding interactions facilitated by
13
residues in EL2 may also be important for the effects of biased ligands (Warne
et al., 2012).
Below the ligand binding site, at the cytoplasmic end of TM3, is the location of
the DRY motif. This is a highly conserved motif in GPCRs consisting of the
three consecutive amino acids aspartic acid (D), arginine (R) and tyrosine (Y)
in TM3, and is important in receptor activation (Audet et al., 2012; Deupi et
al., 2007). A salt bridge that forms between the positively charged amino acid
arginine of the DRY motif, and a negatively charged glutamic acid residue in
TM6 has been described as the ionic lock (Angel et al., 2009; Deupi et al.,
2007). In the inactive conformation of the receptor, the TM domains are
arranged such that non-covalent interactions between the two residues lock
the receptor into a closed state, and that, upon ligand binding and receptor
activation, the TM domains rearrange to an open (i.e. active) state, i.e. the
distance between the two residues is too great for any interactions to occur
(Angel et al., 2009; Audet et al., 2012; Deupi et al., 2007). In an activated
receptor, this conformational change is linked to the binding of the G proteins
to the receptor. However, this amino acid interaction was not found in the
ƐƚƌƵĐƚƵƌĞŽĨƚŚĞƚƵƌŬĞǇɴ1-adrenoceptor, even though the receptor structure
was complexed with an antagonist when it was resolved, thus representing an
inactive conformation. This, at least, questions the structural role of the ionic
lock in the structure of the inactive conformation of the receptor (Audet et al.,
2012; Warne et al., 2008). Another residue that has been implicated to play a
ƌŽůĞ ŝŶ ƌĞĐĞƉƚŽƌ ĂĐƚŝǀĂƚŝŽŶ ŝƐ Ă ƚƌǇƉƚŽƉŚĂŶ ŝŶ dD ? ?t ? ? ? ŝŶ ŚƵŵĂŶ ɴ1AR),
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which is reported to re-organise upon ligand binding, together with other
residues including a highly conserved proline to cause TM6 to bend in a
rotamer toggle switch, thus allowing G protein binding (Deupi et al., 2007).
 ? ? ? ? ?ɴ1-adrenoceptor-induced intracellular signalling
G proteins
GPCRs transmit the signal they receive from the bound ligand inside the cell
by coupling to heterotrimeric G proteins (guanine nucleotide-binding
ƉƌŽƚĞŝŶƐ ? ? ƚŚĂƚ ĐŽŶƐŝƐƚ ŽĨ ŽŶĞ ŽĨ ĞĂĐŚ ɲ ? ɴ ĂŶĚ ɶ ƐƵďƵŶŝƚƐ ? dŚĞ ŝŶƚƌĂĐĞůůƵůĂƌ
ůŽŽƉ ?ŝƐƌĞƉŽƌƚĞĚƚŽƉƌŽǀŝĚĞĂĚŽĐŬŝŶŐƐŝƚĞĨŽƌƚŚĞɲƐƵďƵŶŝƚŽĨƚŚĞ'ƉƌŽƚĞŝŶ
(Tesmer, 2010) to act as a switch upon receptor activation, by directly
interacting with the DRY motif within TM3 of GPCRs, facilitating G protein
binding and activation (Burstein et al., 1998; Warne et al., 2008). The C-
terminal domain is also implicated in facilitating G protein coupling (Palm et
al., 1989), especially via helix 8 (a stretch of 10 residues a few residues
following TM7) that may aid G protein binding (Delos Santos et al., 2006).
dŚĞŝŶĂĐƚŝǀĞ'ƉƌŽƚĞŝŶŚĂƐ'WďŽƵŶĚƚŽŝƚƐɲƐƵďƵŶŝƚ ?'ƉƌŽƚĞŝŶďŝŶĚŝŶŐƚŽĂŶ
ĂĐƚŝǀĂƚĞĚƌĞĐĞƉƚŽƌĐĂƵƐĞƐĂĐŽŶĨŽƌŵĂƚŝŽŶĂůĐŚĂŶŐĞŝŶƚŚĞɲƐƵďƵŶŝƚŽĨƚŚĞ'
protein that results in GDP release, which is followed by the binding of GTP to
ƚŚĞɲƐƵďƵŶŝƚĂŶĚƚŚĞƐƵďƐĞƋƵĞŶƚĚŝƐƐŽĐŝĂƚŝŽŶŽĨƚŚĞŚĞƚĞƌŽƚƌŝŵĞƌŝĐƉƌŽƚĞŝŶ
into two subunits: the Gɲ subunit and the Gɴɶ subunits (Hamm, 1998; Simonds,
1999). Both subunits are signalling units in their own right, activating
downstream signalling pathways. This signalling, however, is terminated
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ǁŚĞŶƚŚĞŝŶƚƌŝŶƐŝĐ'dWĂƐĞĂĐƚŝǀŝƚǇŽĨƚŚĞɲƐƵďƵŶŝƚĐĂƵƐĞƐŚǇĚƌŽůǇƐŝƐŽĨ'dWƚŽ
GDP, as this stops further activation of effector proteins and allows re-
ĂƐƐŽĐŝĂƚŝŽŶ ǁŝƚŚ ƚŚĞ ɴɶ ƐƵďƵŶŝƚ ? dŚŝƐ ĂĐƚŝǀĂƚŝŽŶ ?ŝŶĂĐƚŝǀĂƚŝŽŶ ĐǇĐůĞ ŽĨ '
proteins is regulated by two main enzymes; guanine nucleotide exchange
factors (GEFs) facilitate the GDP release and exchange with GTP to activate
the G protein, whereas GTPase activating proteins (GAPs) increase the
ŚǇĚƌŽůǇƐŝƐŽĨ'dWƚŽ'W ?ƚŚƵƐŝŶĂĐƚŝǀĂƚŝŶŐƚŚĞɲƐƵďƵŶŝƚ ?dĞƐŵĞƌ ? ? ? ? ? ? ?
dŚĞƌĞ ĂƌĞ  ? ? ĚŝĨĨĞƌĞŶƚ ɲ ƐƵďƵŶŝƚƐ ?  ? ĚŝĨĨĞƌĞŶƚ ɴ ƐƵď ŶŝƚƐ ĂŶĚ  ? ? ĚŝĨĨĞƌĞŶƚ ɶ
subunits, which are collectively subdivided into four main groups based on
ƚŚĞɲƐƵďƵŶŝƚ P's, Gi, Gq/11 and G12/13 (Hamm, 1998). Following ligand binding,
GPCRs couple to one or more G protein families. The GƐɲ subunit activates the
transmembrane effector enzyme adenylyl cyclase (AC), which generates the
second messenger cAMP (see below). The Gɲŝ subunit inhibits adenylyl cyclase
activity, thus reducing cAMP levels in the cell. GɲƋ ? ? ?activates the effector
ƉƌŽƚĞŝŶ ƉŚŽƐƉŚŽůŝƉĂƐĞ ɴ  ?W>ɴ ? ? ǁŚŝĐŚ ĐůĞĂǀĞƐ ƉŚŽƐƉŚŽƚŝĚǇůŝŶŽƐŝƚŽů  ? ? ? ?
biphosphate (PIP2) in the plasma membrane to release two second messenger
molecules: diacylglycerol (DAG) and inositol phosphate (Gutkind et al., 2009).
Gɲ ? ? ? ? ?subunits activate Rho-GEFs, which then go on to activate the small G
protein RhoA (Shi et al. ? ? ? ? ? ? ?&ƵƌƚŚĞƌŵŽƌĞ ?Ăůů'ɲƐƵďƵŶŝƚƐĂůƐŽĂĐƚŝǀĂƚĞƚŚĞ
mitogen activating protein (MAP) kinase pathway by interaction with the
tyrosine kinase Src (Ma et al., 2000; New et al. ? ? ? ? ? ? ?ɴɶƐƵďƵŶŝƚƐŚĂǀĞďĞĞŶ
reported to activate adenylyl cyclases, PLC and GRKs (Simonds, 1999; Zhong
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et al., 1999), as well as ion channels and several kinases (Hamm, 1998). All
ƚŚƌĞĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐƉƌĞĚŽŵŝŶĂŶƚůǇĐŽƵƉůĞƚŽ's.
Adenylyl cyclase and intracellular cAMP
Nine different types of the adenylyl cyclase protein family (AC1-9) have thus
far been identified with varying expression patterns and regulatory properties
(Simonds, 1999; Sunahara et al., 2002). Adenylyl cyclases are large
transmembrane proteins that consist of an intracellular N-terminal domain,
ƚǁŽ ƐĞŐŵĞŶƚƐ ŽĨ  ? ŵĞŵďƌĂŶĞ ƐƉĂŶŶŝŶŐ ɲ ŚĞůŝĐĞƐ ? ƚǁŽŚŽŵŽůŽŐŽƵƐ ůĂƌŐĞ
intracellular loops (one following each transmembrane domain), and an
intracellular C-terminal tail (Simonds, 1999). For activation of the enzyme, the
two cytoplasmic domains dimerise to form a catalytic pocket within their
domain interface, in which adenosine triphosphate (ATP) is converted to 3-5-
cyclic adenosine monophosphate (cAMP) and pyrophosphate (Simonds, 1999;
Tesmer et al., 1999). The GƐɲ subunit binds to the N-terminal domain and both
of the cytoplasmic domains to stabilise the active conformation of the
enzyme, thus increasing its catalytic activity (Hanoune et al., 2001; Tesmer et
al., 1997). The lipophilic diterpene molecule forskolin (a Coleus forskohlii plant
product) also increases activity of all types of adenylyl cyclases, but does so
through direct stabilising interactions with a hydrophobic pocket between the
two cytoplasmic domains (Zhang et al., 1997), thus bypassing the G protein-
mediated adenylyl cyclase activation pathway. The Gŝɲ subunit confers an
inhibitory effect on adenylyl cyclase and thus, acts to decrease cAMP levels in
the cell (Simonds, 1999; Sunahara et al., 2002). AC1, AC3 and AC8 isoforms of
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adenylyl cyclases are also activated by calcium/calmodulin, whereas AC5, AC6
and AC9 are inhibited by calcium (Hanoune et al., 2001; Ostrom et al., 2003;
Sunahara et al., 2002). Other AC regulators include protein kinase A (PKA) and
protein kinase C (PKC) and the Gɴɶ subunit (Hanoune et al., 2001; Sunahara et
al., 2002). These various regulatory mechanisms, in conjunction with tissue
specific expression of the different AC isoforms, tightly control the level of
cAMP in the cell and thus generate highly diverse and specific signalling
outcomes (Ostrom et al., 2012). In cardiac myocytes, cAMP levels are raised
by activation of AC isoforms 5 and 6 (Ostrom et al., 2001; Pierre et al., 2009).
Furthermore, Ostrom et al.  ? ? ? ? ? ? ŚĂǀĞ ůŽĐĂůŝƐĞĚ ƚŚĞ ɴ1-adrenoceptor
together with AC6 in caveolae membrane microdomains, and have also
demonstrated that the proximity of the receptor to its effector enzyme
determines the efficiency by which the enzyme is activated (Ostrom et al.,
2001). This compartmentalisation extends from the plasma membrane
(receptor and effector protein) through into the cell, where cAMP levels are
regulated by degradation to AMP by localised phosphodiesterases (PDEs) and
downstream signalling proteins such as PKA, which bind cAMP molecules, and
together mop up the cAMP molecules, thus confining them to a specific
subcellular location (Stangherlin et al., 2011; Xiang, 2011). There are 11 PDE
families, and all PDEs contain a catalytic site that binds to cyclic nucleotides
and an N-terminal domain that allows regulation of PDE activity (Stangherlin
et al., 2012). In human atrium tissue, it has been shown that, following
activation of the ȕ1-adrenoceptor, cAMP levels were reduced in the presence
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of PDE3 (Kaumann et al., 2007) and were increased in the presence of PDE
inhibitors (Sarsero et al., 2003).
Protein kinase A and downstream events
The PKA protein consists of two catalytic and two regulatory subunits in the
inactive state. When the cAMP levels in the cell rise, two molecules of cAMP
bind to each of the two PKA regulatory subunits. This causes the release of
the two catalytic subunits, which then go on to phosphorylate target proteins
in the cell (Taylor et al., 2012). In cardiac myocytes, the cAMP-dependent PKA
targets the protein phospholamban, which, once phosphorylated, activates
the SERCA2a, i.e. sarco-endoplasmic Ca2+-ATPase (Cerra et al., 2012). SERCA2a
facilitates Ca2+ entry into the sarcoplasmic reticulum, thereby increasing the
Ca2+ stores. PKA also phosphorylates the voltage-gated L-type calcium channel
dihydropyridine receptor (DHPR) in the cell membrane to increase Ca2+
uptake into the cell (Endoh, 2008; Haase et al., 1993; Yan et al., 2011). Cardiac
muscle cells are excitable cells, where a membrane potential is established
based on the concentration gradients of ions across the cell membrane with
the voltage (charge separation) being negative inside the cell compared to the
extracellular space. Upon membrane depolarisation, Ca2+ enters the cells
through DHPRs (Endoh, 2008; Polakova et al., 2008). Increased Ca2+ levels in
the cell then results in the release of Ca2+ from the sarcoplasmic reticulum via
the calcium-induced calcium release (CICR) mechanism, where Ca2+ itself
activates ryanodine receptors (RyR) expressed on the sarcoplasmic reticulum
in cardiac myocytes (Endoh, 2008; Van Petegem, 2012). Released Ca2+ then
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binds to troponin-C, a contractile regulatory subunit of troponin that forms
part of the thin (actin) filaments in the contractile apparatus in cardiac
muscles (Endoh, 2008) and thus controls the calcium-mediated interactions
between actin and myosin in cardiac muscles. Following contraction,
intracellular Ca2+ levels are reduced by Ca2+ uptake into the stores of the
sarcoplasmic reticulum via SERCA2a as well as Na+/Ca2+ exchange and Ca2+
pumps (Endoh, 2008; Yang et al., 2009).
Since PKA activity is cAMP-dependent, decreasing cAMP levels directly results
in reduced PKA activity. Interestingly, active PKA also phosphorylates and
activates PDEs, which in turn breaks down cAMP, thus creating a negative
feedback mechanism. PKAs (as well as ACs and PDEs) are confined to distinct
subcellular locations such as mitochondria, nucleus and cell membrane, by A-
kinase anchoring proteins (AKAPs), thus controlling their selectivity (Christian
et al., 2011; Stangherlin et al. ? ? ? ? ? ?dŝůůĞǇ ?  ? ? ? ? ? ?<W ? ? ? ? ? ?ĂŶĚŵ<Wɴ
have been associated with AC5 and/or 6 and thus may play a role in cardiac
myocytes (Christian et al., 2011). AKAPs also bind other signalling proteins,
including PDEs, which contributes to the spatially controlled signalling of
cAMP (Christian et al., 2011), although in adult mice cardiac myocytes non-
ůŽĐĂůŝƐĞĚ ĨĂƌ ?ƌĞĂĐŚŝŶŐ ĐDW ƐŝŐŶĂůůŝŶŐ ŝŶ ƌĞƐƉŽŶƐĞƚŽ ɴ1-adrenoceptor
stimulation has been observed (Nikolaev et al., 2006).
The above cellular response is directly mediated by the cAMP/PKA pathway.
In the cell, components of this pathway may also interact with other
pathways (Gerits et al., 2008), such as the mitogen-activated protein kinase
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(MAPK) pathway that leads to activation of ERK1/2, JNK, p38 and cellular
responses of cell growth, proliferation and apoptosis (Gerits et al., 2008; Liang
et al., 2003). Downstream effects such as gene expression may also be
activated or inhibited via the pathway involving the transcription factor
cAMP-response-element-binding (CREB). CREB is activated by PKA that
translocated to the nucleus. Once phosphorylated, CREB then binds to the
CRE DNA sequence, where it is then bound by, and thus co-activated by, a
CREB-binding protein (CBP), which results in initiation or inhibition of gene
transcription (Shaywitz et al., 1999).
Receptor phosphorylation and internalisation
dŚĞ  ?ƚĞƌŵŝŶĂů ƚĂŝů ŽĨ ƚŚĞ ɴ1-adrenoceptor is rich in serine and threonine
residues, which are phosphorylation sites of PKAs and GRKs, G protein-
coupled receptor kinases (Frielle et al., 1987; Granier et al., 2007; Nobles et
al., 2011). Receptor phosphorylation, following continuous receptor
activation, results in receptor desensitisation and internalisation from the
plasma membrane into the cell (Drake et al., 2006; Liang et al., 2004). GRK
ƉŚŽƐƉŚŽƌǇůĂƚĞĚƐŝƚĞƐĂƌĞďŽƵŶĚďǇɴ ?ĂƌƌĞƐƚŝŶ ?ǁŚŝĐŚƚŚĞŶŵĞĚŝĂƚĞƐƌĞĐĞƉƚŽƌ
internalisation via clathrin-coated pits (Drake et al., 2006; Luttrell et al., 2002;
Wolfe et al., 2007b). GPCRs are tethered to clathrin-coated pit proteins, such
ĂƐĐůĂƚŚƌŝŶĂŶĚƚŚĞĂĚĂƉƚŽƌƉƌŽƚĞŝŶW ? ?ǀŝĂƚŚĞƐĐĂĨĨŽůĚŝŶŐƉƌŽƚĞŝŶɴ ?ĂƌƌĞƐƚŝŶ ?
Dynamin proteins then facilitate the pinching off of the clathrin-coated pit
into endosomal compartments within the cell (Jean-Alphonse et al., 2011).
The receptors then follow either the recycling pathway from early endosomes,
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where the receptors are dephosphorylated and resensitised, back to the cell
surface, or the degradation pathway from early to late endosomes and
lysosomes, where the receptors become ubiquitinated and thus degraded
(Drake et al., 2006; Jean-Alphonse et al., 2011; Marchese et al., 2013). The
ɴ1AR has been reported to be resistant to ubiquitination (Liang et al., 2004).
Zhang et al.  ? ? ? ? ? ? ĚĞŵŽŶƐƚƌĂƚĞĚ ƚŚĞ ƌŽůĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ĂŶĚ ƚŚĞ ĐůĂƚŚƌŝŶ ?
ĐŽĂƚĞĚƉŝƚ ?ŵĞĚŝĂƚĞĚĞŶĚŽĐǇƚŽƐŝƐƉĂƚŚǁĂǇŝŶƚŚĞƌĞŐƵůĂƚŝŽŶŽĨɴ2AR signalling
ďǇ ŽǀĞƌĞǆƉƌĞƐƐŝŶŐ Ă ĚŽŵŝŶĂŶƚ ŶĞŐĂƚŝǀĞ ŵƵƚĂŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ĂŶĚ ĚǇŶĂŵŝŶ ?
both of which decreased receptor dephosphorylation and resensitisation
(Zhang et al., 1997). Many GPCRs are internalised via this mechanism of
ĞŶĚŽĐǇƚŽƐŝƐ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ ɴ2-adrenoceptor, AT1 angiotensin receptor and
PAR1 (Gaborik et al., 2004; Wolfe et al., 2007a; Zhang et al. ?  ? ? ? ? ? ? dŚĞ ɴ2-
adrenoceptor readily desensitises and internalises following stimulation by
the agonist isoprenaline (McLean et al., 2000). dŚĞɴ1AR is more resistant to
ƌĞĐĞƉƚŽƌ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ? ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂŶĚ ĚĞŐƌĂĚĂƚŝŽŶ ƚŚĂŶ ƚŚĞ ɴ2-
adrenoceptor (Liang et al., 2004), but displays increased internalisation when
ĐŽ ?ĞǆƉƌĞƐƐĞĚĂŶĚŚĞƚĞƌŽĚŝŵĞƌŝƐĞĚǁŝƚŚɴ2ARs (Mercier et al., 2002).
Interestingly, PKA receptor phosphorylation also induces receptor
internalisation, but via caveolae-mediated endocytosis (Rapacciuolo et al.,
2003). Caveolae are formed by caveolin proteins and cholesterol embedded
in the plasma membrane, and are pinched off the membrane by the dynamin
protein to facilitate endocytosis (Kiss et al., 2009; Veyrat-Durebex et al., 2005).
Receptor internalisation is generally associated with a termination of G
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ƉƌŽƚĞŝŶ ?ĚĞƉĞŶĚĞŶƚ ƐŝŐŶĂůůŝŶŐ ? ĂƐ ɴ ?ĂƌƌĞƐƚŝŶ ďŝŶĚŝŶŐ ƚŽ ĚĞƐĞŶƐŝƚŝƐĞĚ
phosphorylated receptors uncouples the receptors from the G proteins
(Luttrell et al., 2002). However continued signalling following internalisation
has been shown for TSH receptors, PTH receptors and S1P1 receptors
(Calebiro et al., 2009; Estrada et al., 2009; Ferrandon et al., 2009). Whether
ƚŚŝƐŝƐĂůƐŽƚƌƵĞĨŽƌƚŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐŚĂƐŶŽƚǇĞƚďĞĞŶŝŶǀĞƐƚŝŐĂƚĞĚ ?
G protein-independent signalling
A ligand that binds to a receptor may utilise different residues within the
receptor binding site, and these different noncovalent ionic interactions may
cause different conformational changes within the receptor that transmit to
the C-terminus (Warne et al., 2012). The C-terminus has been described as
ƚŚĞ ƐŝƚĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ďŝŶĚŝŶŐ ? ǁŚŝĐŚ ŚĂƐ ĂůƐŽ ďĞĞŶ ůŝŶŬĞĚ ƚŽ ĚŝĨĨĞƌĞŶƚ
downstream signalling effects than those associated with G protein coupling,
i.e. G protein-independent signalling events (DeWire et al., 2007; Tilley, 2011).
These different pathways have led to the discovery of biased ligands, which
preferentially activate one signalling pathway to a greater extent than
another (Rajagopal et al. ?  ? ? ? ? ? ?dǁŽɴ ?ĂƌƌĞƐƚŝŶƉƌŽƚĞŝŶƐ  ?ɴ ?ĂƌƌĞƐƚŝŶ  ?ĂŶĚ ? ?
are known and have been implicated in a variety of cellular responses such as
cardiomyocyte contractility and cytoskeletal organisation, as a downstream
ƌĞƐƵůƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶƐ ŝŶƚĞƌĂĐƚŝŶŐ ǁŝƚŚ ƐŵĂůů 'dWĂƐĞƐ ZŚŽ ? ĂĐƚŝŶ ĂŶĚ ŵǇŽƐŝŶ
 ?dŝůůĞǇ ?  ? ? ? ? ? ?&ƵƌƚŚĞƌŵŽƌĞ ?ɴ ?ĂƌƌĞƐƚŝŶƐŝŐŶĂůůŝŶŐŚĂƐďĞĞŶ ůŝŶŬĞĚƚŽƚŚĞDW
kinase ERK1/2, Jnk and p38 pathways (DeWire et al., 2007). Interestingly, G
protein-dependent signalling leads to increased nuclear ERK1/2 signalling,
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ǁŚĞƌĞĂƐ Z< ? ? ? ƐŝŐŶĂůůŝŶŐ ŵĞĚŝĂƚĞĚ ďǇ ɴ ?ĂƌƌĞƐƚŝŶ ŚĂƐ ďĞĞŶ ůŽĐĂůŝƐĞĚ ƚŽ ƚŚĞ
cytosol, where it plays a role in cardiomyocyte survival (Tilley, 2011). ERK1/2
signalling is typically mediated by activation of receptor tyrosine kinases (RTK),
such as EGFR, the epidermal growth factor receptor (Patel et al., 2008).
,ŽǁĞǀĞƌ ? ƚŚĞ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĐĂŶ ĂůƐŽ ĂĐƚŝǀĂƚĞ '&Z ǀŝĂ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŚƵƐ
resulting in ERK1/2 signalling and cross-talk of GPCR and RTK signalling, which
has been linked to cardioprotection (Noma et al., 2007; Patel et al., 2008).
1.4 GPCR dimerisation
The association of a GCPR to another GPCR, of either the same or a different
subtype, to form homo- or heterodimers, respectively, was first suggested
based on data obtained in biochemical assays, including photoaffinity
labelling and coimmunoprecipitation experiments (Bouvier, 2001; Franco et
al., 2007). Dimerisation of Class C GPCRs, such as mGluR5 and GABAB
receptors, was shown in coimmunoprecipitation experiments (Kaupmann et
al., 1998; Romano et al., 1996). Dimerisation of Class A GPCRs was also
observed in biochemical assays, and dimers and higher order oligomers were
ƌĞƉŽƌƚĞĚĨŽƌƚŚĞɴ2-adrenoceptor, muscarinic receptors and opioid receptors
(Avissar et al., 1983; Cvejic et al., 1997; Hebert et al., 1996). However, these
studies have several limitations, such as specificity and sensitivity (e.g.
antibodies used in Western blotting experiments), and whether dimerisation
is induced by solubilisation of membranes. Fluorescent and bioluminescence
resonance energy transfer (FRET and BRET, respectively) assays use
fluorescent and bioluminescent proteins that are fused to the two proteins of
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interest to detect and localise GPCR dimers in real time (Marullo et al., 2007).
A RET signal is detected when the fluorophores are within 10 nm of each
ŽƚŚĞƌ ? ĂŶĚ ƌĞĐĞƉƚŽƌ ?ƌĞĐĞƉƚŽƌ ŝŶƚĞƌĂĐƚŝŽŶƐ ŚĂǀĞ ďĞĞŶ ƌĞƉŽƌƚĞĚ ĨŽƌ ɴ2-
adrenoceptor, adenosine A2A and muscarinic M2 homodimers, and GABAB
heterodimer (Canals et al., 2004; Fung et al., 2009; Maurel et al., 2008;
Pisterzi et al., 2010). However, the orientation and distance of the
fluorophores are the deciding factor in the efficiency of the RET signal and
whether RET is detected or not (Iqbal et al., 2008; Marullo et al., 2007; Vogel
et al., 2006). Furthermore, the majority of experiments that were performed
to detect interaction of two GPCRs used recombinant cell systems where the
GPCRs of interest were overexpressed. This could lead to random collision of
receptors as they diffuse through the membrane, although negative controls
are performed using non-interacting receptor and the expression levels are
optimised (Marullo et al., 2007). In addition, the above listed techniques
suggest close proximity of receptors, but do not necessarily imply receptor-
receptor interactions. However, using total internal reflection fluorescence
microscopy (TIRF-M), the association of fluorescently labelled receptors into
dimers and higher oligomeric structures at the single molecule level is
monitored directly in real time, thus highlighting the dynamics of receptor-
receptor interactions (Calebiro et al., 2013; Hern et al., 2010; Kasai et al.,
 ? ? ? ? ? ?/ŶƚĞƌĞƐƚŝŶŐůǇ ?ɴ2-adrenoceptors were observed to formed stable dimers,
ǁŚĞƌĞĂƐ ɴ1-adrenoceptor dimers appeared transient with 70 % of the
receptor population being monomeric in low density expressing cells
(Calebiro et al., 2013; Dorsch et al., 2009). Whilst these single molecule
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studies are performed using low receptor expression levels, recombinant cell
lines do not represent the physiologically relevant native membrane
environment, which can influence receptor organisation and diffusion in the
cell membrane (Pucadyil et al., 2007).
For the class C GPCR GABABB receptor, heterodimerisation of GABAB1 and
GABAB2 receptor is vital for the activity of the receptor dimer as one protomer
facilitates ligand binding and the other protomer transmits the signal (Jones
et al., 1998; White et al., 1998). Apart from orphan receptors, all class C
GPCRs constitutively homo- or heterodimerise (Kniazeff et al., 2011). As
mentioned above, class A GPCRs have been shown to be able to form dimers,
however, their role and functional relevance is still subject to investigations,
although several roles have been reported, such as receptor synthesis and
maturation, and receptor trafficking following internalisation (Bulenger et al.,
2005; Cao et al., 2005; Jordan et al., 1999). However, in the plasma
membrane, the monomeric GPCR has been described as the minimal
functional unit (Chabre et al., 2005). Furthermore, the activation of only one
leukotriene B4 receptor in a dimer conformation was shown to be enough to
cause G protein coupling (Damian et al., 2006). This is termed asymmetric
ĂĐƚŝǀĂƚŝŽŶĂŶĚŚĂƐĂůƐŽďĞĞŶƌĞƉŽƌƚĞĚĨŽƌƌŚŽĚŽƉƐŝŶĂŶĚƚŚĞɴ2-adrenoceptor
(Bayburt et al., 2007; Whorton et al., 2007; Whorton et al., 2008). In contrast,
both protomers are activated in symmetric activation, which was shown to
lead to more efficient activation for serotonin type 4 receptor dimers
(Pellissier et al., 2011). In dopamine D1 and D2 heterodimers, agonist binding
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to both protomer is also required, and interestingly, results in coupling to the
Gq/11 protein that the monomeric D1 and D2 receptors do not couple to
(Rashid et al., 2007). Allosteric modulation describes the simultaneous
binding of the endogenous receptor-activating ligand and an allosteric ligand
to two different binding sites on a receptor complex. Whilst the second
(allosteric) binding site may be within a monomeric receptor (Gregory et al.,
2010), allosteric interactions across dimers have been described for a variety
of GPCR dimers including muscarinic, adenosine A3 and dopamine receptors,
resulting in modulated ligand affinities and/or efficacies (Birdsall et al., 2005;
Han et al., 2009; May et al., 2011; Milligan et al., 2007). Other functional
ŽƵƚƉƵƚƐ ? ƐƵĐŚ ĂƐ ƌĞĐƌƵŝƚŵĞŶƚ ĂŶĚ ƐŝŐŶĂůůŝŶŐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ĂƐ ǁĞůů ĂƐ
internalisation of GPCR dimers still need to be investigated (Gurevich et al.,
2008). However, it is clear that GPCR dimerisation adds to their signalling
diversity (Nakata et al., 2010), which may be exploited for therapeutic
purposes (Congreve et al., 2010; Dalrymple et al., 2008; Panetta et al., 2008).
1.5 GPCR pharmacology principles
1.5.1 Agonists, antagonists and inverse agonists
As described above, in order to induce a cellular response a ligand has to
firstly bind to its receptor, and secondly activate it to transmit the external
stimulus into the cell. The affinity of a ligand for its receptor describes how
well that ligand binds its receptor (Kenakin, 1990). The ability of the ligand to
stimulate the receptor to cause a response, however, is described as efficacy
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 ?<ĞŶĂŬŝŶ ?  ? ? ? ? ? ? dŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĞŶĚŽŐĞŶŽƵƐ ůŝŐĂŶĚƐ ĂĚƌĞŶĂůŝŶĞ ĂŶĚ
ŶŽƌĂĚƌĞŶĂůŝŶĞďŝŶĚƚŽĂŶĚĂĐƚŝǀĂƚĞƚŚĞɴ1-adrenoceptor and thus are agonists
at that receptor. Agonists that display high efficacy are known as full agonists,
whereas partial agonists have low efficacy. Low efficacy agonists exert a
submaximal cellular response compared to full agonists that exert a maximal
cellular response. In addition, a partial agonist occupies all available receptors
to induce a cellular response, whereas an efficacious full agonist is able to
cause a response by occupying only a fraction of available receptors. Thus, the
observed level of cellular response also depends on the number of available
receptors, as a low efficacy agonist may appear to be a full agonist if receptor
ŶƵŵďĞƌƐĂƌĞŚŝŐŚĞŶŽƵŐŚ ?,ŝŐŚůǇĞĨĨŝĐĂĐŝŽƵƐĂŐŽŶŝƐƚƐĂƚƚŚĞɴ1-adrenoceptor
include isoprenaline and cimaterol, and salbutamol and dobutamine are
examples of low efficacy (partial) agonists. The effects of an agonist at a
receptor can be inhibited by blocking the binding of that agonist to the
receptor. This can be done by using a ligand that also has affinity for that
same receptor. If this ligand does not cause a cellular response, i.e. it exerts
no efficacy because it does not activate the receptor, then it is classed as an
ĂŶƚĂŐŽŶŝƐƚ ? ŶƚĂŐŽŶŝƐƚƐ ƚŚĂƚ ŝŶŚŝďŝƚ ɴ ?ĂĚƌĞŶĞƌŐŝĐ ƐŝŐŶĂůůŝŶŐ ĂƌĞ ĐĂůůĞĚ ɴ ?
blockers and include propranolol and atenolol (Baker, 2005). Alternatively,
the ligand may be a different agonist that causes a smaller response (i.e.
partial agonist) or a different response, such as biased ligand bucindolol and
carvedilol (Galandrin et al., 2008; Wisler et al., 2007). Yet another ligand may
reduce the basal activity of the receptor (i.e. in the absence of any agonists)
and thus be an inverse agonist.
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An antagonist may bind the receptor in a reversible or irreversible manner.
Irreversibility of a ligand may be achieved by covalently linking to a residue on
the receptor. Alternatively, ligands that bind to the receptor via strong non-
covalent bonds (i.e. not strictly irreversible), may display very slow
dissociation rates and thus appear irreversible. This effectively removes
receptors as the agonist has less available receptors to bind to. Under these
conditions, less efficacious agonists may be revealed as they utilise a greater
number of receptors than a highly efficacious agonist to yield the same level
of response (Kenakin, 1997; Leff, 1995a). Reversible antagonists are further
divided into competitive and non-competitive antagonists. Competitive
antagonists bind to the same site as the agonist they are competing against,
to block a cellular response. Thus, with higher agonist concentrations the
inhibitory effect of the antagonist used can be overcome. Non-competitive
antagonists do not compete with the agonist for the same endogenous
(orthosteric) binding site, but instead bind to a topographically distinct
(allosteric) binding site of the receptor and influence the agonist effects via
allosteric interactions (see below).
According to the two-state model of agonist action, two receptor
conformations (active, R*, and inactive, R) coexist in equilibrium (Leff, 1995b).
An agonist preferentially binds to and stabilises the active receptor
conformation, thus directing the equilibrium towards R*. An inverse agonist
binds to and stabilises the inactive receptor state, thus directing equilibrium
towards R. Neutral antagonists, however, do not affect the equilibrium of the
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two receptor states as they bind to both conformations with the same affinity
(Leff, 1995b). This model was extended to the three-state model to include an
additional active conformation of the receptor (R* and R**) to take into
account multiple receptor-effector coupling events, i.e. the active receptor
conformation may couple to different G proteins (Leff et al., 1997). Further
extensions lead to the cubic ternary complex (CTC) model, where both the
active and inactive receptor may be bound to a ligand and/or G protein or not.
In this model, the transition of an agonist bound receptor (AR*) to an agonist
bound receptor that couples to a G protein (AR*G) represents the efficacy
parameter (Weiss et al., 1996). Other receptor models have been derived
from the CTC to include, for example, a second ligand binding within the same
receptor or receptor dimerisation (Christopoulos et al., 2002; Franco et al.,
2006).
1.5.2 Allosteric modulators
An endogenous ligand binds to the endogenous (orthosteric) binding site of
its receptor. A ligand that binds to a topographically distinct (allosteric)
binding site on the same receptor is an allosteric ligand. Thus, both the
orthosteric and allosteric ligand can be bound to the same receptor at the
same time. The binding of an allosteric ligand to a receptor causes a
conformational change in the receptor that negatively or positively alters the
interactions the endogenous ligand makes with the orthosteric binding site,
i.e. it affects its binding affinity (Christopoulos et al., 2002). Crucially,
allosteric interactions (also termed co-operativity) between two ligands
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binding to their binding sites are reciprocal. The binding of multiple ligands to
a receptor at the same time and the allosteric interactions between multiple
binding sites were incorporated into the extended ternary complex (ETC)
model (Christopoulos et al., 2002). The simplified scheme in Figure 1.2 shows
the binding of ligands A and B to the receptor R, which is described by their
respective affinities Ka and Kb. However, the binding of A to the receptor
already bound by B is described by its affinity to the receptor and the co-
ŽƉĞƌĂƚŝǀŝƚǇ ĨĂĐƚŽƌ ɲ ? ŝ ?Ğ ? ɲ<a. The same co-operativity factor affects the
binding of ligand B to the receptor already bound by A, highlighting the
reciprocal nature of the co-operativity between two binding sites
(Christopoulos et al., 2002). Allosteric modulation has been reported for a
variety of GPCRs, including muscarinic, free fatty acids, chemokine and
metabolic glutamate receptors (Birdsall et al., 2005; Knoflach et al., 2001;
Milligan, 2009; Watts et al., 2012). Allosteric ligands have also been shown to
affect the efficacy of an agonist at a given receptor. Thus, the concentration-
response curve of an agonist is left-shifted by a positive allosteric modulator
(PAM) and right-shifted by a negative allosteric modulator (NAM). Crucially,
allosteric effects are saturable, which eventually leads to a bunching up of the
agonist concentration-response curve, which clearly distinguishes allosteric
from competitive interactions (Christopoulos et al., 2002; Smith et al., 2010).
Furthermore, some allosteric ligands have been found to display efficacy
themselves, i.e. cause a functional response, and have been termed allosteric
agonists or ago-allosteric ligands (Langmead et al., 2006; Smith et al., 2010).
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Ago-allosteric ligands have been described at the muscarinic M2 receptor
(May et al., 2007) and the free fatty acid 2 receptor (Milligan, 2009).
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Figure 1.2 Model describing the binding of two ligands A and B to the receptor R,
which is governed by their affinity towards the unbound receptor (Ka and Kb,
ƌĞƐƉĞĐƚŝǀĞůǇ ?ĂŶĚƚŚĞĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇĨĂĐƚŽƌɲ ?dĂŬĞŶĨƌŽŵŚƌŝƐƚŽƉŽƵůŽƐet al. (2002).
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 ? ? ?'W ? ? ? ? ?ĂƚƚŚĞɴ1-adrenoceptor
CGP 12177 was synthesized by Staehelin et al.  ? ? ? ? ? ? ĂƐ Ă ŚǇĚƌŽƉŚŝůŝĐ ɴ ?
blocker and radioligand to facilitate ligand binding studies in whole cell assays
(Staehelin et al., 1983). CGP 12177 was shown to antagonise catecholamine
ƌĞƐƉŽŶƐĞƐ Ăƚ ƚŚĞ ɴ1-adrenoceptor with high affinity, but was also shown to
exhibit agonist effects at much higher (circa 100-fold) concentrations
(Kaumann et al., 1997; Staehelin et al., 1983). These agonist effects were not
as pronounced as those stimulated by the full agonist isoprenaline, i.e. they
were partial. Since a partial agonist occupies all available receptors to
produce the maximum effect possible, the EC50 of a partial agonist is expected
to be similar to its affinity. Because of this discrepancy of the EC50 and affinity
values CGP 12177 was termed a non-conventional partial agonist (Kaumann,
1989). The antagonist and partial agonist effects of CGP 12177 were not only
observed in human but also in a variety of other mammalian cardiac tissues
(Lowe et al., 1999; Sarsero et al., 1998). Other non-conventional partial
agonists have also been described (Figure 1.3), including pindolol (Baker et al.,
2003a; Joseph et al., 2003; Kaumann et al., 1980). Interestingly, studies using
ƐĞůĞĐƚŝǀĞ ɴ1 ? ĂŶĚ ɴ2-adrenoceptor antagonists (CGP 20712A and ICI 118,551
ƌĞƐƉĞĐƚŝǀĞůǇ ? ƚŽ ĂƚƚƌŝďƵƚĞ ƚŚĞƐĞ ƉĂƌƚŝĂů ĂŐŽŶŝƐƚ ĞĨĨĞĐƚƐ ƚŽ Ă ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
ƐƵďƚǇƉĞ ƌĞǀĞĂůĞĚ ƚŚĂƚ ƚŚĞƐĞ ƐƚŝŵƵůĂƚŽƌǇ ĞĨĨĞĐƚƐ ĂƉƉĞĂƌĞĚ ƌĞƐŝƐƚĂŶƚ ƚŽ ɴ ?
blocker treatment at the concentrations used to inhibit isoprenaline-induced
effects at the two receptor subtypes. Thus, the partial agonist effects seen at
high concentrations of CGP 12177 are inhibited by antagonists with low
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affinity. This led to the proposal that these partial agonist effects are
ŵĞĚŝĂƚĞĚ ƚŚƌŽƵŐŚ ĂŶ ĂĚĚŝƚŝŽŶĂů ĨŽƵƌƚŚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?<ĂƵŵĂŶŶ ?  ? ? ? ? ? ?
,ŽǁĞǀĞƌ ? ƐƚƵĚŝĞƐ ƉĞƌĨŽƌŵĞĚ ŽŶ ŚƵŵĂŶ ĂŶĚ ƌĂƚ ɴ1-adrenoceptors expressed
ŝŶ Ă ƌĞĐŽŵďŝŶĂŶƚ ĐĞůů ůŝŶĞ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ ƚŚĞ ɴ1-adrenoceptor alone was
sufficient to observe the complex pharmacology of CGP 12177, and the
ƉƵƚĂƚŝǀĞɴ4-adrenoceptor was described as a low affinity site or state of the
ɴ1-adrenoceptor (Pak et al., 1996). This notion was also suggested following
desensitisation experiments in a rat model of cardiac failure that revealed
ĞǆĂĐƚůǇ ĐŽŵƉĂƌĂďůĞ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ƌĞƐƉŽŶƐĞƐ ĨŽƌ ƚŚĞ ɴ1 ? ĂŶĚ ƉƵƚĂƚŝǀĞ ɴ4-
adrenoceptor (Kompa et al., 1999). Finally, studies on cardiac tissues isolated
ĨƌŽŵɴ2ZĂŶĚɴ1 ?ɴ2ZŬŶŽĐŬŽƵƚŵŝĐĞĚĞĨŝŶŝƚŝǀĞůǇĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚƚŚĞɴ1-
adrenoceptor was responsible for the partial agonist effects of CGP 12177
(Kaumann et al., 2001). Several other studies confirmed these findings,
ĚĞƐĐƌŝďŝŶŐ'W  ? ? ? ? ?ĂŶƚĂŐŽŶŝƐƚĞĨĨĞĐƚƐĂƚƚŚĞŚŝŐŚĂĨĨŝŶŝƚǇɴ1-adrenoceptor
ƐŝƚĞ ?ɴ1H ?ƐŝƚĞ ? ?ĂŶĚƉĂƌƚŝĂůĂŐŽŶŝƐƚĞĨĨĞĐƚƐĂƚƚŚĞůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor
ƐŝƚĞ ?ɴ1L ?ƐŝƚĞ ? ?ƚŚĂƚĂƌĞƌĞƐŝƐƚĂŶƚƚŽɴ ?ďůŽĐŬĞƌƐĂƚƚŚĞĐŽŶ ĞŶƚƌĂƚŝŽŶƐƵƐĞĚƚŽ
inhibit isoprenaline-induced agonist effects at the high affinity site (Baker et
al., 2003a; Joseph et al., 2004; Konkar et al., 2000; Pak et al., 1996). The
difference in CGP 12177 affinities at the two sites is at least 1.5 orders of
magnitude (Kaumann et al., 2008). The availability of a radiolabelled version
of CGP 12177 made it an ideal ligand in studies to further understand the two
ɴ1-adrenoceptor sites or conformations. For example, in addition to
establishing two-site binding of [3, ? ?'W  ? ? ? ? ? ƚŽ ƚŚĞ ɴ1-adrenoceptor in
equilibrium binding experiments, Joseph et al. (2004) reported a circa 20-fold
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slower dissociation rate of [3H]-CGP 12177 off the high than off the low
ĂĨĨŝŶŝƚǇɴ1-adrenocptor binding site (Joseph et al., 2004). However, the nature
ŽĨ ƚŚŝƐ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site is still not understood. An effort was
made by Baker et al. (2008) to identify key residues involved in the binding of
ůŝŐĂŶĚƐƚŽƚŚĞŚŝŐŚĂŶĚůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor sites using a site-directed
mutagenesis approach. However, introduced mutations that affected ligand
binding to one site also affected ligand binding to the other site (Baker et al.,
2008). This could be due to structural implications that affect both sites which
may be reflected in co-operativity between the two binding sites. This could,
for example, be the case if the receptor transitioned from one to another
conformation. Perhaps binding of ligand to one site is necessary to facilitate
ƚŚĞ ďŝŶĚŝŶŐ ŽĨ ůŝŐĂŶĚ ƚŽ ƚŚĞ ƐĞĐŽŶĚ ƐŝƚĞ ? ůƚĞƌŶĂƚŝǀĞůǇ ? ɴ1-adrenoceptor
ŚŽŵŽĚŝŵĞƌŝƐĂƚŝŽŶŵĂǇĨĂĐŝůŝƚĂƚĞƚŚĞƚǁŽ ?ƐŝƚĞďŝŶĚŝŶŐɴ1AR pharmacology.
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Figure 1.3 ^ĐŚĞŵĂƚŝĐ ƌĞƉƌĞƐĞŶƚĂƚŝŽŶ ŽĨ ƚŚĞ ƚǁŽ ?ƐŝƚĞ ďŝŶĚŝŶŐ ƐŝƚĞ ŵŽĚĞů ĨŽƌ ƚŚĞ ɴ1-
adrenoceptor. Site a represents the high affinity binding site, whereas site b
represents the low affinity binding site. The nature of the secondary binding site has
not yet been described, and may be a second binding site on the ȕ1-adrenoceptor, an
additional active conformational state of the receptor or possibly an additional ȕ1-
adrenceptor in a homodimeric complex. Taken from Baker et al. (2003).
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1.7 Studying receptor-ligand interactions
1.7.1 Functional assays
The ability of an agonist to activate the receptor and cause a response is
measured in functional assays. Thus, the potency of an agonist in a functional
assay is determined by both its affinity and efficacy. Furthermore, the affinity
of a competitive antagonist can be derived in functional assays from the shift
of the agonist concentration-response curve caused by the presence of a fixed
concentration of antagonist. Functional assay may measure the extent of G
ƉƌŽƚĞŝŶ ĂĐƚŝǀĂƚŝŽŶ  ?'dWɶ^ ĂƐƐĂǇ ? ? Ă ĐŚĂŶŐĞ ŝŶ ůĞǀĞůƐ ŽĨ ƐĞĐŽŶĚ ŵĞƐƐĞŶŐĞƌ
molecules (e.g. cAMP) or the levels of a reporter gene that is transcribed in
response to receptor activation. One of the main considerations for choosing
a given functional readout is the signal:noise ratio, where the minimum (basal)
and maximum response and the difference between those two is defined.
Thus, basal levels of a second messenger in unstimulated cells as well as
breakdown of that molecule need to be taken into account. For example, the
[3H]cAMP accumulation assay uses PDE inhibitors, which prevent the
breakdown of [3H]cAMP, thereby increasing the signal over basal (noise) ratio.
A reporter gene assay is downstream of second messenger production and
takes several hours to allow transcription of the reporter gene (McDonnell et
al., 1998). The reporter gene codes for a protein that has unique properties
(e.g. thermostability, unique substrate for an enzyme, fluorescent or
luminescent properties) which make it easily distinguishable from
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endogenous proteins and easily detectable (Hill et al., 2001). The secreted
placental alkaline protein (SPAP), for example, is thermostable at 65 °C,
whereas endogenous alkaline proteins are not. Therefore, the subsequent
hydrolysis of the substrate p-nitrophenylphosphate (PNPP) to p-nitrophenol
(PNP) is entirely due to SPAP present in the sample, as a result of receptor
activation. The colour change associated with PNPP hydrolysis is then
quantified by measuring the optical density of each sample. The transcription
of a reporter gene is initiated by a transcription factor binding to its
designated promoter region. A CRE promoter is used for SPAP transcription
and is activated as a downstream effect of the cAMP/PKA pathway (Baker et
al., 2004).
However, because gene reporter assay are downstream effects of a signalling
cascade, it is possible that other cellular pathways may interact with the
pathway whose outcomes are being monitored. The presence of serum in cell
culture medium activates the MAP kinase pathway, stimulating cell growth
and proliferation (Hill et al., 2001). This is kept to a minimum by keeping the
cells in serum-free medium for a day before experimentation (McDonnell et
al., 1998). In addition, ligands may interfere with downstream components
and receptors may be desensitised and/or internalised as a result of
prolonged receptor stimulation. This could lead to false potency values, which
is why additional functional assays should be carried out to confirm activity of
a given ligand at the receptor. Whilst there are potential caveats and
interferences with functional assays that monitor downstream responses, it
39
does allow pharmacological analysis of a longer term response and may be
more physiologically relevant (Baker et al., 2003c). Physiological responses
may also be measured in end-organ response assays and include organ bath
studies that, for example, measure the rate and force of cardiac contraction in
isolated tissues.
1.7.2 Conventional radioligand binding techniques
Radiolabelled ligands have been widely used in experimental studies to
examine the binding of ligands to a given receptor. Equilibrium saturation
binding experiments are used to determine the affinity of the labelled ligand
for a receptor. Increasing concentrations of the labelled ligand are used in
these experiments to establish the maximum binding capacity of the ligand to
the receptor which is dependent on the numbers of receptors, thus this
particular technique is also used to gain information on receptor expression in
the system used (Bylund et al., 1993). In classic equilibrium competition
experiments, the unlabelled and labeled ligand compete for the same binding
site on unoccupied receptors. Providing the ligand binding properties of the
labelled ligand are known, the affinities of unlabelled ligands can be derived
in equilibrium binding assays (Cheng, 2001). Time course assays allow the
determination of kinetic parameters of the labelled ligand, and unlabelled
competitor ligands in the presence of the labelled ligand (Motulsky et al.,
1984). Thus, affinity values as well as kinetic parameters of unlabelled ligands
can be obtained using one well-characterised radiolabelled ligand, and this
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has been one of the main approaches to identify new ligands in drug
discovery programs (Noel et al., 2001).
Radioactive isotopes used to label small molecule ligands include the very
small radioisotope 3H, which is not expected to alter the pharmacology of the
ligand of interest. However, bigger isotopes (125I) may be used to label the
ligand of interest, and these may potentially adversely affect the
pharmacology and physicochemical properties of the ligand under
investigation. In either case, full characterisation of the pharmacological
properties of the radiolabelled ligand is required prior to investigations of the
binding properties of unlabelled ligands. Importantly, the use of radioactive
isotopes is associated with strict Health and Safety regulations, as these
substances are harmful to the user and the environment, if not stored,
handled and disposed off appropriately. In light of this, alternative ways of
labelling receptors and ligands have been developed and used, which include
the use of fluorophores.
1.7.3 Fluorescent receptors
Fluorescent proteins (FPs) are circa 27 kDa proteins that absorb light of a
given wavelength (and energy) and emit light at longer wavelength (lower
energy), and, when fused to the protein of interest, have been used to
visualise the distribution of a protein of interest in cells (Deckert et al., 2006)
and tissues (Scherrer et al., 2006). The green fluorescent protein (GFP) was
isolated from the jellyfish Aequorea victoria (avGFP) in 1962 (Shimomura et
41
al., 1962) and cloned in 1992 (Prasher et al., 1992). The wild-type avGFP had
two excitation spectra; a major and minor excitation peak at 395 nm and 475
nm, respectively (Day et al., 2009; Heim et al., 1995). The introduction of one
mutation (S65T) resulted in a shift of the major excitation peak to 490 nm and
increased brightness (Heim et al., 1995). An additional mutation (F64L)
improved the folding efficiency of GFP at 37 °C, resulting in the enhanced GFP
(eGFP) version (Day et al., 2009). The crystal structure of GFP was solved in
1996 (Ormo et al., 1996; Yang et al., 1996), which revealed an eleven-
ƐƚƌĂŶĚĞĚ ɴ ?ďĂƌƌĞů ƐƚƌƵĐƚƵƌĞ ƚŚĂƚ ? ŝŶ ŝƚƐ ĐĞŶƚƌĞ ? ŚŽůĚƐ ƚŚĞ ĐŚƌŽŵŽƉŚŽƌĞ  ? ? ?Ɖ ?
hydroxybenzylidene)imidazolidin-5-one (HBI), which is only fluorescent if
surrounded by a properly folded protein structure (Day et al., 2009).
Mutations that changed residues around the chromophore were found to
shift the fluorescent spectrum of the chromophore, thus resulting in spectral
variants of the enhanced GFP version, including blue FP (eBFP; 383-445nm),
cyan FP (eCFP; 439-476 nm) and yellow FP (eYFP; 514-527 nm) variants (Day
et al., 2009). Additional mutagenesis and engineering studies further
improved brightness, photostability and pH sensitivity of fluorescent proteins
(Day et al., 2009; Sample et al., 2009). In addition, FPs showed tendencies to
form dimers or higher oligomeric complexes, which led to the engineering of
monomeric FPs to avoid artificial aggregation of proteins to which the FPs
were fused (Sample et al., 2009). The palette of fluorescence proteins was
increased when a fluorescent protein was isolated from the sea anemone D.
striata, DsRed, which was excited at 558 nm and emitted at 583 nm. Using a
longer wavelength (i.e. lower energy) laser is better tolerated when working
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with live cells and reduces autofluorescence interference. Extensive
mutagenesis efforts on the DsRed protein led to a series of monomeric red
FPs that emit in the orange (551-575 nm), red (576-610 nm) and far-red (611-
660) spectrum (Sample et al., 2009). Spectral variants of fluorescent proteins
allow the simultaneous labelling of two or more proteins of interest to
monitor their distribution and interaction (Falk et al., 2001; Herrick-Davis et
al., 2006; Overton et al., 2002). The fusion of a 27 kDa protein to a GPCR
protein results in a large fusion protein that is desired to behave in a similar
manner to its untagged counterpart. Indeed, comparable ligand binding
ĂĨĨŝŶŝƚŝĞƐ ǁĞƌĞ ĞƐƚĂďůŝƐŚĞĚ Ăƚ ƚŚĞ '&W ?ƚĂŐŐĞĚ ɴ1 ? ĂŶĚ ɴ2-adrenoceptors and
ɴ1 ?ĂŶĚɴ2-adrenoceptors that were not tagged with GFP (McLean et al., 2000).
,ŽǁĞǀĞƌ ?ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶĂŶĚĚĞŐƌĂĚĂƚŝŽŶŽĨƚŚĞ'&W ?ƚĂŐŐĞĚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ
has been observed to be slower than untagged receptors (McLean et al.,
2000). This may not be unexpected, as the C-terminus of a GPCR plays an
important role in initiating internalisation and degradation processes.
An alternative strategy to fluorescently label a receptor uses the SNAP-tag
that is fused to the N-terminal end of a protein of interest. The SNAP-tag
technology is based on the human DNA repair protein O6-alkylguanine-
transferase (hAGT) which removes an alkyl group from a guanine base of DNA
and transfers it onto a reactive cysteine residue within itself (Figure 1.4) in a
covalent thioether bond (Pegg, 2011). Human AGT (207 amino acids) can also
react with O6-benzylguanine (BG) substrates (Pegg, 2011). Keppler et al. (2003)
first described the use of BG derivatives, such as BG-Fluorescein, for the
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labelling of hAGT fusion proteins in vivo (Keppler et al., 2003). Subsequent
protein engineering led to the smaller 20kDa (180 amino acids) SNAP-tag and
increased enzyme activity compared to wild-type hAGT (Juillerat et al., 2003;
Juillerat et al., 2005; Keppler et al., 2003), thus enhancing specificity of
protein labelling. The observation that the nature of the label does not
influence the reaction rate of hAGT with its substrate led to the synthesis of a
great variety of SNAP-tag fluorescent labels (excitation range from 360-782
nm commercially available), which makes this technology particularly flexible
and adaptable to experimental needs. Another main advantage is the use of
cell impermeable substrates to label SNAP-tagged membrane proteins. The
SNAP-tag is chemically inert to other biomolecules such as double-stranded
DNA and, it is not restricted to a certain subcellular location (Juillerat et al.,
2005). The irreversible and specific labelling of target proteins, which are
preferentially N-terminally fused to the SNAP-tag (Tirat et al., 2006), has been
successfully used, for example, to create an EGFR-specific imaging probe by
fusing the SNAP-tag to a single-chain antibody fragment (Kampmeier et al.,
2010). The applications of the SNAP-tag have been broadened with the
engineering of the CLIP-tag, which is another hAGT mutant. Gautier et al.
(2008) introduced eight mutations to redesign the active site of the SNAP-tag,
resulting in specificity for benzylcytosine (BC) derivatives (Gautier et al., 2008).
Using the CLIP-tag in conjunction with the SNAP-tag allows the simultaneous
labelling of target proteins with two different fluorophores for co-localisation
purposes as well as protein-protein interaction studies.
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Alternative peptide- and protein-tags include His-tag (6 amino acids, oligo-
histidine sequence that binds to nickel or cobalt and uses nickel-
nitrilotriacetic acid fluorophores such as NTA-FITC-Ni2+) and HaloTagΡ (297
amino acids, mutated haloalkane dehalogenase that covalently binds
fluorescent haloalkane ligands) to label proteins of interest (Bohme et al.,
2009; Los et al., 2008). Fluorescently labelled antibodies may also be used
that either directly or indirectly (i.e. one or two antibody method) recognise a
specific epitope which may be a part of the receptor of interest or an
engineered tag such as HA-tag, FLAG-tag or c-myc-tag at the N-terminus of
the receptor (Bohme et al., 2009). Most fluorescent tags require the fusion of
the tag to the protein of interest, which involves generation of a DNA
construct and its transfection into a host cell line, thus this method does not
have the potential of labelling native receptor in native cells, but is invaluable
in establishing an understanding of fundamental properties of cellular and
membrane-bound proteins.
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Figure 1.4 Schematic representation of the SNAP-tag labelling reaction. The
benzylguanine (BG) SNAP-tag substrate is linked to a fluorophore. In a suicide
reaction by the SNAP-tag, the fluorophore is covalently linked to the SNAP-tag, thus
labelling the receptor. The reaction releases a free guanine molecule. Taken from
Tirat et al. (2006).
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1.7.4 Fluorescent ligands
Fluorescently labelled ligands are being used increasingly (Baker et al., 2003d;
Daly et al., 2010; May et al., 2010a; Stoddart et al., 2012) as they are not only
a safer alternative to radiolabelled ligands, but also allow visualisation of
ligand binding to the receptor in living cells and can be used to label native
receptors in primary cells. In addition, it may not always be possible to label a
ligand of choice with a radioactive isotope, or a radioligand for a given
receptor may not be commercially available. A fluorescent ligand is
synthesized by chemically coupling the ligand of interest to a fluorophore. The
fluorophore itself is a similar size to a small molecular weight ligand, thus its
addition to the pharmacophore structure can dramatically alter the ligands
pharmacological profile at a given receptor (Middleton et al., 2005). A linker
may be used to space apart the pharmacophore and the fluorophore in an
attempt to avoid interference with the ligand binding to and activating the
receptor (Baker et al., 2010; Middleton et al., 2005). Interestingly, the affinity
of a ligand may not only be reduced, but may be improved when labelled with
a fluorophore (Vernall et al., 2012). However, there are no definitive
guidelines of point of fluorophore attachment, linker length and composition
that will guarantee a fluorescent ligand of low nanomolar affinity, making the
synthesis of a functional fluorescent ligand a potentially lengthy process.
However, there are many advantages to using a fluorescent ligand over a (not
necessarily easier to synthesise) radioligand that include (1) visualisation of
total and non-specific levels of ligand binding, (2) localisation of receptor
distribution, (3) use in single cell and single molecule studies and (4) labelling
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of endogenous receptors in primary cells. The investigation of ligand-receptor
interactions in a physiologically relevant environment is perhaps the most
important feature, as there is a growing appreciation of the effect of other
receptors, cellular signalling and scaffolding proteins on the signalling
pathway that is initiated (Kenakin et al., 2010; Williams et al., 2009). In
contrast, most radioligand binding assays were done in membrane
preparations, where the membrane structure was disrupted and most
intracellular components were lost. Fluorescent ligands have been used in
binding experiments in low and medium throughput formats (Baker et al.,
2003d; Loison et al., 2012; Stoddart et al., 2012) and in kinetic binding
experiments at the single cell level (May et al., 2010a; May et al., 2011). As
with radioligands, not just antagonist, but also agonists may be fluorescently
labelled. This allows the specific labelling of different receptor conformations
(active and inactive) by using low concentrations of the agonist or antagonist,
as has been done in studies on the A3 adenosine receptor (Cordeaux et al.,
2008). To date, fluorescently labelled noradrenaline, CGP 12177 and
ƉƌŽƉƌĂŶŽůŽůŚĂǀĞďĞĞŶƵƐĞĚŝŶƚŚĞůŝƚĞƌĂƚƵƌĞƚŽůĂďĞůɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?ĂŬĞƌ
et al., 2011a; Baker et al., 2003d; Prenner et al., 2007). Baker et al. (2003)
described the pharmacology and binding properties of the fluorescent
ĂŶĂůŽŐƵĞ ŽĨ 'W  ? ? ? ? ? ? K/Wz ?dDZ ?'W ? Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ2-adrenoceptor
expressed in Chinese hamster ovary cells, whereas Briones et al. (2005) used
ƚŚŝƐ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĚŝƐƚƌŝďƵƚŝŽŶ ŝŶ ƚŚĞ
vascular wall of mesenteric rat artery tissues (Briones et al., 2005). However,
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the pharmacological properties of BODIPY-TMR-CGP have not yet been
ĐŚĂƌĂĐƚĞƌŝƐĞĚĂƚƚŚĞɴ1 ?ĂŶĚɴ3-adrenoceptors.
1.7.5 Fluorescent imaging techniques
Fluorescently labelled proteins and ligands can be used in a variety of
microscopy assays to investigate ligand binding, receptor internalisation and
trafficking and protein-protein interactions in real time in living cells.
Binding assays
In principle, the same binding assays that use radiolabelled ligands can be
performed using fluorescently labelled ligands in conjunction with confocal
fluorescence microscopy, and saturation, competition and kinetic binding
assays have been carried out on recombinant cells (Baker et al., 2003d; May
et al., 2010a; May et al., 2011; Stoddart et al., 2012). Fluorescence based
screening assays have the potential to be used in medium- and high-
throughput ligand screening formats (Nomura et al., 2008; Stoddart et al.,
2012). As with radioligands, the total and non-specific binding properties of a
fluorescent ligand will have to be well defined before it is used in competition
binding assays to determine affinity values of competitor ligands. To further
ensure ligand binding specificity, the fluorescent ligand may be used in
binding experiments on cells expressing a fluorescently tagged receptor (May
et al., 2011). In this set-up, the main considerations are to use two
fluorescent labels that are spectrally separated as far as possible. This will
avoid fluorescence bleed-through, which describes the fluorescence spectrum
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of one fluorophore artificially being registered in the fluorescence readout of
the second fluorophore (e.g. the emission fluorescence of the tagged receptor
bleeds through the optical filter used to capture emission for the
fluorescent ligand, thus recording a false level of ligand binding). If possible,
the optical filters used can also be adjusted accordingly to help avoid
fluorescence bleed-through. Fluorescently labelled ligands may be used alone
or in conjunction with fluorescently tagged receptors in single molecule ligand
binding studies using fluorescence correlation spectroscopy (FCS) and
fluorescence cross correlation spectroscopy (FCCS), respectively (Briddon et
al., 2007). FCS records the fluctuations in fluorescence intensities that are
caused by fluorescently labelled species (free ligand, ligand-bound receptor)
moving through a small defined confocal volume (~0.3 fL) that can be placed
anywhere in the cell (e.g. spanning the cell membrane). Free ligand and
ligand-bound receptor species are then separated based on their different
dwell times, i.e. a small free ligand moves faster through the detection
volume than a much larger ligand-bound receptor that is embedded in the
cell membrane. Since free and bound ligand can be clearly quantified, binding
properties of ligands to receptors in distinct membrane environments can be
determined (Briddon et al., 2007).
Functional assays
Fluorescence confocal microscopy is also used to investigate functional
ƌĞƐƉŽŶƐĞƐƚŽĂŐŽŶŝƐƚƐŝŶůŝǀŝŶŐĐĞůůƐŝŶƌĞĂůƚŝŵĞ ?ƐƐƵĐŚ ?ƚŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?
arrestin to the receptor or the internalisation of a fluorescently labelled
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receptor may be monitored in single cells or in cell populations (Kilpatrick et
al., 2010; Stoddart et al., 2012). The trafficking of multiple proteins labelled
with wavelength-separated fluorophores may be observed in response to
different ligands (Serge et al., 2011; Teichmann et al., 2012; Wagener et al.,
2009). Some studies have also used fluorescent second messengers (e.g. Ca2+
binding to the green fluorescent Fluo-4 dye enhances its fluorescence) in
conjunction with fluorescent ligands in a combined binding and functional
assay, thus investigating the dynamics of ligand-induced responses (Cordeaux
et al., 2008).
Protein-protein interactions
When two fluorescently labelled species (e.g. a ligand and a receptor) are
detected using two different ligands, overlapping (or merging) of the two
captured images reveals areas (pixels) in which both fluorescent species were
detected and are thus colocalised in that area. This infers that the two species
are in close proximity to one another. Colocalisation coefficients are routinely
used in cell biology studies to also indicate a biological interaction based on a
statistically significant relationship between the fluorophores detected per
pixel (Zinchuk et al., 2007).
Förster and bioluminescence resonance energy transfer techniques (FRET and
BRET, respectively) are often used to determine potential interactions
between two proteins. In FRET, two proteins thought to be interacting with
one another are fused to a donor (e.g. CFP) and acceptor (e.g. YFP)
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fluorescent protein that have a partial emission/excitation spectral overlap.
Only the donor fluorophore is excited using a laser, as the photons emitted by
the donor fluorophore then excite the acceptor fluorophore. This transfer of
energy from one to the other fluorophore is only possible if the two
fluorophores are in close proximity to one another (within 10 nm). Thus, if the
two proteins interact with one another and are in close proximity to each
other, YFP fluorescence increases, whereas CFP fluorescence decreases, and
vice versa (Fernandez-Duenas et al., 2012). The same principle is applied in
BRET assays, where a bioluminescent Renilla reniformis luciferase (Rluc)
enzyme is used as a donor and GFP is used as the acceptor protein (Salahpour
et al., 2012). Rluc produces the initial photon emission upon degradation of
its substrate coelenterazine (Salahpour et al., 2012). FRET and BRET assays
have been used to detect ligand-receptor, receptor-receptor and receptor-
protein interactions (Audet et al., 2010; Canals et al., 2004; Gales et al., 2005;
Loison et al., 2012; Milligan, 2004). Another approach to detecting protein-
protein interactions is bimolecular fluorescence complementation (BiFC),
where the N-terminal and C-terminal non-fluorescent half of a fluorescent
protein (e.g. YFPN and YFPC) are fused to two interacting proteins. Upon
interaction of the two proteins (e.g. receptor dimerisation), the two YFP
halves reconstitute to a full length YFP that is fluorescent (Figure 1.5). Thus,
detection of YFP fluorescence indicates protein-protein interactions (Ciruela
et al., 2010). For example, oligomerisation of adenosine A2AƌĞĐĞƉƚŽƌƐĂŶĚɴ2-
adrenoceptors have been shown using BiFC (Kilpatrick et al., 2012; Vidi et al.,
2010). The process of reconstitution of the full length fluorescent protein is
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irreversible, and as such does not allow the investigation of the dynamics of
receptor-receptor interactions. N-terminal fluorescence tags, such as SNAP
and CLIP-tags, can also be used in any of the above fluorescence microscopy
experiments (Fernandez-Duenas et al., 2012). For example, the SNAP-tag
technology has been used in combination with FRET to establish receptor-
receptor and ligand-receptor interactions (Leyris et al., 2011; Maurel et al.,
2008). In addition, SNAP and CLIP-tag specific cross-linking has been proposed
by Gautier et al. (2009), where two different SNAP and CLIP-tagged proteins
can be covalently linked by a specific cross-linking BG-BC substrate when the
two tags are in close proximity to one another (Gautier et al., 2009; Reymond
et al., 2011). Furthermore, a split SNAP-tag protein complementation method
has been reported that can be used in a BiFC approach (Mie et al., 2012).
When designing any of the above experiments, the expression levels of the
two potentially interacting proteins introduced into a cell system has to be
optimized to avoid random aggregation of these proteins leading to false RET
or BiFC signals. Similarly, fluorescence bleed-through in FRET has to be
avoided and FRET of known non-interacting proteins should serve as a
negative control (Fernandez-Duenas et al., 2012).
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Figure 1.5 Schematic diagram of the principle of bimolecular fluorescence
complementation (BiFC). Two non-fluorescent N- and C-terminal halves (YFPN and
YFPC) of the yellow fluorescent protein tagged to two proteins of interest
reconstitute upon interaction of these two proteins. The reconstituted YFP is fully
functional and its fluorescence can be detected in fluorescence microscopy
applications.
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1.8 Aims
The aim of this thesis was to investigate the nature of the secondary binding
ƐŝƚĞŽĨƚŚĞŚƵŵĂŶɴ1-adrenoceptor using a confocal microscopy approach. As
ĚĞƐĐƌŝďĞĚ ĂďŽǀĞ ? ƚŚĞ ĐŽŵƉůĞǆ ƉŚĂƌŵĂĐŽůŽŐǇ ŽĨ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ɴ1-
adrenoceptor is well documented in the literature and has now been firmly
ĂƚƚƌŝďƵƚĞĚ ƚŽ ƚŚĞ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ƌĂƚŚĞƌ ƚŚĂŶ Ă ĨŽƵƌƚŚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ?/ƚ ŝƐ
ƉƌŽƉŽƐĞĚƚŚĂƚƚŚĞɴ1-adrenoceptor has two binding sites through which the
different effects of CGP 12177 are exerted, and affinity values of multiple
ligands have been established at both sites. However, the nature of the
secondary site is not yet understood as a mutagenesis study aiming to identify
key residues of either binding site was inconclusive. In this thesis we aimed to
use the fluorescently labelled CGP 12177 analogue BODIPY-TMR-CGP in
conjunction with confocal microscopy approaches to further investigate the
ůŝŐĂŶĚ ?ƌĞĐĞƉƚŽƌ ŝŶƚĞƌĂĐƚŝŽŶƐ Ăƚ ƚŚĞ ɴ1-adrenoceptor with the view to gain
ŝŶƐŝŐŚƚŝŶƚŽƚŚĞŶĂƚƵƌĞŽĨƚŚĞƐĞĐŽŶĚĂƌǇɴ1-adrenoceptor site.
55
Chapter 2
Materials and Methods
56
2.1 Materials
,K ?< ? ?,K ?Z^WWĐĞůůƐ ?,K ?ɴ1 ?^WWĂŶĚ,K ?ɴ2-SPAP cells were a kind
gift from Dr Jillian G Baker. All cell culture hardware was purchased from
Fisher Scientific (Loughborough, UK) and all medium reagents, including
phosphate-buffered saline (PBS), were from Sigma Aldrich (Gillingham, UK)
except for foetal calf serum (FCS), which was obtained from PAA laboratories
(Pasching, Austria). The chemicals diethanolamine (DEA), NaCl, MgCl2.6H2O,
HCl, KCl, MgSO4, HEPES, sodium pyruvate, NaHCO3, CaCl2, NaOH, Tris-Base,
Boric acid, EDTA, PNPP and DMSO were obtained from Sigma Chemicals
(Poole, UK). The SNAP-tag vector and the SNAP-SurfaceΡ Alexa Fluor® 488
were obtained from New England Biolabs (Ipswich, MA, USA). All
oligonucleotide primers used in this study were synthesized by Eurogentec
(Seraing, Belgium). PolyMate Additive was purchased from Bioline (London,
UK). The GenEluteΡ miniprep, maxiprep, gel extraction and PCR purification
kits were purchased from Sigma Aldrich (Gillingham, UK). The QuikChangeΡ
site-directed mutagenesis kit was purchased from Stratagene (Amsterdam,
Netherlands). Lipofectamine, competent Top10 F E. coli cells, SOC media and
the pcDNA3.1(Neo+) and pcDNA3.1(Zeo+) vectors were from Invitrogen
(Paisley,UK). All restriction enzymes, Pfu Ultra DNA polymerase and the 1 kb
DNA ladder were purchased from Promega (Madison, WI). All other molecular
biology reagents were from Sigma (Gillingham, UK). All DNA sequencing was
done by the DNA Sequencing Laboratory, School of Biomedical Sciences at the
University of Nottingham. The compounds forskolin, isoproterenol
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hydrochloride (isoprenaline), cimaterol, (S)-(-)-propranolol hydrochloride, CGP
20712A dihydrochloride and ICI-118,551 were from Tocris Cookson
(Avonmouth, Bristol, UK). The fluorescent CGP 12177 analogue BODIPY-TMR-
CGP was obtained from Dr Jill Baker who had originally purchased this
compound from Molecular Probes (Eugene, OR). The fluorescent propranolol
derivative BODIPY630/650-S-PEG8-propranolol was purchased from CellAura
(Nottingham, UK). The [3H]-adenosine was from Amersham Biosciences UK,
Ltd. (Buckinghamshire, UK), the poly-prep columns were from Bio-Rad
(Hercules, CA), and the scintillation fluid was from PerkinElmer (Groningen,
Netherlands). All other chemicals were obtained from Sigma Aldrich
(Gillingham, UK).
2.2 Cell culture
The Chinese hamster ovary (CHO) CHO-K1 cell line, a proline-deficient
subclone from the original CHO line (which was first isolated by Puck et al.
(1958)), was used in experiments throughout this thesis. The CHO-K1 cell line
exhibits epithelial morphology and grows in an adherent monolayer. They
were maintained in Dulbeccos modified Eagles medium nutrient mixture F12
(DMEM/F12) medium supplemented with 10 % foetal calf serum (FCS) and 2
mM L-glutamine (=growth medium) in cell culture incubators maintaining a
humidified atmosphere of 5 % CO2/ 95 % air. All cell culture techniques were
carried out in class II laminar flow cell culture hoods. All cell culture medium
and solutions used were pre-warmed in a 37 °C water bath before use to
avoid any harsh temperature changes and stress to the cells. Following
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passaging of cells into cell culture flasks and seeding of cells into plates for
experimentation, the cells were returned to the cell culture incubator (37 °C,
5 % CO2/95 % air atmosphere) to allow cells to adhere and grow until used for
further passaging or experimentation.
Passaging of cells
The cells used in this study were generally maintained in 75 cm2 tissue culture
treated flasks (T75s) and grown to confluence. For passaging, the growth
medium was removed from the flask and cells were washed with 5-10 mL
phosphate buffered saline (PBS) to remove any remaining serum off the cells
and the flask. Cells were lifted off the bottom of the flask by incubation in 1
mL 1x trypsin-EDTA at 37 °C in a cell culture incubator. Trypsin is a serine
protease and is used here to hydrolyse proteins that facilitate the adherence
of the cells to the cell culture dish. After 2-3 minutes the cells were loosened
and easily dislodged by the addition of 5 mL growth medium, which also
prohibited any further action of trypsin on the cells. The cells were then
centrifuged at 1000 rpm for 5 minutes and the supernatant discarded. The
cell pellet was then resuspended in 10 mL growth medium and the
appropriate amount was transferred into a new T75 flask. Cells were routinely
passaged at a 1:10-1:20 dilution once a week. Multiple flasks were gained
from one T75 to keep the passage number low and flasks were used for
experiments the next week.
Seeding cells into plates
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96-well plates
Cells were seeded into 96-well plates for CRE-mediated SPAP transcription,
ImageXpress (IX) Ultra confocal plate reader and PHERAstar FS plate reader
experiments. The cells from one T75 flask were detached from the bottom of
the flask as described above (see above Passaging of cells). The cell pellet was
then resuspended in 10 mL growth medium and 2 mL of this was then
transferred to a further 8 mL of growth medium (to make up 10 mL in total,
i.e. a 1:5 dilution). Of that, 100 µL were transferred into each well of a 96-well
plate (0.3 cm2 surface area per well). The same dilution (1:5) was used for
CRE-mediated SPAP transcription, IX Ultra confocal and PHERAstar FS plate
reader experiments, however, cells for SPAP gene reporter experiments were
plated out 48 hours prior to experimentation and cells for IX Ultra confocal
and PHERAstar FS plate reader experiments were seeded 24 hours prior to
experimentation. This was done to allow cells for SPAP gene reporter
experiments to be serum starved 24 hours prior to experimentation.
24-well plates
The cells were prepared into a 10 mL cell resuspension as described above for
96-well plates. The same dilution (1:5) was prepared and 500 µL of a 10 mL
cell suspension was added to each well of a 24-well cell culture plate (2cm2
surface area per well) for [3H]cAMP accumulation experiments. Cells seeded
into these plates were used for experimentation the following day.
6-well plates
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6-well cell culture plates were used to seed cells to be used in confocal
perfusion experiments. A circular (3.2 cm in diameter) glass coverslip was
placed into each well of a 6-well plate. Cells of one T75 flask were lifted off
the bottom of the flask as described above (see above Passaging of cells). The
cell pellet was then resuspended in 6 mL of growth medium, of which 2 mL
(for a 1:3 dilution) were transferred to a further 10 mL of growth medium (for
a total of 12 mL). 2 mL of this cell suspension were then transferred onto the
glass coverslips in each well of a 6-well plate (9.6 cm2 surface area per well).
The seeded cells were used in experiments the following day.
8-well glass chambers
Cells were prepared into a 10 mL resuspension as described above for 96-well
plates and seeded into 8-well Labtek borosilicate chambered-coverglass
plates (Nalgene Nunc International, Fisher Scientific, Loughborough, UK) for
confocal microscopy experiments. From the 10 mL cell suspension, 1 mL was
transferred into a further 19 mL of growth medium (1:20 dilution). From this
cell suspension, 400 µL were added to each well of an 8-well plate. The cells
were used in confocal imaging experiments two days after seeding.
Long term storage and thawing of cells
Foetal calf serum was supplemented with 10 % (v/v) DMSO (to constitute the
freezing medium) in the cell culture hood and subsequently sterilised by
filtration using a 10 mL syringe and a 0.2 µm sterile filter. The cryoprotective
agent DMSO prevents damage to cell walls by ice crystals that form during the
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freezing process, thus improving cell viability and recovery after thawing. Cells
to be frozen were detached from the bottom of a T75 flask and spun as
described above (see Passaging cells). The cell pellet was then resuspended in
2 mL of freezing medium by careful trituration before aliquoting 1 mL of the
cell suspension into a 2 mL labelled cryogenic tube. Thus, one T75 flask of
confluent cells generated two aliquots of cells in freezing medium. The tightly
capped cryogenic tubes were then put into an isopropanol-filled cryogenic
freezing container that allows controlled and gradual freezing of the cells at a
rate of 1 °C per minute in the -80 °C freezer. After 24 hours, the cryogenic
tubes were then placed into liquid nitrogen (-176 °C) for long term storage.
Cells in cryogenic tubes were taken out of liquid nitrogen storage and the
tubes were thawed in a 37 °C water bath (for circa 2 minutes). The cells were
then immediately placed into a T75 flask containing 20 mL pre-warmed
growth media. Working as quickly as possible reduces the risk of prolonged
stress for the cells and aids the survival and recovery of a larger proportion of
cells. The cells in the T75 flask were placed into the cell culture incubator at
37 °C and in a 5 % CO2/95 % air atmosphere. The following day, the growth
medium was replaced by fresh growth medium to remove any cell debris
from cells that had died during the thawing process. Cells were grown to
confluence and passaged once before being used for experimentation.
2.2 Generation of new cell lines
62
Cells used for transfection were either CHO-K1 cells or a clonal cell line of CHO
cells already expressing the CRE-SPAP (CS) reporter gene construct (CHO-CS
cells). These cells were cultured in T25 flasks to be able to use a lower amount
of DNA and the transfection agent lipofectamine.
Transfection of cells to generate a stable mixed population cell
line
The DNA used in transfections was a circular eukaryotic expression plasmid
(pcDNA3.1) consisting of the desired receptor (e.g. human ȕ1-adrenoceptor)
and an antibody resistance gene (e.g. neomycin). The DNA was in solution (in
double-distilled H2O) and the concentration determined using a UV
spectrophotometer (see Molecular biology: Maxi-prep). The transfection
agent used was lipofectamine, a lipophilic agent that coats the DNA, making it
more membrane permeable to facilitate the uptake of the DNA. Two
solutions were prepared:
Solution A = 3 µg DNA + OPTIMEM (to make up a total of 300 µL)
Solution B = 30 µL lipofectamine + 270 µL OPTIMEM
The two solutions were combined (= transfection mix; total volume 600 µL)
and left at room temperature for 1.5 hours.
After 1 hour, the growth medium on cells that were grown to 60-70 %
confluence in a T25 flask, was replaced with 3 mL OPTIMEM medium and the
cells were incubated for 30 minutes at 37 °C in a 5 % CO2/95 % air atmosphere.
Following this, the transfection mix was added to the cells and the cells were
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incubated at 37 °C in a 5 % CO2/95 % air atmosphere for 24 h to allow the
uptake of DNA by the cells. The next day the OPTIMEM media containing the
transfection mix was removed and the cells were washed by the addition and
removal of 10 mL DPBS to remove any cells that died during the transfection
process, and replaced with 10 mL of fresh growth media to allow the cells
that survived to recover. Cells that recovered from the transfection process
would start to express the new proteins and thus, the selection process was
started the next day.
Selection for the transfected cells was started 24-48 hours after transfection
by replacing the growth medium with growth medium supplemented with the
relevant antibiotic (e.g. 1 mg/mL geneticin (G418) or 500 µg/mL zeocin;
=selection medium). Successfully transfected cells will express the desired
receptor and the antibiotic resistance gene. Antibiotic resistance allows the
cell to survive the cytotoxic effects of a given antibiotic. This treatment
caused death of cells not expressing the transfected construct. In addition,
cells that have not incorporated the transfected construct into the nuclear
DNA of the cell, but only transiently (e.g. in the cytoplasm) expressed the
antibiotic resistance protein, would also not survive the antibiotic treatment
past a few division cycles. Thus, only cells that have incorporated the
transfected construct into their nuclear DNA have the means for survival.
However, the insertion of the external DNA is a random process and may
disrupt DNA sequences essential to the survival and growth of the cell, in
which case this cell will also not survive. The same would be the case for cells
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in which the transfected construct was inserted into an inactive region of the
DNA, thus resulting in very low (or no) transcription of the introduced
sequences. Every couple of days, the selection medium was replaced with
fresh selection medium to remove cells that had died during the selection
process. After 1-2 weeks, the cells were passaged and placed into a new T25
flask. When the rate of cell death declined and the cell population grew
confluent, the cells were moved to a T75 flask and grown to confluence. This
cell population was a mixed population stable cell line where every cell
expressed the new proteins at a different level.
Dilution cloning and generation of a stable clonal cell line
When it was desired to generate a stable clonal cell line, the mixed population
cell line was grown to confluence and the cells were detached from the
bottom of the flask and centrifuged as described above (see Passaging cells).
The cell pellet was resuspended in 20 mL growth media, and 20 µL were
transferred into another 20 mL of growth medium. From that cell suspension,
100 µL and 120 µL were added to 20 mL of selection media, generating final
200,000- and 167,000-fold dilutions. 200 µL of each dilution was transferred
into 96 wells of a 96-well plate (i.e. one plate per dilution) with the aim to
place only one cell into each well, thus isolating a single cell that can be grown
into a clonal cell line. Both dilutions used here resulted in 0-3 cells per well.
After 48 hours, both 96-well plates were examined and the number of cells
counted in each well. Only wells containing one cell were marked and re-
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examined 48 hours later. Most of the single cells had grown into small
colonies (= a clone) which were left to grow to about 40-50 % confluence in
the well. At this stage, the cells tend to grow on top of each other rather than
in a defined monolayer which means that 100 % confluence is unlikely to be
achieved. The selection medium was then removed from the wells containing
single colonies and the cells were washed by addition and removal of 100 µL
DPBS. Then, 100 µL trypsin was added to each marked well. After 2-3 minutes,
the trypsin was pipetted up and down to loosen the cells off the bottom of
the well. The trypsin and the cells were then added to 1 mL selection media in
a well of a 24-well plate (1:7 dilution by surface area difference). This was
done for all wells that were marked to contain a single cell colony. Once
confluent in the 24-well plate, the cells were moved to 6-well plates (1:5
dilution) and then to T25 flasks (1:3 dilution) and finally to T75 flasks (1:3
dilution). From there each clone was tested for the presence and functionality
of the transfected gene of interest.
Transient transfection of cells
CHO-K1 cells were seeded into assay plates/flasks and grown to 60-70 %
confluence. Transient transfections were then carried out in the same manner
as described for transfections to generate stable cell lines (see above), but the
volumes of the reagents were adjusted as outlined in Table 2.1. Following
transfection and incubation of cells in a cell culture incubator at 37 °C
overnight, the cells were not exposed a selection medium, resulting in a cell
population where not all cells have taken up the DNA construct. Cells that
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have taken up the DNA construct will only express the proteins encoded in
the DNA construct transiently (and each cell will do so at a different level), i.e.
do not incorporate the DNA into their nuclear DNA. This is mainly due to time
limitations as cells that are transiently transfected, are used for
experimentation within the next couple of days.
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Table 2.1 Volumes of reagents used to transiently transfect CHO-K1 cells seeded into
8-well plates, 6-well plates and T75 flasks. The amount of DNA used is total amount
for the entire 8-well and 6-well plate assuming transfection of cells in all 8 and 6
wells, respectively. The total volume is the combined volume of solution A and B.
8-well plate 6-well plate T75 flask
Solution A
Total DNA 1.2 µg 4.5 µg 10 µg
OPTIMEMmedium 200 µL 300 µL 300 µL
Solution B
Lipofectamine 20 µL 50 µL 100 µL
OPTIMEMmedium 260 µL 850 µL 600 µL
Total volume 480 µL 1.2 mL 1 mL
Addition per well/flask 60 µL 0.2 mL 1 mL
Final volume per well/flask 300 µL 2 mL 10 mL
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2.3 Molecular Biology
Generation of a SNAP-tagged receptor fusion protein
For experiments carried out for this thesis, the SNAP-tag was fused to the N-
ƚĞƌŵŝŶƵƐŽĨƚŚĞŚƵŵĂŶɴ1-adrenoceptor (accession number: NM_000684) to
ŐĞŶĞƌĂƚĞĂ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein. To achieve this, the
ƐƚĞƉƐ ŽƵƚůŝŶĞĚ ďĞůŽǁ ǁĞƌĞ ĨŽůůŽǁĞĚ ƚŽ ŝŶĐŽƌƉŽƌĂƚĞ ƚŚĞ ɴ1AR sequence
(=insert) into a pcDNA3.1(Neo) plasmid (=vector) that already contained the
SNAP-tag sequence (pcDNA3.1(Neo)-SNAP; kindly provided by Dr Holliday;
SNAP-tag sequence between KpnI and BamHI restriction enzyme sites).
Polymerase chain reaction
&ŝƌƐƚ ? ƚŚĞ ƉŽůǇŵĞƌĂƐĞ ĐŚĂŝŶ ƌĞĂĐƚŝŽŶ  ?WZ ? ǁĂƐ ƵƐĞĚ ƚŽ ĂŵƉůŝĨǇ ƚŚĞ ɴ1AR
receptor DNA sequence. Two short oligonucleotides (primers) were used to
hybridize to the sequences at the start (forward primer) and end (reverse
ƉƌŝŵĞƌ ? ŽĨ ƚŚĞ ɴ1AR DNA sequence, thus defining the DNA region that was
amplified. The sequence of these primers is complementary to the start and
end of the sequence to be amplified. In addition, the primers were designed
to introduce BamHI (GGATCC) and EcoRI (GAATTC) restriction enzyme sites
(short DNA sequence that are recognized by restriction enzymes which cut
ƚŚĞ E Ăƚ ƉƌĞĐŝƐĞůǇ ƚŚĂƚ ƐŝƚĞ ? ŝŵŵĞĚŝĂƚĞůǇ ďĞĨŽƌĞĂŶĚ ĂĨƚĞƌ ƚŚĞ ɴ1AR
ƐĞƋƵĞŶĐĞ ? ƌĞƐƉĞĐƚŝǀĞůǇ ? dŚŝƐ ĂůůŽǁĞĚ ƚŚĞ ŝŶƐĞƌƚŝŽŶŽĨ ƚŚĞ ɴ1AR sequence
exactly downstream of the SNAP-tag sequence in the plasmid vector (see
ǀĞĐƚŽƌŵĂƉŝŶ&ŝŐƵƌĞ ? ? ? ? ?ƚŚƵƐĨƵƐŝŶŐƚŚĞ^EW ?ƚĂŐƚŽƚŚĞɴ1-adrenoceptor.
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Figure 2.1 Map of the pcDNA3.1(Neo+/-) plasmid vector. The SNAP-tag sequence
was inserted between the KpnI and BamHI restriction enzyme site in the
ƉĐE ? ? ? ?EĞŽ ? ?^EW ǀĞĐƚŽƌ ƵƐĞĚ ŚĞƌĞ ? ŽŶƐĞƋƵĞŶƚůǇ ?ƚŚĞ ɴ1AR sequence was
inserted between the BamHI and EcoRI restriction sites to generate a continuous
^EW ?ɴ1AR sequence. This schematic (including the vector composition details) was
taken from the invitrogenΡ life technologies website (www.invitrogen.com).
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Other considerations when designing the PCR primers included (1) an
overhang sequence (increases restriction enzyme activity on the target
sequence fragment), (2) a mismatch to mutate the receptor start codon (to
allow continuous transcription of the fusion protein DNA sequence) and (3)
length of the primer sequence that directly compliments the target DNA (i.e.
ƐĞƌǀĞĚ ĂƐ ĂƉƌŝŵĞƌ ? ĐŝƌĐĂ  ? ?ďĂƐĞƐ ? ? dŚĞ ĚĞƐŝŐŶĞĚ ɴ1AR forward and reverse
primers used for this PCR process were 5  CCGCC/GGATCC/CTG GGC GCG
GGG GTG CTC G  3 (18 complementary bases, 66 °C) and 5 
GGCGG/GAATTC/CTA CAC CTT GGA TTC CGA GG  3 (20 complementary
bases, 62 °C), respectively. The melting temperature (Tm) of primers that form
correctly base-paired hybrids was calculated using the following equation:
܂ܕ = ൫૝ܠ[۵+ ۱] + (૛ܠ[ۯ+ ܂])൯°۱ (eq. 1)
For the PCR mixture, 50 ng of template DNA (kindly provided by Dr Baker) was
used. To this, 125 ng of each primer, 10 mM dNTP (final concentration;
containing the four deoxyribonucleotide triphosphates dATP, dTTP, dCTP,
dGTP), 1 unit of proof-reading Pfu DNA polymerase and 10x Pfu DNA
polymerase compatible buffer (1x final concentration) were added to a 200 µL
clear thin-walled flat-capped PCR tube. 2x PolyMate Additive (1x final
concentration) was also added to the PCR mixture to reduce the formation of
ƐĞĐŽŶĚĂƌǇ ƐƚƌƵĐƚƵƌĞƐ ŽĨ ƚŚĞ ' ƌŝĐŚ ɴ1AR template DNA. Finally, ddH2O was
added to make up a total volume of 50 µL. A control PCR mixture containing
exactly the same components but without the template DNA (the volume of
the ddH2O was adjusted accordingly), was also prepared to highlight potential
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contamination of the PCR sample. The PCR mixture was then placed in an
Eppendorf Mastercylcer® Gradient thermal cycler that controls the
temperature and time of each step of a PCR cycle. A PCR cycle (Figure 2.2)
starts with the denaturation step (95 °C, 1 minute), where the two strands of
the double stranded template DNA was separated into single strands. The
temperature was then cooled to 61 °C for 1 minute to allow the primers to
ĂƚƚĂĐŚ ƚŽ ƚŚĞ ĂƉƉƌŽƉƌŝĂƚĞ ƉŽƐŝƚŝŽŶƐ ŽŶ ƚŚĞ ɴ1AR DNA sequence (i.e.
hybridization step). The annealing temperature is ideally 1-2 °C lower than the
lowest melting temperature of the primers used, to favour specific primer-
template hybrid to form (this temperature should be too high for mismatched
hybrids). Lastly, the primer extension step in the PCR cycle is performed at the
optimal temperature of the thermostable Pfu DNA polymerase (72 °C, 3
minutes), which synthesises complementary strands along each single
ƚĞŵƉůĂƚĞƐƚƌĂŶĚĂƐĂŶĞǆƚĞŶƐŝŽŶŽĨƚŚĞƉƌŝŵĞƌƐŝŶ  ? ?AP ? ?ĚŝƌĞĐƚŝŽŶ ?dŚŝƐWZ
cycle was repeated 29 times generating 230 ůŝŶĞĂƌ ĐŽƉŝĞƐ ŽĨ ƚŚĞ ɴ1AR
sequence from each double-stranded template DNA molecule.
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Figure 2.2 Schematic representation of the steps involved in the PCR cycle. Double-
stranded template DNA was denatured into single strands to which the single-
stranded PCR primers hybridise. Pfu DNA polymerase then synthesised new strands
complementary to the template DNA sequence, thus generating two double-
stranded DNA sequences. In the next PCR cycle, both of these two DNA sequences
were denatured again with each single strand acting as a template, which resulted in
the exponential amplification of the target sequence.
Denaturation
(95 °C, 1 min)
Double-stranded
DNA template
Hybridisation
(61 °C, 1 min)
Primer extension
(72 °C, 3 min)
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Double-digest of insert and vector DNA sequences
To confirm that the PCR was successful, 5 µL of the PCR sample was used to
confirm the presence and approximate size of the amplified target sequence
in a gel electrophoresis analysis (as described below). Following this, 20 µL of
the remaining PCR sample was transferred to a 500 µL sterile Eppendorf tube
and treated with 1 µL of each of the restriction enzymes BamHI and EcoRI in a
double-digest reaction. BamHI and EcoRI cut their restriction enzyme site
DNA sequences in a staggered fashion leaving a 4 nucleotide overhang
(sticky ends) on each strand, which helps to ensure that the target DNA
sequence is inserted in the right orientation. Then, 5 µL of the restriction
enzyme buffer E (Promega, Madison, USA; the composition of this buffer was
compatible with both restriction enzymes used, such that it did not hinder
their activity) and 23 µL of ddH2O were added. The contents of the double-
digest mixture were mixed thoroughly, and then placed onto a heating block
for 2 hours at 37 °C.
dŽĂůůŽǁƐƵĐĐĞƐƐĨƵů ŝŶƐĞƌƚŝŽŶŽĨ ƚŚĞɴ1AR sequence into the pcDNA3.1(Neo)-
SNAP plasmid vector (kindly provided by Dr Holliday), the vector DNA was
treated with the same two restriction enzymes in a double-digest reaction as
described above for the PCR sample containing the insert DNA fragment. 2 µL
of the plasmid vector maxi-prep DNA was transferred to a sterile 500 µL
Eppendorf tube. To this, 1 µL of each restriction enzyme, 5 µL of compatible
buffer E and 41 µL of ddH2O were added to make up a total of 50 µL. The
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sample was mixed and then incubated on the heating block for 2 hours at
37 °C.
Analysis and isolation of the insert DNA fragment using gel electrophoresis
Following this, the digested PCR sample was analysed by agarose gel
electrophoresis which allows the separation of DNA molecules according to
their size (smaller negatively charged DNA molecules migrate quicker than
larger DNA molecules through the pores of the gel towards the positive pole
in an electric field). A 1 % (w/v) agarose gel was prepared by dissolving 0.3 g
agarose in 30 mL TBE buffer (90 mM Tris-Base, 90 mM Boric acid, 2 mM EDTA),
before heating the solution for 2 minutes. The solution was then cooled down
to touch and 3 µL Ethidium Bromide was added. This allowed the amplified
fragment to be visible as a discrete band under ultraviolet (UV) light exposure.
The still liquid gel was poured into a gel cast. Once the gel was set and placed
into a gel tank together with TBE buffer, 40 µL of the dyed PCR sample (50 µL
PCR sample was mixed with 10 µL of a loading dye) run on the gel (80 V, 45
minutes) alongside 6 µL of a 1 kb DNA ladder (5 µL DNA ladder + 1 µL loading
dye), which would allow a rough estimation of the size of the resulting bands.
The visible loading dye contained 0.4 % orange G, 0.03 % bromophenol blue
and 0.03 % xylene cyanol, which run at 50 bp, 300 bp and 4 kpb, respectively
and thus allow the tracking of DNA migration during gel electrophoresis.
Following this, the DNA fragment of the correct size was cut out of the gel in a
UV light box using a razor blade. This was done as quickly as possible to
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minimise damaging effects on the base-pairing in the DNA fragment. The gel
slice containing the DNA fragment was then purified using a GenEluteΡ gel
extraction kit (Sigma Aldrich, Gillingham, UK) according to the manufacturers
instruction. Briefly, the gel was solubilised using a chaotropic agent at 60 °C
and isopropanol added to precipitate the DNA. The solution was then
transferred to a spin column catching the DNA in the column. A 70 % ethanol
wash solution was then used to remove salts and other impurities from the
column, before the purified DNA fragment was eluted in 50 µL elution buffer.
The purified plasmid vector DNA sample was then stored in a -20 °C freezer
and used in the ligation step the next day.
SAP treatment and purification of the vector DNA sequence
Following the double-digest reaction, two restriction enzymes in the reaction
mix were inactivated by incubating the reaction mix at 65 °C for 20 minutes.
Then, 40 µL of the double-digest sample were transferred into a new sterile
500 µL Eppendorf tube, to which 2 µL of the shrimp alkaline phosphatase (SAP)
enzyme and 5 µL of SAP buffer and 3 µL ddH2O were added (total volume of
50 µL). This SAP reaction mix was incubated for 1.5 hour at 37 °C, before the
SAP enzyme was inactivated in a 20 minutes incubation at 65 °C. The SAP
enzyme removes phosphates from exposed nucleotides (i.e. where a DNA
break occurred, such as the one caused by restriction enzymes). This prevents
self-ligation of the exposed ends of the vector DNA sequence. Following the
SAP treatment, the vector DNA sequence was purified using a GenEluteΡ PCR
purification kit (Sigma Aldrich, Gillingham, UK) according to the
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manufacturers instruction. Briefly, a spin column method was used to
remove protein, nucleic acid and other contaminants within the SAP treated
sample and to precipitate and elute the purified DNA sample, which was then
stored in a -20 °C freezer and used in the ligation step the next day.
Ligation of the insert DNA fragment into the plasmid vector
The ligation of the insert DNA fragment into the plasmid vector generates a
recombinant DNA molecule containing the desired DNA sequence (i.e. SNAP-
ƚĂŐŐĞĚɴ1-adrenoceptor). To 500 µL sterile Eppendorf tubes, 7 µL of purified
insert DNA and 1 µL of purified vector DNA were added (i.e. 7:1 insert:vector
ratio). To attempt optimisation of the ligation step, ligation reaction with an
insert:vector ratio of 6:2 were also set up. To each Eppendorf tube, 1 µL of
ligase buffer and 1 µL of the ligase enzyme were added (10 µL total volume).
The ligase enzyme forms new phosphodiester bonds between adjacent
nucleotides in each DNA strand, thus joining two DNA molecules together. A
control reaction was also set up, containing double-distilled water instead of
insert DNA, but the same amount of vector DNA (i.e. 1 or 2 µL), ligase buffer
and ligase enzyme. The sticky overhanging ends of the vector DNA
sequence (created in the double-digest procedure) are different on either end
of its sequence, which reduces the chance of vector re-ligation without an
insert. This effect of vector re-ligation was tested in the control ligation
reaction. The sticky ends of the vector, however, are compatible with the
sticky ends created in the insert fragment DNA sequence, and form base-
pairs through hydrogen bonding, which makes the ligation process more
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efficient. The ligation mixtures were incubated for 5 hours at room
temperature (circa 21 °C) and were subsequently used to transform
competent E. coli cells.
Site-directed mutagenesis
The introduction of the D138A point mutation (changing a single base-pair in
the DNA sequence, i.e. GAC to GCC) into the ȕ1AR DNA sequence of the
pcDNA3.1(Neo)-SNAP-ȕ1AR vector was achieved using the QuickChange site-
directed mutagenesis kit (Stratagene, Amsterdam, Netherlands), a PCR-based
site-directed mutagenesis procedure, according to the manufacturers
instruction. Two exactly complementary mutagenic primers were designed, so
that they both annealed to the same sequence on opposite DNA strands,
containing the mismatched base (that introduces the desired mutation) in the
centre of each primer sequence. Another consideration in primer design was
ƚŚĞ ' ĐŽŶƚĞŶƚ  ?A? ? ? A? ? ? ůĞŶŐƚŚ  ? ? ? ? ? ? ďĂƐĞƐ ? ĂŶĚ ƚŚĞ ŵĞůƚŝŶŐ ƚĞŵƉĞƌĂƚƵƌĞ
(Tm), which is ideally above 78 °C and was calculated using the below equation:
܂ܕ = ૡ૚.૞+ ૙.૝૚(%۵۱)െ ૟ૠ૞ۼ െ %ܕܑܛܕ܉ܜ܋ܐ (eq. 2)
where N is the overall primer length in bases and the % GC and % mismatch
content is simply obtained by dividing the number of GC bases or number of
mismatched bases over N. A melting temperature of 78.4 °C was calculated
ĨŽƌ ƚŚĞ ĚĞƐŝŐŶĞĚ ɴ1D138AAR primers (forward primer 5 GGACCTCAGTGGC
CGTGCTGTGCGT 3; reverse primer 5 ACGCACAGCACGGCCACTGAGGTCC 3).
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For the mutagenesis PCR mixture 50 ng of the template DNA (pcDNA3.1(Neo)-
^EW ?ɴ1AR), 125 ng of each of the mutagenic primers, 10 mM of dNTPs (final
concentration), 2x PolyMate additive (1x final concentration), 10x Pfu DNA
polymerase compatible buffer (1x final concentration) and 1 µL of proof-
reading Pfu DNA polymerase were added to 200 µL PCR tubes, and made up
to a total volume of 50 µL using ddH2O.
The mutagenesis PCR cycle (Figure 2.3) follows a similar pattern as described
above, starting with the denaturation step (double stranded template DNA
denatures to single DNA strands; 95 °C, 30 seconds), followed by the
hybridisation step (primers attach to the target DNA sequence; 58 °C, 2
minutes) and completed by the primer extension step (synthesis of
complementary strands along the template DNA by Pfu DNA polymerase;
68 °C, 10 minutes). The hybridisation temperature is much lower than the Tm
of the primers, which allows specific hybridisation of primers that contain a
mismatched base to the target template DNA sequence. In addition, the
elongation step is much longer in this PCR, because the entire plasmid DNA
(containing the target DNA sequence) is amplified as an extension of the
primers. This PCR cycle was repeated 17 times. The final PCR sample contains
both the original (non-mutated) DNA template and the newly synthesised
(mutated) DNA sequences.
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Figure 2.3 Schematic representation of the steps involved in the site-directed
mutagenesis PCR cycle. Using a template plasmid DNA molecule that contains the
target gene sequence to be mutated and mutagenic primers that hybridise to a
specified region of the target sequence, a mutation is introduced into newly
synthesised DNA sequences.
Template
plasmidDNA
Denaturation
(95 °C, 30 s)
Hybridisation
(58 °C, 2 min)
Primer extension
(68 °C, 10 min)
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Following the PCR process, 1 µL of the DpnI restriction enzyme was added to
the final PCR mixture and thoroughly mixed into the sample. The PCR sample
was then placed on a heating block for 1 hour at 37 °C. The DpnI restriction
enzyme digests methylated DNA (i.e. only the original (non-mutated)
template DNA). The original template DNA was methylated as a result of DNA
replication by E. coli cells (Casadesus et al., 2006). 2 µL of the DpnI-digested
PCR sample were then immediately used to transform competent E. coli cells
as described below.
DNA amplification and purification
Transformation of competent E. coli cells
First, the commercial chemically competent Top 10 F E. coli cells were
thawed gently on ice for 15-30 minutes. 25 µL of E. coli cells were then
transferred into sterile pre-cooled 1.5mL Eppendorf tubes per transformation
reaction. To these cells 1 µL of each ligation mix (including the vector-only
control) were added and incubated on ice for a further 30 minutes. This
allowed the DNA to associate with the cell exterior of the competent cells.
Next, the Eppendorf tubes were held into a 42 °C water bath for 30 seconds
to heat-shock the cells, which causes the DNA uptake by the cells into the
cytoplasm. After that, the tubes were placed back on ice for 2 minutes, before
250 µL of room temperature SOC medium (nutrient-rich bacterial growth
medium) was added to each Eppendorf tube (this was done near a Bunsen
burner to maintain sterile conditions). The cells were incubated at 37 °C for 1
hour with gentle agitation (225 rpm) to allow time for plasmid replication and
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expression. 200 µL of each Eppendorf tube were then plated out (near a
Bunsen burner) onto pre-warmed agar selection plates containing 50 µg/mL
of the antibiotic ampicillin and incubated at 37 °C overnight (o/n; circa 16
hours). Only cells that had successfully taken up the recombinant DNA
molecule were able to express the ampicillin-resistance protein needed to
survive in these conditions and thus, grow colonies. The pcDNA3.1 plasmid
vector is able to independently replicate within the bacterial cell (high copy
number) and is passed on to daughter cell with each cell division. The next
day, the agar plates were placed in the fridge (to stop bacterial cell growth)
for storage or single colonies were picked immediately to continue the
amplification of plasmid vector DNA.
Mini-prep
At least two single E. coli colonies per positive agar plate (i.e. a ligation mix
that contained vector and insert DNA was used to transform the E. coli cells)
were picked using a sterile pipette tip near a Bunsen burner. The picked
colonies were inoculated in 5 mL broth containing ampicillin at 37 °C o/n
(circa 16 hours). This allowed the small bacterial colonies to continue to grow,
and hence continued the amplification of the plasmid vector. The next day,
1.5 mL of each bacterial culture was used to isolate the plasmid DNA using a
GenEluteΡ mini-prep kit (Sigma Aldrich, Gillingham, UK) according to the
manufacturers instructions. Briefly, a spin column method was used to lyse
the bacterial cells, followed by removal of cell debris, protein and nucleic acid
contamination, before the DNA sample was eluted. The mini-prep DNA
82
samples were then stored in a -20 °C freezer until used to generate maxi-prep
DNA stocks.
A small sample of the purified plasmid DNA was then digested (using the two
restriction enzymes used to facilitate the insertion of the target DNA
sequence into the vector) and subsequently analysed using gel
electrophoresis to confirm the presence and correct size of the insert. If the
insert was of the expected size, a small DNA sample was sent to be sequenced
to check the correct sequence of the DNA. If a site-directed mutagenesis PCR
reaction was performed, the sequence containing the desired mutation was
inserted to a native plasmid vector that does not contain potential mutations
that may have been introduced during the PCR amplification reaction.
Maxi-prep
If the sequencing confirmed that the correct insert was present with the
correct sequence, the mini-prep DNA (concentrations of circa 50 ng/µL) was
then used to transform E. coli cells exactly as outlined above. Following
transformation and o/n ampicillin agar plate incubation, two colonies were
picked and inoculated in 5 mL broth for circa 8 hours at 37 °C. Following this,
each 5 mL bacterial culture was transferred into 150 mL agar broth
(containing 50 µg/mL ampicillin) and inoculated o/n (circa 16 hours) to grow
to a larger colony, further amplifying the plasmid DNA copies. The next day,
the plasmid DNA was isolated from each 150 mL bacterial culture using the
GenEluteΡ maxi-prep kit (Sigma Aldrich, Gillingham, UK) according to the
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manufacturers instructions. In essence, it followed the same principles as
outlined for the mini-prep procedure, but at a larger scale. The concentration
of the isolated plasmid DNA was then determined using a UV
spectrophotometer (Eppendorf BioPhotometer) that reads absorbance at 260
nm (a wavelength at which DNA absorbs light) and computes the DNA
concentration form that value. The DNA samples (concentrations of circa 500
ng/µL) were then stored in a -20 °C freezer until used to transfect cells for
experimentation.
DNA sequencing
To check the sequence of the inserted DNA sequence was correct and not
altered at any point during the process of generating the receptor fusion
protein, a small DNA sample (generally a mini-prep DNA sample) was sent to
the DNA sequencing lab at the University of Nottingham. Primers used in the
sequencing reactions included T7 forward primer (5-TAATACGACTCATATA
''' ? ? ? ? ? ', ƌĞǀĞƌƐĞ ƉƌŝŵĞƌ  ? ? ? ?d''''d''' ? ? ? ? ĂŶĚ ƚŚĞ ɴ1-
adrenoceptor reverse primer (5-GGCGGGAATTCCTACACCTTGGATTCCGAGG-
3).
2.4 [
3
H]cAMP accumulation assay
The accumulation of [3H]cAMP is used as a measure of adenylyl cyclase
activity in response to receptor activation, as intracellular pools of adenine
nucleotides, such as ATP, are labelled with [3H]adenine and the adenylyl
cyclase enzyme facilitates the conversion of [3H]ATP to [3H]cAMP.
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Column preparation
Dowex
Distilled water was added to Dowex AC 50 50W-4X resin (hydrogen form)
mesh 200-400 (1:1 (v/v)) and constantly stirred. Whilst this mix was being
stirred, 2.4 mL were transferred into Bio-Rad poly-prep columns. Before
each experiment the columns were regenerated with 10 mL 1 M HCl followed
by 2 washes of 10 mL distilled water each. After each experiment the columns
were cleaned using 10 mL 1 M NaCl followed by 2 washes of 10 mL distilled
water to dissolve and remove any cell debris left following the experiment.
Following this the rack holding the columns was placed in a tray containing
enough water to come at least halfway up each column. This ensured that the
columns did not dry out before the next experiment.
Alumina
To each Bio-Rad poly-prep column 0.6 g of Neutral alumina WN-3 was
added. Before each experiment the columns were prepared with 2 washes of
10 mL 100 mM imidazole. This was repeated after each experiment to clean
the columns.
Assay
This was based on the assay developed by Donaldson et al. (1988). Cells were
seeded into 24-well plates as described above (see Cell culture). Where cells
transiently transfected with bimolecular fluorescence complementation (BiFC)
DNA constructs were used, cells from a T75 flask were first transiently
85
transfected and then seeded into 24-well plates (see Cell culture) and then
prepared as described below (Confocal microscopy). On the day of the
experiment, 100 µL of growth medium containing 1 µL [3H]adenine per well
(i.e. 25 µL [3H]adenine in 2.5 mL growth medium) was added to each well. The
assay plate was then incubated for 2 hours at 37 °C in a cell culture incubator
to allow [3H]adenine to label intracellular pools of adenine nucleotides.
Following this, the cells were washed once by the addition and removal of
400 µL of growth medium to remove extracellular [3H]adenine. Then, 450 µL
of growth medium containing 1 mM IBMX (3-isobutyl-1-methylxanthine, a
phosphodiesterase inhibitor) was added to each well. An additional 50 µL of
growth medium containing 1 mM IBMX was added to negative control wells
(unstimulated cells, i.e. basal readings). The growth medium containing 1 mM
IBMX was used to make up the desired concentrations of ligands used in the
experiment. 50 µL of increasing agonist concentrations were added to
designated wells and 50 µL of a chosen agonist concentration were added to
positive control wells. If an antagonist was used, 50 µL of antagonist and 50
µL of agonist were added simultaneously to 400 µL of growth medium
containing 1 mM IBMX per well. The total volume per well was 500 µL. The
assay plate was incubated for 5 hours at 37 °C in a cell culture incubator.
Finally, the reaction was stopped by the addition of 50 µL 1 M HCl to all wells,
followed by the addition of 100 µL of [14C]cAMP solution (0.25 µL [14C]cAMP
in 2.5 mL ddH2O per plate) to all wells, before freezing and storing of the
assay plates and the remaining [14C]cAMP solution in a radioactivity-
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designated -20 °C freezer until transferring samples to the columns for
[3H]cAMP and [14C]cAMP recovery.
[
3
H]cAMP and [
14
C]cAMP recovery
The method of sequential Dowex and alumina chromatography was based on
that described by Salomon et al. (1974), and was used to resolve [3H]cAMP
from [3H]ATP. The assay plates were thawed at room temperature and the
whole well contents (650 µL) were transferred to the corresponding Dowex
columns. The negatively charged nucleotides (cAMP, AMP, ADP and ATP
molecules) are adsorbed into the resin of the columns, even though the
columns are themselves negatively charged. Following the addition of 3 mL of
distilled water, the most negatively charged nucleotides (ATP and ADP) are
pushed through the columns first as the repulsion of the negative charges
between these nucleotides and the column is the greatest. The columns were
then placed directly above the alumina columns and the remaining
nucleotides ([3H]cAMP, [14C]cAMP, unlabelled cAMP and AMP) were eluted
into the alumina columns using 6 mL distilled water. The alumina columns
were then placed directly over 20 mL scintillation vials and 5 mL 0.1 M
imidazole was added to each column to elute the cAMP molecules. 100 µL of
[14C]cAMP was also directly added (i.e. did not pass through columns) to three
additional scintillation vials representing 100 % (maximum possible)
[14C]cAMP detection control samples (which can be compared to actual
detection of [14C]cAMP recovered through columns). To all scintillation vials, 8
mL of scintillation fluid was added. The vials were capped and then counted
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ŽŶ Ă ɴ ?ĐŽƵŶƚĞƌ ĐĂƉĂďůĞ ŽĨ ĚƵĂů ĐŽƵŶƚŝŶŐ ďŽƚŚ  ?3H]cAMP and [14]cAMP
simultaneously in 4 minutes per vial.
ȕ-particle counting and dual counting
The [14C] and [3, ?ƌĂĚŝŽŝƐŽƚŽƉĞƐĚĞĐĂǇďǇĞŵŝƚƚŝŶŐɴ ?ƉĂƌƚŝĐůĞƐ ?ǁŚŝĐ ƚƌĂŶƐĨĞƌ
energy to scintillators, which in turn re-emit the absorbed energy in the form
of light. These emitted photons were then counted using a scintillation
counter to give counts per minute (cpm). A control radioactive sample was
brought alongside each vial and the efficiency of the scintillation fluid/elute
mix was tested. From this efficiency, the counts per minutes were then
corrected to disintegrations per minute (dpm) to give a more accurate
indication of the total radioactive decay occurring in each vial. Dual counting
relies on the two different isotopes decaying with sufficiently different
ĞŶĞƌŐŝĞƐ ? dŚĞ ɴ ?ƉĂƌƚŝĐůĞƐ ĞŵŝƚƚĞĚ ĨƌŽŵ  ?14C] have more energy than those
from [3, ? ĂŶĚ ƐŽ ƚŚĞ ƐŚŽǁĞƌ ŽĨ ůŝŐŚƚ ƉƌŽĚƵĐĞĚ ďǇ ƚŚĞƐĞ ɴ ?ƉĂƌƚŝĐůĞƐ ŝƐ
recognised by the counter as a different species from that of the [3, ? ɴ ?
particles.
The [3H]cAMP accumulation data shown in this thesis is expressed in dpm
units where raw (actual) data is shown. Where necessary for comparison
across different assay plates, data was normalised using the negative
(unstimulated cells, i.e. basal read = 0 %) and positive (chosen agonist
concentration, i.e. stimulated cells = 100 %) control data. The [14C]cAMP 100%
[14C]cAMP detection control samples allowed calculation of the efficiency of
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the columns to recover [14C]cAMP by comparing dpm values obtained from
experimental samples to those obtained in the control vials. This helped
identify outliers in the [3H]cAMP data set that were due to column
inefficiency. Fresh Dowex and alumina columns were prepared as described
above, when necessary.
2.5 CRE-mediated SPAP transcription assay
CHO cells expressing the CRE-SPAP reporter gene construct were used in this
assay. In these cells, the gene for SPAP (secreted placental alkaline
phosphatase) was under the control of a cAMP response element (CRE), thus
facilitating SPAP transcription in the presence of cAMP. This assay was used as
a downstream measurement of cAMP production in response to receptor
activation, and was based on the method developed by McDonnell et al.
 ? ? ? ? ? ?ĂŶĚĨƵƌƚŚĞƌŽƉƚŝŵŝƐĞĚĨŽƌƚŚĞŝŶǀĞƐƚŝŐĂƚŝŶŐŽĨƚŚĞƉŚĂƌŵĂĐŽůŽŐǇŽĨɴ ?
adrenoceptor ligands at ȕ-adrenoceptors by Baker et al. (2004). Cells were
seeded into 96-well plates two days prior to experimentation (as described in
Cell culture). The following day, the cells were serum starved, which
minimised further production of cAMP by the cells that are normally
stimulated by the growth medium to survive, grow and divide. This reduces
cAMP interference in the SPAP gene reporter assay. The growth medium was
removed using a sterile pipette tip attached to the vacuum pump in the cell
culture incubator. A volume of 100 µL serum free medium (DMEM/F12
supplemented with 2 mM L-glutamine only) was added to each well and the
plate was then returned to the cell culture incubator until the following day.
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On the day of the experiment, the cells were used in either agonist or
antagonist mode experiments.
Agonist mode
On the day of experimentation, the serum-free medium was removed and
replaced with 90 µL fresh serum-free medium. Then, 10 µL of increasing
concentrations of agonist (10x final concentrations) were added to the serum-
free media in the designated wells of the 96-well plate (at least triplicate
determinations of each condition). 10 µL serum-free medium was added to 6
negative control wells (i.e. unstimulated cells) and 10 µL of 100 µM cimaterol
(i.e. 10 µM final concentration) was added to 6 positive control wells (i.e.
maximally stimulated cells). The 96-well plate was then incubated for 5 hours
at 37 °C in a humidified atmosphere of 5 % CO2/95 % air. After the 5 hour
incubation, the medium and drugs were removed and replaced with 40 µL of
fresh serum-free media and incubated for a further hour to collect the (heat
resistant) secreted placental alkaline phosphatase. Then, the assay plate was
heated to 65 °C in an air oven for 30 minutes to destroy any endogenous
ĂůŬĂůŝŶĞ ƉŚŽƐƉŚĂƚĂƐĞƐ ? &ŽůůŽǁŝŶŐ ƚŚŝƐ ? ƚŚĞ ƉůĂƚĞ ǁĂƐ ĐŽŽůĞĚ ƚŽ  ? ? ȗ ďĞĨŽƌĞ
the addition of 100 µL of 5 mM p-nitrophenylphosphate (PNPP) in
diethanolamine (DEA) buffer (100 mM DEA, 280 mM NaCl, 0.5 mM MgCl-
2.6H2O, pH 9.85) to each well. The assay plate was then incubated at 37 °C in
air for 20 minutes, in which the SPAP enzyme hydrolyses its substrate PNPP to
the yellow p-nitrophenol (PNP) under alkaline conditions (created by the basic
DEA buffer). Thus, the CRE-dependent SPAP reporter activity could be
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monitored by following the colour change from pink to yellow in cell culture
serum-free medium.
Antagonist mode
To establish affinity values of antagonists, agonist concentration-response
curves in the absence and presence of one or more fixed antagonist
concentrations were performed. On the day of experimentation, the serum-
free medium was removed and replaced with 80 µL fresh serum-free medium.
Then, cells were incubated with 10 µL of serum-free medium (control agonist
concentration-response curve in the absence of antagonist) and the desired
fixed concentrations of antagonist (10x final concentration) for 1 h at 37 °C in
a 5 % CO2/95 % air atmosphere. After 1 hour, 10 µL of increasing
concentrations of the agonist (10x final concentration) was added to the
designated wells. 10 µL of serum-free medium was added to negative control
wells (i.e. unstimulated cells) and antagonist control wells (i.e. wells that
contained the fixed concentration of the antagonist, but no agonist to
establish effects of the antagonist on its own). 10 µL of 100 µM cimaterol was
added to positive control wells (i.e. maximally stimulated cells). All
determinations were triplicates. Following these additions, the assay plate
was incubated for a further 5 hours at 37 °C in a 5% CO2/95 % air atmosphere.
After this 5 hour agonist incubation step, the assay follows the same protocol
to collect and detect the CRE-mediated SPAP levels as described above in
Agonist mode.
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Data collection
Once the hydrolysis of PNPP to the yellow PNP had taken place and the
associated colour change had occurred following a 20 minute incubation time
(unless otherwise specified), absorbance was read at 405 nm using an MRX
plate reader (Dynatech Labs, Chantilly, VA) to quantify the CRE-dependent
SPAP reporter activity. Optical density (OD) readings were obtained with
higher readings corresponding to higher levels of yellow PNP and thus, higher
amounts of SPAP present in that particular well as a result of higher cAMP
levels. The OD readings can be converted to SPAP concentrations in mU per
mL (McDonnell et al., 1998) using the following equation:
[܁۾ۯ۾](ܕ܃/ܕۺ) = ۯ/૚ૡ.૞ܜ܄ (eq. 3)
where A = optical density, t = time of incubation and V = volume of the
sample (40 µL in all experiments). Since the optical density readings vary with
the time of incubation, the incubation times of every assay plate were
recorded.
In addition, any fluctuations in temperature during the experiment also had
marked effects on the transcription/translation and secretion of SPAP.
Potential deviations from the optimal 37 °C temperature of the assay plate
and assay solutions (e.g. serum-free medium and ligand solutions) thus
contribute to variations in final optical density readings. This is why data
shown in this thesis are either actual raw data (i.e. unmodified optical density
readings) or data that was normalised to control data obtained on the same
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assay plate (generally expressed in percentages with unstimulated cells
representing 0 % and the 10 µM cimaterol response representing 100 %).
2.6 Confocal microscopy
HEPES-buffered saline solution (HBSS; 147 mM NaCl, 24 mM KCl, 1.3 mM
CaCl2, 1 mMMgSO4, 10 mM HEPES, 2 mM sodium pyruvate, 1.43 mM NaHCO3,
pH 7.45) containing 4.5 mM D-glucose was used as the imaging buffer in all
experiments outlined below and was pre-warmed before use to the stated
temperature in which the experiments were carried out. Imaging buffer was
used to dilute both BODIPY-TMR-CGP and BODIPY630/650-S-PEG(8)-
propranolol fluorescent ligands from a 1 mM DMSO stock to achieve the
ĚĞƐŝƌĞĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ĂŶĚ ƚŽ ĚŝůƵƚĞ ƚŚĞ D^K ĐŽŶƚĞŶƚ ƚŽ ĐŽŶĐĞŶƚƌĂƚŝŽŶ A?
0.01 % (v/v; final concentrations), reducing potential harmful effects of this
solvent on the cells (Brayton, 1986). Incubation of cells in a cell culture
incubator refers to a 5 % CO2/95 % air atmosphere.
SNAP-tag labelling
ĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ^EW ?ƚĂŐŐĞĚ ǁŝůĚ ?ƚǇƉĞ Žƌ  ? ? ? ŵƵƚĂŶƚ ɴ1-adrenoceptors
were grown to confluence in 8-well plates as described above (see Cell
culture). Prior to experimentation, the growth medium was removed off the
cells and replaced with fresh medium containing 1 µM of the cell
impermeable SNAP-tag substrate SNAP-Surface® 488 (BG-488; New England
Biolabs, Ipswich, MA). The cells were then incubated at 37 °C in a cell culture
incubator for 30 minutes in the dark (unless otherwise stated). Following this,
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the medium containing the SNAP-tag substrate was removed and the cells
were washed twice in imaging buffer (pre-warmed to 37 °C), before
incubating the cells in 200 µL imaging buffer in a cell culture incubator (37 °C)
for a further 30 minutes in the dark. Finally, the imaging buffer was replaced
with 400 µL fresh imaging buffer and the cells used immediately for imaging.
Saturation binding experiments
The protocol used here was based on that described by Baker et al. (2003d)
ĨŽƌƚŚĞK/Wz ?dDZ ?'WůŝŐĂŶĚŽŶ,KĐĞůůƐĞǆƉƌĞƐƐŝŶŐƚŚĞɴ2-adrenoceptor.
BODIPY-TMR-CGP and BODIPY630/650-S-PEG8-propranolol saturation binding
experiments were performed at room temperature (circa 21 °C) using CHO-
ɴ1 ?^ ĂŶĚ ,K ?ɴ2-CS cells seeded into 8-well plates (as described in Cell
culture). Immediately prior to experimentation, the growth medium was
removed and the cells were then washed once with imaging buffer, before
the addition of 360 µL imaging buffer to each well. The 8-well plate was
placed onto the microscope stage and 40 µL (i.e. 10x dilution to final
concentration) of a range of concentrations from 3-100 nM (final
concentrations) of either BODIPY-TMR-CGP or BODIPY630/650-S-PEG8-
propranolol were added to designated wells. The cells were exposed to the
fluorescent ligand for 10 minutes before imaging. To ensure strict exposure
time for all cells and to allow circa 5 minutes to image each well, the addition
of fluorescent ligands to designated wells was staggered.
Competition binding experiments
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This method was also based on that described by Baker et al. (2003d) for the
K/Wz ?dDZ ?'W ůŝŐĂŶĚ ŽŶ ,K ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ2-adrenoceptors. BODIPY-
TMR-CGP and BODIPY630/650-S-PEG(8)-propranolol inhibition binding
experiments were performed at room temperature (circa 21 °C) using CHO-
ɴ1 ?^ ĂŶĚ ,K ?ɴ2-CS cells seeded into 8-well plates (as described in Cell
culture). CHO-CS cells were used as a negative control. On the day of
experimentation, the growth medium was removed and the cells washed
once with pre-warmed imaging buffer, before 360 µL of imaging buffer was
added to the positive control well, measuring total binding, and the negative
control well (containing CHO-CS cells), measuring non-specific binding levels.
360 µL of imaging buffer containing increasing concentrations of the
competitor (0.01-1000 nM) was added to the designated wells. The cells were
then incubated for 30 minutes at 37 °C in a cell culture incubator. Following
this, the plate was mounted on the microscope stage and the experiment
started by the addition of 40 µL of the desired concentration of the
fluorescent ligand to the first well, which was imaged after a further 10
minutes. To ensure the same exposure time of cells to the fluorescent ligand
in all wells and to allow a 5 minute imaging time for each well, the addition of
the fluorescent ligand and imaging of the wells was staggered and carefully
timed. Where cells expressing SNAP-tagged receptors were used, the SNAP-
tag labelling was performed first (as described above) and the 30 minute
incubation step following the washout of the SNAP-tag substrate was
substituted for the 30 minute incubation of the competitor ligand.
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Internalisation experiments
&Žƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĞǆƉĞƌŝŵĞŶƚƐ ? ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor cells were
seeded into 8-well plates as described in Cell culture and the SNAP-tagged
receptors were labelled as described above, but using 360 µL imaging buffer
in the final incubation step. Next, the 8-well plate was mounted onto the
microscope stage. The unlabelled ligands to be used were diluted in imaging
buffer to the desired concentrations (10x final concentration). Before addition
of any ligands, the first well was imaged to allow optimisation of microscope
settings (laser power, gain and offset), which were then kept constant for all
other wells throughout the experiment. Following this, 40 µL of the ligand
was added to the first well and imaged immediately (at a different site than
that used to determine the microscope settings; time point 0 minutes). After
60 minutes incubation of the ligand, the well was imaged again (time point 60
minutes).
Bimolecular fluorescence complementation (BiFC) experiments
Using the bimolecular fluorescence complementation (BiFC) approach, two
non-fluorescent N- and C-terminal halves of a fluorescence protein (e.g.
yellow fluorescence protein, YFP) are attached to two potentially interacting
proteins (e.g. dimerising receptors). Upon receptor dimerisation, the two non-
fluorescent YFP halves then come together and reconstitute the full length
fluorescent YFP, thus the detection of YFP fluorescence indicates an
interaction of the two proteins studied and was used in this thesis to detect
ɴ1-adrenoceptor homodimers in living cells. For this, CHO-K1 cells were
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seeded into wells of an 8-well plate (day 1) and transiently transfected with
YFPN-tagged and YFPC ?ƚĂŐŐĞĚ ɴ1-adrenoceptor recombinant DNA the
following day (day 2) as described in Generation of new cell lines. The next
day (day 3), the transfection medium was removed off the cells and replaced
with fresh growth medium, before the cells were placed back into the cell
culture incubator (37 °C, 5 % CO2/95 % air atmosphere). After circa 6 hours,
the cells were then moved into a 30 °C incubator (5 % CO2/95 % air
atmosphere) to allow the maturation of the fluorophore following correct
protein folding. On day 4, the cells were used for experimentation.
Confocal imaging
All confocal imaging experiments were performed on the Zeiss LSM710
confocal microscope (unless otherwise stated) with a Zeiss 40x1.3NA oil
immersion lens (Zeiss, Jena, Germany). The laser that emits light at a
wavelength closest to the wavelength needed to cause maximum excitation
of the chosen fluorophore was used. Upon excitation, the fluorophore then
emits light itself at a longer wavelength, which is captured using the
appropriate wavelength filter. The fluorophores, lasers and microscope
settings used throughout this thesis are summarized in Table 2.2. The pinhole
diameter used in all confocal experiments was 1 airy unit (AU), which
represents a near optimal setting that reduces out-of-focus emission
contributions without the loss of intensity of the measured fluorophore. The
pinhole setting and the laser wavelength used determine the optical slice
thickness (z section; with 1 AU pinhole settings, the shorter the wavelength,
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the thinner the optical slice). The first well of an 8-well plate was used for
calibration in each experiment. The cells were imaged and the range indicator
was set to determine brightness (detector gain) of the bound ligand and the
contrast (amplitude offset) such that pixels were either over-saturated or
below the detection limit. The maximal image brightness was then set to a
value greater than that achieved with the control well so that brighter binding
could be detected. The confocal settings (laser power, digital values for image
brightness, background and contrast) were then kept constant for the rest of
the experimental day. This allowed direct comparisons between wells to be
made. This area of the first well used to determine the settings was subjected
to laser exposure much more than any other area and hence had potential for
more photobleaching. A second area of the well was therefore selected for
the first image of the control well of that plate.
Table 2.2 Excitation and emission wavelengths of the fluorescent molecules used in studies within this thesis are listed together with the lasers and
microscope settings used to image cells treated with these fluorescent molecules.
fluorophore
excitation/emission
laser
type
laser
wavelength
Microscope settings used
emission filter gain offset optical slice
BG-488 506/526 Argon 488 nm 505 nm long-pass 600-1100 0-1 0.37 µm
BODIPY-TMR-CGP 545/570 Helium-Neon 543 nm 550 nm long-pass 600-1100 0-1 0.40 µm
BODIPY-TMR-CGP 545/570 Helium-Neon 561 nm 565 nm long-pass 600-1100 0-1 0.41 µm
BODIPY630/650-S-PEG(8)-propranolol 630/650 Helium-Neon 633 nm 650 nm long-pass 600-1100 0-1 0.46 µm
yellow fluorescent protein 514/527 Argon 488 nm 505 nm long-pass 600-1100 0-1 0.37 µm
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Where two lasers were used at the same time (e.g. 488 nm and 561 nm lasers
ƚŽ ŝŵĂŐĞ K/Wz ?dDZ ?'W ďŝŶĚŝŶŐ ƚŽ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors), the
multitracking facility in the Zeiss imaging software was used. This allowed the
sample to be illuminated with one laser at a time in order to avoid any bleed
through of the laser used (e.g. 488 nm) causing excitation of the fluorophore
used (e.g. BODIPY-TMR-CGP). For the same reason, the emission filter of the
higher energy fluorophore was also adjusted (e.g. 505-550 nm band-pass
filter was used to capture BG-488 fluorescence). Furthermore, the pinhole
(thus the optical slice thickness) was set for the highest wavelength laser used
(i.e. 561 nm laser, if both 488 and 561 nm laser where used) and the optical
slice thickness was then matched for the second laser. Using two lasers also
increased the total well laser exposure time. To correct for that, fewer frames
were taken (4-8 frame scans, 1024x1024 pixels), thus limiting each image to
approximately one minute laser exposure.
Data collection
Using 8-well plates limits the number of experimental conditions that can be
tested in a given experiment. In the experiments described above, every well
represented a different experimental condition (e.g. different concentration
of fluorescent ligand or inhibitor ligand or internalising ligand). However, 2-4
different areas were imaged within a given well and each image was analysed
as described below, thus providing duplicate to quadruplicate measures per
condition within a single experiment. The n numbers stated throughout this
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thesis for these experiments, however, refer to number of separate
experiments set up and carried out (i.e. different experimental days).
Total image intensity analysis
All images taken on the Zeiss LSM710 microscope were captured using an 8bit
greyscale, which allows for 256 different intensity levels of a given pixel (from
0-255; where 0 represents the weakest and 255 the strongest fluorescence
intensity). All data analysis was carried out using Zeiss Zen2010 software (Carl
Zeiss, Jena, Germany). This provides the frequency of pixels recorded at each
of the 256 greyscale intensities for each image taken. The total image
intensity (arbitrary units) is calculated as the sum of the product of frequency
x greyscale intensity for each of the 256 grey scale intensity values. This value
was then divided by the total number of pixels per image (1024x1024 for the
total image) to give the average pixel intensity.
Region of interest (ROI) analysis
Where stated, regions of interest were drawn around the membrane of a
given number of cells (stated for each experiment) in each image taken. The
Zeiss software provides the frequency of pixels recorded at the 256 greyscale
intensities and the number of pixels in the combined area of the drawn
regions of interest of one image, and thus allows quantitative analysis as
described above using average pixel intensities that refer to the regions of
interest only.
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Co-localisation analysis
Where two different wavelengths were used to image two different
fluorescently labelled molecules (e.g. SNAP-tagged ȕ1-adrenoceptor using 488
nm and BODIPY-TMR-CGP binding using 561 nm excitation wavelengths), the
individual images obtained for each wavelength were merged. These images
are shown in colour, where yellow pixels clearly identify regions of spatial
overlap of the two fluorescently labelled molecules. The fluorescence
intensities of each individual channel, however, are shown in monochrome to
allow better visualisation of the greyscale intensities of the pixels in each
channel (from 0, i.e. black, to 255, i.e. white pixels).
Where used, a co-localisation plot was obtained and a crosshair placed on this
plot to highlight the region of co-localised pixels (region 3). To do this, a
region of interest was drawn on the background of the image away from the
cells and the average intensity and its standard deviation (SD) of this region
were collected in each of the two channels. The crosshair was then placed to
the intensity levels calculated from adding the average background pixel
intensity to 2x its standard deviation. This represents the background
fluorescent intensity. Pixels with intensity values greater than those
calculated in both channels will be located in region 3 and represent co-
localised pixels (i.e. yellow pixels in the merged image).
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2.7 ImageXpress Ultra confocal plate reader
Assay
The protocol of this assay was based on that described by Stoddart et al.
 ? ? ? ? ? ? ? ,K ?ɴ1 ?^ Žƌ ,K ?ɴ2-CS cells were seeded into 60 wells of a thin
clear-bottomed black wall 96 well plate (Greiner Bio-One Ltd, Stonehouse, UK)
18-24 hours prior to experimentation (see Cell culture). The outermost wells
of the 96-well plate were excluded to avoid edge effects of confocal analysis
of the wells, leaving 60 wells for experimentation. On the day of the
experiment, the growth medium was removed and the cells were washed
once by the addition and removal of 100 µL pre-warmed imaging buffer (HBSS
containing 4.5 mM D-glucose), before 80 µL of imaging buffer was pipetted
into each of the 60 wells. All ligands used in these experiments were diluted
in imaging buffer to the desired concentrations and 10 µL of increasing
concentrations of competitor ligand (i.e. at 10x final concentration) were
added to the designated wells on the assay plate. 10 µL of imaging buffer
were also added to positive control (measuring total binding of fluorescent
ůŝŐĂŶĚƚŽ,K ?ɴ1 ?^Žƌ,K ?ɴ2-CS cells). The assay plate was then incubated
for 30 minutes (unless otherwise stated) at 37 °C in a 0 % CO2/100 % air
atmosphere cell culture incubator. Following this, 10 µL of the desired fixed
concentration of BODIPY-TMR-CGP was added to all 60 wells and the plate
was then incubated for 1 hour at room temperature (circa 21 °C) in the dark
(unless otherwise stated). After 1 hour, the imaging buffer containing all
ligands was removed, the cells were washed once by addition and removal of
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100 µL imaging buffer, before 100 µL imaging buffer was added to each well.
Following this, the assay plate was immediately read on the ImageXpress (IX)
Ultra confocal plate reader. A 561 nm (40 % laser power) was used to excite
BODIPY-TMR-CGP and emission was captured through a 565-605 nm band-
pass filter. BODIPY630/650-S-PEG8-propranolol was excited using a 635 nm
laser (20 % laser power) with emission collected through a 640-685 nm band-
pass filter. The focus (z position of the bottom of the first well) and laser gain
settings used were adjusted and optimized for each plate. The raw data of
different assay plates can therefore not be directly compared. In order to do
that and to be able to group data from different experiments, the data was
normalized as a percentage of total (100 %) and non-specific binding values
 ? ? A? ? ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1 ?^ Žƌ ,K ?ɴ2-CS cells in the
presence of the highest concentration of inhibitor compound, e.g. 100 µM)
determined on each plate.
Automated image analysis
The IX Ultra confocal plate reader is equipped with a Plan Fluor 40x NA0.6
extra-long working distance objective and automatically captured confocal
images in 16bit greyscale at four different central sites in each well, taking
circa 20 minute to read an entire plate (60 wells). Total image intensities of
each image were then obtained using a multiwavelength cell scoring
algorithm within the MetaXpress 2.0 software (Molecular Devices, Sunnyvale,
USA). This analysis provided integrated intensity values for each imaged site
per well and experimental conditions were tested in duplicates (i.e. 8
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separate images were analysed for a given experimental condition in a single
experiment).
2.8 PHERAstar FS plate reader
This assay was performed using the above protocol for measuring fluorescent
ligand binding to living cells on the ImageXpress Ultra confocal plate reader.
The same materials, ligands and solutions were used. This was done to allow
direct comparison of fluorescent ligand binding data obtained on two
different plate readers. Following the assay, the assay plate was first read on
the PHERAstar FS plate reader (BMG Labtech GmbH, Ortenberg, Germany).
The optimal focal height (z positioning of the plate), gain setting and exposure
time were determined automatically for every plate. A high energy Xenon
flash lamp (spectral range of 230-750 nm) and a 545 nm filter were used to
excite BODIPY-TMR-CGP with BODIPY-TMR-CGP emission being detected by
photomultiplier tubes. The fluorescence intensity in each well was assessed in
81 reads per well in a read time of circa 3 minutes per plate (60 wells). The
PHERAstar FS data output is in numerical (arbitrary range of 0-260,000) and
visual form (e.g. rainbow colouring with the red and blue colours representing
high and low levels of binding of the fluorescent ligand, respectively).
2.9 Confocal perfusion system
The association and dissociation of a fluorescent ligand was visualised and
quantified at the single-cell level using a perfusion system as described by
May et al. (2010a) in conjunction with either the Zeiss LSM510 or the Zeiss
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LSM710 confocal microscope. A pressure pump was connected to a closed
perfusion system, which allowed the constant perfusion of fluid from six
reservoirs through an imaging chamber and into a runoff (Figure 2.4). Cells
were grown to near confluence on 32 mm glass coverslips placed into wells of
6-well plates (see Cell culture) one day prior to experimentation. Where
transient transfection of cells with BiFC DNA constructs was required, the cells
were plated out three days prior to experimentation and then prepared as
described above (see Confocal microscopy). On the day of the experiment, the
growth medium was removed from one 6-well plate and the wells were
washed once in pre-warmed (37 °C) imaging buffer (HBSS containing 4.5 mM
D-glucose) and subsequently kept in 2 mL imaging buffer at 37 °C until used
for experimentation (the cells were kept in these conditions for no longer
than 2 hours). To start experimentation, the coverslip was placed into a
specially designed imaging chamber, which was tightly closed and then placed
onto a heated (37 °C) microscope stage where it was connected to tubes on
either side that facilitated the flow of fluid through the imaging chamber.
Following this, the reservoir supplying the imaging buffer was switched on to
perfuse over the cells in a laminar flow imaging chamber that holds a total
ǀŽůƵŵĞŽĨ ? ? ?A?> ?ƚŚƵƐĂůůŽǁŝŶŐA? ? ?ĨůƵŝĚĞǆĐŚĂŶŐĞƐƉĞƌŵŝŶĂƚĂĨůŽǁƌĂƚĞŽĨ
A?  ?ŵ> ?ŵŝŶ  ?DĂǇet al., 2010a). Following this, an area of cells was selected
using the eyepiece of the microscope and the required laser, emission filters
and time series mode were set up. BODIPY-TMR-CGP was excited using a 543
nm Helium-Neon laser on the Zeiss LSM510 microscope and a 561 nm Helium-
Neon laser at the Zeiss LSM710 microscope with emission collected through a
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Figure 2.4 The set-up of the closed perfusion system in conjunction with the Zeiss
LSM510 confocal microscope. The pump allows the flow of fluid at constant pressure
from a reservoir through the imaging chamber (imaging cell) and into a runoff. The
entire system is temperature-controlled and kept at 37 °C. Figure taken from May et
al. (2010b).
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560 and 565 nm long-pass filter, respectively; BODIPY630/650-S-PEG8-
propranolol was excited using a 633 nm argon laser and a 650 nm long-pass
filter at both confocal microscopes. Where cells transiently transfected with
BiFC DNA constructs were used, YFP and BODIPY-TMR-CGP were excited using
a 488 nm argon laser and 561 nm Helium-Neon laser, respectively with
emission being captured through a 505-550 nm narrow band-pass and a 565
nm long band-pass filter, respectively (these experiments were carried out
using the Zeiss LSM710 confocal microscope).
Association and dissociation kinetic binding experiments
The association and dissociation kinetics of increasing concentrations (3-100
nM) of BODIPY-TMR-CGP and BODIPY630/650-S-PEG8-propranolol were
investigated. Both fluorescent ligands used in perfusion experiments were
diluted in ddH2O to working concentrations (100x desired final concentrations)
and subsequently kept on ice. When used, 400 µL of the ligand (at working
concentration) was added to 40 mL imaging buffer in a designated reservoir.
First, a 20-30 second baseline fluorescence read was taken in the presence of
only imaging buffer. To initiate association of the fluorescent ligand, the flow
of fluid from the reservoir containing imaging buffer (reservoir 1) was stopped
and the reservoir containing the fluorescent ligand (reservoir 2) was switched
on for a given length of time (e.g. 5 minutes). After that, flow of fluid from
reservoir 2 was stopped and reservoir 1 was again switched on to begin
dissociation of the fluorescent ligand (generally performed for the same
amount of time as the association). Thus, this system uses infinite dilution to
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remove the labelled ligand, which is possible due a sharp change in
concentration caused by the selected pressure and flow rate for these
experiments (May et al., 2010a). Throughout the experiment (from baseline
to dissociation read) transmitted light and fluorescence images were captured
every 2-3 seconds (512x512 pixels, 2 averages per images). The first glass
coverslip (slide) was used to establish the optimal microscope settings (laser
power, gain and offset) as described above in Confocal microscopy. These
settings were then kept constant within each experiment and between
ĞǆƉĞƌŝŵĞŶƚƐ ƉĞƌĨŽƌŵĞĚ ŽŶ ĚŝĨĨĞƌĞŶƚ ĚĂǇƐ ƵƐŝŶŐ ďŽƚŚ ,K ?ɴ1-CS (used to
measure total binding) and CHO-CS cells (used to measure non-specific
binding levels) to allow for direct comparison of total and non-specific
fluorescent ligand binding levels at the different concentrations tested.
Dissociation kinetic binding experiments in the presence of
unlabelled ligands
All unlabelled ligands were diluted in ddH2O to working concentrations
(10,000x desired final concentration) and 4 µL of the ligand at working
concentration was added to 40 mL imaging buffer in designated reservoir
(reservoir 3). The association of the fluorescent ligand was achieved as
outlined above. Following association, the flow of fluid from reservoir 2
(imaging buffer containing the fluorescent ligand; as defined above) was
stopped and reservoir 3 was switched on, thus initiating the dissociation of
the fluorescent ligand in the presence of an unlabelled ligand (for a given
amount of time, e.g. 5 minutes). Control dissociation reads in the absence of
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any unlabelled ligand were performed on each experimental day. Transmitted
light and fluorescence images were captured every 2-3 seconds and the
microscope settings were set using the first slide (as described above) and
then kept constant within each experiment, but adjusted, if necessary,
between experiments on different days. Dissociation kinetic data was
therefore expressed in % fluorescent intensity, allowing experimental data
from different days to be grouped.
Data collection
During each experiment, 8bit images recording the fluorescence intensity of
the fluorescent ligand binding to cells in the perfusion imaging chamber were
captured. To analyse and quantify the association and dissociation kinetics of
the fluorescent ligands, regions of interest (ROIs) were drawn around the
membranes of ten single cells of each imaged slide. Cells containing
oversaturated pixels were identified using the range palette and were
excluded from the analysis. For cells with low fluorescent intensity, the
transmitted light image was used to aid cell selection. The Zeiss software then
provided average pixel intensity values for each ROI (10 ROIs per slide), which
were plotted against time. The changes in fluorescent intensity over time
were then analysed to obtain association and dissociation rates (see Data
analysis) for either each single cell or per slide (i.e. grouped data from 10
single cells). For kinetic data shown in this thesis, an n number of 1 refers to
data obtained from one slide. Within each experiment, each condition (e.g.
concentration of unlabelled ligand) was investigated on at least two slides.
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Throughout this thesis, the number of different experimental days, in which
the n numbers were acquired, is also stated.
2.10 Data analysis
All data were fitted using the GraphPad Prism 5.0 software (San Diego, USA)
using non-linear regression analysis (unless otherwise stated).
Functional experiments
Agonist concentration responses
Sigmoidal agonist concentration-response curves were fitted to the following
equation:
܀܍ܛܘܗܖܛ܍ = (۳ۻۯ܆ ή ሾ܉܏ܗܖܑܛܜ])/([܉܏ܗܖܑܛܜ] + ۳۱૞૙) (eq. 4)
Where EMAX is the maximal system response, [agonist] is the concentration of
the agonist, and EC50 is the concentration that produces 50 % of the maximal
system response.
CGP 12177 two site functional response curves
CGP 12177 concentration-response curves obtained in the presence of a fixed
concentration of agonist were fitted using a two-site analysis equation:
܀܍ܛܘܗܖܛ܍ = ۰܉ܛ܉ܔ+ (ۯ܀ െ ۰܉ܛ܉ܔ) ቂ૚െ [۱]([۱]ା۷۱૞૙)ቃ+ ۱ۻۯ܆ ቂ [۱]([۱]ା۳۱૞૙)ቃ (eq. 5)
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where Basal is the response produced in the absence of any agonist, AR is the
measured response to the fixed concentration of agonist, [C] is the
concentration of competitor (CGP 12177), IC50 is the concentration of
competitor required to inhibit the agonist-stimulation by 50 %, CMAX is the
maximal stimulation produced by the competitor and EC50 is the
concentration of the competitor (CGP 12177) required to produce 50 % of the
maximal stimulation of that competitor.
Antagonist KD value calculations
Agonist concentration-response curves in the absence and presence of a fixed
concentration of antagonist were fitted to eq. 4. Antagonist equilibrium
dissociation constants (KD values) were then determined by observing the
shift in the concentration-response curve by a fixed antagonist concentration
(assuming competitive antagonism and equilibrium assay conditions) using
the equation below:
۲܀ = ૚+ [۰]/۹۲ (eq. 6)
where KD is as defined above, and DR (dose-ratio) is the ratio of the
concentrations of agonist required to produce the same response in the
absence and presence of a fixed concentration of antagonist [B] (Figure 2.5;
Arunlakshana et al. (1959)).
Where three increasing concentrations of antagonist were used in the same
experiment, Schild plots were determined using the equation:
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ۺܗ܏(۲܀െ ૚) = ܔܗ܏[۰]െ ܔܗ܏[۹۲] (eq. 7)
where DR, [B] and [KD] are as defined previously. The log (DR-1) was then
plotted on the Y-axis and the log [B] was plotted on the X-axis to yield a
straight line. The slope of this line was determined using linear regression
analysis:
܇ = (ܛܔܗܘ܍ ή ܆) + ܑܖܜ܍ܚ܋܍ܘܜ (eq. 8)
where Y and X are as defined above. A slope of 1 is indicative of competitive
antagonism and the intercept of the straight line with the Y-axis (i.e. Y=0)
yields the log KD of the antagonist.
Where partial agonists were used to shift concentration-response curves of
full(er) agonists, KD values of the competing partial agonist were determined
according to the method of Stephenson (1956) using the following equation:
۹۲ = ܇ήሾ۾]૚ି܇ (eq. 9) where ܇ = [ۯ૛]ି[ۯ૚][ۯ૜] (eq. 10)
where [P] is the partial agonist concentration, [A1] is the concentration of the
full agonist at which the concentration-response curve of the full agonist in
the absence and presence of the partial agonist cross (i.e. cause the same
response), [A2] is the concentration of the full agonist causing a given
response (that is greater than that of the partial agonist) and [A3] is the
concentration of the full agonist in the presence of the partial agonist causing
the same response as [A2] (Figure 2.6).
113
Figure 2.5 Schematic representation of the calculation of the dose-ration (DR) of
curve 1 (agonist concentration-response curve) and curve 2 (agonist concentration-
response curve in the presence of a fixed concentration of antagonist). The dose-
ration is then used to calculate the KD value of the antagonist.
Figure 2.6 Schematic representation of A1, A2 and A3 full agonist concentrations in
the absence and presence of a fixed concentration of partial agonist. These
parameters are used in the method of Stephenson (1956) to determine the KD value
of the partial agonist.
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Partial agonist KD value calculations
The affinity (KD) of partial agonists was estimated according to the operational
model of partial agonism (Leff et al., 1985), where concentration-responses of
partial agonists were obtained in the absence of a full(er) agonist (as
described above). However, a concentration-response curve of a full agonist
was obtained in the same experiment to define the system maximal response.
۳ = ۳ۻۯ܆ήૌήሾۯ]۹ۯା[ۯ]ାૌήሾۯ] (eq. 11)
where E is a biological effect (operational maximum) and EMAX is the maximal
system response that was determined by obtaining a concentration-response
curve of the full agonist cimaterol at the same time as the concentration-
ƌĞƐƉŽŶƐĞ ĐƵƌǀĞ ŽĨ ƚŚĞ ƉĂƌƚŝĂů ĂŐŽŶŝƐƚ ? dŚĞ ƉĂƌĂŵĞƚĞƌ ʏ ĂŶĚ <A are the
(operational) efficacy and dissociation constant of the partial agonist and [A]
is the concentration of the partial agonist.
Equilibrium fluorescent ligand binding experiment
Saturation binding experiments
When measuring the binding of fluorescent ligands to living cells using
confocal microscopy, the average pixel intensity values obtained at each
concentration of fluorescent ligand (i.e. total binding values) were fitted using
the following equation:
۴ܔܝܗܚ܍ܛ܋܍ܖ܋܍ܑܖܜ܍ܖܛܑܜܡ = ۰ۻۯ܆ήሾ۰]
[۰]ା۹۲ + (ۻ× ۰) + ۱ (eq. 12)
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where BMAX is the maximal fluorescence intensity, [B] is the concentration of
the fluorescent ligand, M is the slope of the non-specific binding component
and C is the intercept with the Y-axis (i.e. background image intensity).
Inhibition binding experiments
Total and non-specific binding of a fixed concentration of fluorescent ligand
was determined on each assay plate in each experiment, which allowed the
displacement of binding for all unlabelled ligands to be expressed as
percentage of uninhibited binding. Curves of the inhibition of the binding of a
fixed concentration of fluorescent ligand were fitted to a one-site inhibition
equation:
%ܝܖܑܖܐܑ܊ܑܜ܍܌܊ܑܖ܌ܑܖ܏ = (܂ܗܜ܉ܔܛିۼ܁۰)
([۲]/۷۱૞૙ା૚) + ۼ܁۰ (eq. 13)
where Totals is the level of total binding of the fluorescent ligand, NSB is the
level of non-specific binding of the fluorescent ligand, [D] is the concentration
of the unlabelled inhibitor ligand and IC50 is the concentration of this inhibitor
ligand to achieve a 50 % inhibition of the total binding of the fluorescent
ligand. The CGP 20712A curve of the inhibition of the binding of 2 nM
BODIPY-TMR-CGP displayed a shallower slope of binding inhibition (Figure
4.17 and 4.18) and was fitted to the following equation:
%ܝܖܑܖܐܑ܊ܑܜ܍܌܊ܑܖ܌ܑܖ܏ = (܂ܗܜ܉ܔܛିۼ܁۰)
([۲]|۷۱૞૙ା૚)ܖ + ۼ܁۰ (eq. 14)
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where the Totals, NSB, D and IC50 parameters are the same as outlined for
equation 13, and n is the Hill slope coefficient. If the inhibition of the binding
ŽĨƚŚĞĨůƵŽƌĞƐĐĞŶƚůŝŐĂŶĚĨŽůůŽǁĞĚƚǁŽƉŚĂƐĞƐ ?Ğ ?Ő ?ŝŶ,K ?ɴ1-CS cells), a two-
site inhibition equation was used:
%ܝܖܑܖܐܑ܊ܑܜ܍܌܊ܑܖ܌ܑܖ܏ = ܁ܘ܉ܖή۴ܚ܉܋ܜܑܗܖܐܑ܏ܐ
([۲]/۷۱૞૙ܐܑ܏ܐା૚) + ܁ܘ܉ܖή۴ܚ܉܋ܜܑܗܖܔܗܟ([۲]/۷۱૞૙ܔܗܟା૚) + ۼ܁۰ (eq. 15)
where [D] and NSB are as defined above, Span is the difference between the
level of total and non-specific binding of the fluorescent ligand and
Fractionhigh and Fractionlow represent the proportion of fluorescent ligand
binding that is inhibited by lower inhibitor concentrations (yielding IC50high)
and higher inhibitor concentrations (yielding IC50low). Where applicable,
antagonist affinity values (KD) were calculated using the Cheng-Prusoff
equation:
۹۲ = ۷۱૞૙૚ା([۰۽۲۷۾܇ି܂ۻ܀ି۱۵۾] ۹۲۰۽۲۷۾܇ି܂ۻ܀ି۱۵۾Τ ) (eq. 16)
where the previously determined IC50 value of the unlabelled ligand and the
known concentration and affinity of the labeled ligand BODIPY-TMR-CGP are
used.
Kinetic fluorescent ligand binding experiments
Association and dissociation rate constants
Association kinetics data were fitted using the following monoexponential
association equation:
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܇ =  ܇૙ + (۾ܔ܉ܜ܍܉ܝെ ܇૙)(૚െ ܍ିܓܗܖܗ܊ܛήܜ) (eq. 17)
where Y0 is the level of binding of the fluorescent ligand at time (t) 0 (i.e.
baseline fluorescence read), Plateau is the level of binding of the fluorescent
ligand at infinite time, e is a mathematical constant (Eulers number,
approximate value of 2.718), and konobs is the rate of observed association. If a
low level of non-specific binding (less than 10 % of total binding) was
observed for a given concentration of a fluorescent ligand, the dissociation
kinetic data was then analysed using the following monoexponential (one-
phase) decay equation:
܇ = (܇૙ െ ۾ܔ܉ܜ܍܉ܝ) ή ܍ିܓܗ܎܎ήܜ + ۾ܔ܉ܜ܍܉ܝ (eq. 18)
where Y0, Plateau and t are the same as defined above, with Y0 representing
total binding levels of fluorescent ligand at the start of the dissociation (i.e.
t=0). The koff is the dissociation rate of the fluorescent ligand. Where a greater
level of non-specific binding was observed (greater than 10 % of total binding),
the dissociation kinetic data were fitted to a two-phase exponential decay
function:
܇ = ۾ܔ܉ܜ܍܉ܝ+ ܁ܘ܉ܖ܎܉ܛܜ ή ܍ିܓܗ܎܎(܎܉ܛܜ)ήܜ + ܁ܘ܉ܖܛܔܗܟ ή ܍ିܓܗ܎܎(ܛܔܗܟ)ήܜ (eq. 19)
where Plateau and t are as defined above, and Spanfast and Spanslow represent
the proportion of Y0-Plateau accounted for by the fast (koff(fast)) and slow
(koff(slow)) dissociation rate, respectively. Within this analysis, koff(fast) and
Plateau was constrained to the average rate of dissociation and the average
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Plateau (in %) reached by the fluorescent ligand in control CHO-CS cells (i.e.
cell not expressing the receptor of interest). The association rate constants
were then calculated using the following equation:
ܓܗܖ = ܓܗܖܗ܊ܛିܓܗ܎܎(ܛܔܗܟ)[܎ܔܝܗܚ܍ܛ܋܍ܖܜܔܑ܏܉ܖ܌] (eq. 20)
where the kinetic parameters konobs and koff(slow) were previously determined.
Kinetically-derived equilibrium KD value calculations
The negative logarithms of the equilibrium dissociation constant (pKD) were
determined from kinetic parameters using the following equation:
ܘ۹۲ = െ ܔܗ܏ ቀܓܗ܎܎(ܛܔܗܟ)ܓܗܖ ቁ (eq. 21)
where the kinetic parameters koff(slow) and kon were previously determined.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0 software
(San Diego, USA). Statistical analysis involved a one-sample t test to compare
the mean of a set of values obtained in several different experiments to a
hypothetical value (e.g. Schild slopes were compared to a hypothetical Schild
slope of 1.0). Unpaired t-tests were used, where two sets of values
determined in several different experiments were compared. One-way
(analysis of variance) ANOVA was used to compare three or more sets of
values determined in several different experiments. To follow the one-way
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ANOVA, the Tukeys post hoc multiple comparison test was used to compare
two or more sets of values to a set of control values, or the Bonferronis post
hoc multiple comparison test was used to compare each set of values to all of
the other sets of values. In all cases, statistical significance was reflected in P <
0.05 (represents a less than 5 % chance that the interactions compared
happen by chance, thus indicating significance). If applicable, a preferred fit
was determined with statistical significance of P < 0.05 (partial F test and
analysis of residuals performed during fitting of data).
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Chapter 3
The pharmacology of CGP 12177 at
the native and SNAP-tagged human
ɴ1-adrenoceptor.
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3.1 Introduction
dŚĞ ĐĂƌĚŝŽƐƚŝŵƵůĂƚŽƌǇ ĞĨĨĞĐƚƐ ŵĞĚŝĂƚĞĚ ďǇ ƚŚĞ ɴ1-adrenoceptor upon
activation by the endogenous ligands adrenaline and noradrenaline are
ŝŶŚŝďŝƚĞĚďǇɴ ?ďůŽĐŬĞƌƐ ?ƐƵĐŚĂƐƉƌŽƉƌĂŶŽůŽů ? ŝŶĂǀ ƌŝĞƚǇŽĨĐĂƌĚŝĂĐĚŝƐĞĂƐĞƐ ?
such as angina pectoris (Brodde et al. ?  ? ? ? ? ? ? ƚ ƚŚĞ ɴ1-adrenoceptor CGP
12177 has been described as a potent antagonist (Haddad et al., 1987;
Staehelin et al., 1983), but was also shown to exhibit agonist activity at higher
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ? ǁŚŝĐŚ ŝƐ ƌĞƐŝƐƚĂŶƚ ƚŽ ɴ ?ďůŽĐŬĞƌ ĂĐƚŝŽŶƐĂƚ ƚŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ
ƵƐĞĚ ƚŽ ŝŶŚŝďŝƚ ĐĂƚĞĐŚŽůĂŵŝŶĞ ?ŵĞĚŝĂƚĞĚ ɴ1-adrenoceptor stimulation
(Kaumann et al., 2001; Konkar et al., 2000; Pak et al., 1996). This led to the
ƚǁŽ ?ƐŝƚĞŚǇƉŽƚŚĞƐŝƐŽĨƚŚĞɴ1-adrenoceptor which describes a high affinity site
1 (catecholamine site) and a low affinity site 2 (CGP 12177 site; Pak et al.
(1996)). This pharmacology was observed in recombinant (Baker et al., 2003a;
Joseph et al., 2004; Konkar et al., 2000) and human (Kaumann et al., 2007)
and animal tissue preparations (Lowe et al., 1999; Sillence et al., 2005).
However, the nature of the second CGP 12177 site, and how CGP 12177 is
able to display antagonist and agonist effects at the same receptor is not yet
known. A mutagenesis study carried out by Baker et al. (2008) aimed to locate
ĂŶĚ ĚŝƐƚŝŶŐƵŝƐŚ ƚŚĞ ƚǁŽ ƉƌŽƉŽƐĞĚ ďŝŶĚŝŶŐ ƐŝƚĞƐ ŽĨ ƚŚĞ ɴ1-adrenoceptor by
identifying key amino acid residues involved in the ligand binding to the two
sites. Eight single point mutations were introduced and all were found to have
ƐŝŵŝůĂƌĞĨĨĞĐƚƐŽŶďŽƚŚƚŚĞŚŝŐŚĂŶĚůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor binding site
(Baker et al., 2008).
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Using fluorescently labelled G protein-coupled receptors and fluorescent
ligands in conjunction with confocal microscopy has allowed the investigation
of receptor-ligand interactions in live cells and provided insight into ligand-
induced receptor trafficking, receptor dimerisation and receptor co-
operativity (Briddon et al., 2008; Calebiro et al., 2013; May et al., 2011). -
Fluorescently tagging a G protein-coupled receptor (GPCR) has traditionally
been achieved using fluorescent proteins (FPs) such as green FP (GFP) or
yellow FP (YFP). An alternative fluorescent tag is the SNAP-tag, which is an
engineered truncated version of the DNA repair protein O6-alkylguanine
alkyltransferase, and is fused to the N-terminus of the receptor of interest
(Keppler et al., 2003). In a suicide reaction, the 20 kDa SNAP-tag removes the
benzyl group, which is linked to a fluorophore (e.g. Alexa Fluor 488 dye), from
its benzylguanine (BG) substrate and transfers it onto a cysteine residue
within its active site, thereby covalently and irreversibly linking a fluorophore
to the SNAP-tagged receptor (Keppler et al., 2003; Tirat et al., 2006). The
SNAP-tag has been used in a variety of studies, including protein visualisation
and localisation studies in living cells (Campos et al., 2011; Gong et al., 2012),
GPCR oligomerisation studies using fluorescence resonance energy transfer
(FRET) (Alvarez-Curto et al., 2010; Maurel et al., 2008) and protein-protein
interactions studies using a split SNAP-tag protein complementation assay
(Mie et al., 2012). The main advantages of the SNAP-tag are its low non-
specific labelling and the fact that its BG substrate can be linked to a range of
fluorophores, thereby allowing a choice of wavelength in which to image the
tagged receptor. This allows greater flexibility and ease as the same construct
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or cell line can be used in multiple experiments, especially when used in
conjunction with other labelled receptors or potentially interacting proteins
and fluorescent ligands. Using the SNAP-tag technology in an imaging
ĂƉƉƌŽĂĐŚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ɴ1AR pharmacology may provide new insights
into the nature of the second site of this receptor. Single cell and single
molecule techniques such as confocal microscopy and fluorescence
correlation spectroscopy (FCS) detect fluorescently labelled species that can
be tracked over time, allowing changes (e.g. internalisation, membrane
diffusion, receptor oligomerisation) in response to various ligands (agonists
and antagonists) to be measured (Briddon et al., 2007; Calebiro et al., 2013;
May et al., 2011).
In this chapter we aimed (1) to generate and stably express the SNAP-tagged
ŚƵŵĂŶɴ1-adrenoceptor fusion protein in CHO-CS cells, and (2) to characterise
the pharmacology of CGP 12177 at both the native (untagged) and SNAP-
ƚĂŐŐĞĚ ŚƵŵĂŶ ɴ1-adrenoceptor expressed in CHO-CS cells using the CRE-
mediated SPAP transcription assay, with the long term aim to use both cell
lines and the CRE-SPAP reporter gene assay throughout this thesis to
ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ŶĂƚƵƌĞ ŽĨ ƚŚĞ ƐĞĐŽŶĚ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor in both
functional and imaging studies.
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3.2 Methods
Molecular Biology
All steps outlined in Materials and Methods: Generation of a SNAP-tagged
receptor fusion protein were carried out. For this, the plasmid vector
pcDNA3.1(+) containing the neomycin antibiotic resistance gene was used.
dŚĞ ^EW ?ƚĂŐ E ǁĂƐ ŽďƚĂŝŶĞĚ ĨƌŽŵ ƌ ,ŽůůŝĚĂǇ ? dŚĞ ɴ1-adrenoceptor
 ?ĂĐĐĞƐƐŝŽŶŶƵŵďĞƌ PED Y ? ? ? ? ? ? ?ƚĞŵƉůĂƚĞEǁĂƐĨƌŽŵĂɴ1-adrenoceptor
construct previously made by Dr Baker. The following PCR primers were
ĚĞƐŝŐŶĞĚĂŶĚƵƐĞĚĨŽƌɴ1AR amplification: 5 primer (5  CCGCC/GGATCC/CTG
GGC GCG GGG GTG CTC G  3) containing both a BamHI cleavage site and a
mismatch to mutate the receptor start codon (ATGCTG), 3 primer (5 
GGCGG/GAATTC/CTA CAC CTT GGA TTC CGA GG  3) containing an EcoRI site.
'ĞŶĞƌĂƚŝŽŶŽĨĂ,KĐĞůůůŝŶĞĞǆƉƌĞƐƐŝŶŐ^EW ?ƚĂŐŐĞĚŚƵŵĂŶɴ1-
adrenoceptors
This was carried out as described in Materials and Methods: Generation of
new cell lines ?,ĞƌĞ ?ƚŚĞ^EW ?ƚĂŐŐĞĚŚƵŵĂŶɴ1-adrenoceptor fusion protein
construct was transfected into CHO-K1 cells stably expressing the CRE-SPAP
reporter gene (CHO-CS cells; McDonnell et al. (1998)).
Cell culture
dŚĞ ,K ?ɴ1-CS cell line and the generated CHO-CS cell lines expressing the
^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor were used in this chapter. The cell lines were
maintained in growth media (see Materials and Methods: Cell culture for
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details) which was supplemented with 1 mg/mL of geneticin (G418) for
ŵĂŝŶƚĞŶĂŶĐĞŽĨĐĞůů ůŝŶĞƐƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor
construct.
SNAP-tag labelling and confocal microscopy
This was performed as described in Materials and Methods: Confocal
microscopy using 8-well borosilicate chambered-coverglass plates imaged on
a Zeiss LSM710 laser scanning microscope with a 40x1.3NA oil immersion lens.
>ĂďĞůůŝŶŐŽĨĐĞůůƐƵƌĨĂĐĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors was achieved using 1
µM impermeable SNAP-tag substrate SNAP-Surface® 488 BG-488 (final
concentration; 10 min, in the dark, 21 °C). The confocal settings used to image
SNAP-tag labelling were as follows: 488 nm excitation using an argon laser
with emission captured through a 505-634 nm filter (1024x1024 pixels,
averaging at 4 frames). A pinhole diameter of 1 Airy unit was used.
IX Ultra confocal plate reader
,K ?^ĐĞůůůŝŶĞƐƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐ^EW ?ƚĂŐŐĞĚɴ1AR were imaged on the IX
Ultra confocal plate reader using a Plan Fluor 40x NA0.6 objective as
described inMaterials and Methods: ImageXpress Ultra confocal plate reader.
CRE-mediated SPAP transcription
The CRE-dependent transcription of secreted placental alkaline phosphatase
(SPAP) was determined in agonist and antagonist mode as described in
Materials and Methods: CRE-mediated SPAP transcription assay.
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3.3 Results
'ĞŶĞƌĂƚŝŽŶŽĨƚŚĞ^EW ?ƚĂŐŐĞĚŚƵŵĂŶɴ1AR construct
The SNAP-tag sequence used in this study contains an 84 base long signal
sequence (sig; s) upstream of the SNAP-tag sequence (SNAP; s). Throughout
this thesis the SNAP-tag refers to the sequence including both the signal and
the SNAP-tag sequence, which is denoted by a prefix of sig.SNAP or ss in
DNA constructs and cell lines.
The signal sequence is, once transcribed, required for the correct membrane
ŝŶƐĞƌƚŝŽŶ ĂŶĚ ƚĂƌŐĞƚŝŶŐ ŽĨ ƚŚĞ ^EW ?ɴ1AR fusion protein in the cell. Indeed,
the first 25 (75 bases) amino acids of the signal sequence are identical to the
first 25 amino acids (including the ATG start codon) of the (house mouse) 5-
hydroxytryptamine (serotonin) 3A (5-HT3A) receptor sequence (accession
number AY605711; see Appendix I S1 for alignment of the two sequences), a
ligand-gated ion channel membrane protein (Hargreaves et al., 1994). The
downstream SNAP-tag sequence is 549 bases in length and starts with a
Leucine residue as the Methionine start codon was mutated to allow the
continuous transcription downstream of the signal sequence. In total, the
complete SNAP-tag (including the signal sequence) is 633 bases long and was
inserted into the plasmid vector pcDNA3.1(Neo+) (see Methods for detailed
vector map) between the restriction enzyme sites of KpnI and BamHI (633 bp,
Figure3.1, lane 2).
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dŚĞɴ1AR sequence was amplified in a PCR reaction using forward and reverse
primers which were designed to introduce BamHI (upstream of the start of
ƚŚĞɴ1AR sequence) and EcoR/ ?ĚŽǁŶƐƚƌĞĂŵŽĨƚŚĞĞŶĚŽĨƚŚĞɴ1AR sequence)
restriction enzyme sites and a mutated start codon (Methionine to Leucine)
to allow for continued transcription downstream of the SNAP-tag sequence.
dŚĞ ɴ1AR sequence was then inserted into the pcDNA3.1(Neo+) plasmid
vector already containing the SNAP-tag sequence between the restriction
enzyme site BamHI and EcoRI (1434 bp, Figure 3.1, lane 3), thus fusing the
^EW ?ƚĂŐ ƚŽ ƚŚĞ E ?ƚĞƌŵŝŶĂů ŽĨ ƚŚĞ ɴ1-adrenoceptor between restriction
enzyme site KpnI and EcoRI (2067 bp, Figure 3.1, lane 4). The entire sig.SNAP-
ɴ1AR sequence in the pcDNA3.1(Neo+) plasmid vector has been confirmed by
DNA sequencing (see Appendix I S2 for DNA and protein sequence of entire
fusion protein).
128
Figure 3.1 A, schematic diagram of the pcDNA3.1(Neo+) vector, the restriction
enzyme sites within its multiple cloning site and the restriction enzymes used to
ŝŶƐĞƌƚ ƚŚĞ ƐŝŐ ?^EW ?ɴ1AR construct. B, restriction enzyme digests of the sig.SNAP-
ɴ1AR construct were run on a 1% agarose gel. Lane 1, following a KpnI digest the gel
ƐŚŽǁƐ ƚŚĞ ůŝŶĞĂƌŝƐĞĚ ǀĞĐƚŽƌ ĐŽŶƚĂŝŶŝŶŐ ƚŚĞ ĞŶƚŝƌĞ ƐŝŐ ?^EW ?ɴ1AR construct in one
band (7501 bp). Lane 2, following a KpnI/BamHI double digest the gel shows the
sig.SNAP-tag insert (lower band, 633 bp) and the linearised vector containing the
ɴ1AR sequence (upper band, 6862 bp). Lane 3, following a BamHI/EcoRI double
ĚŝŐĞƐƚƚŚĞŐĞůƐŚŽǁƐƚŚĞɴ1AR insert (lower band, 1434 bp) and the linearised vector
containing the sig.SNAP sequence (upper band, 6061 bp). Lane 4, following a
KpnI/EcoR/ĚŽƵďůĞĚŝŐĞƐƚƚŚĞŐĞůƐŚŽǁƐƚŚĞƐŝŐ ?^EW ?ɴ1AR insert (KpnI/EcoRI digest,
lower band, 2073 bp) and the linearised empty vector (upper band, 5428 bp). Lane M
represents the 1 kb DNA marker lane that yields bands of increasing known sizes
which are listed in base pairs (bp) to the left of the image of the gel.
ƐŝŐ ?^EW ɴ1AR
A
ƐŝŐ ?^EW ?ɴ1AR
4321M
500
750
1,000
1,500
2,000
10,000
3,000
bp
B
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Generation of a CHO cell line stably expressing the SNAP-tagged
ŚƵŵĂŶɴ1AR
dŚĞ ƐŝŐ^EW ?ɴ1AR construct was transfected into CHO-CS cells. Following
dilution cloning, 15 clones were generated and each clonal cell line was
screened for (1) cell surface receptor expression and (2) receptor functionality.
dŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors on the cell surface was
examined using confocal microscopy following the labelling of the SNAP-tag
using a cell membrane impermeable benzyl-guanine (BG) substrate linked to a
488 nm excited fluorophore (BG-488). All 15 clonal cell lines were imaged
 ?ƉƉĞŶĚŝǆ / ^ ? ĂŶĚ ^ ? ? ?  ? ƐŚŽǁĞĚ ^EW ?ƚĂŐŐĞĚ ɴ1AR expression on the cell
membrane (such as clone F6; Figure 3.2B), whereas the remaining 10 clonal
cell lines showed no BG-488 labelling (e.g. clone A9; Figure 3.2C). CHO-CS cells
ĞǆƉƌĞƐƐŝŶŐƚŚĞŶĂƚŝǀĞ ?ƵŶƚĂŐŐĞĚ ?ɴ1AR cells were also exposed to BG-488 and
imaged, and no non-specific labelling effect of the BG-488 substrate could be
observed (Figure 3.2A). Receptor functionality was investigated using the CRE
SPAP reporter assay, as all clonal cell lines contained the CRE-SPAP promoter-
reporter gene construct. The CRE-mediated SPAP secretion of unstimulated
cells (basal) and of cells stimulated by 100 µM forskolin (as a positive control)
and by 10 µM isoprenaline and 10 µM cimaterol were determined to give an
ŝŶĚŝĐĂƚŝŽŶ ŽĨ ƚŚĞ ĨƵŶĐƚŝŽŶĂůŝƚǇ ŽĨ ƚŚĞ ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor and to
determine the assay window of each cell line (using value over baseline
calculations; Figure 3.2). All 10 cell lines that were found not to express the
^EW ?ƚĂŐŐĞĚ ɴ1Z ĂůƐŽƐŚŽǁĞĚ ŶŽ ƌĞƐƉŽŶƐĞ ƚŽ ƚŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŐŽŶŝƐƚƐ
isoprenaline and cimaterol, but only to forskolin, suggesting a lack of the
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receptor as the CRE-mediated SPAP transcription was not impaired (Figure
 ? ? ? ?ĐůŽŶĞ ? ? ?ůů ?ĐĞůůůŝŶĞƐƚŚĂƚǁĞƌĞĨŽƵŶĚƚĞǆƉƌĞƐƐƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ĂůƐŽ ƌĞƐƉŽŶĚĞĚ ƚŽ ďŽƚŚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐ  ?&ŝŐƵƌĞ  ? ? ? ?
ĐůŽŶĞ& ? ? ?,K ?ƐƐɴ1-CS clone F6 showed a good level of expression of SNAP-
ƚĂŐŐĞĚ ɴ1-adrenoceptors albeit heterogeneous. A clonal cell line originates
from one single cell and therefore consists of cells of identical genomic DNA.
Thus, cells of a clonal cell line have the potential to express proteins encoded
in the genomic DNA at the same level. The observed heterogeneous
ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞů ŽĨ ƚŚĞ ,K ?ƐƐɴ1-CS F6 cell line may have been due to it
originating from more than one single cell. In order to try to generate a
homogeneous clonal cell line, clone F6 was dilution cloned and its sub-clones
were screened using the same strategy as outlined above. Cell surface
ĞǆƉƌĞƐƐŝŽŶ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ŝŶ ,K ?ƐƐɴ1F6-CS clones was
examined using the IX Ultra confocal plate reader to allow for imaging of all
clones at the same time under the same conditions. The fluorescence
ŝŶƚĞŶƐŝƚŝĞƐŽĨƚŚĞĨůƵŽƌŽƉŚŽƌĞůŝŶŬĞĚƚŽ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors can be
seen for all clones in the montage image of the imaged plate (Figure 3.3B) and
vary from low (clone F6.45) to high (clone F6.1 and F6.13). As all 48 F6 sub-
ĐůŽŶĞƐƐŚŽǁĞĚĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor, they were all
tested for receptor functionality. All clones showed good functional responses,
the responses of five F6 sub-clones are shown in Figure 3.3C (in comparison
ƚŽ ƚŚĞ ƌĞƐƉŽŶƐĞ ƐĞĞŶ ŝŶ ƚŚĞ ƉĂƌĞŶƚĂů ,K ?ƐƐɴ1-CS F6 clone). Subsequent
confocal imaging of the sub-clones revealed a heterogeneous expression level
ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?Ğ ?Ő ? ,K ?ƐƐɴ1-CS clone F6.1, Figure 3.3D)
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as seen in the parent F6 cell line. This suggests that this heterogeneity is an
inherent feature of the expression of this receptor construct in CHO-CS cells
ĨŽůůŽǁŝŶŐ ůŝƉŽĨĞĐƚĂŵŝŶĞ ƚƌĂŶƐĨĞĐƚŝŽŶ ? EĞǀĞƌƚŚĞůĞƐƐ ? ƚŚĞ ,K ?ƐƐɴ1-CS clone
F6.1 cell line was chosen and used for all subsequent experiment in this thesis
ĂŶĚŝƐƌĞĨĞƌƌĞĚƚŽĂƐƚŚĞ,K ?ƐƐɴ1-CS cell line.
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Figure 3.2 ^ĐƌĞĞŶŝŶŐ ,K ?ƐƐɴ1-CS clones for cell surface receptor expression and
functionality. A ? ,K ?^ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ƵŶƚĂŐŐĞĚ ɴ1AR were included in the
screen as a negative SNAP-tag labelling control and a positive control in the SPAP
assay. Data are shown for B ? ,K ?ƐƐɴ1-CS clone F6 and C, clone A9. The left hand
panel shows confocal images following incubation with 1 µM BG-488 (30 min, 37 °C).
The right hand panel shows the response measured in the SPAP assay under
unstimulated conditions (basal) and when stimulated with forskolin, isoprenaline and
cimaterol. Data shown are mean ± s.e.m. of triplicate determinations from one
experiment. The middle panel schematically describes the concept behind the
screening strategy used here which links receptor function to expression. Scale bars
= 50 µm.
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Figure 3.3 ,K ?ƐƐɴ1F6-CS clonal cell lines were screened for cell surface receptor
expression following SNAP-tag labelling using BG-488 in a 96-well plate format. A,
plate map identifying the clonal cell lines in the 49 wells used. B, montage image of
,K ?ƐƐɴ1F6-CS clones (four images per well, i.e. clone) following BG-488 labelling. C,
Z ?ŵĞĚŝĂƚĞĚ^WWƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨ,K ?ƐƐɴ1F6-CS parental clone and five selected
sub-clones in unstimulated cells (basal) and in response to 100 µM forskolin, 10 µM
isoprenaline and 10 µM cimaterol. D, confocal image of sub-clone F6.1 following BG-
488 labelling. Scale bar = 50 µm.
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>ŽƐƐŽĨĞǆƉƌĞƐƐŝŽŶŽǀĞƌƚŝŵĞŽĨƚŚĞ^EW ?ƚĂŐŐĞĚŚƵŵĂŶɴ1AR in
CHO-CS cells
The cimaterol concentration-response curve obtained at a late passage
(passage 18) compared to that of a very early passage (passage 6) was right-
shifted (Figure 3.4A) and the pEC50 derived from that curve (7.27; Table 3.1)
was reduced compared to that from the earlier passage (8.20; Table 3.1). This
was not observed for the partial agonist CGP 12177 as its pEC50 remained
unchanged from cells at passage 6 (7.68; Figure 3.4B; Table 3.1) to cells at
passage 18 (7.51; Table 3.1). However, the maximal response of CGP 12177
reduced from 73.8 % (of 10 µM cimaterol, passage 6) to 37.8 % (of 10 µM
cimaterol, passage 18). This observed trend of reduced efficacy (reduced
pEC50 of full agonist, smaller maximal response of partial agonist) may
indicate a reduced receptor reserve (through a lower level of receptor
expression) in the system. Interestingly, a similar trend was observed using
,K ?^ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ŶĂƚŝǀĞ  ?ƵŶƚĂŐŐĞĚ ? ɴ1-adrenoceptor (Figure 3.4C,
D), suggesting that this is not a SNAP-tag specific observation. Furthermore,
these data highlight that the CGP 12177 and cimaterol responses are
ĚĞƉĞŶĚĞŶƚ ŽŶ ƚŚĞ ůĞǀĞů ŽĨ ɴ1-adrenoceptor expression, indicating that the
ĂĐƚŝŽŶƐŽĨƚŚĞƐĞƚǁŽůŝŐĂŶĚƐĂƚƚŚĞɴ1-adrenoceptor are specific.
dŽ ĨƵƌƚŚĞƌ ĐŽŶĨŝƌŵ Ă ƌĞĚƵĐƚŝŽŶ ŽĨ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞů ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƐŽǀĞƌƚŝŵĞ ?ĐŽŶĨŽĐĂůŝŵĂŐĞƐŽĨ,K ?ƐƐɴ1-CS cells were taken at
ǀĂƌŝŽƵƐƉĂƐƐĂŐĞƐ ?ĨŽůůŽǁŝŶŐ' ? ? ? ?ůĂďĞůůŝŶŐƚŽǀŝƐƵĂůŝƐĞƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-
adrenoceptors expressed on the cell surface (Figure 3.5). Indeed, a similar
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trend was observed as the number of cells labelled by BG-488 in any given
field of view decreased with increasing passages.
ƐƐƵĐŚ ?ďŽƚŚƚŚĞ,K ?ɴ1 ?^ĂŶĚƚŚĞ,K ?ƐƐɴ1-CS clonal cell lines were used
only for up to 5 passages for all subsequent experiments in this thesis.
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Figure 3.4>ŽƐƐŽĨĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞ^EW ?ƚĂŐŐĞĚĂŶĚŶĂƚŝǀĞɴ1-adrenoceptor in CHO-
CS cells over time. CRE-mediated SPAP transcription of cimaterol and CGP 12177 at
ǀĂƌŝŽƵƐ ƉĂƐƐĂŐĞ ŶƵŵďĞƌƐŽĨ ƚŚĞ ,K ?ƐƐɴ1-CS cell line (panel A and B, respectively)
ĂŶĚ ,K ?ɴ1-CS cell line (panel C and D, respectively). Data were normalised to
maximum SPAP production levels determined by 10 µM cimaterol for each passage
number. Data are mean ± s.e.m of triplicate determinations from a single experiment.
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Figure 3.5 ŽŶĨŽĐĂů ŝŵĂŐĞƐ ŽĨ ,K ?ƐƐɴ1-CS cell line at various passages following
incubation with the SNAP-tag substrate BG-488 (1 µM, 37 °C, 30 min). Cells were
imaged at room temperature and the same microscope settings were used for all
passage numbers shown. Scale bar = 50 µm.
P6 P12P9
P15 P18
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Table 3.1 Potency parameters of cimaterol and CGP 12177 at various passage
ŶƵŵďĞƌƐ ŽĨ ƚŚĞ ,K ?ƐƐɴ1 ?^ ĂŶĚ ,K ?ɴ1-CS cell line. Data are from one single
experiment per passage number.
cimaterol CGP 12177
pEC50 pEC50 EMAX (% cimaterol)
,K ?ƐƐɴ1-CS cells
P6 8.20 7.68 73.8
P9 7.94 7.60 74.6
P12 7.76 7.33 62.0
P15 7.51 7.45 46.0
P18 7.27 7.51 37.8
,K ?ɴ1-CS cells
P21 8.05 7.90 71.2
P24 7.97 7.72 53.6
P27 7.79 7.33 43.3
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Two-site pharmacology at the native and SNAP-tagged human
ɴ1AR expressed in CHO-CS cells
&ŝƌƐƚůǇ ?ƚŚĞƉŽƚĞŶĐŝĞƐŽĨɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐŝŶ,K ?ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1-CS
cells were investigated, and determined to be similar in both cell lines (P >
0.05, unpaired t-test, Figure 3.6; Table 3.2). Forskolin was used as a positive
control of CRE-mediated SPAP transcription as it raises cAMP levels by
activating adenylyl cyclase directly (Zhang et al., 1997). Forskolin stimulated
CRE-mediated gene transcription to give concentration-dependent increases
ŝŶ^WWƐĞĐƌĞƚŝŽŶŝŶ,K ?ɴ1-CS cells (pEC50 5.48 ± 0.14, EMAX 123.1 ± 6.0 % of
 ? ? A?D ĐŝŵĂƚĞƌŽů ?  ? ? ? ? A?  ? ? ? ? ĨŽůĚ ŽǀĞƌ ďĂƐĂů ? ŶA? ? ?ŶĚ ,K ?ƐƐɴ1-CS (pEC50
5.52 ± 0.41, EMAX 109.7 ± 11.4 % of 10 µM cimaterol, 1.78 ± 0.08 fold over
ďĂƐĂů ?ŶA? ? ? ?dŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŐŽŶŝƐƚƐ ŝƐŽƉƌĞŶĂůŝŶ ĂŶĚĐŝŵĂƚĞƌŽů ?ŝŶĚƵĐĞĚ
CRE-mediated SPAP transcription with pEC50 values of 7.16 ± 0.21 (EMAX 109.0
± 3.5 % of 10 µM cimaterol, n=8) and 7.93 ± 0.06 (EMAX set to 100 %, n=25),
ƌĞƐƉĞĐƚŝǀĞůǇŝŶ,K ?ɴ1-CS cells and 7.00 ± 0.16 (EMAX 117.7 ± 3.0 % of 10 µM
cimaterol, n=4) and 7.90 ± 0.06 (EMAX set to 100 %, n=20), respectively, in
,K ?ƐƐɴ1-CS cells. CGP 12177 also elicited a concentration-dependent
increase in CRE-mediated SPAP secretion albeit with a smaller maximal
ƌĞƐƉŽŶƐĞ ĐŽŵƉĂƌĞĚ ƚŽ ĨƵůů ĂŐŽŶŝƐƚ ĐŝŵĂƚĞƌŽů ? ŝŶ ďŽƚŚ ,K ?ɴ1-CS and CHO-
ƐƐɴ1-CS cells. The pEC50 values derived from the concentration-response curve
were 7.73 ± 0.11 (EMAX 45.2 ± 3.5 % of 10 µM cimaterol, n=13) and 7.88 ± 0.12
(EMAX ? ? ? ?A? ? ? ?A?ŽĨ ? ?A?DĐŝŵĂƚĞƌŽů ?ŶA? ? ? ?ŝŶ,K ?ɴ1 ?^ ĐĞůůƐĂŶĚ,K ?ƐƐɴ1-
CS, respectively. This partial agonist effect of CGP 12177 is reported in the
ůŝƚĞƌĂƚƵƌĞ ƚŽŽĐĐƵƌƚŚƌŽƵŐŚƚŚĞ ůŽǁĂĨĨŝŶŝƚǇƐĞĐŽŶĚĂƌǇďŝŶĚŝŶŐƐŝƚĞŽĨƚŚĞɴ1-
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adrenoceptor, whereas isoprenaline and cimaterol effects are mediated
through the high affinity catecholamine site (Joseph et al., 2004; Konkar et al.,
2000; Pak et al., 1996).
The potency of an agonist is dictated by two parameters: efficacy and affinity.
For a partial agonist (an agonist that has low efficacy), its EC50 would be
expected to be similar to its KD. The pKD for CGP 12177 derived from the CGP
12177 partial agonist concentration-response curve using the operational
model of partial agonism (Leff et al., 1993) was determined to be 7.58 ± 0.13
 ?ŶA? ? ? ? dĂďůĞ  ? ? ? ? ĂŶĚ  ? ? ? ? A?  ? ? ? ?  ?ŶA? ? ? ? dĂďůĞ  ? ? ? ? ŝŶ ,K ?ɴ1-CS and CHO-
ƐƐɴ1-CS cells, respectively.
dŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ 'W  ? ? ? ? ? ĂŶĚ ƉƌŽƉƌĂŶŽůŽů ǁĞƌĞ ĂůƐŽ
tested in this assay format, but neither ligand induced an increase in SPAP
secretion (Figure 3.7; Table 3.2) and as such confirmed that they have no
ĞĨĨŝĐĂĐǇŝŶƚŚŝƐĂƐƐĂǇŝŶďŽƚŚ,K ?ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1-CS cell lines.
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Figure 3.6 CRE-mediated SPAP transcription in response to forskolin, cimaterol, CGP
12177 and isoprenaline in A ?,K ?ɴ1-CS and B ?,K ?ƐƐɴ1-CS cells. Bar graphs show
basal SPAP secretion from unstimulated cells. Data are mean ± s.e.m. of triplicate
determinations from a single experiment. The single experiment data shown is
representative of at least A, eight and B, three separate experiments for each ligand
in the respective cell lines.
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Figure 3.7 Z ?ŵĞĚŝĂƚĞĚ ^WW ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
antagonists propranolol and CGP 20712A in A ?,K ?ɴ1-CS and B ?,K ?ƐƐɴ1-CS cells.
Bar graphs show basal SPAP secretion and that in response to 10 µM cimaterol. Data
are mean ± s.e.m. of triplicate determinations from a single experiment. The single
experiment data shown is representative of at least A, six and B, five separate
experiments for each ligand in the respective cell lines.
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Table 3.2WŽƚĞŶĐǇƉĂƌĂŵĞƚĞƌƐŽĨɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐĂƚ,K ?ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1-CS cells obtained in the CRE-mediated gene (SPAP) reporter assay.
ĂƚĂĂƌĞŵĞĂŶA?Ɛ ?Ğ ?ŵ ?ŽĨĂŐŝǀĞŶ ?Ŷ ?ŶƵŵďĞƌŽĨƐĞƉĂƌĂƚĞĞǆƉĞƌŝŵĞŶƚƐ ?EŽƐƚĂƚŝƐƚŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞŽĨĚĂƚĂŽďƚĂŝŶĞĚŝŶ,K ?ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1F6.1-CS cells
was determined using unpaired t-test (statistical significance defined as P < 0.05).
  ,K ?ɴ1 ?^ĐĞůůƐ   ,K ?ƐƐɴ1F6.1-CS cells
pEC50 EMAX (% 10 µM cimaterol) n pEC50 EMAX (% 10 µM cimaterol) n
forskolin 5.48 ± 0.14 123.1 ± 6.0 9 5.52 ± 0.41 109.7 ± 11.4 3
isoprenaline 7.16 ± 0.21 109.0 ± 3.5 8 7.00 ± 0.16 117.7 ± 3.0 4
cimaterol 7.93 ± 0.06 100 25 7.90 ± 0.06 100 20
CGP 12177 7.73 ± 0.11 45.2 ± 3.5 13 7.88 ± 0.12 57.5 ± 4.9 16
propranolol no detectable response up to 10 µM 8 no detectable response up to 10 µM 8
CGP 20712A no detectable response up to 10 µM 6 no detectable response up to 10 µM 5
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&ŽůůŽǁŝŶŐ ƚŚŝƐ ? ƚŚĞ ĂĨĨŝŶŝƚŝĞƐ ŽĨ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ 'W  ? ? ? ? ?ĂŶĚ
propranolol for the high affinity catecholamine ȕ1-adrenoceptor site were
ĞǆĂŵŝŶĞĚĂƚƚŚĞŶĂƚŝǀĞĂŶĚ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor expressed in CHO-
CS cells (Table 3.3). Both antagonists caused parallel rightward shifts of the
ĐŝŵĂƚĞƌŽůĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ƌĞƐƉŽŶƐĞĐƵƌǀĞ ŝŶ,K ?ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1-CS cells.
The affinity of CGP 20712A was not significantly different in the two cell lines
(P > 0.05, unpaired t-test), with pA2 values of 8.84 ± 0.11 (Schild slope 1.17 ±
 ? ? ? ? ?ŶA? ? ?ĂŶĚ ? ? ? ?A? ? ? ? ? ?^ĐŚŝůĚƐůŽƉĞ ? ? ? ?A? ? ? ? ? ?ŶA? ? ?ŝŶ,K ?ɴ1-CS (Figure
 ? ? ? ? ĂŶĚ ,K ?ƐƐɴ1-CS cells (Figure 3.9), respectively. The affinity value
ĚĞƚĞƌŵŝŶĞĚĨŽƌƉƌŽƉƌĂŶŽůŽůĂŐĂŝŶƐƚĐŝŵĂƚĞƌŽůĂƚ ƚŚĞŶĂƚŝǀĞɴ1AR (pA2 8.65 ±
0.07, Schild slope 1.00 ± 0.04, n=23; Figure 3.10) also compared well to that
ŽďƚĂŝŶĞĚĂƚƚŚĞ^EW ?ƚĂŐŐĞĚɴ1AR (pA2 8.45 ± 0.07, Schild slope 1.16 ± 0.05,
n=15; Figure 3.11; P > 0.05, unpaired t-test). The Schild slopes obtained for
both antagonists against cimaterol at both the native and the SNAP-tagged
ɴ1-adrenoceptor were not significantly different to unity (P > 0.05, one-
sample t-test comparison to hypothetical value of 1.0), suggesting that the
interactions between the antagonists and cimaterol at the high affinity
catecholamine site are competitive, and were not affected by the N-terminal
SNAP-tag.
CGP 12177, when used as an antagonist, was able to inhibit the cimaterol-
stimulated response in a manner consistent with its partial agonist actions in
ďŽƚŚ ,K ?ɴ1 ?^ ĂŶĚ ,K ?ƐƐɴ1-CS cells (Figure 3.12). The cimaterol
concentration-response curves were right-shifted in the presence of
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increasing CGP 12177 concentrations. However, at the concentrations of CGP
12177 used, the basal levels of the cimaterol concentration-response curves
were raised, which is in line with the CGP 12177 agonist effect described
above. Using the partial agonist method of Stephenson (1956), a log pKB value
of 9.61 ± 0.06 (n=10) and 9.52 ± 0.10 (n=6) for CGP 12177 at the high affinity
ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ ǁĂƐ ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1 ?^ ĂŶĚ ,K ?ƐƐɴ1-CS cells,
respectively.
For any ligand, its affinity to a given receptor would be expected to be
constant. However, the calculated KD value for CGP 12177 when used to
antagonise cimaterol was two orders of magnitude lower than the KD value
derived from the CGP 12177 partial agonist response curve obtained in the
ƐĂŵĞ ĂƐƐĂǇ ŽŶ ,K ?ɴ1-CS (P AM  ? ? ? ? ? ƵŶƉĂŝƌĞĚ ƚ ?ƚĞƐƚ ? ĂŶĚ ,K ?ƐƐɴ1-CS (P <
 ? ? ? ? ? ƵŶƉĂŝƌĞĚ ƚ ?ƚĞƐƚ ? ĐĞůůƐ ? dŚŝƐ 'W  ? ? ? ? ? ƉŚĂƌŵĂĐŽůŽŐǇ Ăƚ ƚŚĞ ɴ1-
adrenoceptor is in line with previously reported data that led to the two-site
ďŝŶĚŝŶŐƐŝƚĞŚǇƉŽƚŚĞƐŝƐĨŽƌƚŚĞɴ1-adrenoceptor that describes a high affinity
ƐŝƚĞ ? ?ĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞ ?ǁŚĞƌĞ'W ? ? ? ? ?ƉŽƚĞŶƚůǇŝŶŚŝďŝƚƐɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
agonists such as cimaterol) and a low affinity site 2 CGP 12177 site (where
CGP 12177 exhibits partial agonist effects; Pak et al. (1996)).
146
Figure 3.8 A, CRE-mediated SPAP transcription to cimaterol in the absence and
ƉƌĞƐĞŶĐĞ ŽĨ  ? ? ?  ? ? ĂŶĚ  ? ? ? ŶD 'W  ? ? ? ? ? ŝŶ ,K ?ɴ1-CS cells. Bar graphs show
basal SPAP secretion from unstimulated cells and that in response to 10, 30 and 100
nM CGP 20712A alone. Data are mean ± s.e.m. of triplicate determinations from a
single experiment which is representative of five separate experiments. B, Schild plot
of data shown in A (slope 1.05, R2 0.99).
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Figure 3.9 A, CRE-mediated SPAP transcription to cimaterol in the absence and
ƉƌĞƐĞŶĐĞŽĨ  ? ? ?  ? ?ĂŶĚ  ? ? ?ŶD'W  ? ? ? ? ? ŝŶ,K ?ƐƐɴ1-CS cells. Bar graphs show
basal SPAP secretion from unstimulated cells and that in response to 10, 30 and 100
nM CGP 20712A alone. Data are mean ± s.e.m. of triplicate determinations from a
single experiment which is representative of seven separate experiments. B, Schild
plot of data shown in B (slope 1.00, R2 0.98).
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Figure 3.10 A, CRE-mediated SPAP transcription of cimaterol in the absence and
ƉƌĞƐĞŶĐĞŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDƉƌŽƉƌĂŶŽůŽůŝŶ,K ?ɴ1-CS cells. Bar graphs show basal
SPAP secretion levels of unstimulated cells and that of cells treated with 10, 30 and
100 nM propranolol only. Data are mean ± s.e.m. from a single experiment which is
representative of 23 separate experiments. B, Schild plot of data shown in A (slope
1.08, R2 1.00).
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Figure 3.11 A, CRE-mediated SPAP transcription of cimaterol in the absence and
ƉƌĞƐĞŶĐĞŽĨ  ? ? ?  ? ? ĂŶĚ  ? ? ? ŶD ƉƌŽƉƌĂŶŽůŽů ŝŶ ,K ?ƐƐɴ1-CS cells. Bar graphs show
basal SPAP secretion levels of unstimulated cells and that of cells treated with 10, 30
and 100 nM propranolol only. Data are mean ± s.e.m. from a single experiment
which is representative of 15 separate experiments. B, Schild plot of data shown in B
(slope 1.03, R2 0.98).
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Figure 3.12 CRE-mediated SPAP transcription of cimaterol in the absence and
presence of 1, 3 and 10 nM CGP 12177 in A ?,K ?ɴ1-CS and B ?,K ?ƐƐɴ1-CS cells. Bars
show basal SPAP secretion of unstimulated cells and that in response to 1, 3 and 10
nM CGP 12177 alone. Data are mean ± s.e.m. of triplicate determinations from a
single experiment which is representative of A, 10 and B, 6 separate experiments.
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dŚĞĂŐŽŶŝƐƚĞĨĨĞĐƚŽĨ'W ? ? ? ? ?ŝƐƌĞƉŽƌƚĞĚƚŽďĞƌƐŝƐƚĂŶƚƚŽɴ ?ďůŽĐŬĞƌĂĐƚŝŽŶ
Ăƚ ƚŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ƵƐĞĚ ƚŽ ŝŶŚŝďŝƚ ĂŐŽŶŝƐƚ ?ŵĞĚŝĂƚĞĚ ƐƚŝŵƵůĂƚŝŽŶ ŽĨ ɴ1AR
through the catecholamine site (Baker et al., 2003a; Konkar et al., 2000). To
confirm that we observe similar pharmacology in the CHO-CS cells expressing
ƚŚĞŶĂƚŝǀĞĂŶĚĂůƐŽƚŚĞ^EW ?ƚĂŐŐĞĚɴ1AR, we determined the affinity values
of CGP 20712A and propranolol using CGP 12177 as the agonist in both CHO-
ɴ1 ?^ĂŶĚ,K ?ƐƐɴ1-CS cells.
CGP 20712A caused parallel rightward shifts of the CGP 12177 concentration-
response curve in both cell lines, yielding similar pA2 values in the two cell
lines (P > 0.05, unpaired t-test) of 6.73 ± 0.22 (Schild slope 1.22 ± 0.21, n=7)
ĂŶĚ ? ? ? ?A? ? ? ? ? ?^ĐŚŝůĚƐůŽƉĞ ? ? ? ?A? ? ? ? ? ?ŶA? ? ?ŝŶ,K ɴ1-CS (Figure 3.13) and
,K ?ƐƐɴ1-CS cells (Figure 3.14), respectively (Table 3.3). Increasing
propranolol concentrations also caused right-ward shifts of the CGP 12177
concentration-response curves to give a pA2 value of 6.04 ± 0.18 (Schild slope
 ? ? ? ?A? ? ? ? ? ?ŶA? ? ?ĂŶĚ ? ? ? ?A? ? ? ? ? ?^ĐŚŝůĚƐůŽƉĞ ? ? ? A? ? ? ? ? ?ŶA? ? ?ŝŶ,K ?ɴ1-CS
 ?&ŝŐƵƌĞ  ? ? ? ? ? ĂŶĚ ,K ?ƐƐɴ1-CS cells (Figure 3.16), respectively. The Schild
slopes obtained for CGP 20712A and propranolol against CGP 12177 at both
ƚŚĞŶĂƚŝǀĞĂŶĚ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor were not significantly different
from unity (P > 0.05, one-sample t-test performed for each ligand in
comparison to a hypothetical value of 1.0), indicating a competitive
ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ƚŚĞ ĂŶƚĂŐŽŶŝƐƚ ĂŶĚ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-
adrenoceptor site.
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According to classical receptor theory, the affinity of an antagonist for a given
receptor should be independent of the agonist used. However, the affinity
ǀĂůƵĞƐ ĐĂůĐƵůĂƚĞĚ ĨŽƌ 'W  ? ? ? ? ? ĂŶĚ ƉƌŽƉƌĂŶŽůŽů ĂŐĂŝŶƐƚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
agonist cimaterol is two orders of magnitude higher than affinity values
calculated for the two antagonists when CGP 12177 was used as an agonist, in
ďŽƚŚ ,K ?ɴ1-CS (P < 0.01, unpaired t-test performed for both antagonists)
ĂŶĚ ,K ?ƐƐɴ1-CS cells (P < 0.01, unpaired t-test performed for both
ĂŶƚĂŐŽŶŝƐƚƐ ? ? dŚŝƐ ŝƐ ŝŶ ůŝŶĞ ǁŝƚŚ ƚŚĞ ƚǁŽ ?ƐŝƚĞ ďŝŶĚ Ő ŚǇƉŽƚŚĞƐŝƐ ĨŽƌ ƚŚĞ ɴ1-
adrenoceptor and describes the resistance of the CGP 12177 partial agonist
ĞĨĨĞĐƚƚŽɴ ?ďůŽĐŬĞƌĂĐƚŝŽŶƐ ?ĂŬĞƌet al., 2003a; Joseph et al., 2004).
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Figure 3.13 A, CRE-mediated SPAP transcription of CGP 12177 in the absence and
ƉƌĞƐĞŶĐĞŽĨ ? ? ?ĂŶĚ  ? ?A?D'W ? ? ? ? ? ŝŶ,K ?ɴ1-CS cells. Bar graphs show basal
SPAP secretion of unstimulated cells and that in response to 10 µM cimaterol and 1,
3 and 10 µM CGP 20712A alone. Data are mean ± s.e.m. of triplicate determinations
from a single experiment which is representative of seven separate experiments. B,
Schild plot of data shown in A (slope 0.90, R2 0.99).
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Figure 3.14 A, CRE-mediated SPAP transcription of CGP 12177 in the absence and
ƉƌĞƐĞŶĐĞŽĨ ? ? ?ĂŶĚ ? ?A?D'W ? ? ? ? ?ŝŶ,K ?ƐƐɴ1-CS cells. Bar graphs show basal
SPAP secretion of unstimulated cells and that in response to 10 µM cimaterol and 1,
3 and 10 µM CGP 20712A alone. Data are mean ± s.e.m. of triplicate determinations
from a single experiment which is representative of nine separate experiments. B,
Schild plot of data shown in B (slope 1.09, R2 1.00).
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Figure 3.15 A, CRE-mediated SPAP transcription of CGP 12177 in the absence and
ƉƌĞƐĞŶĐĞŽĨ  ? ?  ?ĂŶĚ  ? ?A?DƉƌŽƉƌĂŶŽůŽů ŝŶ,K ?ɴ1-CS cells. Bar graphs show basal
SPAP production in unstimulated cells and that in response to 10 µM cimaterol and 1,
3 and 10 µM propranolol alone. Data are mean ± s.e.m. of triplicate determinations
from a single experiment which is representative of five separate experiments. B,
Schild plot of data shown in A (slope 1.03, R2 0.94).
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Figure 3.16 A, CRE-mediated SPAP transcription of CGP 12177 in the absence and
ƉƌĞƐĞŶĐĞŽĨ ? ? ?ĂŶĚ ? ?A?DƉƌŽƉƌĂŶŽůŽůŝŶ,K ?ƐƐɴ1-CS cells. Bar graphs show basal
SPAP production in unstimulated cells and that in response to 10 µM cimaterol and 1,
3 and 10 µM propranolol alone. Data are mean ± s.e.m. of triplicate determinations
from a single experiment which is representative of eight separate experiments. B,
Schild plot of data shown in B (slope 0.88, R2 0.98).
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Table 3.3ĨĨŝŶŝƚǇǀĂůƵĞƐŽĨɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐĂƚƚŚĞE^W ?ƚĂŐŐĞĚĂŶĚŶĂƚŝǀĞɴ1-adrenoceptor expressed in CHO-CS cells. Data are mean ± s.e.m. of a
given (n) number of separate experiments. * denotes statistical significance (p < 0.01, unpaired t-test); for given antagonist compared KD value obtained with CGP
12177 as an agonist to KD value obtained with cimaterol as an agonist; for CGP 12177 compared KD value obtained from partial agonist response curve using the
operational model of partial agonism to KDǀĂůƵĞŽďƚĂŝŶĞĚĂŐĂŝŶƐƚĐŝŵĂƚĞƌŽůƵƐŝŶŐƚŚĞƉĂƌƚŝĂůĂŐŽŶŝƐŵŵĞƚŚŽĚŽĨ^ƚĞƉŚĞŶƐŽŶ ? ? ? ? ? ? ?ĨĨŝŶŝƚǇǀĂůƵĞƐŽĨĞĂĐŚůŝŐĂŶĚĨŽƌɴ1-
adrenoceptor site 1 and site 2 determined at the native receptor were compared to those obtained at the SNAP-tagged receptor using unpaired t-tests, and no statistically
significant difference in affinity values was determined (P > 0.05).
,K ?ɴ1-CS cells ,K ?ƐƐɴ1-CS cells
agonist cimaterol (site 1) pA2 Schild slope n pA2 Schild slope n
CGP 20712A 8.84 ± 0.11 1.27 ± 0.12 5 8.82 ± 0.16 1.21 ± 0.09 7
propranolol 8.65 ± 0.07 1.00 ± 0.04 23 8.45 ± 0.07 1.16 ± 0.05 15
CGP 12177 9.61 ± 0.06 n/a 10 9.52 ± 0.10 n/a 6
agonist CGP 12177 (site 2)
CGP 20712A 6.73 ± 0.22* 1.22 ± 0.21 7 6.79 ± 0.23* 1.18 ± 0.16 9
propranolol 6.04 ± 0.18* 0.85 ± 0.09 5 6.32 ± 0.13* 1.00 ± 0.12 8
CGP 12177 (partial agonism pKA) 7.58 ± 0.13* n/a 13 7.49 ± 0.13* n/a 16
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3.4 Discussion
The SNAP-tag technology provides an alternative strategy for the fluorescent
labelling of target proteins, its main advantages being that the SNAP-tag can
be linked to a variety of different fluorophores to fit experimental needs, and
that cell impermeable labels are available to allow selective labelling of cell
surface over intracellular proteins. In this chapter, the SNAP-tag was fused to
ƚŚĞ E ?ƚĞƌŵŝŶƵƐ ŽĨ ƚŚĞ ɴ1-adrenoceptor and expressed in Chinese hamster
ovary (CHO) cells already containing a cAMP response element (CRE)
promoter and a secreted placental alkaline phosphatase (SPAP) reporter gene.
^ƚĂďůĞ ĐůŽŶĂů ,K ?ƐŝŐ^EW ?ɴ1 ĐĞůů ůŝŶĞƐ  ?,K ?ƐƐɴ1-CS) were generated and
screened for cell surface receptor expression (using fluorescent confocal
microscopy) and receptor functionality (in the CRE-SPAP gene transcription
assay), with the view to be able to use the same clonal cell line for both
imaging and functional studies.
The SNAP-tag is labelled in a suicide enzymatic reaction by means of a
benzylguanine (BG) substrate linked to a fluorophore (e.g. AF-488), resulting
in the fluorophore being covalently and irreversibly linked to the SNAP-tag.
Here, the membrane impermeable substrate BG-488 was used to label SNAP-
ƚĂŐŐĞĚ ɴ1AR expressed on the cell surface of CHO-CS cells. This labelling
strategy revealed a number of clonal cell lines that showed expression of the
target fusion protein on the cell membrane. The SNAP-tag was engineered to
be highly specific for its substrates, a result of truncations and multiple
mutations in the active site of the human DNA repair protein O6-
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methylguanine methyltransferase (MGMT) (see Appendix I S5 for comparison
of human MGMT protein sequence with engineered SNAP-tag protein
sequence). This enzyme removes the methyl group from its DNA target O6-
methylguanine base to prevention of mutations, cytotoxicity and tumor
development (Pegg, 2011). For prevention of the labelling process by an
endogenous O6-alkylguanine alkyltransferase, a cell impermeable SNAP-tag
substrate was used in this study, but in addition CHO cell lines are deficient in
this DNA repair protein (Gautier et al., 2008). Equally, the engineered SNAP-
tag is reported to display low intrinsic activity towards other proteins and
biomolecules, such as double-stranded DNA, in cells (Juillerat et al., 2005). In
line with this, no non-specific labelling effects of BG-488 on cells expressing
ƵŶƚĂŐŐĞĚɴ1-adrenoceptors were observed.
EŽ ^EW ?ƚĂŐŐĞĚ ɴ1AR expression was observed in ten clonal cell lines.
However, they still expressed the antibiotic resistance gene product to allow
these cell lines to survive in a geneticin enriched environment. Why is the
ƌĞƐŝƐƚĂŶĐĞ ŐĞŶĞ ƉƌŽĚƵĐƚ ? ďƵƚ ŶŽƚ ƚŚĞ ɴ1AR receptor expressed? The BG-488
concentration used here was not optimized, but a high concentration (1 µM)
was used to ensure the presence of excess levels of substrate during the
incubation process, and this amount was clearly sufficient to label receptors
ŝŶĨŝǀĞ,K ?ƐƐɴ1-CS cell lines. Incomplete integration of the plasmid may have
occurred, with the result that (1) only a part of the plasmid vector (that
ŝŶĐůƵĚĞĚ ƚŚĞ ĂŶƚŝďŝŽƚŝĐ ƌĞƐŝƐƚĂŶĐĞ ŐĞŶĞ ďƵƚ ŶŽƚ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptor gene) was successfully incorporated into the genomic DNA of
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ƚŚĞ ĐĞůů ? Žƌ  ? ? ? ƚŚĂƚ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor sequence was
integrated in a heavily methylated region of the genomic DNA and as such is
not transcribed at all or at levels too low to detect. Although expression of
^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors was observed for five clonal cell lines, the
level of expression was clearly heterogeneous, with cell surface expression
levels ranging from undetectable to high for cells within the same cell line.
Since these are stable clonal cell lines that have shown some receptor
expression, we can presume that both the antibiotic resistance and the SNAP-
ƚĂŐŐĞĚ ɴ1-adrenoceptor sequence were incorporated into the genomic DNA
of the cell. This integration, however, may still be unstable, leading to the cell
removing the receptor DNA. Alternatively, differences in the transcription and
translation machinery of individual cells (within one clonal cell line) in terms
of their rate or activation / inactivation at different steps, may be a
contributing factor. Having used a cell membrane impermeable SNAP-tag
substrate in this study, an estimation of expression efficiency of the SNAP-
ƚĂŐŐĞĚɴ1-adrenoceptors and thus a potential effect of fusing the N-terminal
^EW ?ƚĂŐ ƚŽ ƚŚĞ ɴ1-adrenoceptor could not be determined. The use of a
membrane permeable SNAP-tag substrate may have been useful here as a
ůĂƌŐĞ ŶƵŵďĞƌƐ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors inside the cell may have
highlighted issues with the transport of the fusion protein to the membrane.
Western blotting experiments could have been used to further confirm those
ĨŝŶĚŝŶŐƐ ?/ƚŝƐĂůƐŽŶŽƚĞǁŽƌƚŚǇƚŚĂƚƚŚĞE ?ƚĞƌŵŝŶƵƐŽĨƚŚĞɴ1-adrenoceptor has
been reported to be subject to cleavage by proteases (Hakalahti et al., 2010b),
which would provide a mechanism that removes the N-terminal SNAP-tag,
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thus resulting in a homogeneous cell line (comparable receptor expression in
cells of clonal cell line) that appears heterogeneous when labelling with a
SNAP-tag substrate. A fluorescent ligand binding approach could be used to
test whether the same heterogenty is observed when labelling the receptor
directly instead of the N-terminal SNAP-tag.
 ,K ĐĞůů ůŝŶĞ ǁĂƐ ƵƐĞĚ ŝŶ ƚŚŝƐ ƐƚƵĚǇ ďĞĐĂƵƐĞ ŝƚ ĚŽĞƐ ŶŽƚ ĞǆƉƌĞƐƐ ƚŚĞ ɴ1-
adrenoceptor endogenously. If unstable integration of the plasmid vector into
the genomic DNA was the cause of the varied receptor expression level, we
ĞŶǀŝƐŝŽŶĞĚďĞŝŶŐĂďůĞƚŽĐŽƌƌĞĐƚƚŚĂƚďǇĚŝůƵƚŝŽŶĐůŽŶŝŶŐŽŶĞĐůŽŶĞ ?,K ?ƐƐɴ1-
CS clone F6) again with the aim to select a sub-clone that has stably
integrated the receptor construct into its genomic DNA and is capable of
expressing the fusion protein on the cell membrane long term. The number of
clones obtained in this screen was unsurprisingly greater (48) as the source
was a clonal cell line rather than a transfected cell population. However, it
appeared that heterogeneity within each sub-clone was still evident, even
though less pronounced. Interestingly, with increasing passages of a clonal
ĐĞůů ůŝŶĞŐĞŶĞƌĂƚĞĚĨƌŽŵŽŶĞƐƵď ?ĐůŽŶĞ ?,K ?ƐƐɴ1-CS clone F6.1), the level of
receptor expression also decreased and appeared increasingly heterogeneous,
although these observations were not further tested in a radioligand binding
assay that would have allowed better quantification of receptor expression
levels in this cell line over time. This may be caused by two scenarios where (1)
the receptor DNA is still present within the genomic DNA but the cell finds it
increasingly difficult to transport the receptors to the surface (as only cell
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surface receptors were labelled), or (2) the receptor DNA but not the
resistance gene sequence was removed or silenced by the host cell (Palmer et
al., 1991). It may be a combination of the two scenarios where initially the
cells express the fusion protein at good levels, but cannot sustain the
expression of the fusion protein, whose transcription is driven by the
immediate-early cytomegalovirus (CMV) promoter. Whilst the strong
enhancement of gene transcription is desired for good expression levels of
the receptor, the constitutive expression of the protein places increased
stress on host cells to facilitate transcription, translation, post-translational
modification, transport to the membrane and degradation. Over time
(passage), cells that cannot cope with the continuous expression of the fusion
protein die, leaving only cells behind which can cope because they either
express the protein at a very low level (if at all), or have removed the receptor
gene entirely. This results in a cell line which gradually expresses the target
protein less and less. Different transfection vectors and systems have been
used to try to address some of the issues mentioned above. Viral vectors such
as the Adenovirus and Semliki Forest virus (SFV) achieve much higher
expression levels in mammalian cells (Drazner et al., 1997; Sen et al., 2003)
although viral vectors are mainly used in structural biology investigations
(Lundstrom et al., 2006). Inducible systems, however, allow expression of the
target protein only when needed for experiments thereby reducing stress for
cells. A cold-inducible expression system, for example, results in low
expression levels at 37 °C and high expression levels at 33 °C temperatures
(Boorsma et al., 2000). However, this is not suitable for studies using
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physiological conditions. A tetracycline-inducible system in which
transcription of the target gene is turned on in the presence of tetracycline
and has been used in in vitro (Chelikani et al., 2006; Lee et al., 2010) and in
vivo studies (Fan et al., 2012; Stieger et al., 2009). If time had allowed, this
would have been a valid strategy here to try to improve expression of SNAP-
ƚĂŐŐĞĚɴ1-adrenoceptors.
The second screening criterion was receptor functionality. Testing both
receptor expression and functionality decreases the chance of selecting false
positives: if only receptor expression is tested, we may assume functionality
of expressed receptors, however, receptor function may be impaired due to
incorrect folding events. Similarly, if only receptor function is tested, we may
assume good receptor expression, however, very few receptors are needed
for efficacious agonists to cause a maximal system response, which may not
be enough receptors to allow detection in imaging studies. In addition,
ŝŶƚĞŐƌĂƚŝŽŶ ŽĨ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1AR construct (or a different part of the
plasmid vector) in one (or more) of the six CRE promoter elements in the
CHO-CS cells could have inactivated those resulting in different levels of
transcription rates of the reporter gene (i.e. functional response readout). To
investigate receptor function, the responses to forskolin, isoprenaline and
cimaterol were determined. Forskolin activates adenylyl cyclase directly via a
GPCR independent route, resulting in a rise in intracellular cAMP which can go
on to activate the CRE SPAP reporter gene, and thus provides a read-out of
ƚŚĞƉƌĞƐĞŶĐĞĂŶĚĨƵŶĐƚŝŽŶĂůŝƚǇŽĨƚŚĞZ ?^WWƌĞƉŽƌƚĞƌŐĞŶĞĐŽŵƉůĞǆ ?dŚĞɴ ?
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AR agonists isoprenaline and cimaterol however, can cause a rise of cAMP
ůĞǀĞůƐ ŝŶ ƚŚĞ ĐĞůů ŽŶůǇ ďǇ ƐƚŝŵƵůĂƚŝŶŐ ƚŚĞ ^EW ?ƚĂŐĞĚ ɴ1-AR. As such, for
observation of a response to only forskolin but not to the agonists an
impaired CRE-SPAP promoter gene could be ruled out and would have to be
ĚƵĞ ƚŽ ƚŚĞ ĂďƐĞŶĐĞ ŽĨ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor or possible
interference of the SNAP-tag. However, for all clones, receptor expression (or
lack of it) could be directly linked to receptor functionality (or lack of it),
ƉƌŽǀŝĚŝŶŐ ĨŝƌƐƚ ĐůƵĞƐ ƚŚĂƚ ƚŚĞ ^EW ?ƚĂŐ ĚŝĚ ŶŽƚ ŝŶƚĞƌĨĞƌĞ ǁŝƚŚ ɴ ?Z ĂŐŽŶŝƐƚƐ
ŝƐŽƉƌĞŶĂůŝŶĞĂŶĚĐŝŵĂƚĞƌŽůďŝŶĚŝŶŐƚŽĂŶĚĂĐƚŝǀĂƚŝŶŐƚŚĞɴ1-adrenoceptor.
The SNAP-tag has been fused to a variety of Class A and C GPCRs for reasons
such as receptor visualisation and to investigate protein-protein interactions
(Alvarez-Curto et al., 2010; Maurel et al., 2008), with no reports of the SNAP-
tag causing hindrance or interference. Interference of the SNAP-tag with the
receptor of interest is not expected (Gautier et al., 2008; Keppler et al., 2003),
ĂůƚŚŽƵŐŚŶŽƐƚƵĚǇŚĂƐǇĞƚƵƐĞĚĂ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein.
Isoprenaline and cimaterol behaved as full agonists in cell lines expressing the
ŶĂƚŝǀĞ  ?ƵŶƚĂŐŐĞĚ ? ĂŶĚ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor, which demonstrates
ƚŚĂƚ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor was functional. CGP 12177 also
exhibited agonist effects although it was less efficacious, producing a smaller
maximal response than cimaterol in the same assay. Partial agonist responses
of CGP 12177 have also been observed in human (Joseph et al., 2003) and
ferret myocardial preparations (Lowe et al., 1999) and in recombinant
systems using various assays (Joseph et al., 2004; Konkar et al., 2000). Whilst
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the EC50 values for the agonists compared well between the native and the
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor, it did not provide a clear insight into possible
ĞĨĨĞĐƚƐ ŽĨ ƚŚĞ ĨƵƐŝŽŶ ŽĨ ƚŚĞ ^EW ?ƚĂŐ ƚŽ ƚŚĞ E ?ƚĞƌŵŝŶƵƐ ŽĨ ƚŚĞ ɴ1-
adrenoceptor on the binding properties of ligands to the receptor as any
effects on affinity may have been masked by receptor expression differences
ďĞƚǁĞĞŶƚŚĞƚǁŽĐĞůů ůŝŶĞƐ ?ƐƐƵĐŚ ?ǁĞŝŶǀĞƐƚŝŐĂƚĞĚƚŚĞĂĨĨŝŶŝƚǇǀĂůƵĞƐŽĨɴ ?
Z ĂŶƚĂŐŽŶŝƐƚƐ ĂŶĚ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ŶĂƚŝǀĞ ĂŶĚ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptor. For a partial agonist, its affinity can be derived from its
concentration-response curve using the operational model of partial agonism
(Leff et al., 1993) and is expected to be similar to its EC50 value as a partial
agonist occupies all available receptors (i.e. no receptor reserve) in order to
elicit its cellular response. This was indeed the case for CGP 12177 with
affinity values in the region of circa 29 nM for both the untagged and SNAP-
ƚĂŐŐĞĚ ɴ1-adrenoceptor. However, when used as an antagonist to inhibit
ĐŝŵĂƚĞƌŽů ?ŝŶĚƵĐĞĚ ɴ1-adrencoeptor responses, CGP 12177 displayed sub-
nanomolar affinity (circa 0.3 nM) at both receptors. The affinity value of a
ligand for its receptor is a constant, and according to classical receptor theory,
should be similar regardless of the assay format used (e.g. partial agonism
and inhibition of full agonist) to determine this value (Kenakin, 2005). Here,
the two affinity values calculated for CGP 12177 are 100-fold different. This is
in line with the literature that reports a two-site binding site hypothesis for
ƚŚĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌĚĞƐĐƌŝďŝŶŐĂ RŚŝŐŚĂĨĨŝŶŝƚǇ ?ĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞ ?ŽĨƚŚĞɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ǁŚĞƌĞ 'W  ? ? ? ? ? ŝŶŚŝďŝƚƐ ɴ ?Z ĂŐŽŶŝƐƚĂĐ ŝŽŶƐ ĂŶĚ Ă ƐĞĐŽŶĚ
 RůŽǁĂĨĨŝŶŝƚǇ ?ƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor where CGP 12177 exhibits agonist
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activity (Baker et al., 2003a; Joseph et al., 2004; Konkar et al., 2000). Here we
ĐŽŶĨŝƌŵĞĚ ƚŚĂƚ ǁĞ ǁĞƌĞ ĂďůĞ ƚŽ ĚĞƚĞĐƚ ƚŚĞ ƉƌĞǀŝŽƵƐůǇ ĚĞƐĐƌŝďĞĚ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƉŚĂƌŵĂĐŽůŽŐǇĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor expressed in CHO
cells using the SPAP gene reporter assay.
The data shown in this chapter indicates that the N-terminal SNAP-tag did not
ĂĨĨĞĐƚ ƚŚĞ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƉƌŽƉĞƌƚŝĞƐ Ăƚ ƚŚĞ ɴ1Z ? ĂƐ ƐŝŵŝůĂƌ ĂĨĨŝŶŝƚŝĞƐ ŽĨ ɴ ?Z
ligands were observed at the native and tagged receptor at both site 1 and
ƐŝƚĞ  ? ŽĨ ƚŚĞ ɴ1-adrenoceptor. The affinities obtained for antagonists
ƉƌŽƉƌĂŶŽůŽů ĂŶĚ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ƚǁŽ ɴ1-adrenoceptor sites displayed
similar differences as those determined for CGP 12177. Affinity values derived
when inhibiting cimaterol concentration-response curves were at least 1.5
orders of magnitude higher than affinity values obtained when CGP 12177
was used as an agonist. According to classical receptor theory, the use of a
different agonist to establish affinity values should not affect the affinity of an
antagonist for a given receptor (Kenakin, 2008). Consistent discrepancies in
affinity values as seen here have traditionally been attributed to ligands
binding to a different receptor (Arunlakshana et al., 1959; Black et al., 1972)
or a different binding site of a receptor (Konkar et al., 2000). However, Baker
et al.  ? ? ? ? ?Đ ? ƐŚŽǁĞĚ ƚŚĂƚ ĂĨĨŝŶŝƚŝĞƐ ŽĨ ĂŶƚĂŐŽŶŝƐƚƐ ĨŽƌƚŚĞ ɴ2-adrenoceptor
were reduced when using a highly efficacious agonist that induces receptor
phosphorylation which results in a different receptor conformation. Partial
agonists were not found to have the same effect (Baker et al., 2003c).
,ŽǁĞǀĞƌ ? ƐƚƵĚŝĞƐ ƵƐŝŶŐ ɴ1AR knockout mice (Kaumann et al., 2001) and
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ƌĞĐŽŵďŝŶĂŶƚ ɴ1AR (Konkar et al., 2000; Pak et al., 1996) have clearly
ĚĞŵŽŶƐƚƌĂƚĞĚ ƚŚĂƚ ƚŚĞ ɴ1-adrenoceptor alone was responsible for the
observed two-site pharmacology. Here, the highly efficacious agonist
cimaterol was used to determined affinity values for site 1. If the determined
ĂĨĨŝŶŝƚŝĞƐ ŽĨ ƚŚĞ ɴZ ĂŶƚĂŐŽŶŝƐƚƐ ƵƐĞĚ ŚĞƌĞ ǁĞƌĞ ĂĨĨĞĐƚĞĚ ďǇ ƚŚĞ ƵƐĞ ŽĨ Ă
highly efficacious agonist as described by Baker et al. (2003c), it would have
resulted in underestimated affinity values of the antagonists at the high
affinity binding site, thus potentially pointing to even higher antagonist
affinity values at the catecholamine site, which would further increase the
differences in affinities of antagonist for the two different sites. The low
affinities of propranolol and CGP 20712A at site 2 also show that the CGP
 ? ? ? ? ?ĂŐŽŶŝƐƚĞĨĨĞĐƚŝƐĂŶƚĂŐŽŶŝƐĞĚĂƚŵƵĐŚŚŝŐŚĞƌɴ ?ďůŽĐŬĞƌĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ?
which is consistent with the findings of Konkar et al. (2000) and Baker et al.
 ? ? ? ? ?Ă ? ĂŶĚ ƚŚĞ ƉƌŽƉŽƐĞĚ ƚǁŽ ?ƐŝƚĞ ŵŽĚĞů ŽĨ ƚŚĞ ɴ1-adrenoceptor.
Furthermore, the interactions between the antagonists and either cimaterol
(site 1) or CGP 12177 (site 2) appear competitive as Schild slopes similar to 1.0
ǁĞƌĞ ŽďƚĂŝŶĞĚ ? /Ŷ ƚŚŝƐ ƐƚƵĚǇ ? ǁĞ ŚĂǀĞ ŶŽƚ ŝŶǀĞƐƚŝŐĂƚĞĚ ƚŚĞ ɴ1-adrenoceptor
two-site pharmacology in a different functional or binding assay to rule out
artefacts associated with receptor over-expression, the cell line or the assay,
as data presented here is in excellent agreement with values reported in the
literature where a variety of expression levels and functional and binding
assays on membrane, whole cell and tissue preparations were used (Baker et
al., 2003a; Joseph et al., 2004; Kaumann et al., 2008; Konkar et al., 2000).
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3.5 Conclusion
In this chapter, the SNAP-tag was successfully fused to the N-terminus of the
ɴ1-adrenoceptor and the fusion protein expressed in CHO-CS cells. Clear
ǀŝƐƵĂůŝƐĂƚŝŽŶ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1AR was observed at the cell surface without
any detectable non-specific labelling effect effects. The SNAP-tag technology
was successfully used to screen for clonal cell lines expressing the fusion
protein. However, expression of the fusion protein appeared to decline with
increasing passages. Furthermore, the two-site pharmacology has been
ŽďƐĞƌǀĞĚ Ăƚ ƚŚĞ ŶĂƚŝǀĞ ŚƵŵĂŶ ɴ1-adrenoceptor expressed in CHO-CS cells
using the CRE-SPAP gene reporter assay. This pharmacology was unaltered by
ƚŚĞĨƵƐŝŽŶŽĨƚŚĞ^EW ?ƚĂŐƚŽƚŚĞE ?ƚĞƌŵŝŶƵƐŽĨƚŚĞɴ1-adrenoceptor. As such,
ƚŚĞ ,K ?ɴ1 ?^ĂŶĚ ,K ?ƐƐɴ1-CS cell lines can be used to further investigate
the two-site hypothesis in subsequent studies.
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Chapter 4
The pharmacology and imaging of
BODIPY-TMR-CGP and
BODIPY630/650-S-PEG8-propranolol
ĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor
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4.1 Introduction
Fluorescent ligands provide an alternative to radiolabelled ligands in studies
determining the affinity values of unlabelled competitor ligands for GPCRs
(McGrath et al., 1996; Stoddart et al., 2012). The use of fluorescent ligands
allows direct visualisation of the receptor of interest in its native environment
(Becker et al., 2001; Schneider et al., 2007). Functional and binding studies
have been carried out on cell populations (Baker et al., 2003d; Stoddart et al.,
2012) and single living cells (Briddon et al., 2007; Hara et al., 2009; May et al.,
2010b) using fluorescent ligands alone or in conjunction with fluorescently
labelled receptors (May et al., 2011).
A large variety of fluorophores are commercially available, and BODIPY
derivatives in particular have been widely used in biological disciplines to
achieve the labelling of protein targets (Hara et al., 2009; Rayo et al., 2011;
Ying et al., 2011). Fluorescent ligands are generated by chemically coupling a
fluorophore to the ligand of interest via a linker (Middleton et al., 2005).
However, the fluorophore itself is comparable in size to a small molecular
weight ligand and thus can markedly influence the pharmacology of that
ligand (Baker et al., 2010). The affinity of a ligand can be reduced but also
increased (Vernall et al., 2012).
'W  ? ? ? ? ? ĂŶƚĂŐŽŶŝƐĞƐ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŐŽŶŝƐƚƐ Ăƚ ƚŚĞ ĞŶĚŽŐĞŶŽƵƐ ŚŝŐŚ
ĂĨĨŝŶŝƚǇĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞ  ?ƐŝƚĞ  ? ?ŽĨƚŚĞɴ1-adrenoceptor, but has also been
shown to exert agonist actions through a second low affinity CGP 12177 site
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 ?ƐŝƚĞ ? ?ŽĨƚŚĞɴ1-adrenoceptor (Baker et al., 2003a; Konkar et al., 2000; Pak et
al., 1996). As a hydrophilic ligand it has been labelled with radioisotopes
(Dubois et al., 1996; Staehelin et al., 1983) and used extensively to determine
affinity values of unlabelled antagonists (Baker, 2005; Joseph et al., 2004).
K/Wz ?dDZ ?'W ŝƐ Ă ƚĞƚƌĂŵĞƚŚǇůƌŚŽĚĂŵŝŶĞ  ?dDZ ? ĚĞƌŝǀĂƚŝǀĞ ŽĨ ƚŚĞ ɴ ?
adrenoceptor ligand CGP 12177 (BY-CGP; Figure 4.1A) and its binding and
ĨƵŶĐƚŝŽŶĂůƉƌŽƉĞƌƚŝĞƐŚĂǀĞďĞĞŶĐŚĂƌĂĐƚĞƌŝƐĞĚĂƚƚŚĞŚƵŵĂŶɴ2-adrenoceptors
in CHO cells (Baker et al., 2003d) and it has been used for visualisation of
adrenoceptors in mouse vascular tissue (Daly et al., 2010). To date, no
ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚ ŚĂƐ ďĞĞŶ ĨƵůůǇ ĞǀĂůƵĂƚĞĚ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor,
ďƵƚ ƚŚĞ ŚŝŐŚ ĂĨĨŝŶŝƚǇ ŽĨ ƚŚĞ 'W  ? ? ? ? ? ǁŝƚŚ ǁŚŝĐŚ ŝƚ ĂŶƚĂŐŽŶŝƐĞƐ ɴ ?
ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŐŽŶŝƐƚƐ Ăƚ ƚŚĞ ĞŶĚŽŐĞŶŽƵƐ ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-
adrenoceptor may suggest a potential use of the fluorescent CGP 12177
ĚĞƌŝǀĂƚŝǀĞƚŽǀŝƐƵĂůŝƐĞƚŚĞŶĂƚŝǀĞɴ1-adrenoceptor. Furthermore, a fluorescent
ůŝŐĂŶĚ ƚŚĂƚ ĚŝƐƉůĂǇƐ Ă ƐŝŵŝůĂƌ ƉŚĂƌŵĂĐŽůŽŐǇ ƚŽ 'W  ? ? ? ? ? Ăƚ ƚŚĞ ɴ1-
adrenoceptor would allow the investigation of receptor-ligand interactions to
further our understanding of the nature of the second CGP 12177 site 2 of
the receptor.
/Ŷ ƚŚŝƐ ĐŚĂƉƚĞƌ ? ǁĞ ŝŶǀĞƐƚŝŐĂƚĞĚ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ ƚǁŽ ĨůƵŽƌĞƐĐĞŶƚ ɴ ?
adrenoceptor ligands: BODIPY-TMR-CGP and BODIPY630/650-S-PEG8-
ƉƌŽƉƌĂŶŽůŽů  ?Ă ĚĞƌŝǀĂƚŝǀĞ ŽĨ ƚŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚ ƉƌŽƉƌĂŶŽůŽů ? z ?
PROP; Figure 4.1B). We aimed to evaluate the pharmacology of both
ĨůƵŽƌĞƐĐĞŶƚůŝŐĂŶĚƐĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor expressed in CHO-CS cells,
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using the same functional assay that was used to investigate the
pharmacology of their unlabelled counterparts (Chapter 3). Secondly, we
aimed to use confocal microscopy to determine the binding properties of
ďŽƚŚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ ĂŶĚ ƚŽ ǀŝƐƵĂůŝƐĞ ƚŚĞ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ŝŶ ,K ?ɴ1-CS
cells with the view to use these fluorescent ligands in subsequent
fluorescence microscopy experiments that allow the investigation of ligand-
receptor interactions at the single cell level in real time.
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Figure 4.1 Structure of A, BODIPY-TMR-CGP (taken from Baker et al. (2003d)) and B,
BODIPY630/650-S-PEG8-propranolol (taken from Baker et al. (2011a)).
A
B
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4.2 Methods
Cell culture
dŚĞ ,K ?ɴ1-CS and CHO-CS cell lines were maintained as described in
Methods: Cell culture ? ,K ?ƐƐɴ1-CS cells were maintained in growth media
supplemented with 1 mg/mL geneticin (G418).
CRE-mediated SPAP transcription
The CRE-dependent transcription of secreted placental alkaline phosphatase
(SPAP) was determined in agonist and antagonist mode as described in
Methods: CRE-mediated SPAP transcription assay.
Confocal microscopy
This was performed as described in Methods: Confocal microscopy using 8-
well borosilicate chambered-coverglass plates imaged on a Zeiss LSM710 laser
scanning microscope with a 40x1.3NA oil immersion lens. In this chapter,
BODIPY-TMR-CGP (BY-CGP) and BODIPY630/650-S-PEG8-propranolol (BY-
WZKW ? ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ɴ1-adrenoceptor was investigated in co-localisation
ƐƚƵĚŝĞƐǁŝƚŚƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor expressed in CHO-CS cells, and
ƐĂƚƵƌĂƚŝŽŶĂŶĚĚŝƐƉůĂĐĞŵĞŶƚďŝŶĚŝŶŐƐƚƵĚŝĞƐŝŶ,K ?ɴ1-CS cells as outlined in
Methods: Confocal microscopy ? Ğůů ƐƵƌĨĂĐĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors
were labelled using 1 µM BG-488 (final concentration; 30 min, in the dark,
37 °C). A 543 nm and 633 nm HeNe and 488 nm argon lasers were used to
excite BY-CGP, BY-PROP and BG-488, respectively. A variable spectral
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detection system was used to capture emission at 545-580 nm, 645-680 nm
and 480-530 nm, respectively. All images were taken at 1024x1024 pixels,
averaging at 4 frames. A pinhole diameter of 1 Airy unit was used. The laser
power, gain and offset settings were kept constant throughout each
experiment to allow direct comparison of binding levels for each fluorescent
ligand.
Internalisation
This was performed as described in Methods: Confocal microscopy using the
,K ?ƐƐɴ1 ?^ ĐĞůů ůŝŶĞ ? Ğůů ƐƵƌĨĂĐĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors were
labelled using 1 µM BG-488 (final concentration; 10 min, in the dark, 21 °C)
and imaged using 488 nm argon laser excitation with emission captured
through a 480-530 nm filter (1024x1024 pixels, averaging at 4 frames). A
pinhole diameter of 1 Airy unit was used.
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4.3 Results
CRE-mediated SPAP transcription
Initial experiments focussed on characterising the pharmacology of the
fluorescent CGP 12177 ligand, BODIPY-TMR-CGP (BY-CGP), and confirming
that it had similar pharmacological properties to the parent compound and
ĐŽƵůĚ ƚŚƵƐ ďĞ Ă ƵƐĞĨƵů ƚŽŽů ŝŶ ƚŚĞ ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-
adrenoceptor site. In the CRE-mediated SPAP transcription assay, BY-CGP
caused a concentration-dependent secretion of SPAP that was 25.6 ± 3.2 % of
the maximum cimaterol response with a pEC50 of 7.12 ± 0.13 (n=8, Figure 4.2,
Table 4.1), and thus, like the parent compound (Chapter 3, Figure 3.6),
appeared as a partial agonist in this system. Using cimaterol as a full agonist
to determine the system maximum response, the pKD for BY-CGP was
extracted from its concentration-response curve using the operational model
of partial agonism (Leff et al., 1993) and was determined to be 7.06 ± 0.13
(n=8). Fixed concentrations of BY-CGP shifted the cimaterol concentration-
response curve in a manner consistent with its partial agonist actions, giving a
pKD value of 9.23 ± 0.06 (n=10, Figure 4.3A). This was two orders of
magnitude different to the affinity value derived from its partial agonist
response curve, which was consistent with the two-site binding hypothesis for
ƚŚĞɴ1-adrenoceptor described in previous studies (Baker et al., 2003a; Konkar
et al., 2000; Pak et al., 1996). To further confirm the lower affinity of BY-CGP
at the second site, CGP 12177 concentration-response curves were obtained
in the absence and presence of two fixed concentrations of BY-CGP, giving a
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pKD of 7.28 ± 0.22 (n=3, Figure 4.3B), which was in good agreement with the
value derived from the partial agonist response curve.
To demonstrate that the BY-CGP agonist response, like the CGP 12177 agonist
ƌĞƐƉŽŶƐĞ  ?ŚĂƉƚĞƌ  ? ? &ŝŐƵƌĞ  ? ? ? ? ĂŶĚ  ? ? ? ? ? ? ƌĞƋƵŝƌĞĚ ŵƵĐŚ ŚŝŐŚĞƌ ɴ ?ďůŽĐŬĞƌ
concentrations to be inhibited compared to the cimaterol agonist response,
BY-CGP-stimulated SPAP secretion was measured in the absence and
presence of 1 µM propranolol, giving an apparent pKD value for propranolol of
6.46 ± 0.26 (n=3, Figure 4.4). Due to cost implications of using very high
concentrations of the fluorescent ligand, the inhibitory effects of only one
unlabelled antagonist at only one concentration could be tested.
BODIPY630/650-S-PEG8-propranolol (BY-PROP) showed no efficacy in the
SPAP gene reporter assay as the SPAP secretion levels were unchanged for all
BY-PROP concentrations used and compared to the levels observed in
unstimulated (basal) conditions (Figure 4.5) and thus, like its parent
compound (Chapter 3, Figure 3.7), appeared as an antagonist in this system.
Fixed concentrations of BY-PROP caused parallel rightward shifts of cimaterol
concentration response curves, yielding a pKD value of 7.55 ± 0.05 (n=8, Figure
4.6). From the shifts of the cimaterol concentration-response curves, using
the Schild plot analysis, a Schild slope of 1.16 ± 0.07 (n=8) was determined,
which was not significantly different from unity (P > 0.05, one-sample t-test in
comparison to a hypothetical value of 1.0) and thus indicating a competitive
ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ƚŚĞ ƚǁŽ ůŝŐĂŶĚƐ Ăƚ ƚŚĞ ĐĂƚĞĐŚŽůĂŵŝŶĞ ɴ1-adrenoceptor
ƐŝƚĞ ?dŽĚĞƚĞƌŵŝŶĞƚŚĞĂĨĨŝŶŝƚǇŽĨz ?WZKWĨŽƌƚŚĞƐĞĐŽŶĚĂƌǇɴ1-adrenoceptor
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site, CGP 12177 concentration-response curves in the absence and presence
of 1 µM BY-PROP were obtained. Due to the expense of using high
concentrations of the fluorescent ligand, only one fixed concentration was
used to shift the CGP 12177 concentration-response curve. From this a pKD
value of 6.57 ± 0.20 (n=4, Figure 4.7) was estimated.
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Figure 4.2 CRE-mediated SPAP secretion in response to cimaterol and BODIPY-TMR-
'W  ?z ?'W ? ŝŶ,K ?ɴ1-CS cells. Bar represents SPAP secretion from unstimulated
cells. Data points are mean ± s.e.m. of triplicate determinations from a single
experiment which is representative of at least eight separate experiments.
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Figure 4.3 SPAP secretion in response to A, cimaterol and B, CGP 12177 in the
absence and presence of BODIPY-TMR-CGP (BY-CGP). The bars represent basal SPAP
secretion and that in response to the fixed BODIPY-TMR-CGP concentrations used.
SPAP secretion in response to 10 µM cimaterol was also determined in panel B. Data
points are mean ± s.e.m. of triplicate determinations from a single experiment and
are representative at least three separate experiments.
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Figure 4.4 SPAP secretion induced by BODIPY-TMR-CGP (BY-CGP) in the absence and
presence of 1 µM propranolol. Bars represent basal SPAP secretion from
unstimulated cells, SPAP secretion in response to 10 µM cimaterol and 1 µM
propranolol alone. Data points are mean ± s.e.m. of triplicate determinations of a
single experiment which is representative of 3 separate experiments.
[BY-CGP] Log (M)
[S
PA
P]
(O
D
u
n
its
)
1.0
1.1
1.2
1.3
1.4
2.2
2.6
-10 -9 -8 -7 -6
BY-CGP
BY-CGP + 1 PM propranolol
basal
10 PM cimaterol
1 PM propranolol
182
Figure 4.5 CRE-mediated SPAP secretion in response to cimaterol and
K/Wz ? ? ? ? ? ? ? ?^ ?W' ? ?ƉƌŽƉƌĂŶŽůŽů  ?z ?WZKW ? ŝŶ ,K ?ɴ1-CS cells. Bar represents
SPAP secretion from unstimulated cells. Data points are mean ± s.e.m. of triplicate
determinations from a single experiment which is representative of at least four
separate experiments.
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Figure 4.6 A, SPAP secretion of cimaterol in the absence and presence of increasing
concentrations of BODIPY630/650-S-PEG8-propranolol (BY-PROP). Bars show basal
SPAP secretion from unstimulated cells and that in response to 30, 100 and 300 nM
BY-PROP. Data points are mean ± s.e.m. of triplicate determinations from a single
experiment and are representative of a total of eight separate experiments. B, Schild
plot of data shown in A (slope 1.09, R2 1.00).
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Figure 4.7 SPAP secretion of CGP 12177 in the absence and presence of 1 µM
BODIPY630/650-S-PEG8-propranolol (BY-PROP). Bars show basal SPAP secretion
from unstimulated cells and that in response to 10 µM cimaterol and 1 µM BY-PROP
alone. Data points are mean ± s.e.m. of triplicate determinations from a single
experiment and are representative of a total of three separate experiments.
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Table 4.1 Potency and affinity parameters of BODIPY-TMR-CGP 12177 (BY-CGP) and BODIPY630/650-S-PEG8-propranolol (BY-PROP) compared to their
respective parent ligands. Data are mean ± s.e.m of (n) numbers of separate experiments. Data shown for unlabelled CGP 12177 and propranolol were
obtained in Chapter 3.
CGP 12177 n BY-CGP n propranolol n BY-PROP n
pEC50 7.73 ± 0.11 14 7.12 ± 0.13 8 no response 8 no response 4
EMAX (% cimaterol) 47.8 ± 3.6 14 25.6 ± 3.2 8 no response 8 no response 4
pKA (partial agonism) 7.62 ± 0.13 14 7.06 ± 0.13 8 n/a n/a
pA2 (agonist CGP 12177) n/a 7.28 ± 0.22 3 6.04 ± 0.18 5 6.57 ± 0.20 4
pA2 (agonist cimaterol) 9.61 ± 0.06 10 9.23 ± 0.06 10 8.65 ± 0.07 23 7.55 ± 0.05 8
pA2 (agonist BY-CGP) 6.46 ± 0.26 3
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ZĞƐƉŽŶƐĞƐŽĨɴ ?ZůŝŐĂŶĚƐĂƌĞƐƉĞĐŝĨŝĐƚŽ,KĐĞůůƐĞǆƉƌĞƐƐŝŶŐƚŚĞ
ɴ1-adrenoceptor
dŽ ƐŚŽǁ ƚŚĂƚ ƚŚĞ Z ?ŵĞĚŝĂƚĞĚ ^WW ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ɴ ?
ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ ǁĂƐ ƐƉĞĐŝĨŝĐ ƚŽ ƚŚĞ ɴ1-adrenoceptor expressed in CHO
ĐĞůůƐ ?ĂůůɴZůŝŐĂŶĚƐƵƐĞĚƚŚƌŽƵŐŚŽƵƚƚŚŝƐƚŚĞƐŝƐǁĞƌĞƚĞƐƚĞĚŝŶ,K ?^ĐĞůůƐ
 ?ŝ ?Ğ ?ĐĞůůƐĐŽŶƚĂŝŶŝŶŐƚŚĞZ ?^WWƌĞƉŽƌƚĞƌ ?ďƵƚŶŽƚ ŚĞɴ1-adrenoceptor gene)
and untransfected CHO-K1 cells (i.e. cells not transfected with either the CRE-
^WW ƌĞƉŽƌƚĞƌ Žƌ ƚŚĞ ɴ1-adrenoceptor). No SPAP secretion was detected in
untransfected CHO-K1 cells following treatment with any of the ligands used
(Figure 4.8). However, forskolin stimulated a CRE-SPAP response in control
CHO-CS cells (pEC50 5.14 ± 0.04, n=3; Figure 4.8A) similar to that seen in CHO-
ɴ1-CS cells (pEC50 5.48; chapter 3, Figure 3.1). There was no stimulation of
^WWƐĞĐƌĞƚŝŽŶ ŝŶ ƌĞƐƉŽŶƐĞƚŽĂŶǇŽĨ ƚŚĞɴ ?ĂŐŽŶŝƐƚƐĂŶĚĂŶƚĂŐŽŶŝƐƚƐƵƐĞĚ ŝŶ
control CHO-CS cells (n=3; Figure 4.8B). These data confirm that the SPAP
ƌĞƐƉŽŶƐĞƐƚŽɴ ?ĂŐŽŶŝƐƚƐĚĞƐĐƌŝďĞĚƚŚƌŽƵŐŚŽƵƚƚŚŝƐƚŚĞƐŝƐǁĞƌĞĚĞƉĞŶĚĞŶƚŽŶ
ƚŚĞƉƌĞƐĞŶĐĞŽĨƚŚĞƚƌĂŶƐĨĞĐƚĞĚɴ1-adrenoceptor.
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Figure 4.8 A, CRE-mediated SPAP transcription of forskolin in CHO-K1 and CHO-CS
cells. B, SPAP secretion in response to 10 µM cimaterol, 10 µM CGP 12177, 1µM
BODIPY-TMR-CGP 12177 (BY-CGP), 10 µM propranolol, 1 µM BODIPY630/650-S-
PEG8-propranolol (BY-PROP) and 1 µM CGP 20712A in CHO-K1 and CHO-CS cells.
Response to 100 µM forskolin was also measured as a control.
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z ?'WĂŶĚz ?WZKWďŝŶĚŝŶŐƚŽƚŚĞ^EW ?ƚĂŐŐĞĚŚƵŵĂŶɴ1AR
In order to confirm that BODIPY-TMR-CGP and BODIPY630/650-S-PEG8-
ƉƌŽƉĂŶŽůŽů ǁĞƌĞ ĂďůĞ ƚŽ ƐƉĞĐŝĨŝĐĂůůǇ ůĂďĞů ƚŚĞ ɴ1-adrenoceptor, their binding
ƚŽƚŚĞ^EW ?ƚĂŐŐĞĚɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌŝŶ,K ?ƐƐɴ1-CS cells was examined. The
cell impermeable SNAP-tag substrate BG-488 was used to label cell surface
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors and clear membrane labelling can be seen in
,K ?ƐƐɴ1-CS cells when imaged using the 488 nm (green) channel. As
ƉƌĞǀŝŽƵƐůǇ ĚĞƐĐƌŝďĞĚ  ?ŚĂƉƚĞƌ  ? ? ? ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptor is not homogenous and different expression levels of the SNAP-
ƚĂŐŐĞĚɴ1-adrenoceptor can be seen in Figure 4.9 and 4.10. However, only a
very small percentage of cells showed no or very low expression of the
receptor such that it was not detected at the settings used. 2 nM BODIPY-
TMR-CGP (circa 3x KD concentration at site 1; Figure 4.9) and 20 nM BY-PROP
(circa 1x KD concentration at site 1; Figure 4.10) were able to bind to CHO-
ƐƐɴ1-CS cells and clear membrane labelling was observed in the 543 nm and
633 nm (both red) channels, respectively. It can also be seen that cells with
ŐƌĞĂƚĞƌ^EW ?ɴ1 expression were able to bind more of the fluorescent ligand
used. When superimposed (yellow pixels), the binding of both fluorescent
ligands was clearly seen to localise well with the cell membrane SNAP-tagged
ɴ1AR fluorescence. The co-localisation plots show that most pixels are in
ƋƵĂĚƌĂŶƚ  ? ƌĞƉƌĞƐĞŶƚŝŶŐ ĐŽ ?ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ^EW ?ɴ1 (Ch1) and fluorescent
ligand (Ch2). Furthermore, BY-CGP and BY-PROP binding levels were reduced
in the presence of 100 nM CGP 20712A (60 x KD concentration at the
catecholamine site to achieve complete inhibition; pre-incubation for 30
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ŵŝŶƵƚĞƐ Ăƚ  ? ?  ? ? ? ǁŚŝůƐƚ ŐŽŽĚ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor labelling with
BG-488 was seen. The co-localisation plot now shows most pixels in quadrant
 ? ? ƌĞƉƌĞƐĞŶƚŝŶŐ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors labelled with BG-488 but not
with the fluorescent ligand. This indicates that both fluorescent ligands
specifically bind to the SNAP-tagged receptor.
Figure 4.9ŝŶĚŝŶŐŽĨ ?ŶDz ?'WƚŽ,K ?ƐƐɴ1-CS cells in the absence and presence of 100 nM CGP 20712A. The panels from left to right show the phase
ĐŽŶƚƌĂƐƚŝŵĂŐĞŽĨƚŚĞĨŝĞůĚŽĨǀŝĞǁŝŵĂŐĞĚ ?ƚŚĞĨůƵŽƌĞƐĐĞŶĐĞŵŽŶŝƚŽƌĞĚŝŶƚŚĞŐƌĞĞŶ ? ? ? ?Ŷŵ ?ĐŚĂŶŶĞů ?'  ? ? ?ůĂďĞůůĞĚ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors), the
fluorescence monitored in the red 543 nm channel (2 nM BY-CGP), an overlay of the images collected in the 488 nm (Ch1) and 561 nm (Ch2) channel with
co-localisation of red and green fluorescence shown by the yellow pixels, and a co-localisation plot with co-localised pixels in compartment 3. Co-
localisation analysis was done as described in Methods  ?ŚĂƉƚĞƌ  ? ? ?WƌŝŽƌƚŽ ŝŵĂŐŝŶŐ ? ƚŚĞ,K ?ƐƐɴ1-CS cells were incubated with 1 µM BG-488 (30 mins,
 ? ? ? ?ƚŽůĂďĞůƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor. The cells were then washed and pre-incubated with 100 nM CGP 20712A (30 mins, 37 °C) before the cells
were exposed to 2 nM BY-CGP (10 min, 21 °C). Both CGP 20712A and BY-CGP were not washed out before imaging. Scale bars = 50 µm.
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Figure 4.10ŝŶĚŝŶŐŽĨ  ? ?ŶDz ?WZKWƚŽ,K ?ƐƐɴ1-CS cells in the absence and presence of 100 nM CGP 20712A. The panels from left to right show the
ƉŚĂƐĞ ĐŽŶƚƌĂƐƚ ŝŵĂŐĞ ŽĨ ƚŚĞ ĨŝĞůĚ ŽĨ ǀŝĞǁ ŝŵĂŐĞĚ ? ƚŚĞ ĨůƵŽƌĞƐĐĞŶĐĞ ŵŽŶŝƚŽƌĞĚ ŝŶ ƚŚĞ ŐƌĞĞŶ  ? ? ? ? Ŷŵ ? ĐŚĂŶŶĞů  ?' ? ? ? ? ůĂďĞůůĞĚ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptors), the fluorescence monitored in the red (633 nm) channel (20 nM BY-PROP), an overlay of the images collected in the 488 nm (Ch1) and 633
nm (Ch2) channel with co-localisation of red and green fluorescence shown by the yellow pixels, and a co-localisation plot with co-localised pixels in
compartment 3. Co-localisation analysis was done as described in Methods ?ŚĂƉƚĞƌ ? ? ?WƌŝŽƌƚŽŝŵĂŐŝŶŐ ?ƚŚĞ,K ?ƐƐɴ1-CS cells were incubated with 1 µM
' ? ? ? ? ? ? ?ŵŝŶƐ ? ? ? ? ?ƚŽůĂďĞůƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor. The cells were then washed and pre-incubated with 100 nM CGP 20712A (30 mins, 37 °C)
before exposure of cells to 2 nM BY-PROP (10 min, 21 °C). Both CGP 20712A and BY-PROP were not washed out before imaging. Scale bars = 50 µm.
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z ?'WĂŶĚz ?WZKWďŝŶĚŝŶŐƚŽƚŚĞŶĂƚŝǀĞŚƵŵĂŶɴ1AR
ĞĨŽƌĞ ƵŶĚĞƌƚĂŬŝŶŐ ƚŚĞ ĨŝƌƐƚ ƐƚƵĚŝĞƐ ƚŽ ǀŝƐƵĂůŝƐĞ ƚŚĞ ɴ1-adrenoceptor using
fluorescently labelled CGP 12177 and propranolol, we confirmed that we
ĐŽƵůĚ ǀŝƐƵĂůŝƐĞ ƚŚĞ ɴ2-adrenoceptor using the fluorescently labelled CGP
12177, as has been previously reported (Baker et al., 2003d). Here, we
examined the binding of BODIPY-TMR-CGP (BY-CGP) and BODIPY630/650-S-
W' ? ?ƉƌŽƉƌĂŶŽůŽů  ?z ?WZKW ? ƚŽ ,K ?ɴ2-CS cells. Figure 4.11 shows clear
ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ  ? ? ŶD z ?'W ŝŶ ,K ?ɴ2-CS cells, which could be
ŝŶŚŝďŝƚĞĚ ďǇ ƉƌĞ ?ŝŶĐƵďĂƚŝŽŶ ǁŝƚŚ  ? A?D ŽĨ ƚŚĞ ɴ2-adrenoceptor selective
antagonist ICI 118,551. No detectable BY-CGP binding was observed to CHO-
^ĐĞůůƐ ?ŝŶĚŝĐĂƚŝŶŐƚŚĂƚƚŚĞďŝŶĚŝŶŐŽĨz ?'WƚŽƚŚĞɴ2AR was specific. Clear
ůĂďĞůůŝŶŐ ŽĨ ,K ?ɴ2-CS cell membranes was also seen following exposure of
these cells to 3 nM BY-PROP (Figure 4.12), which was inhibited in a
ĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ĚĞƉĞŶĚĞŶƚŵĂŶŶĞƌďǇ// ? ? ? ? ? ? ? ?dŚĞɴ1-selective antagonist
CGP 20712A was also able to inhibit BY-PROP binding albeit at 1000 fold
higher concentrations, which is in line with the lower affinity CGP 20712A has
ĨŽƌƚŚĞɴ2-adrenoceptor compared to ICI 118,551 (Baker, 2005).
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Figure 4.11 ŝŶĚŝŶŐ ŽĨ  ? ? ŶD K/Wz ?dDZ ?'W  ? ? ? ? ?  ?z ?'W ? ƚŽ,K ?ɴ2-CS and
,K ?^ĐĞůůƐ ?z ?'WďŝŶĚŝŶŐ ? ? ?ŵŝŶ ? ? ? ? ?ƚŽ,K ɴ2-CS cells was inhibited to non-
specific binding levels in the presence of 1 µM ICI 118,551 (pre-incubation for 30
minutes at 37 °C). Images are representatives of a total of two images taken per well
on one experimental day. Scale bar = 50 µm.
CHO-CS cells
20 nM BY-CGP20nM BY-CGP + 1 µM ICI 118,551
,K ?ɴ2-CS cells
Figure 4.12ŝŶĚŝŶŐŽĨ ?ŶDK/Wz ?^ ?W' ? ?ƉƌŽƉƌĂŶŽůŽů ?z ?WZKW ? ? ?ŵŝŶ ? ? ? ? ?ƚŽ,K ?ɴ2-CS and CHO-CS cells in the absence and presence of 1, 10 and
100 nM ICI 118,551 and 1, 10 and 100 µM CGP 20712A (antagonist pre-incubation for 30 minutes at 37 °C). Non-specific binding of 3 nM BY-PROP was
determined in CHO-CS cells. Images are representatives of a total of three images taken of different fields of view within each well on four separate
experimental days. Scale bar = 50 µm.
3 nMBY-PROP + 10 nM ICI 118,551 + 100 nM ICI 118,551+ 1nM ICI 118,551
,K ?ɴ2-CS cells
CHO-CS cells
3 nMBY-PROP+ 1µM CGP20712A + 10 µM CGP20712A + 100 µM CGP20712A
,K ?ɴ2-CS cells
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EĞǆƚ ?ǁĞĞǆĂŵŝŶĞĚƚŚĞďŝŶĚŝŶŐŽĨďŽƚŚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ ƚŽ ƚŚĞŶĂƚŝǀĞɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌŝŶ,K ?ɴ1-CS cells. Both, 2 nM BODIPY-TMR-CGP (BY-CGP) and
20 nM BODIPY630/650-S-PEG8-propranolol (BY-PROP) were able to label the
ƉůĂƐŵĂŵĞŵďƌĂŶĞŽĨ,K ?ɴ1-CS cells following 10 minutes exposure at 21 °C
 ?&ŝŐƵƌĞ ? ? ? ? ? ?,K ?^ĐĞůůƐ ?ĐĞůůƐŶŽƚĞǆƉƌĞƐƐŝŶŐƚŚĞɴ1-adrenoceptor) did not
show clear membrane labelling with the two fluorescent ligands under the
ƐĂŵĞĐŽŶĚŝƚŝŽŶƐ ?&ŝŐƵƌĞ ? ? ? ? ? ?dŚĞďŝŶĚŝŶŐŽĨz ?'WĂŶĚz ?WZKWƚŽ,K ?ɴ1-
CS cells could be displaced by 100 nM CGP 20712A (pre-incubation for 30
minutes at 37 °C) to levels comparable to those detected at CHO-CS cells (i.e.
non-specific). Pre-incubation of CHO-CS cells with CGP 20712A did not reduce
the level of BY-CGP and BY-PROP binding any further.
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Figure 4.13 Binding of A, 2nM BY-CGP and B ? ? ?ŶDz ?WZKWƚŽ,K ?ɴ1-CS and CHO-
CS cells. Confocal images were taken following pre-incubation with HBSS in the
absence and presence of 100 nM CGP 20712A (30 min, 37 °C) and 10 minute
exposure (at 21 °C) of A, 2 nM BY-CGP and B, 20 nM BY-PROP. For each fluorescent
ligand the microscope settings were kept constant for all wells. Images are
representative of at least two different fields of view per well per experimental day.
This experiment was repeated on at least three separate days. Scale bar = 50 µm.
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Following this, we aimed to confirm the affinity values determined for both
fluorescent ligands in functional studies by examining the binding affinity of
ďŽƚŚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ ƚŽ ƚŚĞŶĂƚŝǀĞ ɴ1-adrenoceptor in saturation binding
experiments. Thus, the binding of a range of concentrations (3-100 nM) of BY-
'W ?&ŝŐƵƌĞ ? ? ? ? ?ĂŶĚz ?WZKW ?&ŝŐƵƌĞ ? ? ? ? ?ƚŽ,K ?ɴ1-CS cells was assessed.
For BY-CGP, clear concentration-dependent membrane labelling was seen up
ƚŽ ? ?ŶDŝŶ,K ?ɴ1-CS cells. At BY-CGP concentrations higher than 50 nM (i.e.
100 nM in Figure 4.14A), intracellular BY-CGP could be seen in addition to
membrane labelling. A similar observation of high BY-CGP concentrations
resulting in intracellular fluorescence was reported for this ligand in CHO cells
ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ɴ2-adrenoceptor (Baker et al., 2003d). In order to obtain
affinity values, the image fluorescence (i.e. level of BY-CGP binding) was
quantified and analysed. Quantification of image fluorescence was achieved
using two different methods: (1) total image intensities which included non-
specific background and intracellular fluorescence, and (2) cell membrane
analysis by drawing regions of interest (ROIs) around membranes of six cells
per field of view (which were then averaged per given field of view). Non-
specific binding was not derived separately in the presence of a high
concentration of unlabelled antagonist. Instead, the quantified fluorescence
intensity values per concentration of fluorescent ligand were analysed using
non-linear total binding curve fits (for equation used see Methods: Data
analysis section). This analysis determined the level and slope of background
non-specific binding (shown in dotted lines, Figure 4.14B and C) from the total
binding curve fits. As expected, a higher non-specific binding component was
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present using the total image intensity analysis (55.9 ± 11.1 % of total binding,
n=4; Figure 4.14B) compared to data obtained from membrane regions that
excluded the intracellular fluorescence (41.8 ± 5.6 % of total binding, n=4;
Figure 4.14C). However, the pKD values taken from the total binding curves
using the total image intensity and cell membrane intensity were 7.77 ± 0.13
(n=4) and 8.10 ± 0.09 (n=4), respectively, and were not statistically different
from one another (P > 0.05, unpaired t-test; specific binding curves compared
in Figure 4.14D).
The fluorescent propranolol derivative BY-PROP also showed clear membrane
labelling up to 30 nM (Figure 4.15A). At higher concentrations, intracellular
fluorescence was observed, although it was less pronounced than the clear
membrane labelling. The images were analysed for BY-PROP fluorescence
intensity and quantified using total image intensity (Figure 4.15B) and cell
membrane analysis (Figure 4.15C) as described above for BY-CGP. The non-
specific binding component (dotted lines in Figure 4.15B and C) was derived
from the total binding curve fits which was higher using total image intensity
analysis (55.6 ± 18.5 % of total binding, n=3; Figure 4.15B) than cell
membrane analysis (15.2 ± 0.9 % of total binding, n=3; Figure 4.15C). The
obtained pKD values of 7.23 ± 0.07 (n=3) and 7.19 ± 0.12 (n=3) using total
image and cell membrane analysis, respectively, were not statistically
different (P > 0.05, unpaired t-test; Figure 4.15D).
Figure 4.14 A ?ŝŶĚŝŶŐŽĨŝŶĐƌĞĂƐŝŶŐĐŽŶĐĞŶƚƌĂƚŝŽŶƐŽĨz ?'WƚŽ,K ?ɴ1-CS cells. Scale bar = 50 µm. Images were analysed using B, total intensity analysis
and C, cell membrane analysis (fluorescence intensity data obtained from drawing regions of interest around the membrane of six cells per field of view) to
give total and non-specific and D, specific binding (normalised) data. Images are from one experiment and are representative of at least two additional
images taken on the same day and of two additional experiments. Quantitative data obtained from images shown in A.
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Figure 4.15ŝŶĚŝŶŐŽĨŝŶĐƌĞĂƐŝŶŐĐŽŶĐĞŶƚƌĂƚŝŽŶƐŽĨz ?WZKWƚŽ,K ?ɴ1-CS cells. Scale bar = 50 µm. Images were analysed using B, total intensity analysis
and C, cell membrane analysis (fluorescence intensity data obtained from drawing regions of interest around the membrane of six cells per field of view) to
give total and non-specific and D, specific binding (normalised) data. Images are from one experiment and are representative of at least two additional
images taken on the same day and of two additional experiments. Quantitative data obtained from images shown in A.
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Pre-incubation with increasing concentrations of CGP 20712A inhibited the
ďŝŶĚŝŶŐ ŽĨ  ? ĂŶĚ  ? ? ŶD K/Wz ?dDZ ŝŶ ,K ?ɴ1-CS cells (Figure 4.16 and
Figure 4.17, respectively). The pIC50 values obtained for the inhibition of 2 nM
and 20 nM BODIPY-TMR-CGP binding by CGP 20712A were 9.03 ± 0.08 (n=4)
and 8.76 ± 0.18 (n=3), respectively. This right-ward shift of the CGP 20712A
inhibition curve is expected when competing against a higher concentration
ŽĨƚŚĞůĂďĞůůĞĚůŝŐĂŶĚ ?dŽƚĂůďŝŶĚŝŶŐůĞǀĞůƐŽĨ ?ĂŶĚ ? ?ŶDz ?'WƚŽ,K ?ɴ1-
CS cells were obtained in the absence of CGP 20712A, whilst non-specific
binding and background fluorescence was determined in CHO-CS cells (i.e.
ĐĞůůƐŶŽƚĞǆƉƌĞƐƐŝŶŐ ƚŚĞɴ1-adrenoceptor). Both displacement binding curves
were normalised to total (100 %) and non-specific (0 %) binding levels to give
specific binding curves which could be directly compared (Figure 4.18).
Interestingly, the slope of the CGP 20712A inhibition curves is shallower
(although not statistically significant; P > 0.05, unpaired t-test) when
displacing 20 nM BY-CGP (-0.72 ± 0.06, n=3), than it is when antagonising 2
nM BY-CGP (-1.06 ± 0.14, n=4). However, the displacement slope of CGP
20712A inhibiting 20 nM BY-CGP binding was significantly shallower than a
slope of unity (P < 0.05, one-sample t-test comparison to hypothetical value
of 1.0).
Pre-incubation with CGP 20712A was also able to displace the binding of 20
ŶD z ?WZKW ŝŶ ,K ?ɴ1-CS cells and a pIC50 of 8.85 ± 0.12 (n=4) was
determined (Figure 4.19). Total binding of 20 nM BY-PROP was measured in
ƚŚĞĂďƐĞŶĐĞŽĨ'W  ? ? ? ? ? ŝŶ,K ?ɴ1-CS cells and non-specific binding was
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assessed in CHO-CS cells. The inhibition slope of CGP 20712A displacing 20 nM
BY-PROP was -1.06 ± 0.31 (n=3).
Figure 4.16 A ?ĐŽŶĨŽĐĂů ŝŵĂŐĞƐŽĨ  ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence and presence of increasing concentrations of CGP 20712A. B,
ƋƵĂŶƚŝƚĂƚŝǀĞĚĂƚĂŽĨŝŵĂŐĞƐƐŚŽǁŶŝŶ ?ĂƌŐƌĂƉŚƐƐŚŽǁ ?ŶDz ?'WďŝŶĚŝŶŐůĞǀĞůƐĚĞƚĞƌŵŝŶĞĚŝŶ,K ?^ĐĞůůƐ ?ŶŽŶ ?ƐƉĞĐŝĨŝĐďŝŶĚŝŶŐ ?ĂŶĚ,K ?ɴ1-CS cells
(total binding). The images shown are representative of two additional images taken of different field of views within the same well, and are
representatives of images taken on a total of four separate experimental days. Scale bar = 50 µm.
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Figure 4.17 A ?ĐŽŶĨŽĐĂů ŝŵĂŐĞƐŽĨ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence and presence of increasing concentrations of CGP 20712A. B,
ƋƵĂŶƚŝƚĂƚŝǀĞĚĂƚĂŽĨ ŝŵĂŐĞƐƐŚŽǁŶŝŶ ?ĂƌŐƌĂƉŚƐƐŚŽǁ ? ?ŶDz ?'WďŝŶĚŝŶŐ ůĞǀĞůƐĚĞƚĞƌŵŝŶĞĚ ŝŶ,K ?^ĐĞůůƐ  ?ŶŽŶ ?ƐƉĞĐŝĨŝĐďŝŶĚŝŶŐ ?ĂŶĚ,K ?ɴ1-CS
cells (total binding). The images shown are representative of two additional images taken of different field of views within the same well, and are
representatives of images taken on a total of three separate experimental days. Scale bar = 50 µm.
A
20 nM BY-CGP + 0.1 nMCGP20712A + 1 nM CGP20712A
CHO-CS cells+ 100 nM CGP20712A+ 10 nMCGP20712A
+ 0.01 nM CGP20712A
+ 1000 nMCGP20712A
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Figure 4.18'W ? ? ? ? ?ŝŶŚŝďŝƚŝŽŶŽĨ ?ĂŶĚ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells.
Both binding curves were normalised to their respective total (100%) and non-
specific (0%) binding levels to give normalised specific binding data. Data shown are
pooled data from at least three separate experiments.
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Figure 4.19 A ?ĐŽŶĨŽĐĂůŝŵĂŐĞƐŽĨ ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence and presence of increasing concentrations of CGP 20712A. B,
The fluorescence intensities of the images shown in A were quantified using total image intensity analysis. Bar graphs show 20 nM BY-PROP binding levels
ĚĞƚĞƌŵŝŶĞĚ ŝŶ ,K ?^ ĐĞůůƐ  ?ŶŽŶ ?ƐƉĞĐŝĨŝĐ ďŝŶĚŝŶŐ ? ĂŶĚ ,K ?ɴ1-CS cells (total binding). Images are representatives of two additional images taken of
different fields of view within the same well and are representative of a total of four separate experimental days. Scale bar = 50 µm.
A
20 nM BY-PROP + 0.1 nMCGP20712A + 1 nM CGP20712A
CHO-CS cells+ 100 nM CGP20712A+ 10 nMCGP20712A
+ 0.01 nM CGP20712A
+ 1000 nMCGP20712A
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/ŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞɴ1-adrenoceptor by BY-CGP
Receptor internalisation removes receptors from the cell surface to regulate
receptor-mediated cellular responses (Jean-Alphonse et al., 2011). Thus, using
a fluorescently labelled agonist in binding experiments may result in fewer
receptors being available at the cell surface following a given incubation time.
As a result, reduced levels of binding of the fluorescent ligand may be
observed that are due to receptors having being internalised instead of
binding being displaced by the competing ligand. To ensure that this was not
case using the low efficacy fluorescent agonist BODIPY-TMR-CGP, we
investigated whether BODIPY-TMR-CGP caused internalisation of the SNAP-
ƚĂŐŐĞĚ ɴ1-adrenoceptor. When treated with HEPES-buffered saline solution
 ?,^^ ?ďƵĨĨĞƌĂůŽŶĞ  ?ŶĞŐĂƚŝǀĞĐŽŶƚƌŽů ? ?ŶŽ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^EW ?ƚĂŐŐĞĚɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƐǁĂƐŽďƐĞƌǀĞĚ ?&ŝŐƵƌĞ ? ? ? ? ? ?,ŽǁĞǀĞƌ ?ƚƌĞĂƚŵĞŶƚŽĨ,K ?ƐƐɴ1-
CS cells with 10 µM isoprenaline (positive control) resulted in visible
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptor. The fluorescence
intensity of the cell membrane appeared reduced after treatment with 10 µM
ŝƐŽƉƌĞŶĂůŝŶĞ ?ĂŶĚĂŐŐƌĞŐĂƚĞĚ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors were seen in the
intracellular space (see white arrows in Figure 4.20). In contrast, treatment
with 10 µM CGP 12177 and 1 µM BY-CGP did not result in intracellular
ĂŐŐƌĞŐĂƚĞƐ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors, suggesting that neither ligand
ĐĂƵƐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ ƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor after 60 minutes
(Figure 4.20). It can, however, be seen that the shape of cells exposed to 10
µM CGP 12177 and 1 µM BY-CGP was changed after 60 minutes (white arrows
in Figure 4.20). This was not observed in the negative control (HBSS treatment)
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and indicates that CGP 12177 and BY-CGP treatment elicited cellular
responses that did not involve the internalisation of the receptor in an
incubation time of 60 minutes.
Figure 4.20ŽŶĨŽĐĂůŝŵĂŐĞƐŽĨ,K ?ƐƐɴ1 ?^ĐĞůůƐƚŚĂƚǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚ ?A?D' ? ? ? ? ? ? ?ŵŝŶƐ ? ? ? ? ?ŝŶŽƌĚĞƌƚŽůĂďĞůƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor.
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors were imaged before (0 min) and after (60 min) treatment with HBSS buffer, 10 µM isoprenaline, 10 µM CGP 12177 and 1
A?Dz ?'W ?dŚĞĂƌƌŽǁƐƉŽŝŶƚŽƵƚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptors following 60 minute exposure to 10 µM isoprenaline and change of cell
ƐŚĂƉĞ ǁŝƚŚŽƵƚ ĚĞƚĞĐƚĂďůĞ ^EW ?ƚĂŐŐĞĚ ɴ1AR internalisation following 60 minute incubation with 10 µM CGP 12177 and 1 µM BY-CGP. Images are
representative of a further two images taken on the same day of experimentation and images obtained in two additional separate experiments. Scale bar =
50 µm.
HBSSonly 10µM CGP12177 1 µM BY-CGP10µM isoprenaline
0
m
in
60
m
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4.4 Discussion
Fluorescent ligands allow the visualisation and therefore the localisation of
the native receptor in living cells using confocal microscopy. However, the
coupling of a large fluorophore to a small molecular weight ligand can
markedly affect its pharmacological profile (Baker et al., 2010; Middleton et
al., 2005). In this chapter, we described the pharmacology of two fluorescent
ůŝŐĂŶĚƐ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor: BODIPY-TMR-CGP, a CGP 12177
derivative (BY-CGP) and BODIPY630/650-S-PEG8-propranolol, a fluorescent
analogue of propranolol (BY-PROP).
Firstly, we investigated the efficacy and affinity of both fluorescent ligands at
ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor expressed in CHO-CS cells. BY-PROP exerted no
efficacy of its own and antagonised cimaterol at the catecholamine site of the
ɴ1-adrenoceptor with a 13-fold lower affinity compared to its parent
compound. Interestingly however, BY-PROP displayed a higher affinity at the
ƐĞĐŽŶĚĂƌǇƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor compared to is unlabelled counterpart,
albeit only 3-fold. Affinity values of an antagonist would be expected to be
similar regardless of the agonist used, but the affinity value determined for
BY-PROP against cimaterol was one order of magnitude higher than that
obtained against CGP 12177 which is in line with the two sites hypothesis of
ƚŚĞ ɴ1-adrenoceptor and is similar to the pharmacology described for its
parent ligand propranolol in Chapter 3.
211
BY-CGP displayed a similar pharmacology to its parent compound CGP 12177,
albeit with a reduced affinity at both the high and low affinity site of the
ŚƵŵĂŶ ɴ1-adrenoceptor. Like CGP 12177, BY-CGP caused parallel right-ward
shifts of the cimaterol concentration response curve. This suggests that the
two ligands are competing for the same site, i.e. the catecholamine site (site 1)
ŽĨƚŚĞɴ1-adrenoceptor. The raised basal levels of the cimaterol curves caused
in the presence of increasing BY-CGP concentrations are reminiscent of the
raised basal levels caused by CGP 12177 in the same assay format, suggesting
that BY-CGP also exerts agonist activity. Indeed, BY-CGP retained agonist
ĂĐƚŝǀŝƚǇ ƚŚƌŽƵŐŚ ƚŚĞ ƐĞĐŽŶĚ ůŽǁ ĂĨĨŝŶŝƚǇ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor, albeit
with lower efficacy (25.6 % of that determined using the full agonist cimaterol)
compared to CGP 12177 (47.8 % of the cimaterol response; Chapter 3). BY-
CGP showed no response in CHO-CS and CHO-K1 cells, indicating that the
ƌĞƐƉŽŶƐĞƐƐĞĞŶĂƌĞŵĞĚŝĂƚĞĚƚŚƌŽƵŐŚƚŚĞɴ1-adrenoceptor. The affinity value
of BY-CGP derived from its partial agonist response curve was similar to that
determined when used to antagonise the agonist actions of CGP 12177. BY-
CGP caused parallel right-ward shifts of the CGP 12177 concentration-
response curves, whilst also raising the basal levels of the CGP 12177
response curves in a manner consistent with the partial agonist actions of BY-
CGP. Against CGP 12177, both the antagonist and agonist effects of BY-CGP,
ĂƌĞ ŵĞĚŝĂƚĞĚ ƚŚƌŽƵŐŚ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site. According to
classical receptor theory the affinity values of a ligand for a given receptor (or
receptor site) would be expected to be similar even though two different
methods were used to derive the affinity value (Kenakin et al., 1984). This
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ŚŽůĚƐƚƌƵĞĨŽƌƚŚĞz ?'WĚĂƚĂĂƚƚŚĞƐĞĐŽŶĚĂƌǇƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor
(partial agonism KD circa 87 nM; pA2 (agonist CGP 12177) circa 52 nM).
However, the affinity value determined for BY-CGP against cimaterol was 1.5
orders of magnitude higher than the affinity value derived from its partial
agonist response (or against CGP 12177) which is consistent with the two-site
ŚǇƉŽƚŚĞƐŝƐŽĨƚŚĞɴ1-adrenoceptor.
Furthermore, in order to shift the BY-CGP concentration-response curve to a
similar extent as the cimaterol concentration-response curve (see Chapter 3),
a 100-fold higher concentration of propranolol had to be used. Interestingly,
the affinity value of propranolol derived from the shifted BY-CGP
concentration-response curve was comparable to that obtained when
inhibiting CGP 12177 (Table 4.1). Thus, it appears that the affinity values are
ŝŶĚĞƉĞŶĚĞŶƚ ŽĨ ƚŚĞ ĂŐŽŶŝƐƚ ƵƐĞĚ Ăƚ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site.
Unfortunately we could not confirm this for a different antagonist such as
CGP 20712A due to the costs implicated in using high concentration of the
fluorescent ligand (which is needed for a full concentration-response curve).
dŚŝƐĂŐŽŶŝƐƚŝŶĚĞƉĞŶĚĞŶĐĞŝƐĂůƐŽƚƌƵĞĨŽƌƚŚĞĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞ ?ŽĨƚŚĞɴ1-
adrenoceptor, as the affinity values established for propranolol and CGP
20712A using cimaterol as the agonist (Chapter 3) all compare well to affinity
ǀĂůƵĞƐƚŚĂƚǁĞƌĞƌĞƉŽƌƚĞĚĂŐĂŝŶƐƚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŐŽŶŝƐƚŝƐŽƉƌĞŶĂůŝŶĞ ?ĂŬĞƌ
et al., 2003a). This provides strong evidence that the changes in affinity seen
against cimaterol and CGP 12177 are due to the two ligands eliciting their
response through two different receptor sites or conformations.
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As mentioned above the BY-CGP affinities were reduced at both sites of the
ɴ1-adrenoceptor compared to CGP 12177. It is noteworthy that the affinity of
BY-CGP was reduced 2-fold at the high affinity and 4-fold at the low affinity
ƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor. Thus, the addition of a fluorophore to CGP 12177
resulted in a fluorescent ligand whose binding affinity is reduced by equal
ŵĞĂƐƵƌĞƐĂƚďŽƚŚƐŝƚĞƐŽĨƚŚĞɴ1-adrenoceptor. This is intriguing as one would
expect that a chemical change of a ligand (especially one that results in a
molecule twice the size of the parent compound) will have different effects at
different binding sites, i.e. binding sites of different electrostatic composition
and environment as they can or cannot provide more hydrogen bond, ionic or
van der Waals interactions (Klebe et al., 1997). Whilst similar affinity changes
may be caused by different ligand-receptor interactions in different binding
pockets, it is also consistent with two binding pockets that are in fact the
ƐĂŵĞďƵƚŚĂǀĞďĞĐŽŵĞ RƚǁŽ ?ďŝŶĚŝŶŐƐŝƚĞƐ ŝŶĂɴ1-adrenoceptor homodimer.
The low affinities associated with the second site may be due to
conformational changes as a result of dimer formation (Breitwieser, 2004).
This theory would be in line with a mutagenesis study carried out by Baker et
al. (2008) to identify amino acid residues that play key roles in the binding of
ǀĂƌŝŽƵƐ ůŝŐĂŶĚƐ ƚŽ ƐŝƚĞ  ? ĂŶĚ ƐŝƚĞ  ? ŽĨ ƚŚĞ ɴ1-adrenoceptor. Every residue
identified to cause a loss of affinity of ligand for site 1 (therefore being a
crucial residue of this binding site) was also found to cause a loss of affinity of
ƚŚĞƐĂŵĞůŝŐĂŶĚĂƚƚŚĞƐĞĐŽŶĚƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor (Baker et al., 2008).
Not one residue could be isolated to only affect one but not the other binding
ƐŝƚĞ ?dŚŝƐɴ1-adrenoceptor homodimer hypothesis is examined in Chapter 7.
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CGP 12177 has also been described as partial agonist with high affinity at the
ɴ2-adrenoceptor (Baker et al., 2002). Interestingly, BY-CGP retained its
ĞĨĨŝĐĂĐǇ ? ďƵƚ ĚŝƐƉůĂǇĞĚ Ă  ? ? ? ?ĨŽůĚ ůŽǁĞƌ ĂĨĨŝŶŝƚǇ  ? ? ? ŶD ? Ăƚ ƚŚĞ ɴ2-
adrenoceptor compared to CGP 12177 at that receptor (Baker et al., 2003d).
tŚŝůƐƚƚŚĞĂĨĨŝŶŝƚǇŽĨ'W ? ? ? ? ?ĨŽƌƚŚĞɴ2AR (0.22 nM, Baker et al. (2002)) is
ǀĞƌǇ ƐŝŵŝůĂƌ ƚŽ ƚŚĂƚ ŽĨ ƚŚĞ ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ  ? ŽĨ ƚŚĞ ɴ1AR (0.25 nM), the
fluorescent CGP 12177 derivative is 35-fold selective for the high affinity site
ŽĨ ƚŚĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌŽǀĞƌƚŚĞɴ2-adrenoceptor. This further highlights the
effects that the addition of fluorophore to a ligand can have at different
binding sites.
The binding properties of BODIPY-TMR-CGP and BY-PROP were investigated in
living cells using confocal microscopy. We were able to confirm the previously
ƌĞƉŽƌƚĞĚďŝŶĚŝŶŐ ŽĨ K/Wz ?dDZ ?'W  ? ? ? ? ? ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ2-adrenoceptor
(Baker et al. ? ? ? ? ?Ě ? ?K/Wz ?dDZ ?'W ? ? ? ? ?ďŝŶĚŝŶŐƚŽ,K ?ɴ2-CS cells was
ĚŝƐƉůĂĐĞĚďǇƚŚĞɴ2 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐĞůĞĐƚŝǀĞĂŶƚĂŐŽŶŝƐƚ// ? ? ? ? ? ? ?ĂŶĚƚŚĞɴ1-
adrenoceptor selective antagonist CGP 20712A in line with their reported
affinities for the receptor (Baker, 2005).
The binding specificity of both fluorescent ligands was clearly demonstrated
Ăƚ ďŽƚŚ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ĂŶĚ ŶĂƚŝǀĞ ɴ1-adrenoceptor expressed in CHO-CS
ĐĞůůƐ  ?ĨŽƌ ĨƵŶĐƚŝŽŶĂů ĚĂƚĂ ŽĨ ďŽƚŚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ Ăƚ ƚŚĞ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptor see Appendix I S6 and S7). Localised membrane labelling of 2
ĂŶĚ ? ?ŶDz ?'WĂŶĚ ? ?ŶDz ?WZKWǁĂƐƐĞĞŶŝŶ,K ?ɴ1-CS cells and could
ďĞ ĚŝƐƉůĂĐĞĚ ƵƐŝŶŐ ɴ1-adrenoceptor selective antagonist CGP 20712A. The
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concentrations of BY-CGP and BY-PROP used to achieve clear membrane
labelling were in line with affinity values determined for the two ligands in
functional studies. No detectable binding of BY-CGP could be seen to CHO-CS
ĐĞůůƐ  ?ŝ ?Ğ ? ĐĞůůƐ ƚŚĂƚ ĚŽ ŶŽƚ ĞǆƉƌĞƐƐ ƚŚĞ ɴ1-adrenoceptor), indicating its
ƐĞůĞĐƚŝǀŝƚǇ ƚŽ ƚŚĞ ɴ1-adrenoceptor. Very low, but more apparent membrane
labelling of CHO-CS cells was seen by 20 nM BY-PROP, which is consistent with
the reported lipophilicity of propranolol (Neil-Dwyer et al., 1981) and the
BODIPY fluorophore (Sueyoshi et al., 2011). However, the selectivity of BY-
WZKW ƚŽ ƚŚĞ ɴ1-adrenoceptor resulted in total binding that was markedly
greater than non-specific binding.
dŚĞ ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ z ?'W ĂŶĚ z ?WZKW ŽĨ ,K ?ɴ1-CS cells was
concentration-dependent and saturable. However, at concentrations of 30
nM and above, low levels of diffuse intracellular fluorescence were observed
for both ligands. CGP 12177 and its fluorescent counterpart have been
described as hydrophilic ligands (Baker et al., 2003a; Staehelin et al., 1983).
The hydrophobicity of BY-PROP would suggest that BY-PROP crosses the cell
membrane more readily than BY-CGP thus resulting in higher intracellular
fluorescence. However, the non-specific binding levels determined for BY-
PROP (55.6 % of total binding) were similar to those for BY-CGP (55.9 % of
total binding) using the total image average fluorescence intensity analysis
method. The non-specific binding component was theoretically determined
from a one-site total binding fit for both fluorescent ligands and, in the case
of BY-CGP may be artificially increased due to 100 nM BY-CGP labeling circa
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 ? ? A? ŽĨ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ůŽǁ ĂĨĨŝŶŝƚǇ ɴ1-adrenoceptor sites. Whilst the same
ƉƌŝŶĐŝƉůĞ ĂƉƉůŝĞƐ ƚŽ z ?WZKW ? ŝƚƐ ĂĨĨŝŶŝƚǇ ĨŽƌ ƚŚĞƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor
site is lower (KDsite2 ~270 nM) and would therefore contribute less to an
overestimation of non-specific binding determined from a one-site total
binding fit. In addition, intracellular fluorescence may be due to the
internalisation of fluorescent ligands via the receptor (Baker et al., 2003d;
Daly et al., 2003; Rose et al., 2012). Rapid ligand-receptor dissociation inside
the cell would lead to accumulation of intracellular fluorescence, whilst the
receptor recycles back to the surface, leading to no (or little) observed
ƌĞĐĞƉƚŽƌ ĞŶĚŽĐǇƚŽƐŝƐ ? ,ĞƌĞ ? ŶŽ ŵĂƌŬĞĚ ŝŶƚĞƌŶĂůŝǌĂƚŝŽŶ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1-
adrenoceptors was observed. Receptor-mediated internalization of
fluorescent ligands may be prevented by preincubation with an unlabelled
antagonist, but no distinguishable level or localisation of BY-CGP and BY-PROP
ĨůƵŽƌĞƐĐĞŶĐĞǁĂƐŽďƐĞƌǀĞĚŝŶƵŶƚƌĂŶƐĨĞĐƚĞĚ ?,K ?^ ?ĐĞůůƐĐŽŵƉĂƌĞĚ,K ?ɴ1-
CS cells treated with 100 µM CGP 20712A in the conditions used, suggesting a
ɴ1-adrenoceptor independent route for intracellular fluorescence. Using the
total image intensity analysis method, the fluorescence intensity of the entire
image was measured, including the fluorescence intensities of the cytoplasm
and of cells with very low (or no) receptor expression and of parts of the
image that did not contain any cells were included in the analysis. This firstly
resulted in lower average fluorescence intensities per any given image, and
secondly, increased the non-specific binding fraction. However, potential
interference of non-membrane related fluorescence can be avoided by
drawing regions of interests (ROIs) around the cell membranes of a number of
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cells within one image. Using this analysis method, the non-specific binding
levels were reduced for BY-CGP (41.8 % of total binding) and BY-PROP (15.2 %
of total binding) compared to the total image analysis. This suggests that the
majority of the BY-CGP non-specific binding is membrane related whereas the
majority of the non-specific binding of BY-PROP was related to intracellular
fluorescence as the non-specific binding fraction was reduced markedly using
the ROI intensity analysis. Interestingly, the KD values that were derived from
the total binding curves using the two different analysis method compared
well for both fluorescent ligands, suggesting that either method can be used
for the analysis of the binding properties of fluorescent ligands.
The KD values for BY-CGP and BY-PROP derived from the saturation binding
curves did not compare to the affinity values determined in the CRE-mediated
SPAP transcription assay (Table 4.2). The saturation binding analysis for the
determination of an affinity value assumes that equilibrium has been reached.
However, images were taken after 10 min exposure to the fluorescent ligand,
after which it is unlikely that equilibrium was reached. The kinetics of BY-
WZKW ĂŶĚ z ?'W Ăƚ ƚŚĞ ɴ1-adrenoceptor are not known, but slow
dissociation rates were reported for a radiolabelled CGP 12177 derivative at
ƚŚĞ ɴ1-adrenoceptor (Joseph et al., 2004). Slow kinetics have also been
ĂƚƚƌŝďƵƚĞĚ ƚŽ z ?'W ? ĂůďĞŝƚ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ2-adrenoceptor (Baker et al.,
2003d). The affinity values are likely to be underestimated, if the fluorescent
ligand has slow kinetics as it would not have had enough time to label all
available receptors. It could be assumed that an increased incubation time
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would result in a higher affinity value, possibly one that compares to the
ĂĨĨŝŶŝƚǇ ǀĂůƵĞ ĨŽƌ ƚŚĞ ɴ1-adrenoceptor site 1 obtained in functional
experiments. Furthermore, if equilibrium was reached, a two-phase specific
binding curve of BY-CGP might be expected, as full receptor occupancy will
have been achieved by 100 nM (the highest concentration used in the
ƐĂƚƵƌĂƚŝŽŶ ďŝŶĚŝŶŐ ĂƐƐĂǇ ? z ?'W Ăƚ ƚŚĞ ŚŝŐŚ ĂĨĨŝŶŝƚǇ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-
adrenoceptor and greater than 50 % of receptor occupancy at the site 2.
However, even when a defined secondary binding phase is not detected (as
shown here), we know from earlier functional studies that both fluorescent
ligands bind to the secondary site, which will be reflected in the apparent KD
value calculated. As the fluorescent ligand concentrations are increased more
secondary site binding will be recruited, which will have the effect of masking
early saturation of the curve. Without detailed information of the kinetic
parameters of the fluorescent ligands it is difficult to be sure that equilibrium
conditions were achieved. In addition, the kinetic parameters of the same
ůŝŐĂŶĚǁŝůůďĞĚŝĨĨĞƌĞŶƚĂƚƚŚĞƚǁŽƐŝƚĞƐŽĨƚŚĞɴ1-adrenoceptor (Joseph et al.,
2004). The kinetics of BY-CGP and BY-PROP are examined in more detail in
Chapter 6.
Both BY-PROP and BY-CGP binding could be displaced in a concentration-
dependent manner by CGP 20712A. The CGP 20712A IC50 value was greater
when inhibiting 20 nM (30 x KDsite1) than 2 nM (3 x KDsite1) BY-CGP as would be
expected for two ligands competing for the same binding site, however the
inhibition slope of CGP 20712A was shallower (-0.7) when inhibiting 20 nM
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BY-CGP than when inhibiting 2 nM (-1.0). This suggests there was some
competition binding resistance to increasing CGP 20712A concentrations
ǁŚŝĐŚĐŽƵůĚďĞĚƵĞĂƉƌŽƉŽƌƚŝŽŶŽĨƚŚĞƐĞĐŽŶĚ ůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor
site, as 20 nM is also 0.3 x KDsite2 and thus labels approximately 16 % of site 2
(2 nM of BY-CGP is 0.03 x KDsite2 and labels only 2 % of site 2). As described for
the saturation binding assay, equilibrium is unlikely to have been reached
after 10 minutes of incubation with the fluorescent ligand, thus the shallower
slope could be an artefact of hemi-equilibrium. Alternatively, it may point to
receptor-ligand interactions at both the high and low affinity binding site of
ƚŚĞɴ1-adrenoceptor. This is further explored in Chapter 5.
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4.5 Conclusion
The fluorescent derivatives of propranolol (BY-PROP) and CGP 12177 (BY-CGP)
displayed similar pharmacological profiles compared to their respective
parent compounds in the CRE-mediated SPAP transcription assay. Crucially,
BY-CGP retained agonist activity through the secondary low affinity site of the
ɴ1-adrenoceptor. Confocal microscopy studies demonstrated clear membrane
ůĂďĞůůŝŶŐ ďǇ ďŽƚŚ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ ŝŶ Ă ɴ1-adrenoceptor selective manner.
Interestingly, displacement binding studies revealed a shallower CGP 20712A
inhibition slope against 20 nM BY-CGP than 2 nM BY-CGP, possibly indicating
ƚŚĞ ƌĞĐĞƉƚŽƌ ?ůŝŐĂŶĚ ŝŶƚĞƌĂĐƚŝŽŶƐ Ăƚ ƚŚĞ ƐĞĐŽŶĚ ɴ1-adrenoceptor sites. Higher
throughput automated confocal microscopy approaches could be used to
investigate whether the shallower displacement slope is dependent on BY-
'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site, as it would allow
investigation of binding of a range of BY-CGP concentrations in the presence
ŽĨĂƌĂŶŐĞŽĨɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐ ?
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Chapter 5
Live cell high-content fluorescent
ligand binding assay using BODIPY-
TMR-CGP and BODIPY630/650-S-
PEG8-propranolol
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5.1 Introduction
Cell-based ligand binding studies are traditionally carried out using
radiolabelled ligands (Hulme et al., 2010). Fluorescently labelled ligands,
which have become more readily available in recent years (Daly et al., 2010;
Middleton et al., 2005; Vernall et al., 2012), circumvent the safety risks
associated with the use of radioisotopes and allow visualisation of ligand
binding to living cells. Other advantages of fluorescent ligands include their
application in ligand binding studies in single cell as well as cell population
assays, primary as well as recombinant cells, real time as well as end-point
binding assays. However, more importantly, there is no need to separate free
from bound ligand in fluorescent ligand binding assays as is traditionally done
in radioligand binding assays. This is because some fluorophores are
quenched in aqueous solution, resulting in detection of fluorescent ligand
bound to receptors in the lipid environment of the cell membrane. Thus, high
throughput assays using fluorescent ligands alone or in conjunction with a
fluorescently labelled receptor have the potential to replace radiolabelled
ligands for the purpose of determining affinity parameters of unlabelled
ligands and have most recently been described for the arginine-vasopressin V2
and adenosine A3 and A1 receptor (Loison et al., 2012; Stoddart et al., 2012).
The pharmacology of the fluorescent ligand BODIPY-TMR-CGP (a CGP 12177
ĂŶĂůŽŐƵĞ ? ŚĂƐ ďĞĞŶ ĚĞƐĐƌŝďĞĚ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ2-adrenoceptor (Baker et al.,
2003d). In the previous chapter, we described BODIPY-TMR-CGP as a high
ĂĨĨŝŶŝƚǇĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor that allows specific
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labelling of the receptor in living cells (Chapter 4). We also showed that
BODIPY-TMR-CGP binds to both the high affinity catecholamine site 1 and the
ůŽǁĂĨĨŝŶŝƚǇ  S'W ? ? ? ? ? ?ƐŝƚĞ  ?ŽĨƚŚĞɴ1-adrenoceptor whilst, like its parent
compound, retaining agonist efficacy through the second low affinity site.
In this chapter, we aimed to set up a live cell high-content screening
fluorescent ligand binding assay using the fluorescent ligands BODIPY-TMR-
'WĂŶĚz ?WZKW ?ĂĚĞƌŝǀĂƚŝǀĞŽĨƚŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŶƚĂŐŽŶŝƐƚƉƌŽƉƌĂŶŽůŽů ?
and the IX Ultra confocal plate reader. This higher throughput method will
allow further investigation of the ligand-receptor interactions at the second
ůŽǁ ĂĨĨŝŶŝƚǇ ƐŝƚĞ ŽĨ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor. In addition, we aimed to
compare the high-content IX Ultra confocal plate reader to the high-
throughput plate reader PHERAstar FS for the determination of antagonists
affinity values in a live cell ligand binding assay format.
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5.2 Methods
Cell culture
This was performed as described in Methods: Cell culture. The cell lines used in this
ĐŚĂƉƚĞƌ ǁĞƌĞ ,K ?ɴ1 ?^ ĂŶĚ ,K ?ɴ2-CS. CHO-CS cells were used as controls were
appropriate.
IX Ultra confocal plate reader
This was performed as outline in Methods: ImageXpress Ultra confocal plate
reader. When reproducing the data obtained on the Zeiss LSM710 confocal
microscope, the following incubation times were used: 30 min pre-incubation
of CGP 20712A (37 °C), then 10 min exposure to the fluorescent ligand (21 °C).
Unless otherwise stated, for all other experiments the antagonists were
incubated for 1 hour at 37 °C, before addition of the fluorescent ligand for
another hour and incubation at 21 °C.
PHERAstar FS plate reader
This was performed as outlined in Methods: PHERAstar FS plate reader. For
direct comparison of data obtained from the same assay plate, each plate was
read on the PHERAstar FS plate reader first and immediately afterwards read
on the IX Ultra confocal plate reader.
Data analysis
The data analysis of displacement binding data was carried out as described in
Methods: Data analysis. GraphPad Prism 5.0 was used to determine whether
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a one-site or a two-site inhibition fit was preferred on every displacement
binding curve. Using GrpahPad Prism 5.0, a preferred fit was determined with
statistical significance of P < 0.05 (partial F test and analysis of residuals
performed during fitting of data). The preferred fit was then used to derive
IC50 and KI values of the antagonists.
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5.3 Results
Comparison of manual versus automated determination of BY-
'WĂŶĚz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
Firstly, we aimed to reproduce the binding data obtained manually in 8-well
plates using the Zeiss710 LSM confocal microscope (Chapter 4), in a high-
content screen automated format using 96-well plates and the IX Ultra
confocal plate reader. The latter approach allows the introduction of more
competing ligand concentrations, thus allowing better definition of
concentration-displacement curves and simultaneous screening of multiple
compounds. The same incubation times and temperatures for both
antagonist and fluorescent ligand incubations were used as in binding
experiments described in Chapter 4. A CGP 20712A inhibition curve against 20
nM BODIPY-TMR-CGP (BY-CGP) with duplicate determinations of 12 data
points was obtained (Figure 5.1A). The total (T) and non-specific (B, basal)
ďŝŶĚŝŶŐ ůĞǀĞůƐ ŽĨ  ? ?ŶDz ?'W ǁĞƌĞĚĞƚĞƌŵŝŶĞĚ ŝŶ ,K ?ɴ1-CS and CHO-CS
cells, respectively. The montage image gives a good indication of the level of
BY-CGP binding across the plate (Figure 5.1B). The IX Ultra confocal plate
reader captures 4 different sites per well and reads an entire assay plate in
vertical serpentine fashion (i.e. along columns starting with column B) in circa
20 minutes. No systematic change in the clear membrane labelling by 20 nM
BY-CGP in the absence (totals) of CGP 20712A was observed across the plate.
Furthermore, the duplicate wells of each BY-CGP binding condition tested (i.e.
absence and presence of varying antagonist concentrations) showed
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comparable levels of BY-CGP binding and fluorescence intensity (Figure 5.1B),
indicating this fluorescence-based binding assay as a robust assay format for
ƚŚĞŝŶǀĞƐƚŝŐĂƚŝŽŶŽĨƚŚĞĚŝƐƉůĂĐĞŵĞŶƚŽĨz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells.
The binding levels of 20 nM BY-CGP to CHO-CS cells were similar to those
ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1-CS cells in the presence of 100 µM CGP 20712A
suggesting that the non-specific binding levels can be determined using either
strategy (Figure 5.1C). The data were analysed using the MetaXpress software
and integrated fluorescence intensity (average fluorescence intensity per
pixel) of the whole image was plotted against the CGP 20712A concentrations
used (Figure 5.1D). The pIC50 of CGP 20712A against 20 nM BY-CGP was 8.56 ±
0.07 (n=3) with a slope of -0.78 ± 0.13 (n=3) when analysed using a 4
parameter equation. The inhibition curves obtained using manual and
automated confocal microscopy approach were very similar with overlaying
data points (Figure 5.2A). However, the secondary shoulder, which is seen at
higher CGP 20712A concentrations and causes this shallower slope, is better
defined in the 12-point inhibition curve and could be analysed separately
using a two-site equation to yield pIC50 values for site 1 and site 2 of 8.49 ±
0.04 and -4.89 ± 0.24 (n=3), respectively, with a relative fraction of the high
affinity to the low affinity site of 91.6 ± 2.4 % (n=3; Figure 5.2B).
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Figure 5.1 /ŶŚŝďŝƚŝŽŶ ŽĨ  ? ? ŶD z ?'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor. A,
plate map of 30 wells highlighting the designated wells for total (T) and non-specific
binding (B, basal) binding of 20 nM BY-CGP and chosen log concentrations of CGP
20712A. B, montage image of 20 nM BY-CGP binding levels in all 30 wells (4 images
per well) used in this experiment. C, confocal image of 20 nM BY-CGP non-specific
 ?ďĂƐĂůƐ ?ďŝŶĚŝŶŐƚŽ,K ?^ĐĞůůƐĂŶĚďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence (totals)
and presence of 10-11 M and 10-4 M CGP 20712A. Each image is representative of 4
images taken per well. D, quantification of all images shown in A. The data shown
here are from a single experiment with the error bars indicating range of error for
duplicate determinations for all CGP 20712A concentration and the bar graph
describing non-specific BY-CGP binding levels. Quadruplicate determinations of total
BY-CGP binding are shown as mean ± s.e.m. in the designated bar graph. This
experiment is representative of three separate experiments.
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Figure 5.2  ? ? ŶD z ?'W ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells in the presence of increasing
concentrations of CGP 20712A. A, comparison of CGP 20712A displacement binding
curves determined manually on the Zeiss710 confocal microscope and using the
automated approach on the IX Ultra confocal plate reader. Both inhibition curves
were analysed using a 4 parameter equation. B, CGP 20712A displacing binding curve
determined using the IX Ultra confocal plate reader analysed using the two-site
displacement binding fit.
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EĞǆƚ ?ǁĞĂƐƐĞƐƐĞĚƚŚĞďŝŶĚŝŶŐŽĨ ? ?ŶDz ?WZKWƚŽ,K ?ɴ1-CS cells using the
automated confocal plate reader system. Again, the same antagonist and
fluorescent ligand incubation times and temperatures were used as in
experiments using the Zeiss LSM710 confocal microscope (Chapter 4) to
validate the use of the automated confocal microscopy approach for this
fluorescent ligand. As can be seen in Figure 5.3B the binding of BY-PROP to
,K ?ɴ1-CS is highly variable for duplicate readings across the assay plate,
which is reflected in the large range of error associated with the mean for
every data point of the CGP 20712A displacement binding curve (Figure 5.3D).
This variability of BY-PROP binding did not appear to be associated with
specific CGP 20712A concentrations (e.g. the duplicates of 10-8 M CGP 20712A
concentrations on the assay plate show marked differences in measured
fluorescent intensity, Figure 5.3B). The individual images shown in Figure 5.3C
also highlight bright, non-specific fluorescent particles, which may be dead
cells that have taken up high amounts of the fluorescent ligand or aggregates
of the fluorescent ligand. In the total image intensity analysis used to quantify
z ?WZKW ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells, these bright particles will have
contributed to an overall smaller assay window of BY-PROP binding as specific
BY-PROP binding fluorescence was lower than that of the bright particles.
However, it is unlikely that those contributed to the high fluorescence
variability observed for duplicate determinations as they were present in all
wells to similar degrees. High levels of intracellular BY-PROP fluorescence
ĐŽƵůĚ ďĞ ƐĞĞŶ ŝŶ ,K ?^ ĐĞůůƐ  ?ĐĞůůƐ ŶŽƚ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ ɴ1-adrenoceptor),
which further limits the detection of a defined robust assay window. However,
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the binding levels of BY-PROP to CHO-CS cells were comparable to those seen
Ăƚ ,K ?ɴ1-CS cells in the presence of 100 µM CGP 20712A (Figure 5.3C),
ƐƵŐŐĞƐƚŝŶŐƚŚĂƚƚŚĞz ?WZKWŝŶƚƌĂĐĞůůƵůĂƌĨůƵŽƌĞƐĐĞŶĐĞŝƐŶŽƚĐĂƵƐĞĚďǇĂɴ1-
adrenoceptor mediated process.
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Figure 5.3 /ŶŚŝďŝƚŝŽŶ ŽĨ  ? ? ŶD z ?WZKW ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor. A,
plate map of 30 wells highlighting the designated wells for total (T) and non-specific
binding (B, basal) binding of 20 nM BY-PROP and chosen concentrations of CGP
20712A. B, montage image of 20 nM BY-PROP binding levels in all 30 wells (4 images
per well) used in this experiment. C, confocal images of 20 nM BY-PROP non-specific
 ?ďĂƐĂůƐ ?ďŝŶĚŝŶŐƚŽ,K ?^ĐĞůůƐĂŶĚďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence (totals)
and presence of 10-11 M and 10-4 M CGP 20712A. Each image is representative of 4
images taken per well. D, quantification of all images shown in A. The data shown
here is from a single experiment with the error bars indicating range of error for
duplicate determinations. This experiment is representative of three separate
experiments.
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Optimising conditions for a high-content live cell equilibrium
binding assay
Initial experiments were designed to match previous experimental conditions
used on the LSM710. However, to achieve equilibrium conditions, the
antagonist pre-incubation was increased to 1 hour (37 °C) and the effects of
varying fluorescent ligand incubation temperature and time was assessed.
Following CGP 20712A pre-incubation, BY-CGP and BY-PROP were incubated
for 30 minutes at room temperature (21 °C) and at 37 °C. This increase in
incubation temperature enhances the kinetics of ligand binding to the
receptor, thereby speeding up the time it takes to reach equilibrium
conditions. The absolute fluorescence intensity value of 20 nM BY-CGP
ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells was increased at 37 °C compared to 21 °C
suggesting equilibrium conditions were not reached at 21 °C. In addition, the
CGP 20712A displacement binding curve was shifted at 37 °C compared to
21 °C incubation conditions, resulting in increased IC50 values at site 1 (pIC50
8.53 and 8.83 at 37 °C and 21 °C, n=1, respectively) and decreased IC50 values
at site 2 (pIC50 5.26 and 4.61 at 37 °C and 21 °C, n=1, respectively; Figure 5.4).
The confocal images taken by the IX Ultra plate reader show less defined
ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ z ?'W Ăƚ  ? ?  ? ŝŶ ,K ?ɴ1-CS cells, and the
intracellular fluorescence appears to be increased at higher incubation
temperatures.
A similar observation of less defined membrane labelling at 37 °C was made
ĨŽƌ z ?WZKW ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells (Figure 5.5). Interestingly, the
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absolute fluorescence intensity values obtained for the CGP 20712A
displacement binding curves were similar at the two BY-PROP incubation
temperatures used. No IC50 values could be derived from the CGP 20712A
inhibition curves obtained following BY-PROP incubation at 21 °C and 37 °C, as
intra-experimental variability was too great and was not improved in
comparison to the initial incubation conditions used above (when replicating
the manual confocal microscopy data).
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Figure 5.4 A ?'W ? ? ? ? ?ĚŝƐƉůĂĐĞŵĞŶƚŽĨ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
following a 30 minute incubation of BY-CGP at 21 °C and 37 °C. Data are mean ±
range of error of duplicate determinations from one single experiment. B, confocal
ŝŵĂŐĞƐŽĨ  ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence (left panel) and
presence (right panel) of 100 µM CGP 20712A following incubation at 21 °C (top
panel) and 37 °C (bottom panel).
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Figure 5.5 A ?'W ? ? ? ? ?ĚŝƐƉůĂĐĞŵĞŶƚŽĨ ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
following a 30 minute incubation of BY-PROP at 21 °C and 37 °C. Data are mean ±
range of error of duplicate determinations from one single experiment. B, confocal
ŝŵĂŐĞƐŽĨ ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence (left panel) and
presence (right panel) of 100 µM CGP 20712A following incubation at 21 °C (top
panel) and 37 °C (bottom panel).
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Next, CGP 20712A displacement binding curves were obtained following BY-
CGP and BY-PROP incubation times of 30 and 60 minutes at 21 °C. The IC50
values of CGP 20712A against 20 nM BY-CGP at site 1 were 8.37 (n=1) and
8.30 (n=1) following a 30 and 60 minute incubation, respectively. At site 2 the
pIC50 values were also very similar with values of 5.37 (n=1) and 5.22 (n=1)
determined for 30 and 60 minutes incubation time, respectively (Figure 5.6).
The fluorescence intensity values determined following a 60 minutes
incubation time of BY-CGP were higher for both total (20 nM BY-CGP binding
in the absence of CGP 20712A) and non-specific (20 nM BY-CGP binding in the
presence of 100 µM CGP 20712A) binding than those determined after 30
minutes incubation of the fluorescent ligand. We have already shown that a
much higher concentration (1 µM) of the low efficacy agonist BY-CGP caused
ŶŽĚĞƚĞĐƚĂďůĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor following a
60 minutes incubation time at 21 °C (Chapter 4, Figure 4.20), which was
consistent with the clear membrane labelling of 20 nM BY-CGP observed here
following 30 and 60 minutes incubation times. BY-PROP also showed good
ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ ,K ?ɴ1-CS cells (Figure 5.7), albeit with greater
intracellular fluorescence than observed for BY-CGP. The binding levels of BY-
PROP were similar between the two different incubation conditions used and
the quantified data was still too variable to determine confident and
reproducible displacement binding parameters.
Whilst we could not be certain that equilibrium conditions were achieved, all
subsequent experiments on the IX Ultra confocal plate reader used BY-CGP
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only, with 60 minute incubation at 21 °C, to limit non-specific binding and
internalisation effects.
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Figure 5.6 A ?'W ? ? ? ? ?ĚŝƐƉůĂĐĞŵĞŶƚŽĨ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
following a 30 and 60 minute incubation of BY-CGP at 21 °C. Data are mean ± range
of error of duplicate determinations from one single experiment. B, confocal images
ŽĨ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the absence (left panel) and presence
(right panel) of 100 µM CGP 20712A following a 30 (top panel) and 60 (bottom panel)
minute incubation.
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Figure 5.7 A ?'W ? ? ? ? ?ĚŝƐƉůĂĐĞŵĞŶƚŽĨ ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
following a 30 and 60 minute incubation of BY-PROP at 21 °C. Data are mean ± range
of error of duplicate determinations from one single experiment. B, confocal images
ŽĨ  ? ? ŶD z ?WZKW ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells in the absence (left panel) and
presence (right panel) of 100 µM CGP 20712A following a 30 (top panel) and 60
(bottom panel) minute incubation.
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ĞƚĞƌŵŝŶĂƚŝŽŶ ŽĨ z ?'W ďŝŶĚŝŶŐ ƉĂƌĂŵĞƚĞƌƐ ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ1-
ĂŶĚ ɴ2-adrenoceptor using the high-content IX Ultra confocal
plate reader
Since it was not possible to use a BY-CGP concentration as low as 2 nM to
ƉƌĞĚŽŵŝŶĂŶƚůǇ ůĂďĞů ƚŚĞ ŚŝŐŚ ĂĨĨŝŶŝƚǇ ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-
adrenoceptor, we aimed instead to use higher concentrations of BY-CGP with
the hypothesis that increasing concentrations of BY-CGP will increase the
ŽĐĐƵƉĂŶĐǇŽĨƚŚĞƐĞĐŽŶĚůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor site. First, we assessed
the binding of 10, 20 and 100 nM BY-CGP in the presence of increasing
concentrations of CGP 20712A. Indeed, the second phase of the two-phase
binding curve appeared to become more pronounced with increasing BY-CGP
concentrations, which was observed in the decrease of the percentage of the
BY-CGP bound high affinity site to the overall BY-CGP bound sites (89.1 ±
1.2 %, 85.8 ± 1.2 % and 58.3 ± 4.0 % for 10, 20 and 100 nM BY-CGP,
respectively; Figure 5.8A). Furthermore, the CGP 20712A competition curve
shifted rightward with increasing BY-CGP concentrations. This rightward shift
could be seen for both the high affinity and the low affinity site. The pIC50
values derived from the displacement binding curves for 10, 20 and 100 nM
were 8.76 ± 0.04 (n=4), 8.68 ± 0.03 (n=4) and 8.21 ± 0.11 (n=6), respectively,
at the high affinity site. The pIC50 values determined for site 2 for 10, 20, 100
nM were 5.54 ± 0.03 (n=4), 5.16 ± 0.12 (n=4) and 5.07 ± 0.09 (n=6),
respectively (Table 5.1). The IC50 values of CGP 20712A was significantly lower
when inhibiting 100 nM BY-CGP compared to 10 nM BY-CGP at both site 1 and
site 2 (P < 0.05, two-way ANOVA followed by Bonferronis post hoc test).
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From equilibrium competition binding antagonist IC50 values, the affinity
values of antagonists that are competing for the same binding site with a
labelled ligand can be determined using the Cheng-Prusoff equation. Taking
into account the BY-CGP concentration used, and the affinity of BY-CGP for
ƐŝƚĞ ?ĂŶĚƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor (as determined in the CRE-mediated
SPAP transcription assay; Chapter 4), CGP 20712A affinity values were
calculated for each BY-CGP concentration and are summarised in Table 5.1.
Similar rightward shifts of antagonist displacement binding curves were seen
for increasing BY-CGP concentration when displaced by propranolol and CGP
12177 (Figure 5.8B and C, respectively). Increasing IC50 values were
determined for both propranolol and CGP 12177 when displacing increasing
concentrations of BY-CGP (Table 5.1). Furthermore, the secondary phase of
the two-phase displacement binding curves was also increasingly pronounced
with increasing BY-CGP concentrations when displaced by propranolol
 ?ƉĞƌĐĞŶƚĂŐĞŽĨz ?'WďŽƵŶĚƚŽƐŝƚĞ ?ŝŶƌĂƚŝŽƚŽŽǀĞƌĂůůz ?'W ?ďŽƵŶĚɴ1AR
sites: 89.3 ± 0.4 %, 87.0 ± 0.6 % and 72.1 ± 3.7 % for 10, 20 and 100 nM BY-
CGP, respectively) and CGP 12177 (92.6 ± 1.3 %, 88.8 ± 0.6 % and 72.2 ± 2.1%
for 10, 20 and 100 nM BY-CGP, respectively).
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Figure 5.8ŝƐƉůĂĐĞŵĞŶƚŽĨ  ? ? ? ? ? ? ? ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells by A,
CGP 20712A, B, propranolol and C, CGP 12177. The data was normalised to total
ďŝŶĚŝŶŐ ?z ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells; 100 %) and non-specific binding (BY-CGP
ďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells in the presence of 100 µM antagonist; 0 %) for each BY-
CGP concentration used. The data shown are normalised data representing the mean
± s.e.m. of combined data from 4-6 separate experiments per BY-CGP concentration.
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Table 5.1 Summary of pIC50 and pKIǀĂůƵĞƐŽĨ'W ? ? ? ? ? ?ƉƌŽƉƌĂŶŽůŽůĂŶĚ'W ? ? ? ? ?ĂŐĂŝŶƐƚ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells. The
pKIǀĂůƵĞƐǁĞƌĞĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐƚŚĞŚĞŶŐ ?WƌƵƐŽĨĨĞƋƵĂƚŝŽŶĂŶĚz ?'WĂĨĨŝŶŝƚǇǀĂůƵĞƐĨŽƌƚŚĞɴ1-adrenoceptor site 1 and site 2 determined in the CRE-
mediated SPAP transcription assay (Chapter 4). Data are mean ± s.e.m of n separate experiments. both pIC50 and pKI values determined at site 1 were significantly
different (P < 0.05) from those determined for site 2, and * denotes statistical significance (P < 0.05) from pIC50 or pKI value determined for
a10 nM BY-CGP and b20 nM BY-
CGP as determined by two-way ANOVA followed by Bonferronis multiple comparison test
CGP 20712A propranolol CGP 12177
site 1 site 2 n site 1 site 2 n site 1 site 2 n
pIC50
10 nM BY-CGP 8.76 ± 0.04 5.54 ± 0.03 4 7.94 ± 0.18 5.33 ± 0.12 3 8.93 ± 0.04 5.57 ± 0.20 3
20 nM BY-CGP 8.68 ± 0.03 5.16 ± 0.12 4 7.76 ± 0.13 5.19 ± 0.09 3 8.77 ± 0.07 5.36 ± 0.15 3
100 nM BY-CGP 8.21 ± 0.11*a,b 5.07 ± 0.09*a 6 7.12 ± 0.02*a,b 5.01 ± 0.06 3 8.19 ± 0.13*a 5.27 ± 0.16 3
pKI
10 nM BY-CGP 10.01 ± 0.04 5.59 ± 0.03 4 9.19 ± 0.18 5.37 ± 0.12 3 10.18 ± 0.04 5.62 ± 0.20 3
20 nM BY-CGP 10.21 ± 0.03 5.25 ± 0.12 4 9.29 ± 0.13 5.33 ± 0.08 3 10.31 ± 0.07 5.45 ± 0.15 3
100 nM BY-CGP 10.44 ± 0.11*a 5.41 ± 0.09 6 9.34 ± 0.02 5.34 ± 0.06 3 10.42 ± 0.13 5.60 ± 0.16 3
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z ?'W ŚĂƐ ĂůƌĞĂĚǇ ďĞĞŶ ĐŚĂƌĂĐƚĞƌŝƐĞĚ Ăƚ ƚŚĞ ɴ2-adrenoceptor in functional
and fluorescence imaging binding studies (Baker et al. ? ? ? ? ?Ě ? ?hŶůŝŬĞƚŚĞɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ? ŽŶůǇ ŽŶĞ ďŝŶĚŝŶŐ ƐŝƚĞ ŚĂƐ ďĞĞŶ ĚĞƐĐƌŝďĞĚ Ăƚ ƚŚĞ ɴ2-
adrenoceptor, to which BY-CGP binds with low nanomolar affinity (Baker et
al. ?  ? ? ? ?Ě ? ? tĞ ŚĂǀĞ ĂůƌĞĂĚǇ ƐŚŽǁŶ ĐůĞĂƌ ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ ,K ?ɴ2-CS
cells by BY-CGP using the manual confocal microscopy approach (Chapter 4).
,ĞƌĞ ?ǁĞĞǆĂŵŝŶĞĚƚŚĞďŝŶĚŝŶŐŽĨz ?'WƚŽƚŚĞŚƵŵĂŶɴ2-adrenoceptor in
,K ?ɴ2-CS cells using the IX Ultra confocal plate reader, in order to confirm
ƚŚĂƚƚŚĞƐĞĐŽŶĚƐŝƚĞĚŝƐƉůĂĐĞŵĞŶƚďŝŶĚŝŶŐĐƵƌǀĞƐƐĞĞŶĂƚƚŚĞɴ1-adrenoceptor
were not an artefact of the experiment conditions used.
hƐŝŶŐ  ? ? ŶD z ?'W ? ǁĞ ƐĂǁ ĐůĞĂƌ ŵĞŵďƌĂŶĞ ůĂďĞůůŝŶŐ ŽĨ ,K ?ɴ2-CS cells
(Figure 5.9B). Non-specific binding levels detected in CHO-CS cells were very
ůŽǁĂŶĚĐŽŵƉĂƌĂďůĞƚŽůĞǀĞůƐŵĞĂƐƵƌĞĚŝŶ,K ?ɴ2-CS cells in the presence of
100 µM propranolol (Figure 5.9C). In addition, the binding of 20 nM BY-CGP
was displaced by propranolol in a concentration-dependent manner,
ƐƵŐŐĞƐƚŝŶŐƚŚĂƚz ?'WďŝŶĚŝŶŐǁĂƐƐƉĞĐŝĨŝĐƚŽƚŚĞɴ2-adrenoceptor expressed
ŝŶ,K ?ɴ2-CS cells. BY-CGP has been described as a long acting partial agonist
ĂƚƚŚĞŚƵŵĂŶɴ2-adrenoceptor (Baker et al., 2003d), but no BY-CGP-mediated
internalisation was apparent following a 60 minutes exposure to the
fluorescent ligand at 21 °C (Figure 5.9B), suggesting that any reduced BY-CGP
ďŝŶĚŝŶŐƚŽ,K ?ɴ2-CS was due to antagonist displacement.
 ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?'WďŝŶĚŝŶŐǁĂƐŝŶŚŝďŝƚĞĚďǇɴ2-selective antagonist ICI
 ? ? ? ? ? ? ? ĂŶĚ ŶŽŶ ?ƐĞůĞĐƚŝǀĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ ƉƌŽƉƌĂŶŽůŽů ĂŶĚ 'W
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12177. The antagonist displacement binding curves were right-shifted in the
presence of increasing BY-CGP concentrations (Figure 5.10). As a result,
increasing IC50 values were determined with increasing BY-CGP
concentrations for ICI 118,551, propranolol and CGP 12177 (Table 5.2). From
these IC50 values and the BY-CGP affinity value reported in the literature for
ƚŚĞ ɴ2-adrenoceptor (25 nM; Baker et al. (2003d)), the antagonist affinity
values were determined using the Cheng-Prusoff equation (Table 5.2). All
ŝŶŚŝďŝƚŝŽŶĐƵƌǀĞƐŽďƚĂŝŶĞĚŝŶ,K ?ɴ2-CS cells preferred a one-phase binding fit,
suggesting that the two-phase binding fit is specific of the ligand interactions
ǁŝƚŚƚŚĞɴ1-adrenoceptor.
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Figure 5.9 /ŶŚŝďŝƚŝŽŶ ŽĨ  ? ? ŶD z ?'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ2-adrenoceptor. A,
plate map of 30 wells highlighting the designated wells for total (T) and non-specific
binding (B, basal) binding of 20 nM BY-CGP and chosen concentrations (in M) of
propranolol. B, montage image of 20 nM BY-CGP binding levels in all 30 wells (4
images per well) used in this experiment. C, confocal image of 20 nM BY-CGP non-
ƐƉĞĐŝĨŝĐ  ?ďĂƐĂůƐ ? ďŝŶĚŝŶŐ ƚŽ ,K ?^ ĐĞůůƐ ĂŶĚ ďŝŶĚŝŐ ƚŽ ,K ?ɴ2-CS cells in the
absence (totals) and presence of 0.01 nM (-11) and 100 µM (-4) CGP 20712A. Each
image is representative of 4 images taken per well. D, quantification of all images
shown in A. The data shown here are from a single experiment with the error bars
indicating range of error for duplicate determinations. This experiment is
representative of three separate experiments.
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Figure 5.10ŝƐƉůĂĐĞŵĞŶƚŽĨ ? ? ? ? ? ? ? ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ2-CS cells by A,
ICI 118,551 and B, propranolol and C, CGP 12177. The data were normalised to total
ďŝŶĚŝŶŐ ?z ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ2-CS cells; 100 %) and non-specific binding (BY-CGP
binding to CHO-CS cells; 0 %) for each BY-CGP concentration used. The normalised
data is the mean of at least two separate experiments pooled together with error
bars representing range of error (where only two separate experiments were
performed) and standard error of the mean (where three separate experiments were
performed).
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Table 5.2 Summary of IC50ǀĂůƵĞƐŽĨ// ? ? ? ? ? ? ? ?ƉƌŽƉƌĂŶŽůŽůĂŶĚ'W ? ? ? ? ?Ăƚ,K ?ɴ2-CS cells. The pKI values were determined using the Cheng-Prusoff
ĞƋƵĂƚŝŽŶĂŶĚƚŚĞz ?'WĂĨĨŝŶŝƚǇǀĂůƵĞĨŽƌƚŚĞɴ2-adrenoceptor reported by Baker et al. (2003d). Data shown are mean ± s.e.m of n separate experiments.
For each antagonist, the IC50 values obtained for 10, 20 and 100 nM BY-CGP were not statistically different (P > 0.05, one-way ANOVA followed by
Bonferronis multiple comparison test). The same analysis was performed for KI values of each antagonist, and no statistical difference (P > 0.05) was
determined.
ICI 118,551 n propranolol n CGP 12177 n
pIC50
10 nM BY-CGP 9.00 ± 0.25 3 9.02; 8.46 2 9.11; 9.17 2
20 nM BY-CGP 8.95 ± 0.12 3 8.65 ± 0.18 3 8.70; 8.99 2
100 nM BY-CGP 8.61 ± 0.02 3 8.43 ± 0.17 3 8.51 ± 0.13 3
pKI
10 nM BY-CGP 9.14 ± 0.25 3 9.16; 8.61 2 9.25; 9.32 2
20 nM BY-CGP 9.20 ± 0.12 3 8.91 ± 0.18 3 8.96; 9.24 2
100 nM BY-CGP 9.31 ± 0.02 3 9.13 ± 0.17 3 9.20 ± 0.13 3
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The rightward shifts of the two-phase antagonist displacement curves
describing the inhibition of the binding of increasing BY-CGP concentrations at
ƚŚĞ ɴ1-adrenoceptor may be indicative of competitive interactions between
ƚŚĞůĂďĞůůĞĚĂŶĚƵŶůĂďĞůůĞĚ ?ĐŽŵƉĞƚŝƚŽƌ ?ůŝŐĂŶĚƐĂƚďŽƚŚɴ1-adrenoceptor sites.
However, similar shifts may also be caused by allosteric modulators that
ŶĞŐĂƚŝǀĞůǇĂĨĨĞĐƚƚŚĞďŝŶĚŝŶŐŽĨz ?'WƚŽƚŚĞɴ1-adrenoceptor (Christopoulos
et al., 2002; Hulme et al., 2010). A competitive interaction between ligands
competing for the same binding site should result in log IC50 values that can
be fitted to a slope of unity using linear regression analysis when plotted
against the concentrations of the labelled ligand used to obtain the antagonist
IC50 values. Using this analysis, the slopes describing the interactions of CGP
 ? ? ? ? ? ?ƉƌŽƉƌĂŶŽůŽůĂŶĚ'W ? ? ? ? ?ĂƚƚŚĞŚŝŐŚĂĨĨŝŶŝƚǇɴ1-adrenoceptor site
1 were 0.57 ± 0.11(n=4), 0.84 ± 0.17 (n=3) and 0.76 ± 0.12 (n=3), respectively
(Figure 5.11A). When plotting the IC50 values obtained from the secondary
inhibition phase, slope of 0.39 ± 0.13 (n=4), 0.31 ± 0.12 (n=3) and 0.27 ± 0.22
(n=3) were determined for CGP 20712A, propranolol and CGP 12177,
respectively (Figure 5.11B). Whilst the slope describing ligand binding
interactions of CGP 20712A at site 1, and the slopes for all three antagonists
at site 2 were significantly different to unity (P < 0.05, one-sample t-test
comparison to hypothetical value of 1.0), it is important to note that we could
not be certain whether equilibrium conditions were achieved in the
fluorescence-based binding assay used to derive the antagonist IC50 values.
Slopes significantly different to unity were also obtained for ICI 118,551 (0.40
± 0.21, n=3), propranolol (0.32 ± 0.25, n=3) and CGP 12177 (0.60 ± 0.16, n=3)
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ĂƚƚŚĞɴ2-adrenoceptor, respectively (P < 0.05, one-sample t-test comparison
to hypothetical value of 1.0; Figure 5.11C). Only one binding site has been
ĚĞƐĐƌŝďĞĚĨŽƌƚŚĞŚƵŵĂŶɴ2-adrenoceptor, to which the fluorescent analogue
of CGP 12177 binds (Baker et al., 2003d). However, the interactions of this
ĨůƵŽƌĞƐĐĞŶƚůŝŐĂŶĚĂƚƚŚĞɴ2-adrenoceptor are long lasting (Baker et al., 2003d),
such that it is unlikely that equilibrium conditions were achieved in the
binding assay used here. This highlights the effects of non-equilibrium
conditions on the log IC50 ratio plot used here, and demonstrates that this
analysis cannot be used under these conditions to gain insight into the
ŵĞĐŚĂŶŝƐŵƐŽĨŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶůŝŐĂŶĚƐĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor.
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Figure 5.11 The log IC50 values obtained for CGP 20712A, propranolol and CGP 12177
at the A ? ɴ1-adrenoceptor site 1 and B, site 2 (in Figure 5.8 and Table 5.1) were
plotted against the log of the BY-CGP concentration used to determine these IC50
values (Table 5.2). C, the same analysis was performed using log IC50 values of ICI
 ? ? ? ? ? ? ? ?ƉƌŽƉƌĂŶŽůŽůĂŶĚ'W ? ? ? ? ?ŽďƚĂŝŶĞĚĂƚƚŚĞɴ2-adrenoceptor (in Figure 5.10
and Table 5.2). Data are mean ± s.e.m. of 3-4 separate experiments.
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Different gain settings were used for measuring the different BY-CGP
concentrations on the IX Ultra confocal plate reader to maximise the signal-
to-noise ratio for each concentration. To confirm that higher BY-CGP
concentration yield higher fluorescence intensity readings as a result of BY-
'WďŝŶĚŝŶŐ ƚŽ ƚŚĞɴ1 ?ĂŶĚɴ2-adrenoceptor in CHO cells, saturation binding
experiments were carried out. The binding of increasing BY-CGP
concentrations in the absence (total binding) and presence (non-specific
ďŝŶĚŝŶŐ ?ŽĨ ? ? ?ŶD'W ? ? ? ? ? ?,K ?ɴ1-CS cells; Figure 5.12) and 100 nM ICI
 ? ? ? ? ? ? ?  ?,K ?ɴ2-CS cells; Figure 5.13) was determined. The specific binding
ŽĨz ?'WǁĂƐƐĂƚƵƌĂďůĞĂƚƚŚĞɴ1 ?ĂŶĚƚŚĞɴ2-adrenoceptor, and both binding
curves were preferably fit to a one-site saturation binding curve. The pKD
ǀĂůƵĞ ĚĞƌŝǀĞĚ ĨƌŽŵ ƚŚĞ ƐĂƚƵƌĂƚŝŽŶ ďŝŶĚŝŶŐ ĐƵƌǀĞƐ ŽĨ z ?'W Ăƚ ƚŚĞ ɴ1-
adrenoceptor was 6.69 ± 0.17 (n=3). Two separate saturation binding
ĞǆƉĞƌŝŵĞŶƚƐ ǁĞƌĞ ƉĞƌĨŽƌŵĞĚ ƵƐŝŶŐ ,K ?ɴ2-CS cells yielding pKD values 7.13
and 7.43.
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Figure 5.12 dŚĞ ďŝŶĚŝŶŐ ŽĨ ŝŶĐƌĞĂƐŝŶŐ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ z ?'W ƚŽ ,K ?ɴ1-CS cells
was determined in the absence (total binding) and presence (non-specific binding) of
100 nM CGP 20712A. The non-specific binding levels were deducted from total
ďŝŶĚŝŶŐƚŽŐŝǀĞƐƉĞĐŝĨŝĐďŝŶĚŝŶŐĚĂƚĂŽĨz ?'WƚŽ,K ?ɴ1-CS cells. The data shown
are from a single experiment with error bars showing range of error of duplicate
determinations. These data are representative of three separate experiments.
[BY-CGP] (nM)
in
te
gr
a
te
d
in
te
n
s
ity
(1
x
10
6 )
0 100 200 300
0
10
20
30
total binding
non-specific binding
(100 nM CGP 20712A)
specific binding
255
Figure 5.13 dŚĞ ďŝŶĚŝŶŐ ŽĨ ŝŶĐƌĞĂƐŝŶŐ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ z ?'W ƚŽ ,K ?ɴ2-CS cells
was determined in the absence (total binding) and presence (non-specific binding) of
100 nM ICI 118,551. The non-specific binding levels were deducted from total
ďŝŶĚŝŶŐƚŽŐŝǀĞƐƉĞĐŝĨŝĐďŝŶĚŝŶŐĚĂƚĂŽĨz ?'WƚŽ,K ?ɴ2-CS cells. The data shown
are from a single experiment with error bars showing range of error of duplicate
determinations. These data are representative of two separate experiments.
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ĞƚĞƌŵŝŶĂƚŝŽŶ ŽĨ z ?'W ďŝŶĚŝŶŐ ƉĂƌĂŵĞƚĞƌƐ ƚŽ ƚŚĞ ŚƵŵĂŶ ɴ1-
ĂŶĚ ɴ2-adrenoceptor using the high-throughput PHERAstar FS
plate reader
Whilst the IX Ultra confocal plate reader delivers confocal images of each well
to allow visualisation of the binding of a fluorescent ligand to living cells, it
takes circa 20 minutes to read one 96-well plate. A faster, high-throughput
plate reader is the PHERAstar FS, which measures the fluorescence intensity
in each well without taking confocal images, thus it takes circa 3 minutes to
read one 96-well plate. Here, we compare the BY-CGP binding data obtained
using both plate readers. Each plate was read first on the PHERAstar FS and
immediately afterwards on the IX Ultra confocal plate reader to allow for
direct comparison of data from the same assay plate. We examined the
ŝŶŚŝďŝƚŝŽŶŽĨ ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1 ?^ĂŶĚ,K ?ɴ2-CS cells by the
ŶŽŶ ?ƐĞůĞĐƚŝǀĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚ ƉƌŽƉƌĂŶŽůŽů ? ƚŚĞ ɴ1-selective
ĂŶƚĂŐŽŶŝƐƚ'W ? ? ? ? ?ĂŶĚƚŚĞɴ2-selective antagonist ICI 118,551. As can be
seen in Figure 5.14 and 5.15, the IX Ultra and PHERAstar FS montage images
of the assay plates compare well at both receptors, respectively.
ƚ ƚŚĞ ɴ1-adrenoceptor (Figure 5.14), a two-site fit was the preferred fit for
the CGP 20712A inhibition curve and similar IC50 values of CGP 20712A at site
1 and site 2, and percentages of BY-CGP-bound site 1 of overall BY-CGP-bound
receptor sites were determined using the PHERAstar FS (pIC50 site 1: 8.71 ±
0.08, site 2: 4.81 ± 0.48, percentage site 1: 85.1 ± 4.9 %, n=4) and the IX Ultra
(site 1: 8.44 ± 0.05, site 2: 4.75 ± 0.50, percentage site 1: 90.7 ± 3.4 %, n=4; P >
0.05, unpaired t-test performed for each parameter). The definition of the
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propranolol inhibition curve was not great enough to detect a second
displacement binding phase, although it can be seen that the data points
were very similar to those for CGP 20712A. Propranolol pIC50 values obtained
using the PHERAstar FS were 9.11 ± 0.26 (n=4) and compared well to those
determined from data obtained using the IX Ultra confocal plate reader (pIC50
8.95 ± 0.11, n=4; P > 0.05, unpaired t-test). The ICI 118,551 displacement
curve was right-shifted compared to the CGP 20712A and propranolol
inhibition curves, and similar IC50 values were determined from the PHERAstar
FS (pIC50 of 7.56 ± 0.16, n=4) and the IX Ultra data (pIC50 7.45 ± 0.05, n=4; P >
0.05, unpaired t-test).
ƚƚŚĞɴ2-adrenoceptor (Figure 5.15) all inhibition binding curves were fitted
to a one-site binding equation. ICI 118,551 displayed similar pIC50 values of
8.73 ± 0.06 (n=4) and 8.67 ± 0.01 (n=4) determined from PHERAstar FS and IX
Ultra data, respectively (P > 0.05, unpaired t-test). Propranolol also displaced
10 nM BY-CGP binding with comparable pIC50 values of 9.00 ± 0.08 (n=4,
PHERAstar FS) and 8.98 ± 0.09 (n=4, IX Ultra; P > 0.05, unpaired t-test). The
'W  ? ? ? ? ? ĚŝƐƉůĂĐĞŵĞŶƚ ĐƵƌǀĞ ǁĂƐ ƌŝŐŚƚ ?ƐŚŝĨƚĞĚ ĂƚƚŚĞ ɴ2-adrenoceptor
with pIC50 values of 5.68 ± 0.06 (n=3, PHERAstar FS) and 5.57 ± 0.03 (n=3, IX
Ultra; P > 0.05, unpaired t-test).
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Figure 5.14ŝŶĚŝŶŐŽĨ ? ?ŶDz ?'WƚŽ,K ?ɴ1-CS cells in the absence and presence
of unlabelled competitor ligands. A, montage image showing the fluorescent
intensity of BY-CGP binding determined on the IX Ultra confocal plate reader and B,
the PHERAstar FS plate reader. C, inhibition curves of propranolol, CGP 20712A and
ICI 118,551 obtained from the IX Ultra confocal plate reader data shown in A and D,
the PHERAstar FS data shown in B. The data shown are mean ± s.e.m. from a single
experiment and are representative of three separate experiments.
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Figure 5.15ŝŶĚŝŶŐŽĨ ? ?ŶDz ?'WƚŽ,K ?ɴ2-CS cells in the absence and presence
of unlabelled competitor ligands. A, montage image showing the fluorescent
intensity of BY-CGP binding determined on the IX Ultra confocal plate reader and B,
the PHERAstar FS plate reader. C, inhibition curves of propranolol, CGP 20712A and
ICI 118,551 obtained from the IX Ultra confocal plate reader data shown in A and D,
the PHERAstar FS data shown in B. The data shown are mean ± s.e.m. from a single
experiment and are representative of three separate experiments.
B
A
propranolol
CGP 20712A
ICI 118,551
Antagonist Log (M)
-11 -10 -9 -8 -7 -6 -5 -4 --
Fluorescence Intensity
C D
[antagonist] Log (M)
%
s
pe
c
ifi
c
bi
n
di
n
g
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3
-10
10
30
50
70
90
110
130
propranolol
CGP 20712A
ICI 118,551
[antagonist] Log (M)
%
s
pe
c
ifi
c
bi
n
di
n
g
-12 -11 -10 -9 -8 -7 -6 -5 -4 -3
-10
10
30
50
70
90
110
130
propranolol
CGP 20712A
ICI 118,551
Antagonist Log (M)
-11 -10 -9 -8 -7 -6 -5 -4 --
IX Ultra PHERAstar FS
PHERAstar FS
IX Ultra
260
5.4 Discussion
Fluorescent ligands allow the visualisation of native receptors in living cells
and thus facilitate investigations of receptor-ligand interactions without any
of the safety hazards or disposal costs associated with using radioisotopes for
ƐŝŵŝůĂƌ ƐƚƵĚŝĞƐ ? ,ĞƌĞ ? ǁĞ ĞǆĂŵŝŶĞĚ ƚŚĞ ƵƐĞ ŽĨ ƚŚĞ ĨůƵŽƌĞƐĐĞŶƚůǇ ůĂďĞůůĞĚ ɴ ?
adrenoceptor ligands CGP 12177 and propranolol in a live cell automated
high-content screening format with the aim to further assess the ligand
ďŝŶĚŝŶŐ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ŽĨ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ůŽǁ ĂĨĨŝŶŝƚǇ ďŝŶĚŝŶŐ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-
adrenoceptor.
The IX Ultra confocal plate reader automatically captured and analysed
confocal images from four separate sites in each well used on a 96-well assay
plate. Using the same experimental conditions (incubation times and
temperatures) in both manual and automated confocal microscopy
approaches, the data obtained for CGP 20712A inhibiting the binding of 20
nM BY-CGP compared very well. Additional data points clearly defined a
secondary binding inhibition phase which was best fitted to a two-site
displacement binding curve. However, the use of BY-PROP proved
unsuccessful in this assay due to great intra-experimental variability. This may
ŚĂǀĞ ďĞĞŶ ĚƵĞ ƚŽ Ă ůŽǁĞƌ ĂĨĨŝŶŝƚǇ ŽĨ z ?WZKW ĨŽƌ ƚŚĞ ɴ1-adrenoceptor. A
ŚŝŐŚĞƌ ? ƐƵď ?ŶĂŶŽŵŽůĂƌ ĂĨĨŝŶŝƚǇ ŽĨ z ?WZKW ǁĂƐ ĚĞƚĞƌŵŝŶĞĚ ĨŽƌ ƚŚĞ ɴ2-
adrenoceptor by Baker et al. (2011a), which is consistent with the clear
ŵĞŵďƌĂŶĞůĂďĞůůŝŶŐŽďƐĞƌǀĞĚŽĨ ?ŶDz ?WZKWŝŶ,K ?ɴ2-CS cells (Chapter 4,
Figure 4.12; Baker et al. (2011a)). The 20 nM BY-PROP concentration used in
261
,K ?ɴ1-CS cells was similar to the affinity value of BY-PROP for the
ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ  ? ŽĨ ƚŚĞ ɴ1-adrenoceptor (circa 28 nM) compared to a
circa 30-fold KD concentration of BY-CGP (KD circa 0.6 nM) used in
experiments in the same cells. It takes longer for ligands to reach equilibrium
at low concentrations than at higher concentrations, which is one of the
reasons why it is desirable to have a high affinity labelled ligand for
competition binding experiments. In addition, the lipophilic properties of BY-
PROP as well as a short incubation time may have been contributing factors in
the variability of data points observed. The diffusion time for a sticky ligand
may have been limited in the assay conditions used, although increasing
incubation times and temperatures did not seem to resolve this problem.
Furthermore, using total image intensity analysis the intracellular
fluorescence intensities were included in the analysis of the confocal images
and ultimately contributed to a reduced assay window in which the
ĚŝƐƉůĂĐĞŵĞŶƚŽĨz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells could be measured.
Using a 96-well format allowed the investigation of the secondary low affinity
ďŝŶĚŝŶŐ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor in more detail by examining receptor-
ligand interactions of multiple BY-CGP concentrations and competitor ligands.
Increasing BY-CGP concentrations resulted in rightward shifted displacement
binding curves of CGP 20712A, propranolol and CGP 12177. The IC50 values for
both site 1 and site 2 increased with increasing BY-CGP concentrations which
is indicative of competitive antagonism at both sites. The derived affinity
values, however, did not compare well with the affinity values obtained for
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the three antagonists in the CRE-mediated SPAP transcription assay in
Chapter 3 (Table 5.3). An incubation time of 5 hours with both the antagonist
and the agonist present is necessary in the CRE-SPAP assay to allow for
transcription of the reporter gene. This was a considerably longer incubation
time than was used in the competition binding experiments used in this
chapter and thus allowed more time for antagonist and agonist to reach
equilibrium or at least a closer-to-equilibrium state in the gene reporter assay.
Equilibrium is achieved when the concentrations of free and bound
ligand/receptor do not change any more and the same number of ligand
molecules associate with the receptor as dissociate. The Cheng-Prusoff
equation was used to derive the affinity values of the antagonists from their
IC50 values against different BY-CGP concentrations. This equation assumes
equilibrium conditions in the competition binding assay and mutually
exclusive binding sites (i.e. no allosteric interactions between multiple binding
sites). To check whether equilibrium has been reached displacement binding
curves can be obtained using different incubation times. The binding curves
will shift until equilibrium is reached. Alternatively, Motulsky et al. (1984)
have estimated that four times the dissociation half time (of the slowest
dissociating ligand) is needed to reach equilibrium. BODIPY-TMR-CGP was
ĚĞƐĐƌŝďĞĚĂƐĂůŽŶŐ ?ĂĐƚŝŶŐƉĂƌƚŝĂůĂŐŽŶŝƐƚĂƚƚŚĞɴ2-adrenoceptor (Baker et al.,
 ? ? ? ?Ě ? ?  ƐůŽǁ ĚŝƐƐŽĐŝĂƚŝŽŶ ŽĨĨ ƌĂƚĞ ĨƌŽŵ ƚŚĞ ɴ1-adrenoceptor can also be
assumed, because the fluorescence intensity reading of a given BY-CGP
concentration was unchanged across the assay plate following the washout of
all ligands and a 20 minute read time on the IX Ultra confocal plate reader. A
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Table 5.3 Comparison of affinity values of CGP 20712A, propranolol and CGP 12177
Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor obtained in the CRE-mediated SPAP transcription
assay and the BODIPY-TMR-CGP live cell high-content screening binding assay. Data
are mean ± s.e.m. of (n) separate experiments. 1The CRE-SPAP data shown here was
obtained in experiments described in Chapter 3. *statistical significance (P < 0.05) of
difference in affinity values determined in the BY-CGP binding assay compared to affinities
obtained in the CRE-SPAP assay, according to unpaired t-test analysis
BY-CGP binding assay CRE-SPAP assay1
pKI n pKB n
CGP 20712A
site 1 10.29 ± 0.06* 6 8.84 ± 0.11 5
site 2 5.40 ± 0.09* 6 6.73 ± 0.22 7
propranolol
site 1 9.28 ± 0.10* 3 8.65 ± 0.07 23
site 2 5.35 ± 0.06* 3 6.04 ± 0.18 5
CGP 12177
site 1 10.30 ± 0.07* 3 9.61 ± 0.06 10
site 2 5.56 ± 0.17* 3 7.58 ± 0.13 13
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fast dissociating ligand would have resulted in lower fluorescence intensity
readings following washout of the ligand. But without knowing the exact
kinetic parameters of the ligands involved it is difficult to predict when
equilibrium might be reached. However, reading of the assay plate on the IX
Ultra confocal plate reader in the presence (rather than the absence) of both
unlabelled and labelled ligands may have improved the competition binding
ĚĂƚĂ ? ƉĂƌƚŝĐƵůĂƌůǇ ĨŽƌ z ?'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ůŽǁĞƌĂĨĨŝŶŝƚǇ ƐĞĐŽŶĚĂƌǇ ɴ1-
adrenoceptor site and also when using the fluorescent propranolol ligand.
Equilibrium is achieved when the rate of ligand-receptor formation is equal to
the rate of ligand-receptor dissociation, thus including free ligand, free
receptors and ligand-bound receptor complexes. The wash step used in the
experiments described in this chapter removed the free ligands, thereby
facilitating the opportunity of ligand-receptor complexes to dissociate and to
attempt to reach a new equilibrium in washed conditions. This may have
resulted in an underestimation of the amount of bound fluorescent ligand
and contributed to lower BY-CGP site 2 and BY-PROP binding levels, although
the competition binding data obtained from the IX Ultra confocal plate reader
(20 minute read per plate) and the PHERAstar FS plate reader (3 minute read
per plate) did not show a noticeable difference in the fluorescent ligand
binding data for the antagonists tested. The binding kinetics of BY-CGP and
z ?WZKW ƚŽ ,K ?ɴ1-CS are investigated in more detail in Chapter 6. In
addition, increased incubation times and temperatures of BY-CGP appeared
to increase the non-specific cytoplasmic fluorescence intensity measured,
thus making long incubation times difficult.
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Interestingly, the affinity values determined for site 1 are overestimated in
the binding assay whereas the affinity values for the second site are
underestimated for all three antagonists tested, in comparison to the affinity
values obtained in the SPAP assay (Chapter 3). This suggests that the kinetics
of BY-CGP are very different at the two sites potentially with faster kinetics at
site 2 and slower kinetics at site 1. If BY-CGP displays slow kinetics at site 1 it
could mean that less receptor sites will have been occupied in a shorter
incubation time than if equilibrium was reached, thus allowing the unlabelled
antagonist to compete against less ligand than is presumed, resulting in the
antagonists to appear more potent at that site. However, overestimation of
antagonist affinities may also be due to slow antagonist dissociation rates,
especially following the antagonist pre-incubation used in these experiments.
By contrast, faster BY-CGP kinetics at site 2 could mean that too much
ligand initially associates with the receptor site, thus giving the antagonists
too much to compete against, making them appear less potent at that site.
This is consistent with the shifts of IC50 values observed at site 1 and site 2
when BY-CGP incubation was carried out at 37 °C compared to 21 °C. A
comparable shift of the IC50 values, however, was not seen when increasing
the incubation time from 30 to 60 minutes at 21 °C. Whilst not observing a
shift of the displacement binding curve can be indicative of having reached
equilibrium it may also mask very slow kinetics of the fluorescent ligand. In
fact, Joseph et al. (2004) reported a circa 20-fold faster dissociation rate of
the radioligand [3H]-CGP 12177 off the low affinity site than off the high
affinity site (Joseph et al., 2004). However, the addition of a large fluorophore
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to the small molecule CGP 12177 cannot be compared to the addition of a
comparably small radioisotope and the kinetic parameters of BY-CGP at the
ɴ1-adrenoceptor are examined in Chapter 6.
dŚĞůŽǁĞƌĂĨĨŝŶŝƚǇǀĂůƵĞƐĚĞƚĞƌŵŝŶĞĚĨŽƌƚŚĞŚŝŐŚĂĨĨŝŶŝƚǇɴ1-adrenoceptor site
1 in the CRE-SPAP assay compared to the BY-CGP binding may also have been
due to receptor desensitisation caused by using the full agonist cimaterol in
ƚŚĞ Z ?^WW ĂƐƐĂǇ ? >ŽǁĞƌ ĂĨĨŝŶŝƚŝĞƐ ǁĞƌĞ ŵĞĂƐƵƌĞĚĨŽƌ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
ligands in the CRE-SPAP assay when using a full agonist compared to using a
partial agonist (Baker et al., 2003c). In addition, a potential impact of an
allosteric mechanism of action being responsible for the secondary site may
also be considered, as allosteric modulators that cause negative co-
operativity between two binding sites may display similar pharmacology to
competitive antagonists, and may not easily identified using an equilibrium
binding approach (Christopoulos et al., 2002). Such a mechanism that links
the two ȕ1-adrenoceptor binding sites also invalidates the use of the Cheng-
Prusoff equation to derive antagonist affinity values from the IC50 values in
the competition binding assay.
ŽŶĨŽĐĂů ŝŵĂŐĞƐ ŽĨ ƚŚĞ ,K ?ɴ2-CS cell line revealed a homogenous cell line
with good levels of BY-CGP binding to all cells. Displacement binding curves of
ƚŚƌĞĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ ŽďƚĂŝŶĞĚ ƵƐŝŶŐ ,K ?ɴ2-CS cells were best
fitted using a one-site displacement binding curve, indicating that the two-site
ďŝŶĚŝŶŐĨŝƚƉƌĞĨĞƌƌĞĚĂƚƚŚĞɴ1-adrenoceptor is specific to the receptor and not
due to artefacts of the assay format. The affinity values that were calculated
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ĨŽƌ ƚŚĞ ĂŶƚĂŐŽŶŝƐƚƐ Ăƚ ƚŚĞ ɴ2-adrenoceptor were in good agreement with
values reported in the literature (Baker (2005); Table 5.4). Considering the
ƉƌŽƉŽƐĞĚƐůŽǁŬŝŶĞƚŝĐƐŽĨz ?'WĂƚƚŚĞɴ2-adrenoceptor (Baker et al., 2003d),
this was unexpected.
Interestingly, the proportion of the second site also increased with increasing
BY-CGP concentrations. This is consistent with increased labelling of the
second site by higher concentrations due to higher occupancy at the second
ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor (Figure 5.16, Table 5.5). From the percent
occupancy of 10, 20 and 100 nM BY-CGP at site 1 and site 2, the percentage of
BY-CGP bound to the high affinity site over the low affinity site was calculated
(i.e. theoretical percentage site 1; Table 5.5) for each BY-CGP concentration
used, and those values compared well to the values obtained from
experimental data. The calculated values were based on the assumption that
both sites were present in equal proportions (i.e. 1:1), which would mean for
ĞĂĐŚ ƐŝƚĞ  ? ƚŚĞƌĞ ŝƐ ĂůƐŽ Ă ƐŝƚĞ  ? ? ǁŚŝĐŚ ǁŽƵůĚ ďĞƚŚĞ ĐĂƐĞ ŝĨ ƚŚĞ ɴ1-
adrenoceptor did in fact have two separate binding sites or if the receptor
was present in stable homodimers thus also providing two binding sites.
ǆƉĞƌŝŵĞŶƚĂůĚĂƚĂ ?ŚŽǁĞǀĞƌ ?ƐƵŐŐĞƐƚƐƚŚĂƚɴ1-adrenoceptors exist in transient
homodimer formations (Dorsch et al., 2009; Calebiro et al., 2013).
Furthermore, these calculations were based on the assumption that
equilibrium had been reached in the assay which, as discussed above, is
unlikely.
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Table 5.4 Comparison of affinity values of ICI 118,551, propranolol and CGP 12177 at
ƚŚĞŚƵŵĂŶɴ2-adrenoceptor obtained in the BODIPY-TMR-CGP live cell high-content
screening binding assay with values determined in a [3H]-CGP 12177 competition
binding assay (Baker et al., 2005). Data are mean ± s.e.m. of (n) separate
experiments.
BODIPY-TMR-CGP binding assay [3H]-CGP 12177 binding assay
pKI n pKB
ICI 118,551 9.22 ± 0.13 3 9.26
propranolol 9.00 ± 0.15 4 9.08
CGP 12177 9.20 ± 0.08 3 9.39
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Figure 5.16 BY-CGP occupancy curves at the high affinity catecholamine site 1 and
ůŽǁĂĨĨŝŶŝƚǇ S'W ? ? ? ? ? ?ƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor. The occupancy curves were
determined using the affinity constants of BY-CGP at the high and low affinity site of
ƚŚĞ ɴ1-adrenoceptor derived in the CRE-mediated SPAP transcription assay in
ŚĂƉƚĞƌ ? ?dŚĞĚŽƚƚĞĚůŝŶĞƐŚŝŐŚůŝŐŚƚƚŚĞA?ŽĐĐƵƉĂŶĐǇĂƚƚŚĞɴ1-adrenoceptor site 1
and site 2 for 10, 20 and 100 nM BY-CGP.
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Table 5.5 ^ƵŵŵĂƌǇŽĨƉĞƌĐĞŶƚĂŐĞŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?'WďŽƵŶĚƚŽƐŝƚĞ ?ĂŶĚƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor (taken from the BY-CGP occupancy curves
shown in Figure 5.16) and the calculated (theoretical) and experimentally obtained percentages of 10, 20 and 100 nM BY-CGP binding to site 1 over site 2 of
ƚŚĞɴ1-adrenoceptor.
% bound % site 1 % site 1
site 1 site 2 theoretical experimental
CGP 20712A n propranolol n CGP 12177 n
10 nM BY-CGP 95.0 8.7 91.2 89.1 ± 1.2 4 89.3 ± 0.4 3 92.6 ± 1.3 3
20 nM BY-CGP 97.6 16.7 85.4 85.8 ± 1.2 3 87.0 ± 0.6 3 88.8 ± 0.6 3
100 nM BY-CGP 99.5 49.1 66.9 58.3 ± 4.0 6 72.1 ± 3.7 3 72.2 ± 2.1 3
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The saturation binding data best fitted to a one-site specific binding curve and
the KDǀĂůƵĞŽďƚĂŝŶĞĚĨŽƌz ?'WĂƚƚŚĞɴ1-adrenoceptor (circa 202 nM) was
similar to the affinity value of BY-CGP determined for the second low affinity
ɴ1-adrenoceptor site (circa 87 nM) in the CRE-SPAP assay (Chapter 4). This
may be because the circa 100-fold difference in affinity (KDsite1 circa 0.6 nM) is
difficult to capture in one saturation binding curve which spans ten BY-CGP
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐĨƌŽŵ ? ? ? W ? ? ?ŶD ?dŚĞĂĨĨŝŶŝƚǇǀĂůƵĞŽĨz ?'WĂƚƚŚĞĨŝƌƐƚɴ1-
adrenoceptor site is circa 0.6 nM (Chapter 4) and was the lowest
concentration and first data point of the saturation binding curve.
Furthermore, additional data points facilitating an even broader range of BY-
CGP concentrations would not necessarily have enabled the detection of both
sites due to the limits in the dynamic range the IX Ultra plate reader can
detect at any given gain setting. The gain settings used in the experiments for
this study were always optimised to the highest BY-CGP concentration used
(i.e. the concentration which resulted in the highest reading of fluorescence
intensity) and thus better at detecting higher than lower fluorescence
intensities.
As mentioned earlier, the IX Ultra confocal plate reader has a read time of 20
minutes per assay plate. The PHERAstar FS plate reader has a much quicker
read time of circa 3 minutes in which it records the fluorescence intensity of
81 sites per well of a 96-well plate. Whilst it does not capture confocal images
of the wells and thus collects only numerical data, this plate reader provides
an opportunity for higher throughput screening campaigns. The IC50 values of
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//  ? ? ? ? ? ? ? ? ƉƌŽƉƌĂŶŽůŽů ĂŶĚ 'W  ? ? ? ? ? ĂŐĂŝŶƐƚ  ? ?ŶD z 'W Ăƚ ƚŚĞ ɴ1-
ĂŶĚ ɴ2-adrenoceptor were determined using the IX Ultra confocal plate
reader and the PHERAstar FS plate reader and were in excellent agreement
and all three antagonists inhibited the binding of 10 nM BY-CGP according to
ƚŚĞŝƌĂƚƚƌŝďƵƚĞĚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐĞůĞĐƚŝǀŝƚŝĞƐ ?dŚŝƐŚŝŐŚůŝŐŚƚƐƚŚĞƉŽƚĞŶƚŝĂůƵƐĞ
of the PHERAstar FS plate reader for high-throughput screening programs but
also demonstrates the versatile use of the BODIPY-TMR-CGP ligand in
multiple assays using different methods of detecting ligand binding
parameters.
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5.5 Conclusion
We have successfully used the fluorescent ligand BODIPY-TMR-CGP in a live
cell fluorescence-based ligand binding assay to examine ligand binding
ƉĂƌĂŵĞƚĞƌƐ Ăƚ ƚŚĞ ɴ1 ? ĂŶĚ ƚŚĞ ɴ2-adrenoceptor expressed in CHO cells. The
fluorescent propranolol derivative BY-PROP however could not be used in this
assay format due to high non-specific binding levels. The high-content IX Ultra
confocal plate reader allowed the automatic capture and analysis of confocal
images of every well of the assay plate and revealed two-phase displacement
binding curves of antagonists against BY-CGP. In addition, we examined the
high-throughput PHERAstar FS plate reader as an alternative high-throughput
screening platform and data obtained on this plate reader compared well to
data determined on the IX Ultra. Both plate readers provide the opportunity
for screening programs to determine affinity values of unlabelled ligands at
ƚŚĞŶĂƚŝǀĞɴ1 ?ĂŶĚɴ2-receptors in their native membrane environment.
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Chapter 6
Investigating kinetic parameters of
BODIPY-TMR-CGP and
BODIPY630/650-S-PEG8-propranolol
ďŝŶĚŝŶŐĂƚƚŚĞŚƵŵĂŶɴ1-
adrenoceptor at the single cell level
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6.1 Introduction
The determination of the dissociation rate of a radiolabelled ligand at a G
protein-coupled receptor (GPCR) is traditionally achieved by preventing the
re-association of the radioligand with its receptor through the addition of a
saturating concentration of the unlabelled counterpart at various time points
(Dowling et al., 2006; May et al., 2007). The dissociation rate of a labelled
ligand is not affected in the presence of a competitive ligand if both ligands
target the same binding site of a monomeric receptor. However, secondary
binding sites and receptor dimerisation provide allosteric sites to which
unlabelled ligands can potentially bind and thus affect the dissociation rate of
the labelled ligand (Christopoulos et al., 2002). In a confocal perfusion system,
assay buffer is perfused over live cells in an imaging cell perfusion chamber at
a constant flow rate of at least 12 complete fluid exchanges within the
perfusion chamber, to allow the determination of kinetic parameters of a
fluorescently labelled ligand under infinite dilution conditions (May et al.,
2010a). Using this method, the dissociated labelled ligand is physically
removed from the receptor without the need for high concentrations of
unlabelled ligands. Using a confocal microscopy approach to address the
kinetics of receptor-ligand interactions allows visualisation of ligand binding
to single living cells under physiological conditions (37 °C) and the
investigation of the dynamics of receptor-ligand interactions in real time and
is particularly useful when the presence, number or nature of potential
allosteric binding sites of a GPCR is not yet fully known.
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dŚĞ ɴ1-adrenoceptor has been reported to have two binding sites or
conformations. Endogenous ligands adrenaline and nor-adrenaline exhibit
their stimulatory effects through the orthosteric catecholamine site which are
ĞĨĨĞĐƚŝǀĞůǇ ŝŶŚŝďŝƚĞĚďǇ ɴ ?ďůŽĐŬĞƌƐ ƐƵĐŚ ĂƐ 'W  ? ? ? ? ? ? ,ŽǁĞǀĞƌ ? 'W  ? ? ? ? ?
was also found to exert agonist effects at approximately 100-fold higher
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ƚŚƌŽƵŐŚ Ă ůŽǁĞƌ ĂĨĨŝŶŝƚǇ  S'W  ? ? ? ? ? ? ɴ1-adrenoceptor site
(Baker et al., 2003a; Konkar et al., 2000; Pak et al., 1996).
/Ŷ ĐŚĂƉƚĞƌ  ? ŽĨ ƚŚŝƐ ƚŚĞƐŝƐ ǁĞ ĚĞƐĐƌŝďĞĚ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ ƚǁŽ ĨůƵŽƌĞƐĐĞŶƚ ɴ ?
adrenoceptor ligands BODIPY-TMR-CGP (a CGP 12177 derivative) and
BODIPY630/650-S-PEG8-propranolol (an analogue of propranolol) to both, the
orthosteric high affinity and the secondary CGP 12177 low affinity binding
ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor. In this chapter, we aimed to characterise the
ŬŝŶĞƚŝĐ ƉĂƌĂŵĞƚĞƌƐ ŽĨ ƚŚĞƐĞ ƚǁŽ ĨůƵŽƌĞƐĐĞŶƚ ůŝŐĂŶĚƐ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-
adrenoceptor and secondly, to examine the effects of unlabelled ligands on
the dissociation rate of the fluorescent ligands under infinite dilution
conditions in single living cells to further our understanding of the dynamics
ŽĨ ƚŚĞ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ɴ1-adrenoceptor and a potential role of the
ƐĞĐŽŶĚĂƌǇɴ1-adrenoceptor binding site.
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6.2 Methods
Cell culture
This was performed as described in Methods: Cell culture ? ,K ?ɴ1-CS and
CHO-CS cell lines were used in this chapter.
Confocal perfusion system
The perfusion experiments were carried out at 37 °C as described inMethods:
Confocal perfusion system. The confocal perfusion systems of both, the Zeiss
LSM510 and LSM710 microscope, were used. Confocal and transmitted light
images of live cells were taken every 2-3 seconds. BY-CGP fluorescence
intensity was measured using a 543 nm and 561 nm excitation wavelength on
the LSM510 and LSM710 confocal microscope, respectively. The fluorescence
intensity of BY-PROP was measured using a 633 nm wavelength on both
microscopes. The use of both confocal perfusion systems was validated by
comparing kinetic data of the fluorescent adenosine derivative ABA-X-BY630
(for structure see Middleton et al. (2007)) at the adenosine A3 receptor
obtained using the above two microscopes to published data (Appendix I S8).
Data analysis
The equations describing the curve fits used in this chapter are listed and
described in Methods: Data analysis. GraphPad Prism 5.0 was used to fit all
kinetic data. Association traces of fluorescent ligands were fit using a
monophasic exponential fit. The association plateau predicted by GraphPad
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Prism 5.0 was used to define 100 % of ligand binding to allow data to be
normalised and grouped. For the analysis of dissociation rates, a monophasic
exponential fit was compared to a two-phase decay equation to find the best
fit, which was then used to derive the dissociation rate. This was done for
every concentration of fluorescent ligand used.
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6.3 Results
Characterising the kinetic parameters of BODIPY-TMR-CGP at the
ŚƵŵĂŶɴ1-adrenoceptor
The Zeiss LSM510 confocal microscope was used in conjunction with a closed
perfusion system that allowed the constant perfusion of ligands or buffer
from switch-operated fluid reservoirs, thus allowing the determination of
kinetic parameters of the fluorescent ligand under infinite dilution conditions.
Using a pump, constant pressure generated a fluid flow rate that was
constant, which ensured that the imaged cells were kept in focus during the
captured time series. The fluid flow was maintained at a rate fast enough to
ŐĞŶĞƌĂƚĞ ƚŚĞ ŶĞĐĞƐƐĂƌǇ ŶƵŵďĞƌ ŽĨ ĨůƵŝĚ ĞǆĐŚĂŶŐĞƐ ƉĞƌ ŵŝŶƵƚĞ  ?A?  ? ?
exchanges per minute, i.e. 5 mL per minute) within the perfusion imaging
chamber that allowed sharp changes in concentration upon reservoir
switching (May et al., 2010a). Confocal and phase images were taken every 3
seconds before perfusion of the fluorescent ligand (to obtain a 30 seconds
recording of the baseline fluorescence for a given coverslip of cells), during its
perfusion (to obtain a trace of association) and after its perfusion (i.e.
perfusion of buffer to obtain a trace of dissociation; Figure 6.1B). Drawing
regions of interests (ROIs) around the membranes of individual cells allowed
the analysis of kinetic parameters at the single cell level (Figure 6.1A). Actual
(raw) fluorescence intensity data varied from cell to cell, but the normalised
data was similar for the cells examined (Figure 6.1C).
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Figure 6.1 ŶĂůǇƐŝƐŽĨz ?'WĨůƵŽƌĞƐĐĞŶĐĞŝŶƚĞŶƐŝƚŝĞƐŝŶ,K ?ɴ1-CS cells at the single
cell level. A, regions of interest (ROIs) were drawn around the membrane of
individual cells to obtain fluorescence intensity readings over time. B, BY-CGP
fluorescence intensities were measured from 0-30 seconds to obtain a baseline
fluorescence read by perfusing HBSS buffer only (1), from 30-330 seconds to
determine BY-CGP association by perfusing BY-CGP (2) and from 330-630 seconds to
determine BY-CGP dissociation by perfusing HBSS buffer only (3). The actual (raw)
BY-CGP fluorescence intensity traces are shown for two individual cells (red and blue
ROI). C, baseline-corrected normalised association and dissociation data of cell 1 (ROI
1, red) and cell 2 (ROI 2, blue).
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The association and dissociation of 10, 30 and 100 nM BY-CGP at the human
ɴ1-adrenoceptor were examined. The same microscope settings were used for
Ăůůz ?'WĐŽŶĐĞŶƚƌĂƚŝŽŶƐƵƐĞĚŽŶďŽƚŚ,K ?ɴ1-CS and CHO-CS cells, to allow
the direct comparison of fluorescence intensities between the three BY-CGP
concentrations and the two cell lines. The CHO-CS cell line was used to define
the non-specific binding component of BY-CGP binding. The fluorescence
intensity increased with increasing BY-CGP concentrations and increasing
ĞǆƉŽƐƵƌĞƚŝŵĞƚŽz ?'W ŝŶďŽƚŚ,K ?ɴ1-CS (Figure 6.2) and CHO-CS (Figure
6.3) cells. The same trend could be seen for low levels of diffuse intracellular
fluorescence in both cell lines, suggesting that the cytoplasmic non-specific
ĨůƵŽƌĞƐĐĞŶĐĞ ŝŶƚĞŶƐŝƚǇ ŝƐ ŶŽƚ ɴ1-adrenoceptor-mediated. Clear membrane
ůĂďĞůůŝŶŐ ŽĨ z ?'W ǁĂƐ ŽŶůǇ ĞǀŝĚĞŶƚ ŝŶ ,K ?ɴ1-CS cells and not in CHO-CS
cells, thus the phase image was used to define the plasma membrane of cells
to draw ROIs (Figure 6.4). As expected, the non-specific cell membrane-
associated fluorescence intensity in CHO-CS cells was markedly lower than
the total binding cell membrane-associated fluorescence intensity measured
ŝŶ,K ?ɴ1-CS cells (Figure 6.4 and 6.5).
The association and dissociation traces obtained in CHO-CS could only be
accurately analysed for 30 and 100 nM BY-CGP. Monoexponential association
and dissociation equations were used and revealed rapid observed
association (konobs; 1.40 ± 0.26 min
-1, n=6 and 1.56 ± 0.11 min-1, n=4 for 30 and
100 nM BY-CGP, respectively) and dissociation rates (koff; 2.46 ± 0.48 min
-1,
n=6 and 2.46 ± 0.09 min-1, n=4 for 30 and 100 nM BY-CGP, respectively; Figure
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6.5; Table 6.1), which is characteristic of non-specific binding components
(May et al., 2010b).
dŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ƚƌĂĐĞƐ ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1-CS cells revealed that the
fluorescence intensity increase from 30 to 100 nM BY-CGP was smaller than
ƚŚĂƚĨƌŽŵ ? ?ƚŽ ? ?ŶD ?ƐƵŐŐĞƐƚŝŶŐƐĂƚƵƌĂďŝůŝƚǇŽĨz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS
cells (Figure 6.5C). This was not the case with the non-specific binding
component determined in CHO-CS cells which was best described as a linear
relationship for the three concentrations tested (Figure 6.5D), and is
characteristic of non-specific binding components. The association of 10, 30
ĂŶĚ ? ? ?ŶDz ?'WǁĂƐŵŽŶŽĞǆƉŽŶĞŶƚŝĂůŝŶ,K ?ɴ1-CS cells and a plateau of
z ?'W ďŝŶĚŝŶŐ ǁĂƐ ƌĞĂĐŚĞĚ ĨŽůůŽǁŝŶŐ ĨŝǀĞ ŵŝŶƵƚĞƐ ĞǆƉŽƐƵƌĞ ŽĨ ,K ?ɴ1-CS
cells to 30 and 100 nM, but not 10 nM BY-CGP. The observed association rates
(konobs) derived were concentration-dependent with 0.59 ± 0.08 min
-1 (n=6),
1.64 ± 0.08 min-1 (n=6) and 3.07 ± 0.15 min-1 (n=3) for 10, 30 and 100 nM BY-
CGP, respectively. The dissociation of 10 nM BY-CGP was also
monoexponential, however two components, a fast (koff(fast)) and a slow
(koff(slow)) component, were detected in the dissociation of 30 and 100 nM BY-
CGP. The rate of the fast dissociation component was comparable to the
dissociation rate determined in CHO-CS cells and, as expected for a non-
specific binding component, its proportion was increased at higher BY-CGP
concentrations. The fast component of BY-CGP dissociation curves obtained in
,K ?ɴ1-CS cells was constrained to the average dissociation rate obtained in
CHO-CS cells (2.46 min-1). The slow dissociation component determined for 10,
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30 and 100 nM BY-CGP were 0.08 ± 0.01 min-1 (n=6), 0.09 ± 0.01 min-1 (n=6)
and 0.14 ± 0.02 min-1 (n=3), respectively, and were significantly slower than
the fast component described in CHO-CS cells (P < 0.05, two-way ANOVA
followed by Bonferronis post hoc test). Interestingly, the dissociation rate
determined for 100 nM BY-CGP was markedly faster than that determined for
10 nM BY-CGP (P < 0.05, one-way ANOVA followed by Tukeys post hoc test).
This may be due to allosteric effects caused by 100 nM BY-CGP binding to the
secondary ȕ1-adrenoceptor site that were not evident for 10 nM BY-CGP due
to its lower occupancy at the secondary ȕ1-adrenoceptor site compared to
100 nM BY-CGP. The concentration-independence of the dissociation rates of
10 and 30 nM BY-CGP, and the concentration-dependence of the observed
ĂƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞƐ ŽĨ  ? ? ?  ? ? ĂŶĚ  ? ? ? ŶD z ?'W Ăƚ ƚŚĞ ɴ1-adrenoceptor was
clearly seen for normalised grouped data as well as single cell data (Figure
6.6). The konobs and the koff(slow) of each BY-CGP concentration were used to
determine the association rate constants (kon). The kon and the koff(slow) were
then used to calculate the equilibrium dissociation constant (KD) for each BY-
CGP concentration and are summarised in Table 6.1.
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Figure 6.2ŽŶĨŽĐĂůŝŵĂŐĞƐŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
after 1.5, 3 and 5 minutes association and 5 minutes dissociation under infinite
dilution conditions. The microscope settings were kept constant for the recordings of
fluorescence intensities of all three BY-CGP concentrations used to allow for direct
comparison of the level of BY-CGP binding. Images are representatives of a total of 4-
6 confocal perfusion slides per BY-CGP concentration, obtained on three separate
experimental days. Scale bars = 50 µm.
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Figure 6.3 Confocal images of 10, 30 and 100 nM BY-CGP binding to CHO-CS cells
after 1.5, 3 and 5 minutes association and 5 minutes dissociation under infinite
dilution conditions. The microscope settings were kept constant for the recordings of
fluorescence intensities of all three BY-CGP concentrations and are also the same
ƐĞƚƚŝŶŐƐƚŚĂƚǁĞƌĞƵƐĞĚƚŽŝŵĂŐĞz ?'WďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells (Figure 6.6) used
to allow for direct comparison of the level of BY-CGP binding. Images are
representatives of a total of 3-6 confocal perfusion slides per BY-CGP concentration,
obtained on three separate experimental days. Scale bars = 50 µm.
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Figure 6.4 Confocal images of 10, 30 and 100 nM BY-CGP binding to A, CHO-ȕ1-CS
and B, CHO-CS cells following 5 minutes association and 5 minutes dissociation under
infinite dilution conditions. The microscope settings were kept constant for the
recordings of fluorescence intensities of all three BY-CGP concentrations in both
,K ?ɴ1-CS and CHO-CS cells to allow for direct comparison of the level of BY-CGP
binding. Images are representatives of a total of 3-6 confocal perfusion slides per BY-
CGP concentration, obtained on three separate experimental days. Scale bars = 50
µm.
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Figure 6.5ƐƐŽĐŝĂƚŝŽŶĂŶĚĚŝƐƐŽĐŝĂƚŝŽŶŽĨ  ? ? ?  ? ?ĂŶĚ  ? ? ?ŶDz ?'WĂƚ,K ?ɴ1-CS
and CHO-CS cells. Confocal images shown in Figure 6.4 were analysed by drawing
regions of interests (ROIs) around the membrane of 10 cells per field of view, and the
measured fluorescence intensity was then plotted against time for A ?,K ?ɴ1-CS and
B, CHO-CS cells. The fluorescence intensity values measured in C, CHO-ȕ1-CS and D,
CHO-CS cells following 5 min association of 10, 30 and 100 nM BY-CGP were plotted
against the corresponding BY-CGP concentration, and highlight the saturable binding
of BY-CGP to CHO-ȕ1-CS, but not CHO-CS cells at the concentrations used. The
quantitative data show the mean of grouped data ± s.e.m. of 3-6 separate confocal
perfusion slides obtained on three separate experimental days.
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Figure 6.6 Association and dissociation kinetics of 10, 30 and 100 nM BY-CGP at CHO-
ȕ1-CS cells. Normalised A, association and B, dissociation data of BY-CGP. Data shown
are mean ± s.e.m of at least three separate experiments. C, observed association rate
and D, dissociation rate constant for 10, 30 and 100 nM BY-CGP with each replicate
representing the kinetic parameter of one single cell. The data shown are mean ±
s.e.m of 30-60 replicates obtained from 3-6 confocal perfusion slides on three
separate experimental days.
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Table 6.1 <ŝŶĞƚŝĐ ƉĂƌĂŵĞƚĞƌƐŽĨ  ? ? ?  ? ? ĂŶĚ  ? ? ? ŶD z ?'W Ăƚ,K ?ɴ1-CS and CHO-CS cells. Data are mean ± s.e.m with n representing the number of
separate experiments carried out. In each experiment, regions of interest were drawn around the membrane of 10 cells. *denotes statistically significant
difference (P < 0.05) from the value determined for a10 nM and b30 nM BY-CGP within the same cell line, and ൱ denotes statistically significant difference (P < 0.05) from the
value determined for the same concentration in a different cell line (two-way ANOVA followed by Bonferronis multiple comparison test)
BODIPY-TMR-CGP konobs koff(fast) koff(slow) kon pKD n
min
-1
min
-1
min
-1
x 10
6
M
-1
min
-1
CHO-CS
10 nM N/A N/A 6
30 nM 1.40 ± 0.26 2.46 ± 0.48 6
100 nM 1.56 ± 0.11 2.46 ± 0.09 4
,K ?ɴ1-CS
10 nM 0.59 ± 0.08 N/A 0.08 ± 0.01ࢿ 4.81 ± 0.82 8.64 ± 0.11 6
30 nM 1.64 ± 0.08*a 2.46 0.09 ± 0.01ࢿ 5.17 ± 0.28 8.77 ± 0.08 6
100 nM 3.07 ± 0.15*a,b ࢿ 2.46 0.14 ± 0.02*a ࢿ 2.93 ± 0.17 8.33 ± 0.09*b 3
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Characterising the kinetic parameters of BY-PROP at the human
ɴ1-adrenoceptor
Confocal and phase images were taken every 3 seconds on the Zeiss LSM510
confocal microscope using the same settings for all BY-PROP concentrations
ŽŶ ďŽƚŚ ,K ?ɴ1-CS and CHO-CS cells to allow the direct comparison of
fluorescence intensities between total (CHO-ȕ1-CS cells) and non-specific
(CHO-CS cells) binding of the three BY-PROP concentrations used. Clear
membrane labelling of 10, 30 and 100 nM BY-PROP could be seen following
 ? ? ? ŵŝŶƵƚĞƐ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ z ?WZKW ŝŶ ,K ?ɴ1-CS (Figure 6.7) and CHO-CS
(Figure 6.8) cells. As expected, the fluorescence intensity increased with
increasing BY-PROP concentrations. However, the non-specific intracellular
fluorescence also increased with increasing BY-PROP concentrations and
prolonged BY-PROP association in both cell lines and made it difficult to
clearly define the plasma membrane of cells. Even the perfusion of buffer for
 ? ?ŵŝŶƵƚĞƐĚŝĚŶŽƚĂƉƉĞĂƌƚŽĐĂƵƐĞƚŚĞĚŝƐƐŽĐŝĂƚŝŽŶŽĨz ?WZKWŝŶ,K ?ɴ1-CS
cells. In CHO-CS cells, the dissociation of BY-PROP was also difficult to
visualise which was mainly due to the very high levels of intracellular
fluorescence intensity. Thus, the very early time points were used to draw the
regions of interests in both cell lines. The association and dissociation traces
obtained from these ROIs revealed that the actual (raw) fluorescence
ŝŶƚĞŶƐŝƚŝĞƐ ŵĞĂƐƵƌĞĚ ŝŶ ,K ?ɴ1-CS and CHO-CS cells were very similar for
each BY-PROP concentration used (Figure 6.9 and 6.10). The observed
association rates (konobs) obtained in CHO-CS cells significantly increased with
increasing BY-PROP concentrations (Table 6.2). The dissociation rates of 10,
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30 and 100 nM BY-PROP in CHO-CS cells were determined using monophasic
exponential curve fits, and were expectedly similar for all three BY-PROP
concentrations tested (Table 6.2), but were substantially slower than those
determined for BY-CGP in CHO-CS cells (P < 0.05, two-way ANOVA followed by
Bonferroni's multiple comparison test). This suggests that the BY-PROP non-
specific binding is of a different nature, where the much slower dissociation
rates may, for example, be due to increased association of BY-PROP with the
cell membrane. The non-specific component of BY-PROP binding does not
follow a linear regression (Figure 6.10D), but fits to a saturation hyperbola for
the concentrations tested, as does the total binding component of BY-PROP
ďŝŶĚŝŶŐĚĞƚĞƌŵŝŶĞĚĂƚ,K ?ɴ1-CS cells (Figure 6.10C). The saturability of BY-
WZKWďŝŶĚŝŶŐƚŽďŽƚŚ,K ?ɴ1-CS and CHO-CS cells at the concentrations used
suggests similar affinities of BY-PROP to non-specific and receptor specific
binding sites.
dŚĞ ŽďƐĞƌǀĞĚ ĂƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞƐ ŝŶ ,K ?ɴ1-CS cells were enhanced with
increasing BY-PROP concentrations (0.14 ± 0.02 min-1, n=6, 0.17 ± 0.01 min-1,
n=7 and 0.26 ± 0.04 min-1, n=6 for 10, 30 and 100 nM BY-PROP, respectively;
Figure 6.11; Table 6.2). Interestingly, only for 100 nM BY-PROP was the
observed association rate significantly different from the observed
association rate obtained in CHO-CS cells (P < 0.05, two-way ANOVA followed
by Bonferronis multiple comparison test; Table 6.2). The dissociation traces
obtained in CHO-ȕ1-CS cells were best fitted using a monophasic exponential
decay curve fit as the non-specific component defined in CHO-CS cells could
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not be detected, even though the non-specific (CHO-CS cells) dissociation
ƌĂƚĞƐǁĞƌĞƐŝŐŶŝĨŝĐĂŶƚůǇĨĂƐƚĞƌƚŚĂŶƚŚŽƐĞĚĞƌŝǀĞĚŝŶ,K ?ɴ1-CS cells (P < 0.05,
two-way ANOVA followed by Bonferronis multiple comparison test). This
ƐƵŐŐĞƐƚƐƚŚĂƚƚŚĞďŝŶĚŝŶŐŽĨz ?WZKWƚŽƚŚĞɴ1-adrenoceptor affects the non-
specific off rate (koff(fast) ? ?dŚĞĚŝƐƐŽĐŝĂƚŝŽŶƌĂƚĞƐŽĨ ? ? ?ŶDz ?WZKWŝŶ,K ?ɴ1-
CS cells was significantly faster than those obtained for 10 and 30 nM BY-
PROP, which may be due to an increased inclusion of false positives, i.e. cells
that were analysed by drawing membrane ROIs as they showed clear
membrane labelling following BY-PROP association, but did not express the
ɴ1-adrenoceptor, thus resulting in increased non-specific off rates. This can be
seen in Figure 6.11D where dissociation rates of individual analysed cells are
shown and the dotted line highlights the mean dissociation rate (0.27 min-1)
of BY-PROP in CHO-CS cells (i.e. non-specific dissociation). The observed
association rate and dissociation rate determined for each BY-PROP
concentration was used to determine the association rate (kon) and the
equilibrium dissociation constant (KD) and are summarised in Table 6.2.
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Figure 6.7ŽŶĨŽĐĂůŝŵĂŐĞƐŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS cells
after 1.5, 4 and 10 minutes association and 10 minutes dissociation under infinite
dilution conditions. The microscope settings were kept constant for the recordings of
fluorescence intensities of all three BY-PROP concentrations used to allow for direct
comparison of the level of BY-PROP binding. Images are representatives of a total of
6-7 confocal perfusion slides per BY-CGP concentration, obtained on four separate
experimental days. Scale bars = 50 µm.
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Figure 6.8 Confocal images of 10, 30 and 100 nM BY-PROP binding to CHO-CS cells
after 1.5, 4 and 10 minutes association and 10 minutes dissociation under infinite
dilution conditions. The microscope settings were kept constant for the recordings of
fluorescence intensities of all three BY-PROP concentrations and are also the same
ƐĞƚƚŝŶŐƐ ƚŚĂƚ ǁĞƌĞ ƵƐĞĚ ƚŽ ŝŵĂŐĞ z ?WZKW ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells (Figure 6.6)
used to allow for direct comparison of the level of BY-PROP binding. Images are
representatives of a total of 3-5 confocal perfusion slides per BY-CGP concentration,
obtained on three separate experimental days. Scale bars = 50 µm.
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Figure 6.9 Confocal images of 10, 30 and 100 nM BY-PROP binding to A ?,K ?ɴ1-CS
and B, CHO-CS cells following 10 minutes association and 10 minutes dissociation
under infinite dilution conditions. The microscope settings were kept constant for
the recordings of fluorescence intensities of all three BY-PROP concentrations in both
,K ?ɴ1-CS and CHO-CS cells to allow for direct comparison of the level of BY-PROP
binding. Images are representatives of a total of 3-7 confocal perfusion slides per BY-
PROP concentration, obtained on 3-4 separate experimental days. Scale bars = 50 µm.
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Figure 6.10ƐƐŽĐŝĂƚŝŽŶĂŶĚĚŝƐƐŽĐŝĂƚŝŽŶŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?WZKWĂƚ,K ?ɴ1-CS
and CHO-CS cells. Confocal images shown in Figure 6.9 were analysed by drawing
regions of interests (ROIs) around the membrane of 10 cells per field of view, and the
measured fluorescence intensity was then plotted against time for A ?,K ?ɴ1-CS and
B, CHO-CS cells. The fluorescence intensity values measured in C, CHO-ȕ1-CS and D,
CHO-CS cells following 5 min association of 10, 30 and 100 nM BY-PROP were plotted
against the corresponding BY-PROP concentration, and highlight that the binding of
BY-PROP to both CHO-ȕ1-CS and CHO-CS cells is saturable at the concentrations used.
The quantitative data show the mean of grouped data ± s.e.m. of 3-7 separate
confocal perfusion slides obtained on 3-4 separate experimental days.
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Figure 6.11 Association and dissociation kinetics of 10, 30 and 100 nM BY-PROP at
,K ?ɴ1-CS cells. Normalised A, association and B, dissociation data of BY-PROP. Data
shown is mean ± s.e.m of at least six separate experiments. C, observed association
rate and D, dissociation rate constant for 10, 30 and 100 nM BY-CGP with each
replicate representing the kinetic parameter of one single cell. The mean ± s.e.m of
at least sixty replicates is shown. The dotted line represents the mean dissociation
rate of BY-PROP determined in CHO-CS cells.
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Table 6.2<ŝŶĞƚŝĐƉĂƌĂŵĞƚĞƌƐŽĨ ? ? ? ? ?ĂŶĚ ? ? ?ŶDz ?WZKWďŝŶĚŝŶŐƚŽ,K ?ɴ1-CS and CHO-CS cells. Data are mean ± s.e.m with n representing the number
of separate perfusion preparations used. *denotes statistically significant difference (P < 0.05) from the value determined for a10 nM and b30 nM BY-PROP within the
same cell line, and ൱ denotes statistically significant difference (P < 0.05) from the value determined for the same concentration in a different cell line (two-way ANOVA
followed by Bonferronis multiple comparison test)
BY-PROP konobs koff(fast) koff(slow) kon pKD n
min
-1
min
-1
min
-1
x 10
6
M
-1
min
-1
CHO-CS
10 nM 0.14 ± 0.02 0.28 ± 0.07 3
30 nM 0.21 ± 0.02*a 0.26 ± 0.03 6
100 nM 0.45 ± 0.04*a,b 0.26 ± 0.08 4
CHO-ȕ1-CS
10 nM 0.14 ± 0.02 n.d. 0.07 ± 0.01ࢿ 6.20 ± 1.86 7.72 ± 0.32 6
30 nM 0.17 ± 0.01 n.d. 0.07 ± 0.01ࢿ 3.21 ± 0.47 7.67 ± 0.13 7
100 nM 0.26 ± 0.04*a,b ࢿ n.d. 0.12 ± 0.01*a,b ࢿ 1.41 ± 0.46*a 6.95 ± 0.17 6
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The high intensity levels of non-specific binding fluorescence and the slow
dissociation of BY-PROP observed in CHO-CS cells may be due to the
lipophilicity of BY-PROP. Previous binding experiments using BY-PROP
(Chapter 4) were performed at 21 °C, whereas perfusion experiments were
carried out at 37 °C. Increased temperature has been associated with
increased membrane fluidity (Vigh et al., 2007), which may increase the
inclusion of lipophilic ligands such as BY-PROP in the cell membrane. To test
that hypothesis the binding of BY-PROP and BY-CGP in the absence (total
ďŝŶĚŝŶŐ ?ĂŶĚƉƌĞƐĞŶĐĞ ?ŶŽŶ ?ƐƉĞĐŝĨŝĐďŝŶĚŝŶŐ ?ŽĨ ?A?D'W ? ? ? ? ?ŝŶ,K ?ɴ1-
CS and CHO-CS cells in 8-well plates under static (no perfusion) conditions was
tested. The assay window of BY-PROP binding at 21 °C was small but clearly
defined, in line with previous BY-PROP data obtained in experiments carried
out at 21 °C (Chapter 4). However, this assay window was lost at 37 °C due to
increased non-specific intracellular fluorescence intensities (Figure 6.12). In
contrast, the assay window of BY-CGP was not compromised at higher
temperatures (Figure 6.13). As a result, we used BY-CGP in subsequent kinetic
experiments on the confocal perfusion system.
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Figure 6.12 A, confocal images of 30 nM BY-PROP binding to CHO-ȕ1-CS and CHO-CS
cells after 10 minutes exposure to BY-PROP at 37 °C (top panel) and 21 °C (bottom
panel) in the absence and presence of 1 µM CGP 20712A (30 min pre-incubation with
antagonist at 37 °C). B, the confocal images shown in A were analysed using total
image intensity analysis and the data shown is representative of three separate
experiments. Scale bars = 50 µm.
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Figure 6.13 A, confocal images of 30 nM BY-CGP binding to CHO-ȕ1-CS and CHO-CS
cells after 10 minutes exposure to BY-CGP at 37 °C (top panel) and 21 °C (bottom
panel) in the absence and presence of 1 µM CGP 20712A. B, the confocal images
shown in A were analysed using total image intensity analysis and the data shown is
representative of three separate experiments. Scale bars = 50 µm.
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Effects of unlabelled ligands on the dissociation of 30 nM BY-CGP
ĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor
The dissociation rate of a ligand should not be altered in the presence of a
second ligand if it competes for the same binding site. However, if the second
ligand binds to a second binding site, resulting conformational changes could
lead to co-operative (allosteric) effects, i.e. the dissociation rate of the first
ligand (usually the labelled ligand) may be decreased or enhanced
(Christopoulos et al., 2002; May et al., 2007). Using the perfusion system, the
infinite dilution prevents the re-association of dissociated ligand (May et al.,
2010a; May et al., 2010b). This allows dissociation rates of the labelled ligand
to be determined in the absence of unlabelled competitor ligands and can
then be compared to the dissociation rate of the labelled ligand in the
presence of unlabelled competitor ligands. This is a very powerful tool in the
detection of potential allosteric interactions between two ligands binding to a
receptor (Christopoulos et al., 2002).
Here, we examined the effect of increasing CGP 12177 and propranolol
concentrations on the dissociation of 30 nM BY-CGP. Both the Zeiss LSM510
and LSM710 microscopes were used for these studies. The microscope
settings used were optimised at the start of each experiment and then kept
constant within each experiment. The data was normalised and fitted using a
two-phase decay equation constraining the fast dissociation component to
the non-specific binding dissociation rate determined in CHO-CS cells above.
The slow component of the dissociation rate of 30 nM determined using the
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Zeiss LSM510 microscope was 0.14 ± 0.02 min-1 (n=7) and compared well to
the dissociation rate determined using the Zeiss LSM710 microscope (0.12 ±
0.02 min-1, n=7; unpaired t-test) in the absence of unlabelled ligand. The
dissociation rate of BY-CGP was significantly enhanced in the presence of 10
µM CGP 12177 (0.26 ± 0.01 min-1, n=5), but not in the presence of 1 µM CGP
12177 (0.18 ± 0.01 min-1, n=5 and 0.19 ± 0.02 min-1, n=3 using the LSM510
and LSM710 microscope, respectively; Figure 6.14; Table 6.3; P < 0.05, one-
way ANOVA followed by Dunnetts post hoc test). The dissociation rate of 30
nM BY-CGP was also significantly enhanced in the presence of 10 µM
propranolol (0.33 ± 0.04 min-1, n=5; Figure 6.15), but not in the presence of 1
µM propranolol (0.18 ± 0.04 min-1, n=5, LSM510; 0.20 ± 0.03 min-1, n=3,
LSM710; P < 0.05, one-way ANOVA followed by Dunnetts post hoc test).
Concentrations lower than 1 µM CGP 12177 and propranolol also did not
significantly affect the dissociation of 30 nM BY-CGP, whereas concentrations
higher than 10 µM did (Table 6.3). The effects of 1 and 10 µM CGP 12177 and
propranolol on the dissociation rate of 30 nM BY-CGP at the single cell level
can be seen in Figure 6.14 and 6.15.
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Figure 6.14 A, grouped data showing the dissociation of 30 nM BY-CGP under infinite
dilution conditions in the absence and presence of 1 and 10 µM CGP 12177. Data are
mean ± s.e.m of 3-7 separate experiments in each of which ROIs were drawn around
membranes of ten cells. B, dissociation rate constants of 30 nM BY-CGP in the
absence and presence of 1 and 10 µM CGP 12177 with each replicate representing
one single cell. The mean ± s.e.m shown is of 30-70 replicates. *denotes statistical
significance (P < 0.05) as determined by one-way ANOVA analysis followed by
Dunnetts multiple comparison test.
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Figure 6.15 A, grouped data showing the dissociation of 30 nM BY-CGP under infinite
dilution conditions in the absence and presence of 1 and 10 µM propranolol. Data
are mean ± s.e.m of 3-7 separate experiments in each of which ROIs were drawn
around membranes of ten cells. B, dissociation rate constants of 30 nM BY-CGP in
the absence and presence of 1 and 10 µM propranolol with each replicate
representing one single cell. The mean ± s.e.m shown is of 30-70 replicates. *
denotes statistical significance (P < 0.05) as determined by one-way ANOVA analysis
followed by Dunnetts multiple comparison test.
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Table 6.3 Dissociation rate constants of 30 nM BY-CGP in the absence and presence of CGP 12177 and propranolol. Data was collected using either the
LSM510 or LSM710 confocal perfusion system. Data are mean ± s.e.m and n represents the number of separate perfusion preparations used. * statistically
significant (p < 0.05) to control conditions (infinite dilution) as determined by one-way ANOVA analysis followed by Dunnetts post hoc test
CGP 12177 propranolol
LSM510 LSM710 LSM510 LSM710
30 nM BY-CGP koff (min
-1
) n koff (min
-1
) n koff (min
-1
) n koff (min
-1
) n
infinite dilution 0.14 ± 0.02 7 0.12 ± 0.02 7 0.14 ± 0.02 7 0.12 ± 0.02 7
+ 0.1 nM 0.18 ± 0.04 5 0.14 ± 0.02 4
+ 1 nM 0.15 ± 0.01 4 0.13 ± 0.02 5
+ 10 nM 0.17 ± 0.01 5 0.18 ± 0.04 5
+ 100 nM 0.20 ± 0.01 3 0.19 ± 0.02 5
+ 1 µM 0.18 ± 0.01 5 0.19 ± 0.02 3 0.18 ± 0.04 5 0.20 ± 0.03 3
+ 10 µM 0.26 ± 0.01* 5 0.33 ± 0.04* 5
+ 100 µM 0.32; 0.21* 2 0.34 ± 0.06* 4
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Effects of unlabelled ligands on the dissociation of 3 nM BY-CGP
ĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor
&ƌŽŵƚŚĞz ?'WĂĨĨŝŶŝƚŝĞƐĨŽƌƚŚĞĨŝƌƐƚĂŶĚƐĞĐŽŶĚƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor
and the occupancy curves (Chapter 4) we know that the occupancy of 30 nM
BY-CGP at site 1 and site 2 is 98 and 23 %, respectively. In contrast, 3 nM BY-
CGP labels 86 and 3 % of the ȕ1-adrenoceptor site 1 and site 2, respectively.
Using a BY-CGP concentration as low as 3 nM, limits the competition of
ůĂďĞůůĞĚ ĂŶĚ ƵŶůĂďĞůůĞĚ ůŝŐĂŶĚ Ăƚ ƚŚĞ ƐĞĐŽŶĚ ɴ1-adrenoceptor site (Figure
6.16), which may result in increased effects of unlabelled ligands on the
dissociation rate of BY-CGP at the high affinity catecholamine site. However,
imaging of lower concentrations of fluorescent ligands on the confocal
microscope was difficult due to a reduced signal:noise ratio. In order to detect
the binding of 3 nM BY-CGP to CHO-ȕ1-CS cells, the laser power and gain had
to be increased. This is why this BY-CGP concentration was not included with
the above data (10-100 nM BY-CGP data), as 3 nM BY-CGP binding was not
detectable with the settings that were used to measure 10-100 nM BY-CGP
binding kinetics.
First, we assessed the association and dissociation kinetics of 3 nM BY-CGP at
,K ?ɴ1-CS and CHO-CS cells (Figure 6.17). The fluorescence intensities
measured in CHO-CS cells were too low to accurately determine observed
association and dissociation rates. However, the non-specific binding
component was too low to be detected in the 3 nM BY-CGP dissociation trace
ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1-CS cells, and therefore was analysed using a one-phase
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dissociation equation. This gave a dissociation rate of 0.09 ± 0.01 min-1 (n=9)
in the absence of unlabelled ligands, which was similar to the dissociation rate
obtained for 10, 30 and 100 nM BY-CGP above (P > 0.05, one-way ANOVA
followed by Tukeys post hoc test). Following a four minute exposure to 3 nM
BY-CGP, the association trace did not reach a plateau and the association rate
could not be accurately determined from this trace. However, when analysed
in combination with the dissociation trace an association rate of 5.27 ± 0.53 x
107 M-1 min-1 (n=9), a dissociation rate of 0.08 ± 0.01 min-1 (n=9) and a pKD of
8.83 ± 0.06 (n=9) was determined (Figure 6.17).
The dissociation rate of 3 nM BY-CGP was significantly enhanced in the
presence of 100 nM (0.21 ± 0.02 min-1,n=5), 1 µM (0.20 ± 0.02 min-1, n=7) and
10 µM (0.22 ± 0.03 min-1, n=5) CGP 12177 (P < 0.05, one-way ANOVA followed
by Dunnetts post hoc test; Figure 6.18; Table 6.4). The effect of the enhanced
dissociation rate appeared to saturate, which is characteristic of allosteric
interactions (Christopoulos et al., 2002). The dissociation rate was enhanced
to a similar extent in the presence of 1 µM (0.19 ± 0.01 min-1, n=6) and 10 µM
(0.22 ± 0.03 min-1, n=5) propranolol (Figure 6.19; Table 6.4). The midpoint of
the concentration-response curve fitted through dissociation rates plotted
against concentrations of unlabelled ligand revealed the affinity of the
unlabelled ligand to the allosteric (secondary ȕ1-adrenoceptor) site with a
ligand bound to the orthosteric (catecholamine ȕ1-adrenoceptor) site (KB
ƵƉŽŶ ɲ ? ǁŝƚŚ ɲ ďĞŝŶŐ ƚŚĞ ĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇ ĨĂĐƚŽƌ ĚĞƐĐƌŝďŝŶŐ ƚŚĞ ĐŽ ?ŽƉĞƌĂƚŝǀĞ
interaction between two binding sites). The pKB ?ɲĚĞƚĞƌŵŝŶĞĚĨŽƌ'W ? ? ? ? ?
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and propranolol against 3 nM BY-CGP were 7.79 ± 0.34 (n=5) and 6.65 ± 0.33
(n=3), respectively.
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Figure 6.16 Schematic representation of A, 30 nM and B, 3 nM BY-CGP binding to the
high (site 1) and low (site 2) affinity site of the ȕ1-adrenoceptor in the presence of an
unlabelled ligand. 30 nM BY-CGP is 0.3 x KD concentration at the secondary ȕ1-
adrenoceptor site. Labelling of site 2 by 30 nM BY-CGP prevents the binding of
unlabelled ligands to the same site and thus prevents the detection of potential
positive or negative allosteric effects caused by the binding of unlabelled ligands on
the ligand binding kinetics of the labelled ligand binding to the orthosteric site 1.
A B 3 nMBY-CGP30 nM BY-CGP
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Figure 6.17ƐƐŽĐŝĂƚŝŽŶĂŶĚĚŝƐƐŽĐŝĂƚŝŽŶŽĨ ?ŶDz ?'WŵĞĂƐƵƌĞĚŝŶ,K ?ɴ1-CS and
CHO-CS cells. Confocal images show BY-CGP binding to A ?,K ?ɴ1-CS and B, CHO-CS
cells after 4 minutes BY-CGP association. Scale bar = 50 µm. C, The data was analysed
by drawing regions of interests (ROIs) around the membrane of 10 cells per field of
view and the measured fluorescence intensity was then plotted against time for
,K ?ɴ1-CS and CHO-CS cells. The confocal images are representative of images taken
during at least three separate experiments. D, Normalised data showing the mean of
grouped data ± s.e.m. of nine separate experiments.
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Figure 6.18 A, grouped data showing the dissociation of 3 nM BY-CGP under infinite
dilution conditions in the absence and presence of 10 nM, 100 nM, 1 µM and 10 µM
CGP 12177. Data are mean ± s.e.m of at least five separate experiments. B,
dissociation rate constants of 3 nM BY-CGP in the absence and presence of
increasing CGP 12177 concentrations. Data are mean ± s.e.m of at least five separate
experiments. *denotes statistical significance (P < 0.05) as determined by one-way
ANOVA analysis followed by Dunnetts multiple comparison test.
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Figure 6.19 A, grouped data showing the dissociation of 3 nM BY-CGP under infinite
dilution conditions in the absence and presence of 100 nM, 1 µM and 10 µM
propranolol. Data are mean ± s.e.m of at least four separate experiments. B,
dissociation rate constants of 3 nM BY-CGP in the absence and presence of
increasing CGP 12177 concentrations. Data are mean ± s.e.m of at least four separate
experiments. *denotes statistical significance (P < 0.05) as determined by one-way
ANOVA analysis followed by Dunnetts multiple comparison test.
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Table 6.4 Dissociation rate constants of 3nM BY-CGP in the absence and presence of
CGP 12177 and propranolol. Data are mean ± s.e.m of (n) separate slide preparations.
n.d. not determined; * statistically significant (P < 0.05) from control conditions (infinite
dilution) as determined by one-way ANOVA analysis followed by Dunnetts post hoc test
CGP 12177 propranolol
3 nM BY-CGP koff (min
-1
) n koff (min
-1
) n
infinite dilution 0.09 ± 0.01 9 0.09 ± 0.01 9
+ 10 nM 0.13 ± 0.02 6 n.d.
+ 100 nM 0.21 ± 0.02* 5 0.13 ± 0.03 3
+ 1 µM 0.20 ± 0.02* 7 0.19 ± 0.01* 6
+ 10 µM 0.22 ± 0.03* 5 0.22 ± 0.03* 5
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6.4 Discussion
Here we examined the kinetic properties of BODIPY-TMR-CGP and
BODIPY630/650-S-PEG8-propranolol in single living cells to establish whether
ĐŽ ?ŽƉĞƌĂƚŝǀĞŝŶƚĞƌĂĐƚŝŽŶƐďĞƚǁĞĞŶƚŚĞƚǁŽƉƌŽƉŽƐĞĚɴ1-adrenoceptor binding
ƐŝƚĞƐ ƉůĂǇ Ă ƌŽůĞ ŝŶ ƚŚĞ ƌĞĐĞƉƚŽƌ ?ůŝŐĂŶĚ ŝŶƚĞƌĂĐƚŝŽŶƐ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-
adrenoceptor.
The difference of the BY-CGP dissociation rates in the absence and the
presence of unlabelled ligands revealed co-operativity between the two
ƉƌŽƉŽƐĞĚŚŝŐŚĂŶĚůŽǁĂĨĨŝŶŝƚǇɴ1-adrenoceptor sites. Using a closed perfusion
system under constant controlled pressure allows a constant flow rate of
labelled ligand from one reservoir followed by a sharp concentration gradient
upon switching to the buffer reservoir that facilitates the removal of the
labelled ligand and thus, the measurement of its dissociation (May et al.,
2010a). The determination of kinetic parameters under infinite dilution
conditions is the main advantage over radioligand dissociation experiments
that use unlabelled competitor ligands to prevent the re-association of the
radioligand (Christopoulos et al., 1997; May et al., 2010a). It is widely
appreciated that the presence of unlabelled ligands can profoundly affect the
dissociation rate of a labelled ligand due to allosteric effects which may be
caused through a second binding site (Gao et al., 2001; Lazareno et al., 2000;
Lazareno et al., 2002) or dimerisation (Christopoulos et al., 2002; May et al.,
2011; Smith et al., 2010). In addition, there is a growing appreciation that
intracellular signalling proteins can also cause allosteric effects and generate
316
distinct subsets of receptor conformations that ultimately display unique
receptor-ligand interactions resulting in, for example, ligand bias (Goupil et al.,
2010; Kenakin et al., 2010; Luttrell et al., 2011). To fully appreciate the
complexity of receptor-ligand interactions it is vital to maintain the correct
membrane and cellular environment at physiological conditions, creating a
need for non-invasive pharmacological techniques. The perfusion system used
in this chapter allows the visualisation of dynamic receptor-ligand interactions
in real time in single cells using non-invasive fluorescent ligands and as such
provides the opportunity to study the pharmacology of ligands on
endogenous receptors in primary cells.
First, we examined the kinetic parameters of the fluorescent analogue of CGP
12177 (BODIPY-TMR-CGP; BY-CGP) binding to the human ȕ1-adrenoceptor
and showed that the specific binding of BY-CGP to the ȕ1-adrenoceptor was
ǁĞůů ĚĞĨŝŶĞĚ ? ǁŝƚŚ ŐƌĞĂƚĞƌ ůĞǀĞůƐ ŽĨ z ?'W ďŝŶĚŝŶŐ ŽďƐĞƌǀĞĚ ŝŶ ,K ?ɴ1-CS
than in CHO-CS cells. In CHO-CS cells, the dissociation traces did not come
down to the same level of fluorescence intensity as was measured at the start
of each experiment. This was most likely due to the ROIs that were drawn
around cell membranes that also included a small proportion of cytoplasm.
Thus, residual intracellular fluorescence that does not dissociate, forms the
ƉůĂƚĞĂƵŽĨĚŝƐƐŽĐŝĂƚŝŽŶƚƌĂĐĞƐŝŶ,K ?^ĐĞůůƐ ?/Ŷ,K ?ɴ1-CS cells, the observed
association rates were dependent on the BY-CGP concentrations used,
whereas the dissociation rates were independent for 10 and 30 nM BY-CGP. A
five minute perfusion of buffer was not enough to see complete dissociation
317
ŽĨ z ?'W ? dŚĞ ɴ1-adrenoceptor-specific dissociation component was
monophasic unlike the two components detected in the dissociation of [3H]-
CGP 12177 (Joseph et al., 2004). The BY-CGP dissociation rates determined
here are likely that of the catecholamine site as, for example, the dissociation
rates of 30 nM and 3 nM BY-CGP were not significantly different (compared
data obtained on the Zeiss LSM710 microscope; unpaired t-test) and we know
ƚŚĂƚ  ? ŶD z ?'W ƉƌĞĚŽŵŝŶĂŶƚůǇ ďŝŶĚƐ ƚŽ ƚŚĞ ŚŝŐŚ ĂĨĨŝŶŝƚǇ ƐŝƚĞ  ? ŽĨ ƚŚĞ ɴ1-
adrenoceptor. This is not altogether unsurprising considering that BY-CGP has
a circa 150-fold higher affinity for the catecholamine site 1 than the
ƐĞĐŽŶĚĂƌǇƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor. In addition, this data would also be
consistent with a faster dissociation of BY-CGP off the secondary site
compared to the catecholamine site, as a faster dissociation of a smaller
proportion of BY-CGP off site 2 would be masked by the slower dissociation of
a larger proportion of BY-CGP off site 1, at least at the BY-CGP concentrations
used here. Much higher BY-CGP concentrations would have to be tested,
possibly also at longer dissociation reads than five minutes, to examine this
further. However, using very high BY-CGP concentrations is costly.
Interestingly, the KD derived from the kinetic parameters obtained for 3 nM
BY-CGP (circa 2.6 nM) compares well to the affinity value of BY-CGP
determined in functional studies (0.6 nM, Chapter 4) for the high affinity site
ŽĨƚŚĞɴ1-adrenoceptor.
Next, we aimed to investigate potential allosteric effects between the two
proposed ȕ1-adrenoceptor binding sites by monitoring the dissociation rate of
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30 nM BY-CGP in the absence and presence of increasing concentrations of
unlabelled ligands under infinite dilution conditions. The dissociation rate of
30 nM BY-CGP was enhanced only in the presence of very high concentrations
of CGP 12177 and propranolol (10 and 100 µM). Both ligands have much
higher affinity (at least 100-fold) for site 1 than site 2, but at the
concentrations used will bind to both sites. The dissociation rate of a labelled
ligand is not altered in the presence of a competitive ligand, as such any
change in the dissociation rate will have been caused by the unlabelled ligand
binding to a secondary site. However, we know from previous studies that 30
ŶDz ?'WĂůƐŽďŝŶĚƐƚŽƚŚĞƐĞĐŽŶĚĂƌǇɴ1-adrenoceptor site (Chapter 4). This
poses two potential problems; firstly, it causes competition of the unlabelled
ligand with BY-CGP at the second site and therefore reduces any potential
allosteric effects that may be caused by the binding of the unlabelled ligands
to this site and may explain why the dissociation rate of 30 nM BY-CGP was
only enhanced in the presence of very high concentrations of CGP 12177 and
propranolol. Secondly, BY-CGP binding to the secondary site may itself
allosterically affect its own dissociation rate off site 1. However, considering
that for CGP 12177 a concentration greater than its KDsite2 was needed to see
any effects on the dissociation rate, it is unlikely that a 0.3 x KDsite2
concentration of BY-CGP caused a significant effect. Furthermore, the
dissociation rate observed for 30 nM BY-CGP was similar to that for 3 nM BY-
CGP (which predominantly binds to site 1), suggesting that no significant
allosteric interactions were detectable for 30 nM. In contrast, the dissociation
rate of 100 nM BY-CGP was enhanced compared to the dissociation rate
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determined for 10 nM BY-CGP under infinite dilution condition. Considering
the effect of unlabelled CGP 12177, it is likely that the fluorescent CGP 12177
analogue can also elicit allosteric interactions between the two ȕ1-
adrenoceptor binding sites at higher concentrations.
To avoid these complications, we used 3 nM BY-CGP to investigate the effects
of unlabelled ligands on the dissociation rate of BY-CGP. Using a lower BY-CGP
concentration, the BY-CGP dissociation rate was enhanced by 100 nM CGP
12177 and propranolol (and concentrations above). The effects must occur
through the secondary site as we know 3 nM predominantly binds site 1. This
ĐůĞĂƌůǇĚĞŵŽŶƐƚƌĂƚĞƐƚŚĂƚƚǁŽƐĞƉĂƌĂƚĞɴ1-adrenoceptor binding sites can be
ŽĐĐƵƉŝĞĚ Ăƚ ƚŚĞ ƐĂŵĞ ƚŝŵĞ ĂŶĚ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ Ă ůŝŐĂŶĚ ƚŽ Ă ƐĞĐŽŶĚĂƌǇ ɴ1-
adrenoceptor site affects the ligand binding properties at the catecholamine
ƐŝƚĞ ŽĨ ƚŚĞ ɴ1-adrenoceptor. Furthermore, the affinities of CGP 12177 and
propranolol determined from plotting the dissociation rates against the
concentrations of unlabelled ligands (KB ?ɲĐŝƌĐĂ ? ?ĂŶĚ ? ? ?ŶD ?ƌĞƐƉĞĐƚŝǀĞůǇ ?
compared well to the affinity values of CGP 12177 and propranolol for the
ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site in functional studies (circa 19 and 912 nM,
respectively; P < 0.05, unpaired t-test for each ligand comparing affinity
values obtained in two different assays). This was expected as both reflect the
affinity of the ligand to the secondary site with site 1 being ligand-bound.
Thus, the site 2 affinity values determined in this thesis are products of the
affinity of the ligands to the secondary site of a free receptor (i.e. no ligand
ďŽƵŶĚƚŽƐŝƚĞ ? ?ĂŶĚƚŚĞĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇĨĂĐƚŽƌɲ ?,ŽǁĞǀĞƌ ?Ăůů ůŝŐĂŶĚƐƵƐĞĚŝŶ
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this thesis have a much higher affinity for site 1 than site 2, making it
impossible to determine affinity values to site 2 without a ligand being bound
to site 1 and therefore to establish a co-operativity factor describing the
allosteric interaction between the two binding sites. However, the co-
operativity between two sites is reciprocal (May et al., 2011), thus the
examination of the dissociation rates of the fluorescent propranolol derivative
BODIPY630/650-S-PEG8-propranolol (BY-PROP) in the absence and presence
of unlabelled CGP 12177 in the same assay format would be expected to
confirm the findings obtained using BY-CGP and unlabelled propranolol.
When examining the association and dissociation kinetics of BY-PROP in CHO-
ɴ1-CS (total binding) and CHO-CS (non-specific binding) cells, the non-specific
fluorescence intensity levels of BY-PROP binding were as high as the total
fluorescence intensity BY-PROP binding levels, suggesting no specific binding
ŽĨ z ?WZKW ƚŽ ,K ?ɴ1-CS cells. Furthermore, the observed association rates
for 10 and 30 BY-PROP concentrations were similar in CHO-CS cells and in
,K ?ɴ1-CS cells. Only for 100 nM BY-PROP, a significant difference in the
observed association rates in the two cell lines was determined, to suggest
specific binding of BY-PROP to the receptor. From previous chapters in this
ƚŚĞƐŝƐ  ?ŚĂƉƚĞƌ  ? ? ? ŚŽǁĞǀĞƌ ? ǁĞ ŬŶŽǁ ƚŚĂƚ z ?WZKW ĚŽĞƐ ďŝŶĚ ƚŽ ƚŚĞ ɴ1-
adrenoceptor expressed in CHO-CS cells at the concentrations used here.
Indeed, close inspection of the BY-PROP dissociation rates derived from CHO-
ɴ1 ?^ ĂŶĚ ,K ?^ ĐĞůůƐ ĂůƐŽ ƐƵŐŐĞƐƚƐ ƐƉĞĐŝĨŝĐ z ?WZKW ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ɴ1-
adrenoceptor. The non-specific binding component could not be detected in
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ƚŚĞĚŝƐƐŽĐŝĂƚŝŽŶƌĂƚĞƐĚĞƚĞƌŵŝŶĞĚŝŶ,K ?ɴ1-CS cells like we could for BY-CGP.
dŚŝƐ ƐƵŐŐĞƐƚƐ ƚŚĂƚ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ɴ1 ?ĂĚƌĞŶŽĐĞƉŽƌ ŝŶ ,K ?ɴ1-CS cells
affected the dissociation of the non-specific binding component. This could
potentially be explained by a mechanism in which BY-PROP association with
ƚŚĞ ŵĞŵďƌĂŶĞ ŝŶ ďŽƚŚ ,K ?^ ĂŶĚ ,K ?ɴ1-CS cells is faster than its
association to the receptor alone, which results in the slow association to the
receptor being masked by the faster association to the membrane
environment. From a membrane sink, BY-PROP may then diffuse to the
receptor, where once it is bound to the receptor its dissociation is significantly
ƐůŽǁĞĚ  ?&ŝŐƵƌĞ  ? ? ? ? ? ? ǁŚŝĐŚ ƐƚƌŽŶŐůǇ ƐƵŐŐĞƐƚƐ ƚŚĂƚz ?WZKW ďŝŶĚƐ ƚŽ ƚŚĞ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ŝŶ,K ?ɴ1-CS cells. It also indicates that the fluorescent ligand
does not dissociate off the receptor back into the membrane environment,
ǁŚŝĐŚ ŝƐ ĚĞƐĐƌŝďĞĚ ĂƐ ƚŚĞ ŵĞĐŚĂŶŝƐŵ ŽĨ ĂĐƚŝŽŶ ĨŽƌ ůŽŶŐ ?ĂĐƚŝŶŐ ɴ2-
adrenoceptor agonists formoterol and salmeterol (Green et al., 1996;
Vauquelin et al., 2009; Waldeck, 1996). If this was the case, the dissociation
ƌĂƚĞŽĨz ?WZKWŽĨĨƚŚĞɴ1-adrenoceptor would be expected to be masked by
the dissociation off the membrane and be similar to the dissociation rate seen
in CHO-CS cells (as is the case for the association of BY-PROP).
322
Figure 4.20 Schematic representation describing a potential mechanism of BY-PROP
ďŝŶĚŝŶŐƚŽ,K ?^ĐĞůůƐĂŶĚ,K ?ɴ1-CS cells. BY-PROP association rates determined
ŝŶ ,K ?^ ĂŶĚ ,K ?ɴ1-CS cells were similar, whilst BY-PROP dissociation was
ŵĂƌŬĞĚůǇƐůŽǁĞƌŝŶ,K ?ɴ1-CS cells compared to CHO-CS cells. Thus, the first step of
z ?WZKW ĂƐƐŽĐŝĂƚŝŽŶ ǁŝƚŚ ƚŚĞ ɴ1-adrenoceptor may be the association to the
membrane, which is described by the same association rates in cells expressing the
receptor and cells not expressing the receptor. This is followed by lateral membrane
ĚŝĨĨƵƐŝŽŶŽĨz ?WZKWƚŽƚŚĞƌĞĐĞƉƚŽƌ ?KŶĐĞz ?WZKWŝƐďŽƵŶĚƚŽƚŚĞɴ1-adrenoceptor,
its dissociation is slowed. The markedly slower dissociation rate therefore reveals the
ƐƉĞĐŝĨŝĐŝŶƚĞƌĂĐƚŝŽŶŽĨz ?WZKWǁŝƚŚƚŚĞɴ1-adrenoceptor.
ɴ1AR
dissociation
(fast)
dissociation
(slow)
same association rates
,K ?^ĐĞůůƐ ,K ?ɴ1-CS cells
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Even though the fluorescent derivative of propranolol is a lipophilic ligand,
thus favouring the membrane environment and leading to membrane-
associated non-specific binding levels, the non-specific binding levels of BY-
PROP observed in previous imaging studies on the confocal microscope were
not as high as seen here. One of the main differences of previous confocal
studies and the perfusion experiments is the constant perfusion of buffer and
ůŝŐĂŶĚ ŽǀĞƌ ƚŚĞ ůŝǀŝŶŐ ĐĞůůƐ Ăƚ Ă ƌĂƚĞ ŽĨ A?  ? ? ĐŽŵƉůĞƚĞ ĨůƵŝĚ ĞǆĐŚĂŶŐĞƐ ƉĞƌ
minute (i.e. 5 mL/min) within the perfusion chamber (May et al., 2010a).
Under these conditions cells may experience fluid shear stress which has been
reported to increase membrane fluidity (Haidekker et al., 2000) and as such
the uptake of a lipophilic ligand may also be increased. This did not appear to
be an issue for BY-CGP. Another main difference was the temperature which
was kept constant at 37 °C in all perfusion experiments to ensure optimal
physiological conditions for the live cells used in the experiment. Even under
static (no perfusion) conditions, the non-specific levels of BY-PROP binding at
37 °C (compared to 21 °C) were too high to clearly define a specific binding
assay window. Increasing temperatures are also associated with increased
fluidity of plasma membranes and, in the case of lipophilic ligand, higher non-
specific binding levels. Thirdly, some of the high intracellular fluorescence
intensity of BY-PROP will also have been measured in the region of interests
(ROIs) drawn around the cell membranes and since the intracellular
fluorescence cannot be dissociated or washed away it may make the BY-
PROP dissociation seem slower than it actually is, especially in the CHO-CS
cells which displayed very high levels of intracellular fluorescence intensity.
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Nevertheless, the KD derived from the association and dissociation rates for
10 and 30 nM BY-PROP (19 and 21 nM, respectively) compared very well to
the affinity value determined at site 1 for BY-PROP in functional studies (28
nM; Chapter 4). Although not statistically significantly different, the kinetically
derived affinity value for 100 nM BY-PROP was circa 5-fold lower (112 nM),
which may be due to the unexpectedly faster dissociation rate of 100 nM BY-
PROP. The faster dissociation rates of BY-PROP observed in CHO-CS cells could
not be included in the analysis of the dissociation rate of BY-PROP measured
ŝŶ ,K ?ɴ1-CS cells possibly because they were too similar to be accurately
separated apart in the curve fit. Thus, the enhanced dissociation rate of 100
ŶD ƐĞĞŶ ŝŶ ,K ?ɴ1-CS cells may be an artefact of increased non-specific
binding at 100 nM BY-PROP. In addition, it is noteworthy that even after 10
ŵŝŶƵƚĞƐ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ  ? ? ĂŶĚ  ? ? ŶD z ?WZKW ƚŽ ƚŚĞɴ1-adrenoceptor
expressed in CHO-CS cells a plateau could not be reached. The dissociation
rates of 10, 30 and 100 nM BY-PROP were also very slow. Thus, it was difficult
to accurately determine observed association and dissociation rates which are
reflected in the affinity values calculated for each BY-PROP concentration.
Unfortunately, it was beyond the scope of this thesis to test and characterise
additional novel fluorescent propranolol ligands to potentially identify a
ligand that displayed lower non-specific binding levels and faster association
and dissociation rates, thus making it more suitable to kinetic binding
experiments using the confocal perfusion system.
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The data shown here points to the presence of two separate, topographically
distinct binding sites which now poses the question as to what and where
that binding site is. Using a mutagenesis approach, Baker et al. (2008)
ŵƵƚĂƚĞĚ ĞŝŐŚƚ ĂŵŝŶŽ ĂĐŝĚƐ ŽĨ ƚŚĞ ŚƵŵĂŶ ɴ1-adrencoeptor and determined
ƚŚĞ ďŝŶĚŝŶŐ ĂŶĚ ĨƵŶĐƚŝŽŶĂů ƉƌŽƉĞƌƚŝĞƐ ŽĨ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ Ăƚ ĞĂĐŚ
receptor mutation. Interestingly, this study concluded that the two binding
sites must be overlapping as residues that affected site 1 also affected site 2
(Baker et al. ?  ? ? ? ? ? ? Ŷ ĂůƚĞƌŶĂƚŝǀĞ ĞǆƉůĂŶĂƚŝŽŶ ŵĂǇ ďĞ ƚŚĂƚ ƚŚĞ ƐĞĐŽŶĚ ɴ1-
adrenoceptor is in fact a second orthosteric catecholamine site that is
ƉƌŽǀŝĚĞĚďǇĂƐĞĐŽŶĚɴ1-adrenoceptor in a homodimer formation which now
ƌĞƉƌĞƐĞŶƚƐ ĂŶ ĂůůŽƐƚĞƌŝĐ ƐŝƚĞ ƚŽ ǁŚŝĐŚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ ŚĂǀĞ ůŽǁĞƌ
affinity.
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6.5 Conclusion
The kinetic parameters of BODIPY-TMR-CGP (a CGP 12177 analogue) were
successfully determined, and the kinetically derived KD could be compared to
ƚŚĞĂĨĨŝŶŝƚǇǀĂůƵĞŽĨz ?'WĨŽƌƚŚĞŚŝŐŚĂĨĨŝŶŝƚǇĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞŽĨƚŚĞɴ ?
adrenoceptor determined in previous functional studies (Chapter 4). The
dissociation rates were independent of BODIPY-TMR-CGP concentrations
used and revealed only one specific dissociation rate component, which was
that of the primary high affinity catecholamine site. 3 nM BY-CGP was used to
predominantly label the high affinity catecholamine site, and the dissociation
rate of 3 nM BODIPY-TMR-CGP was enhanced in the presence of unlabelled
CGP 12177 and propranolol demonstrating co-operative interactions between
ƚǁŽ ĚŝƐƚŝŶĐƚ ɴ1-adrenoceptor binding sites. We could not investigate the
reciprocal nature of the observed allosteric effect, as the fluorescent
derivative of propranolol, BODIPY630/650-S-PEG8-propranolol, proved too
ůŝƉŽƉŚŝůŝĐƚŽĚĞƚĞĐƚǁĞůůĚĞĨŝŶĞĚƐƉĞĐŝĨŝĐďŝŶĚŝŶŐƚŽƚŚĞɴ1-adrenoceptor in the
confocal perfusion system at the concentrations used. However, affinity
values derived from the change in BY-CGP dissociation rates with increasing
CGP 12177 and propranolol concentrations compared well to those from
previous functional studies (Chapter 4), which further supports an allosteric
ŵŽĚĞŽĨĂĐƚŝŽŶŽĨ'W ? ? ? ? ?ĂƚƚŚĞɴ1-adrenoceptor.
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Chapter 7
Investigating a role of dimerisation in
co-operative interactions and
ĨƵŶĐƚŝŽŶĂůƌĞƐƉŽŶƐĞƐŽĨŚƵŵĂŶɴ1-
adrenoceptors
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7.1 Introduction
The examination of the dissociation rate of 3 nM BY-CGP in the absence and
ƉƌĞƐĞŶĐĞ ŽĨ ƵŶůĂďĞůůĞĚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ 'W  ?  ? ? ? ĂŶĚ ƉƌŽƉƌĂŶŽůŽů
ƌĞǀĞĂůĞĚŶĞŐĂƚŝǀĞĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇďĞƚǁĞĞŶƚŚĞƚǁŽƉƌŽƉŽƐĞĚɴ1-adrenoceptor
binding sites (Chapter 6). An allosteric binding site is described to be
topographically distinct from the orthosteric site, which could describe a
second binding site within a monomeric receptor, but could also describe a
second binding site provided by a second receptor in a homodimer formation
(May et al., 2011). A mutagenesis study carried out by Baker et al. (2008)
ĐŽŶĐůƵĚĞĚƚŚĂƚƚŚĞƚǁŽƉƌŽƉŽƐĞĚɴ1-adrenoceptor binding sites must overlap.
Here, we investigate whether the observed co-operative effects are mediated
ĂĐƌŽƐƐ Ă ɴ1Z ŚŽŵŽĚŝŵĞƌ ŝŶƚĞƌĨĂĐĞ ĂŶĚ ǁŚĞƚŚĞƌ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƐŝƚĞŝƐĂƐĞĐŽŶĚɴ1AR in a homodimer formation. A similar mode
of action of co-operativity has recently been described for the A3 adenosine
receptor (May et al., 2011). The formation of GPCR dimers can be detected
using bimolecular fluorescence complementation (BiFC) where two non-
fluorescent halves of a split fluorescence protein (FP) are fused to the C-
terminus of the target GPCRs and reconstitute to a fully functional fluorescent
protein upon receptor dimerisation (Rose et al., 2010). The reconstitution of
N- and C-terminal YFP fragments (YFPN and YFPC, respectively) to a full length
YFP is an irreversible process, which results in receptors that have formed into
dimers being trapped in that formation (Kerppola, 2008). Crucially, the YFP
fragments fused to proteins of interest do not affect the efficiency of
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dimerisation of the proteins under investigation as demonstrated by Hu et al.
(2003a) for the heterodimerisation of the transcription factors Fos and Jun
(Hu et al. ?  ? ? ? ?Ă ? ? ,ŽŵŽĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ƚŚĞ ɴ1AR has been reported to be
transient (Calebiro et al., 2013; Dorsch et al., 2009). Thus, using BiFC, we
ĂŝŵĞĚ ŶŽƚ ŽŶůǇ ƚŽ ĚĞƚĞĐƚ ďƵƚ ĂůƐŽ ƚŽ ŝƌƌĞǀĞƌƐŝďůǇ ůŽĐŬ ƚƌĂŶƐŝĞŶƚ ɴ1-
adrenoceptors homodimers into stable homodimers, and to investigate the
ĞĨĨĞĐƚŽĨƚƌĂƉƉŝŶŐɴ1AR homodimers on the dissociation rate of BODIPY-TMR-
'W ?dŽĨƵƌƚŚĞƌĐŽŶĨŝƌŵƚŚĞƉŽƚĞŶƚŝĂůƌŽůĞŽĨƚŚĞƐĞĐŽŶĚĂƌǇɴ1-adrenoceptor
ƐŝƚĞ ?ŝ ?Ğ ?ŽŶĞɴ1-adrenoceptor protomer), we mutated the aspartic acid amino
ĂĐŝĚ ƌĞƐŝĚƵĞ  ? ? ? ŽĨ ƚŚĞ ɴ1-adrenoceptor to alanine. This mutation has been
shown to disrupt the binding of ligands to both the orthosteric (site 1) and
ĂůůŽƐƚĞƌŝĐ ƐŝƚĞ  ?ƐŝƚĞ  ? ? ŽĨ ƚŚĞ ɴ1-adrenoceptor (Baker et al., 2008) and we
ŚǇƉŽƚŚĞƐŝƐĞĚ ƚŚĂƚ ĐŽŶƐƚƌĂŝŶĞĚ ɴ1AR dimers containing a non-ligand binding
protomer would reverse the effects on the BODIPY-TMR-CGP dissociation
kinetics seen in constrained wild-type dimers and more closely match the
ƉŚĂƌŵĂĐŽůŽŐǇ ĚĞƐĐƌŝďĞĚ ŝŶ ,K ?ɴ1-CS cells (Chapter 6). Finally, we also
ĞǆĂŵŝŶĞĚƚŚĞĨƵŶĐƚŝŽŶĂůƌĞƐƉŽŶƐĞŽĨ,KĐĞůůƐĞǆƉƌĞƐƐŝŶŐɴ1AR homodimers
ĐŽŶƚĂŝŶŝŶŐĂǁŝůĚ ?ƚǇƉĞŽƌŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐƐĞĐŽŶĚɴ1AR protomer.
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7.2 Methods
Molecular Biology
As described in Methods: Molecular Biology, the D138A (aspartic acid, GAC ->
ĂůĂŶŝŶĞ ?' ?ŵƵƚĂƚŝŽŶǁĂƐŝŶƚƌŽĚƵĐĞĚŝŶƚŽƚŚĞɴ1YFPC construct, which was
made in the Hill lab in 2007 and used as the DNA template in the mutagenesis
reaction. The forward (5-GGACCTCAGTGGCCGTGCTGTGCGT-3) and reverse
(5-ACGCACAGCACGGCCACTGAGGTCC3) mutagenesis primers containing
ƚŚĞĚĞƐŝƌĞĚƉŽŝŶƚŵƵƚĂƚŝŽŶǁĞƌĞĚĞƐŝŐŶĞĚĂŶĚƵƐĞĚŝŶƚŚĞɴ1AR mutagenesis
ƌĞĂĐƚŝŽŶ ? dŚĞ ƌĞƐƵůƚĂŶƚ ɴ1D138AYFPC ĂŶĚ ƚŚĞ ŽƌŝŐŝŶĂů ɴ1YFPC sequences were
inserted into separate plasmid vector pcDNA3.1(+) containing the zeocin
antibiotic resistance gene. The plasmid pcDNA3.1(+) vectors containing the
ŶĞŽŵǇĐŝŶĂŶƚŝďŝŽƚŝĐƌĞƐŝƐƚĂŶĐĞĂŶĚĞŝƚŚĞƌƚŚĞɴ1z&WŽƌƚŚĞɴ1YFPN sequences
were also made in the Hill lab in 2007 and used in studies presented in this
chapter.
Cell culture
This was performed as described in Methods: Cell culture. CHO-K1 cells were
ƵƐĞĚ ĨŽƌ ƐƚĂďůĞ ĂŶĚ ƚƌĂŶƐŝĞŶƚ ƚƌĂŶƐĨĞĐƚŝŽŶƐ ? ,K ?ɴ1-CS cells were used as a
control where appropriate.
Transient transfections
Transient transfections were carried out as outline in Methods: Generation of
new cell lines. The total amount of DNA used per well was 150 ng and 750 ng
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in 8-well and 6-well plates, respectively. For transient transfections in T75
flasks, a total of 10 µg DNA was used. Cells were used for experimentation 48
hours following transfection.
Generation of stable cell lines
/ŶƚŚŝƐĐŚĂƉƚĞƌ ?ƚŚĞĐůŽŶĂůƐƚĂďůĞĐĞůů ůŝŶĞ,K ?ɴ1YFPN was generated using 3
µg DNA to transfect CHO-K1 cells grown to 70 % confluence in a T25 flask. The
transfection was performed as outlined in Methods: Generation of new cell
lines, followed by selection of transfectants, dilution cloning and generation
of a stable cell line. The initial selection of transfectants and the maintenance
of the stable cell line were achieved through supplementation of the growth
media with 100 µg/mL of geneticin (G418).
^ƵďƐĞƋƵĞŶƚůǇ,K ?ɴ1YFPN cells were grown to 70 % confluence in a T25 flask
ĂŶĚƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚĞŝƚŚĞƌ ?A?Őɴ1YFPCŽƌɴ1D138AYFPC DNA to generate stable
ŵŝǆĞĚ ƉŽƉƵůĂƚŝŽŶ ,K ?ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell lines.
Both cell lines were maintained using the growth media supplemented with
100 µg/mL geneticin and 50 µg/mL zeocin.
Confocal microscopy
This was performed as described in Methods: Confocal microscopy using 8-
well borosilicate chambered-coverglass plates imaged on a Zeiss LSM710 laser
scanning microscope with a 40x1.3NA oil immersion lens. YFP fluorescence
was imaged using an argon laser and 488 nm excitation with emission
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captured through a 505-634 nm filter and BODIPY-TMR-CGP fluorescence was
imaged using a 561 nm DPSS laser with emission captured through a 565 nm
long-pass filter (1024x1024 pixels, averaging at 4 frames). A pinhole diameter
of 1 Airy unit was used. For bimolecular fluorescence complementation (BiFC)
experiments, transiently transfected cells were incubated at 30 °C overnight
(circa 16 hours) before imaging.
Confocal perfusion system
The perfusion system of the Zeiss LSM710 confocal microscope was used and
experiments were carried out as described in Methods: Confocal perfusion
system. Confocal and transmitted light images of live cells were taken every 2
seconds. BY-CGP fluorescence intensity was measured using a 561 nm
excitation wavelength.
[
3
H]cAMP accumulation assay
This was performed as described in Methods: [3H]cAMP accumulation assay.
The exact same experimental setup was used on cells stably and transiently
ĞǆƉƌĞƐƐŝŶŐƚŚĞĚĞƐŝƌĞĚɴ1-adrenoceptor constructs.
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7.3 Results
ĞƚĞĐƚŝŶŐɴ1-adrenoceptor homodimers using BiFC
In bimolecular fluorescence complementation (BiFC) approaches, two
fragments of a fluorescent protein, which on their own are not fluorescent,
come together when in close proximity to one another, to reconstitute the
full length fluorescent protein which is fluorescent (Rose et al., 2010). The N-
terminal fragment (amino acids 1-155), the C-terminal fragment (amino acids
156-239) of the yellow fluorescent protein (YFPN and YFPC, respectively) and
the full length YFP (amino acids 1-239) were each fused to the C-terminal end
ŽĨ ƚŚĞ ŚƵŵĂŶ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ŐĞŶĞƌĂƚŝŶŐ ƚŚĞ ɴ1YFPN ĂŶĚ ɴ1YFPC constructs
(all constructs were made in the Hill lab in 2007; all constructs were
sequenced before being used in this study and the DNA and protein sequence
of each construct are listed in Appendix I S9-11).
&ŝƌƐƚ ?ǁĞĞǆĂŵŝŶĞĚƚŚĞĨůƵŽƌĞƐĐĞŶĐĞŝŶƚĞŶƐŝƚŝĞƐŽĨƚŚĞŝŶĚŝǀŝĚƵĂůɴ1YFP (Figure
 ? ? ? ? ? ɴ1YFPN  ?&ŝŐƵƌĞ  ? ? ? ? ĂŶĚ ɴ1YFPC constructs (Figure 7.3) transiently
transfected into CHO-K1 cells. The expression of the constructs was confirmed
by measuring the binding of 20 nM BY-CGP to all transfected cells. Clear
membrane labelling of all transfected cells was observed following 10 minute
exposure to 20 nM BY-CGP, indicating good cell surface expression of all three
constructs. Good YFP fluorescence could also be seen in membranes of cells
ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ɴ1z&W ? ďƵƚ ŶŽƚ ɴ1YFPN ĂŶĚ ɴ1YFPC ? dŚĞ ɴ1YFPN ĂŶĚ ɴ1YFPC
constructs were transiently co-transfected in CHO-K1 to investigate the
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ĨůƵŽƌĞƐĐĞŶĐĞ ŽĨ ƌĞĐŽŶƐƚŝƚƵƚĞĚ z&W ƵƉŽŶ ɴ1-adrenoceptor homodimerisation
(Figure 7.4). Clear membrane labelling of 20 nM BY-CGP demonstrated the
ĐĞůů ƐƵƌĨĂĐĞ ĞǆƉƌĞƐƐŝŽŶ ŽĨ ĞŝƚŚĞƌ ɴ1YFPN Žƌ ?ĂŶĚ ɴ1YFPC, whereas the YFP
ĨůƵŽƌĞƐĐĞŶĐĞŝŶĚŝĐĂƚĞĚƚŚĂƚɴ1AR homodimerisation and reconstitution of the
YFP had taken place. It is noteworthy that the fluorescence of the
reconstituted YFP was dimmer than that of the full length YFP and a higher
gain setting had to be used to detect it (1100 instead of 600). Using these
higher gain settings on cells transfected with the YFPN and YFPC fragments
only revealed higher background YFP fluorescence indicating the detected
BiFC fluorescence was specific.
Figure 7.1 ŽŶĨŽĐĂů ŝŵĂŐĞƐ ŽĨ  ? ? ŶD z ?'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ z&W ?ƚĂŐŐĞĚ ɴ1-receptor construct transiently expressed in CHO-K1 cells. The fluorescence
ŝŶƚĞŶƐŝƚǇŽĨ ƚŚĞ ĨƵůů ůĞŶŐƚŚz&WǁĂƐŵĞĂƐƵƌĞĚ ŝŶĐŚĂŶŶĞů  ? ? ?ƵƐŝŶŐĂŐĂŝŶƐĞƚƚŝŶŐŽĨ  ? ? ? ?dŚĞďŝŶĚŝŶŐŽĨ  ? ?ŶDz ?'WƚŽƚŚĞĞǆƉƌĞƐƐĞĚz&W ?ƚĂŐŐĞĚɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƐǁĂƐŵĞĂƐƵƌĞĚƵƐŝŶŐƚŚĞ ? ? ?ĐŚĂŶŶĞů ?ǁŝƚŚĂŐĂŝŶƐĞƚƚŝŶŐŽĨ ? ? ? ? ?dŚĞŵĞƌŐĞĚŝŵĂŐĞƐŚŝŐŚůŝ ƚĐŽ ?ůŽĐĂůŝƐĂƚŝŽŶŽĨĐĞůůƐƵƌĨĂĐĞz&W ?ƚĂŐŐĞĚɴ1-
adrenoceptor (green) and BY-CGP binding (red) to these receptors in yellow pixels. The images are representative of two different fields of view imaged on
one experimental day. Scale bar = 50 µm.
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Figure 7.2 Confocal imaging of 20 nM BY-CGP binding to YFPN ?ƚĂŐŐĞĚ ɴ1-receptor constructs transiently expressed in CHO-K1 cells. YFP fluorescence
intensity was measured in channel 488 using two different gain settings: 700 and 1100. The binding of 20 nM BY-CGP to the expressed YFPN ?ƚĂŐŐĞĚɴ1-
adrenoceptors was measured using the 543 channel (gain setting 600 in all images). The merged images highlight co-localisation of cell surface YFPN-tagged
ɴ1-adrenoceptor (green) and BY-CGP binding (red) to these receptors in yellow pixels. The images are representative of two different fields of view imaged on
one experimental day. Scale bar = 50 µm.
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Figure 7.3 Confocal imaging of 20 nM BY-CGP binding to YFPC ?ƚĂŐŐĞĚ ɴ1-receptor constructs transiently expressed in CHO-K1 cells. YFP fluorescence
intensity was measured in channel 488 using two different gain settings: 700 and 1100. The binding of 20 nM BY-CGP to the expressed YFPC ?ƚĂŐŐĞĚɴ1-
adrenoceptors was measured using the 543 channel (gain setting 600 in all images). The merged images highlight co-localisation of cell surface YFPC-tagged
ɴ1-adrenoceptor (green) and BY-CGP binding (red) to these receptors in yellow pixels. The images are representative of two different fields of view imaged on
one experimental day. Scale bar = 50 µm.
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Figure 7.4 Confocal imaging of 20 nM BY-CGP binding to CHO-K1 cells transiently transfected with ɴ1YFPNĂŶĚɴ1YFPC constructs. The fluorescence intensity of
the re-constituted YFP was measured in channel 488 using two different gain settings: 700 and 1100. The binding of 20 nM BY-CGP to expressed YFPN- and
YFPC ?ƚĂŐŐĞĚ ɴ1-adrenoceptors was measured using the 543 channel (gain setting 600 in all images). The merged images highlight co-localisation of cell
surface YFPreconstituted ?ƚĂŐŐĞĚɴ1-adrenoceptor homodimers (green) and BY-CGP binding (red) to these receptor complexes in yellow pixels. The images are
representative of two different fields of view imaged on one experimental day. Scale bar = 50 µm.
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Investigating the dissociation rate of 3 nM BODIPY-TMR-CGP at
ǁŝůĚ ?ƚǇƉĞɴ1AR homodimers constrained and detected by BiFC
,ŽŵŽĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ɴ1-adrenoceptors has been reported to be transient
(Calebiro et al., 2013; Dorsch et al., 2009). Using BiFC, the dimers that formed
at any given time were trapped and stabilised, which allowed their detection
and pharmacological investigation. Constraining dimers using BiFC will
ŝŶĐƌĞĂƐĞ ƚŚĞ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1-adrenoceptors dimers as a result of BiFC-
mediated prevention of dimer dissociation into receptor monomers. This
would be expected to enhance any dimer-mediated pharmacological effects,
although we could not determine what that increase in percentage of dimers
was, and therefore could not know what increase (if any) of an effect to
expect. To investigate the BODIPY-TMR-CGP binding kinetics at irreversibly
ĐŽŶƐƚƌĂŝŶĞĚƐƚĂďůĞǁŝůĚ ?ƚǇƉĞɴ1AR homodimers, CHO-K1 cells were transiently
ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ƚŚĞ ƚǁŽ ŶŽŶ ?ĨůƵŽƌĞƐĐĞŶƚ ǁŝůĚ ?ƚǇƉĞɴ1-adrenoceptor
ĐŽŶƐƚƌƵĐƚƐɴ1YFPNĂŶĚɴ1YFPC ?ĂŶĚƐƚĂďůĞɴ1AR homodimers were detected by
measuring YFP fluorescence. In these cells, the fluorescence intensity of YFP
and BODIPY-TMR-CGP was measured every two seconds during a four minute
association followed by a four minutes dissociation. In order to determine the
z ?'WďŝŶĚŝŶŐŬŝŶĞƚŝĐƐƚŽɴ1AR homodimers, regions of interests (ROIs) were
drawn around membranes of cells that were identified to express
homodimers by YFP fluorescence. The obtained association traces of 3 nM
BODIPY-TMR-CGP did not reach a plateau in 4 minutes (Figure 7.5), and
association rates could not be accurately determined. However, the
dissociation rate of 3 nM BODIPY-TMR-CGP was quantified using a
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monophasic exponential decay equation and was determined to be 0.019 ±
0.006 min-1 (n=5), which was significantly slower than the dissociation rate
ĚĞƚĞƌŵŝŶĞĚŝŶ,K ?ɴ1 ?^ĐĞůůƐ ?ŝ ?Ğ ?ƵŶĐŽŶƐƚƌĂŝŶĞĚƚƌĂŶƐŝĞŶƚɴ1AR homodimers,
Chapter 6; P < 0.05, two-way ANOVA analysis followed by Bonferronis
ŵƵůƚŝƉůĞ ĐŽŵƉĂƌŝƐŽŶ ƚĞƐƚ ? ? dŚŝƐ ŝŶĚŝĐĂƚĞƐ ƚŚĂƚ ƚŚĞĨŽƌŵĂƚŝŽŶ ŽĨ ɴ1AR into
dimers affected the conformation of the catecholamine binding site such that
the dissociation rate of 3 nM BY-CGP was slowed, suggesting distinct BY-CGP
ĚŝƐƐŽĐŝĂƚŝŽŶŬŝŶĞƚŝĐƐĂƚɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌĚŝŵĞƌƐĐŽŵƉĂƌĞĚƚŽɴ1-adrenoceptor
monomers.
The binding levels of 3 nM BODIPY-TMR-CGP (BY-CGP) to CHO-K1 cells
ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1YFPC homodimers were unchanged following a four
minute dissociation in the absence of unlabelled ligands. However, reduced
binding of 3 nM BY-CGP was observed following dissociation in the presence
of 1 µM CGP 12177 and 1 µM propranolol (Figure 7.6). YFP fluorescence was
measured at the same time as BY-CGP fluorescence to confirm the presence
ŽĨɴ1-adrenoceptor homodimers (Figure 7.6). The dissociation rates of 3 nM
BY-CGP in the presence of 1 µM CGP 12177 and 1 µM propranolol were
determined to be 0.186 ± 0.008 min-1 (n=6) and 0.189 ± 0.007 min-1 (n=6),
respectively, and were significantly faster than the dissociation rate
determined above in the absence of unlabelled ligands (P < 0.05, two-way
ANOVA followed by Bonferronis post hoc test; Figure 7.7). The change in the
3 nM BY-CGP dissociation rate in the absence and presence of unlabelled
ůŝŐĂŶĚƐǁĂƐ ? ?ĨŽůĚŝŶ,K ?ɴ1-CS cells (Chapter 6, Table 6.4), but was 10-fold in
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,K ?< ? ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ǁŝůĚ ?ƚǇƉĞ ɴ1YFPN ? ɴ1YFPC homodimers. This fold
increase in the effects of unlabelled ligands on the BY-CGP dissociation rate in
ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ Ă ŐƌĞĂƚĞƌ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ĚŝŵĞƌƐ  ?ĐŽŶƐƚƌĂŝŶĞĚ ɴ1YFPN ?ɴ1YFPC
dimers unable to dissociate) than in cells expressing unconstrained transient
ɴ1Z ĚŝŵĞƌƐ  ?ĚŝŵĞƌ ĚŝƐƐŽĐŝĂƚŝŽŶ ƵŶƌĞƐƚƌŝĐƚĞĚ ŝŶ ,K ?ɴ1-CS cells), suggests
that the effects of the unlabelled ligands are mediated through a secondary
ɴ1-adrenoceptor site across a homodimer interface.
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Figure 7.5 Normalised association and dissociation of 3 nM BY-CGP in CHO-K1 cells
ƚƌĂŶƐŝĞŶƚůǇĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1YFPC homodimers constrained by BiFC. Data shown
are mean ± s.e.m. of data from five separate perfusion slides imaged on three
separate experimental days. For each experiment regions of interest were drawn
around the membranes of 10 individual cells.
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Figure 7.6 Binding of 3 nM BY-CGP to CHO-K1 cells transiently expressing
ɴ1YFPN ?ɴ1YFPC constrained by BiFC. Confocal images following 4 min BODIPY-TMR-
CGP association and a further 4 minutes of dissociation in the absence (infinite
dilution) and presence of either 1 µM CGP 12177 or 1 µM propranolol. The
ĨůƵŽƌĞƐĐĞŶĐĞ ŽĨ z&W ?ƚĂŐŐĞĚ ɴ1-adrenoceptor homodimers was measured
simultaneously. Images are representative of six separate perfusion slides imaged on
three separate experimental days. Scale bar = 50 µm.
BY-CGPassociation BY-CGPdissociationBiFC
ǁŝůĚ ?ƚǇƉĞɴ1YFPN  ?ǁŝůĚ ?ƚǇƉĞɴ1YFPC
in
fi
n
it
e
d
ilu
ti
o
n
1
µ
M
C
G
P
12
17
7
1
µ
M
p
ro
p
ra
n
o
lo
l
344
Figure 7.7ŝƐƐŽĐŝĂƚŝŽŶŽĨ ?ŶDz ?'WĨƌŽŵ,K ?< ?ĐĞůůƐƚƌĂŶƐŝĞŶƚůǇĞǆƉƌĞƐƐŝŶŐɴ1-
YFPN ?ɴ1-YFPC homodimers constrained by BiFC in the absence and presence of 1 µM
CGP 12177 and 1 µM propranolol. Data are mean ± s.e.m. of data obtained from 5-6
separate perfusion slides imaged on three separate experimental days. For each
perfusion slide, regions of interest were drawn around the membranes of 10
individual cells.
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ĨĨĞĐƚŽĨĂŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐɴ1AR protomer on the dissociation
ƌĂƚĞŽĨ ?ŶDK/Wz ?dDZ ?'WĂƚĐŽŶƐƚƌĂŝŶĞĚɴ1AR homodimers
Next, we aimed to confirm whether the enhanced difference between the
BODIPY-TMR-CGP dissociation rate in the absence and presence of unlabelled
ůŝŐĂŶĚƐ ŽďƐĞƌǀĞĚ ŝŶ ĐŽŶƐƚƌĂŝŶĞĚ ǁŝůĚ ?ƚǇƉĞ ɴ1AR homodimers compared to
,K ?ɴ1-CS cells, is in fact due to the constrained presence of a second site in
ĨŽƌŵŽĨĂƐĞĐŽŶĚɴ1ZƉƌŽƚŽŵĞƌ ŝŶĂɴ1AR homodimer complex. In order to
ĂĐŚŝĞǀĞ ƚŚŝƐ ? ǁĞ ŝŶƚƌŽĚƵĐĞĚ ƚŚĞ  ? ? ? ŵƵƚĂƚŝŽŶ ŝŶƚŽ ƚŚĞ ŚƵŵĂŶ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ƐĞƋƵĞŶĐĞ ? ǁŚŝĐŚ ŚĂƐ ďĞĞŶ ƐŚŽǁŶ ƚŽ ĂďŽůŝƐŚ ďŝŶĚŝŶŐ ŽĨ ɴ ?
ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐƚŽďŽƚŚɴ1-adrenoceptor sites (Baker et al., 2008). If the
ƐĞĐŽŶĚ ƐŝƚĞ ŝƐ ĨĂĐŝůŝƚĂƚĞĚ ďǇ Ă ƐĞĐŽŶĚ ɴ1-adrenoceptor protomer in a
homodimer formation, then the introduction of the D138A mutation would
remove the second site and with that the ability of unlabelled ligands to
affect the BODIPY-TMR-CGP dissociation rate through allosteric interactions
across the homodimer interface (Figure 7.8). This mutation, however, would
not be expected to affect the BODIPY-TMR-CGP dissociation rate, if the
ƐĞĐŽŶĚƐŝƚĞǁĂƐĨĂĐŝůŝƚĂƚĞĚǁŝƚŚŝŶŽŶĞɴ1AR protomer.
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Figure 7.8 Schematic diagram detailing potential allosteric effects on the ligand-
binding properties of a labelled ligand caused by an unlabelled ligand across a
homodimer interface. A, the kinetic parameters of a labelled ligand at the orthosteric
ƐŝƚĞ  ?ƉƌŽƚŽŵĞƌ  ? ? Ğ ?Ő ? ŶĂƚŝǀĞ ɴ1AR) may be positively or negatively affected by the
ďŝŶĚŝŶŐŽĨĂŶƵŶůĂďĞůůĞĚůŝŐĂŶĚƚŽĂŶĂůůŽƐƚĞƌŝĐƐŝƚĞ ?ƉƌŽƚŽŵĞƌ ? ?Ğ ?Ő ?ŶĂƚŝǀĞɴ1AR). B,
these allosteric effects are inhibited if the binding of the unlabelled ligand to the
allosteric site is prevented, for example, by the introduction of a single amino acid
ĐŚĂŶŐĞ ?&Žƌ ƚŚĞɴ1-adrenoceptor, the non-ligand binding mutation D138A (Baker et
al., 2008) was chosen.
A B ǁŝůĚ ?ƚǇƉĞɴ1Z ? ? ? ?ɴ1ARmutantǁŝůĚ ?ƚǇƉĞɴ1Z ?ǁŝůĚ ?ƚǇƉĞɴ1AR
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First, we confirmed that the D138A mutation abolished ligand binding to the
ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ? tĞ ŐĞŶĞƌĂƚĞĚ Ă  ? ? ? ɴ1-adrenoceptor mutant fused to
ƚŚĞ^EW ?ƚĂŐ ?ƐƐɴ1D138A; for DNA and protein sequence see Appendix I S12) in
order to visualise the mutant receptor and confirm its expression on the cell
surface following transient transfection. Indeed, no binding of 2 nM BODIPY-
dDZ ?'W ĐŽƵůĚ ďĞ ƐĞĞŶ ŝŶ ,K ?< ? ĐĞůůƐ ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ƚŚĞ ƐƐɴ1D138A
construct, but clear membrane fluorescence following labelling of the SNAP-
tag with 1 µM BG-488 confirmed the cell surface expression of the receptor
ĐŽŶƐƚƌƵĐƚ  ?&ŝŐƵƌĞ  ? ? ? ? ? dŚĞ ^EW ?ƚĂŐŐĞĚ ŶĂƚŝǀĞ ɴ1AR was also transiently
transfected as a positive control, and clear fluorescence of the BG-488
labelled SNAP-tag and 2 nM BY-CGP binding to the receptor could be seen
(Figure 7.9), indicating that the lack of BY-CGP fluorescence seen for the
ƐƐɴ1D138A ƚƌĂŶƐĨĞĐƚĞĚ ĐĞůůƐ ǁĂƐ ĚƵĞ ƚŽ ƚŚĞ ŵƵƚĂƚŝŽŶ ŝŶƚƌŽĚƵĐĞĚ ŝŶƚŽ ƚŚĞ ɴ1-
adrenoceptor.
&ŽůůŽǁŝŶŐ ƚŚŝƐ ? ƚŚĞ ƐĂŵĞ ŵƵƚĂƚŝŽŶ ǁĂƐ ŝŶƚƌŽĚƵĐĞĚ ŝŶƚŽ ƚŚĞ ɴ1YFPC construct
ƚŽ ŐĞŶĞƌĂƚĞ ƚŚĞ ɴ1D138AYFPC construct (for DNA and protein sequence see
Appendix I S13). No YFP fluorescence was detected in CHO-K1 cells
ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ƚŚĞ ɴ1D138AYFPC construct and no BODIPY-TMR-CGP
fluorescence was observed following a 10 minute exposure to 3 nM BODIPY-
dDZ ?'W ?&ŝŐƵƌĞ ? ? ? ? ? ?,ŽǁĞǀĞƌ ?ǁŚĞŶĐŽ ?ƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚǁŝůĚ ?ƚǇƉĞɴ1YFPN,
z&W ĂŶĚ z ?'W ĨůƵŽƌĞƐĐĞŶĐĞ ǁĂƐ ĚĞƚĞĐƚĞĚ ? ŝŶĚŝĐĂƚŝŶŐ ƚŚĂƚ ɴ1-adrenoceptor
homodimerisation and reconstitution of the YFP had taken place (Figure 7.10).
The BODIPY-TMR-CGP fluorescence measured represents the binding of
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K/Wz ?dDZ ?'W ƚŽ ƚŚĞ ɴ1YFPN construct either as part of a
ɴ1YFPN ?ɴ1D138AYFPC homodimer (yellow pixels in merged image), a
ɴ1YFPN ?ɴ1YFPN homodimer or a monomer (latter two scenarios are both
reflected in BODIPY-TMR-CGP fluorescence only, i.e. red pixels in merged
image).
Figure 7.9 ŽŶĨŽĐĂů ŝŵĂŐŝŶŐ ŽĨ ŶŽŶ ?ůŝŐĂŶĚ ďŝŶĚŝŶŐ ɴ1D138A ƌĞĐĞƉƚŽƌ ŵƵƚĂƚŝŽŶ ? dŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ǁŝůĚ ?ƚǇƉĞ  ?ƚŽƉ ƉĂŶĞů ? ĂŶĚ ŵƵƚĂŶƚ  ?ďŽƚƚŽŵ ƉĂŶĞů ? ɴ1-
adrenoceptor was visualised by labelling the SNAP-tag with 1 µM BG-488 (30 mins, 37 °C) prior to imaging its fluorescence using 488 nm excitation. The
ligand binding properties of the wild-type and mutant receptor was examined by exposing the cells to 2 nM BY-CGP (10 mins, 37 °C). BY-CGP fluorescence
ǁĂƐ ŵĞĂƐƵƌĞĚ ƵƐŝŶŐ  ? ? ? Ŷŵ ĞǆĐŝƚĂƚŝŽŶ ? dŚĞ ŵĞƌŐĞĚ ŝŵĂŐĞƐ ŚŝŐŚůŝŐŚƚ ĐŽ ?ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ĐĞůů ƐƵƌĨĂĐĞ ^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors (green) and BY-CGP
binding (red) to these receptors in yellow pixels. The images are representative of two different fields of view imaged on one experimental day. Scale bar =
50 µm.
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Figure 7.10ŽŶĨŽĐĂůŝŵĂŐŝŶŐŽĨŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐɴ1D138A receptor mutation using BiFC. The fluorescence intensities of the YFP-tag and 3 nM BY-CGP were
ŵĞĂƐƵƌĞĚŝŶƚŚĞ ? ? ?ĂŶĚ ? ? ?ĐŚĂŶŶĞů ?ƌĞƐƉĞĐƚŝǀĞůǇ ?ĨŽƌƚŚĞŵƵƚĂŶƚɴ1D138YFPCĐŽŶƐƚƌƵĐƚĂůŽŶĞ ?ƚŽƉƉĂŶĞů ?ĂŶĚǁŚĞŶĐŽ ?ƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚǁŝůĚ ?ƚǇƉĞɴ1YFPN
(bottom panel). The merged images highlight co-localisation of cell surface YFPreconstituted ?ƚĂŐŐĞĚɴ1-adrenoceptor homodimers (green) and BY-CGP binding
(red) to these receptor complexes in yellow pixels. The images are representative of two different fields of view imaged on one experimental day. Scale bar = 50
µm.
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Following these imaging studies, we investigated the dissociation rate of 3 nM
BODIPY-TMR-CGP in CHO-K1 cells transiently transfected with one wild-type
ĂŶĚ ŽŶĞ ŶŽŶ ?ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƌĞĐĞƉƚŽƌ ŵƵƚĂŶƚ ɴ1-adrenoceptor construct
 ?ɴ1YFPN ?ɴ1D138AYFPC) using the confocal perfusion system. YFP and BY-CGP
fluorescence was measured every two seconds during a four minute
association followed by a four minutes dissociation. The association traces of
 ? ŶD K/Wz ?dDZ ?'W ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC homodimers
did not reach a plateau after four minutes (Figure 7.11), and association rates
could not be accurately determined. However, when comparing the
normalised association traces obtained for 3 nM BY-CGP at unconstrained (i.e.
ƚƌĂŶƐŝĞŶƚ ? ɴ1Z ? ĐŽŶƐƚƌĂŝŶĞĚ ɴ1YFPN ?ɴ1YFPC homodimers and
ɴ1YFPN ?ɴ1D138AYFPC homodimers, it appeared that the association rates were
very similar during the duration tested (4 minutes; Figure 7.12A). The
dissociation rate of 3 nM BODIPY-TMR-CGP in cells expressing
ɴ1YFPN ?ɴ1D138AYFPC homodimers was quantified using monophasic
exponential decay equations and was determined to be 0.054 ± 0.011 min-1
 ?ŶA? ? ? ?ǁŚŝĐŚǁĂƐƐůŽǁĞƌƚŚĂŶƚŚĞĚŝƐƐŽĐŝĂƚŝŽŶƌĂƚĞĚĞ ƌŵŝŶĞĚ ŝŶ,K ?ɴ1-CS
cells (Chapter 6), but faster than the dissociation rate determined in
ĐŽŶƐƚƌĂŝŶĞĚ ǁŝůĚ ?ƚǇƉĞ ɴ1AR homodimers, although the observed differences
were not statistically significant (P > 0.05, two-way ANOVA followed by
Bonferronis multiple comparison test; Figure 7.12B). This difference, albeit
small, may suggest that the introduced mutation influenced the dimer
conformation, thereby affecting the BY-CGP dissociation kinetics.
Alternatively, the dissociation rate intermediate between the transient dimers
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ĂŶĚ ĐŽŶƐƚƌĂŝŶĞĚ ǁŝůĚ ?ƚǇƉĞ ĚŝŵĞƌƐ  ?ɴ1YFPN ?ɴ1YFPC as described above) may
represent a different (smaller) percentage of constrained stable dimers of the
overall population of receptors in the transiently transfected cells, resulting in
ĂƐŵĂůůĞƌŽďƐĞƌǀĞĚĞĨĨĞĐƚ ŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1D138AYFPC compared to
ĐĞůůƐĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1YFPChomodimers.
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Figure 7.11 Normalised association and dissociation of 3 nM BY-CGP in CHO-K1 cells
ƚƌĂŶƐŝĞŶƚůǇ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC homodimers constrained by BiFC. Data
shown are mean ± s.e.m. of data from five separate perfusion slides imaged on three
separate experimental days. For each experiment regions of interest were drawn
around the membranes of 10 individual cells.
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Figure 7.12 A, association and B, dissociation of 3 nM BODIPY-TMR-CGP 12177 (BY-
'W ? ƚŽ ƵŶƚĂŐŐĞĚ ŶĂƚŝǀĞ ɴ1Z  ?ƚƌĂŶƐŝĞŶƚ ĚŝŵĞƌƐ ŝŶ ,K ?ɴ1-CS cells; data from
ŚĂƉƚĞƌ  ? ? ĂŶĚ ,K ?< ? ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1YFPC (wild-type BiFC trapped
ĚŝŵĞƌƐ ? ĂŶĚ ɴ1YFPN ?ɴ1D138AYFPC (wild-type/non-ligand binding mutant BiFC trapped
dimers). Data are mean ± s.e.m. of data obtained from 5-9 separate perfusion slides
on 3-7 separate experimental days. For each perfusion slide, ROIs were drawn
around the membranes of 10 individual cells.
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Reduced binding of 3 nM BY-CGP to CHO-K1 cells expressing
ɴ1YFPN ?ɴ1D138AYFPC homodimers can be seen following four minute
dissociation in the presence of unlabelled ligands (Figure 7.13). YFP
fluorescence was measured at the same time as BY-CGP fluorescence to
ĐŽŶĨŝƌŵƚŚĞĨŽƌŵĂƚŝŽŶŽĨɴ1-adrenoceptor homodimers (Figure 7.13). In cells
ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC homodimers, the dissociation rate of 3 nM
BODIPY-TMR-CGP was increased in the presence of 1 µM CGP 12177 (koff
0.169 ± 0.010 min-1, n=6) and 1 µM propranolol (koff 0.144 ± 0.009 min
-1, n=5,
P < 0.05, two-way ANOVA followed by Bonferronis post hoc test; Figure 7.14;
Table 7.1). Although the BY-CGP dissociation rate in the presence of 1 µM
ƉƌŽƉƌĂŶŽůŽů ĂƉƉĞĂƌĞĚ ƐůŽǁĞƌ ƚŚĂŶ ƚŚĂƚ ĚĞƚĞƌŵŝŶĞĚ ŝŶ ,K ?ɴ1-CS cells and
ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ǁŝůĚ ?ƚǇƉĞ ɴ1YFPN ?ɴ1YFPC homodimers (Table 7.1), the
differences were not statistically significant (P < 0.05, two-way ANOVA
followed by Bonferronis post hoc test). Interestingly, the difference in the 3
nM BODIPY-TMR-CGP dissociation rate in the presence of unlabelled ligands
compared to in the absence of unlabelled ligands was 3-fold in cells
ĞǆƉƌĞƐƐŝŶŐ ĐŽŶƐƚƌĂŝŶĞĚ ǁŝůĚ ?ƚǇƉĞ ?ŵƵƚĂŶƚ ɴ1AR homodimers
 ?ɴ1YFPN ?ɴ1D138AYFPC ? ?ǁŚŝĐŚǁĂƐĐŽŵƉĂƌĂďůĞƚŽƚŚĞĚŝĨĨĞƌĞŶĐĞƐĞĞŶŝŶ,K ?ɴ1-
CS cells (2-fold; Chapter 6, Table 6.4).
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Figure 7.13 Binding of 3 nM BY-CGP to CHO-K1 cells transiently expressing
ɴ1YFPN ?ɴ1D138AYFPC homodimers constrained by BiFC. Confocal images following 4
min BY-CGP association and a further 4 minutes of dissociation in the absence
(infinite dilution) and presence of either 1 µM CGP 12177 or 1 µM propranolol. The
ĨůƵŽƌĞƐĐĞŶĐĞ ŽĨ z&W ?ƚĂŐŐĞĚ ɴ1-adrenoceptor homodimers was measured
simultaneously. Images are representative of 5-6 separate perfusion slides imaged
on three separate experimental days. Scale bar = 50 µm.
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Figure 7.14 Dissociation of 3 nM BY-CGP from CHO-K1 cells transiently expressing A,
ɴ1-YFPN ?ɴ1-YFPC and B ?ɴ1-YFPN ?ɴ1D138A-YFPC in the absence and presence of 1 µM CGP
12177 and 1 µM propranolol. Data are mean ± s.e.m. of data obtained from 5-6
separate perfusion slides imaged on three separate experimental days. For each
perfusion slide, regions of interest were drawn around the membranes of 10
individual cells.
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Table 7.1 Summary of dissociation rates of 3 nM BY-CGP in the absence and presence of 1 µM CGP 12177 and 1 µM propranolol determined in CHO-CS cells
ƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐƚŚĞŶĂƚŝǀĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŶĚ ŝŶ,K ?< ?ĐĞůůƐƚƌĂŶƐŝĞŶƚůǇĐŽ ?ƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚƚŚĞɴ1YFPNĂŶĚɴ1-YFPC ĐŽŶƐƚƌƵĐƚƐĂŶĚƚŚĞɴ1-YFPN and
ɴ1D138A-YFPC constructs. 1,K ?ɴ1-CS data was determined in Chapter 6. Data are mean ± s.e.m. of (n) separate perfusion slide preparations. *statistical
significance (P < 0.05) of values compared to the value determined aunder control conditions (infinite dilution) and bin the presence of 1 µM propranolol within each set of
ɴ1ZŚŽŵŽĚŝŵĞƌƐ  ?ƚƌĂŶƐŝĞŶƚƐ ŝŶ,K ?ɴ ? ?^ĐĞůůƐ ?ĐŽŶƐƚƌĂŝŶĞĚǁŝůĚ ?ƚǇƉĞɴ1YFPN ?ɴ1YFPC ĂŶĚĐŽŶƐƚƌĂŝŶĞĚǁŝůĚ ?ƚǇƉĞ ?ŵƵƚĂŶƚɴ1YFPN ?ɴ1D138AYFPChomodimers) as determined
by two-way ANOVA analysis followed by Bonferronis post hoc test; ൱statistical significance (P < 0.05) of values compared to the equivalent value determined in c,K ?ɴ1-CS
cells and dɴ1YFPN ?ɴ1YFPC co-transfected CHO-K1 cells according to two-way ANOVA analysis followed by Bonferronis post hoc test.
CHO-ɴ1-CS cells1 ɴ1YFPN ?ɴ1YFPC ɴ1YFPN ?ɴ1D138AYFPC
koff (min
-1
) n koff (min
-1
) n koff (min
-1
) n
infinite dilution 0.092 ± 0.008 9 0.019 ± 0.006൱a 4 0.054 ± 0.011 5
+ 1 µM CGP 12177 0.202 ± 0.024*a 7 0.186 ± 0.008*a 6 0.169 ± 0.010*a 6
+ 1 µM propranolol 0.194 ± 0.010*a 6 0.189 ± 0.007*a 6 0.144 ± 0.009*a 5
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&ƵŶĐƚŝŽŶĂů ƌĞƐƉŽŶƐĞ ŽĨ ĐŽŶƐƚƌĂŝŶĞĚ ɴ1Z ŚŽŵŽĚŝŵĞƌƐ ƚŽ ɴ ?
adrenoceptor agonists
Following the kinetic binding studies, we aimed to investigate whether
ĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ɴ1-adrenoceptors played a role in the functional responses
ŵĞĚŝĂƚĞĚďǇ ƚŚĞ ƌĞĐĞƉƚŽƌ ? &Žƌ ƚŚŝƐ ? Ă ƐƚĂďůĞ ĐůŽŶĂů ,K ?ɴ1YFPN cell line was
ŐĞŶĞƌĂƚĞĚ ĂŶĚ ƐƵďƐĞƋƵĞŶƚůǇ ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ĞŝƚŚĞƌ ƚŚĞ ɴ1YFPC or the
ɴ1D138AYFPC construct to generate two further stable cell lines: CHO-
ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC. Studies investigating the
oligomerisation state of receptors at the single molecule level demonstrated
ƚŚĂƚ ɴ1-adrenoceptors form transient homodimers (Calebiro et al., 2013). In
ƚŚĞ,K ?ɴ1YFPN ?ɴ1YFPCĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell lines, YFPN- and YFPC-
ƚĂŐŐĞĚɴ1-adrenoceptors that spontaneously formed dimers, were trapped in
stable conformations as a result of the irreversibility of the reconstitution of
the full length YFP from YFPN and YFPC fragments that were brought into close
ƉƌŽǆŝŵŝƚǇƚŚƌŽƵŐŚƐƉĞĐŝĨŝĐŝŶƚĞƌĂĐƚŝŽŶƐďĞƚǁĞĞŶɴ1-adrenoceptors. Whilst we
ĐŽƵůĚ ŶŽƚ ĚŝƌĞĐƚůǇ ĚĞƚĞƌŵŝŶĞ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ ŽĨ ɴ1YFPN ? ɴ1YFPC and
ɴ1D138AYFPC ŝŶ ƚŚĞ ,K ?ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell lines,
ĂŶĚƚŚĞƉĞƌĐĞŶƚĂŐĞŽĨz&WĨƌĂŐŵĞŶƚ ?ƚĂŐŐĞĚɴ1-adrenoceptors that dimerised,
ǁĞ ĂŝŵĞĚƚŽ ŝŶĐƌĞĂƐĞ ƚŚĞ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1AR dimers in these two cell lines
through BiFC. Using this approach, we detected changes in BY-CGP
dissociation rates, and we hypothesised that it may also highlight altered
ɴ1AR pharmacology in a functional assay.
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'W ? ? ? ? ?ŚĂƐďĞĞŶĚĞƐĐƌŝďĞĚƚŽĂŶƚĂŐŽŶŝƐĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŐŽŶŝƐƚĂĐƚŝŽŶƐ
ĂƚƚŚĞĐĂƚĞĐŚŽůĂŵŝŶĞƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor, as well as exerting agonist
ĂĐƚŝŽŶƐ ŽĨ ŝƚƐ ŽǁŶ ƚŚƌŽƵŐŚ Ă ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site at higher
concentrations (Pak et al., 1996). To examine both the antagonist and agonist
properties of CGP 12177, concentration-response curves of CGP 12177 in the
absence and presence of 100 nM cimaterol were obtained in the [3H]cAMP
accumulation assay. 100 nM is the cimaterol EC80ĐŽŶĐĞŶƚƌĂƚŝŽŶŝŶ,K ?ɴ1-CS
cells (Chapter 3), and allows a robust enough assay window to detect
ŝŶŚŝďŝƚŝŽŶ ďǇ 'W  ? ? ? ? ? ŝŶ ,K ?ɴ1-CS cells. Functional responses were
ŵĞĂƐƵƌĞĚ ŝŶ ,K ?ɴ1 ?^ ĂŶĚ ,K ?ɴ1YFPN cells to examine whether the
responses mediated by the YFPN ?ƚĂŐŐĞĚ ɴ1AR were comparable to those of
ƚŚĞƵŶƚĂŐŐĞĚƌĞĐĞƉƚŽƌ ?/ŶďŽƚŚĐĞůů ůŝŶĞƐ ?ɴ1-adrenoceptor homodimers were
transient (i.e. not constrained), and the CGP 12177 pharmacology was similar
in these two cell lines (Figure 7.15). CGP 12177 (10-11  10-8 M) inhibited 100
nM cimaterol-stimulated [3, ?ĐDW ĂĐĐƵŵƵůĂƚŝŽŶ ŝŶ ,K ?ɴ1-CS and CHO-
ɴ1YFPN cells with pIC50 values of 8.56 ± 0.05 (n=3) and 8.47 ± 0.09 (n=3),
respectively. At higher concentrations CGP 12177 caused a [3H]cAMP
accumulation that was partial compared to the response of 100 nM cimaterol
alone, in both cell lines (Table 7.2; Figure 7.15). Furthermore, the CGP 12177
EC50 values were similar in the presence or absence of 100 nM cimaterol
 ?dĂďůĞ  ? ? ? ? &ŝŐƵƌĞ  ? ? ? ? ? ŝŶ ,K ?ɴ1-CS (P > 0.05, unpaired t-test) and CHO-
ɴ1YFPN cells (P > 0.05, unpaired t-test). Although these data are preliminary
and the affinity of CGP 12177 at the catecholamine site was not further
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investigated, these data suggest that the YFPN-tag did not affect the CGP
 ? ? ? ? ?ƉŚĂƌŵĂĐŽůŽŐǇĂƚƚŚĞɴ1-adrenoceptor.
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Figure 7.15 CGP 12177 concentration-response curves in the absence and presence
of 100 nM cimaterol on A ?,K ?ɴ1-CS and B ?,K ?ɴ1YFPN cells determined in a total
[3H]cAMP accumulation assay. Bar graphs show basal level of total [3H]cAMP
accumulation in unstimulated cells and [3H]cAMP accumulation following stimulation
with 100 nM cimaterol. Bar graph and 0.01 nM (10 -11M) CGP 12177 data are mean ±
range of error of duplicate determinations, whereas all other data are mean ± s.e.m.
of triplicate determinations from one single experiment which is representative of a
total of three separate experiments.
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Table 7.2 'W ? ? ? ? ?ƐƚŝŵƵůĂƚŽƌǇĂŶĚŝŶŚŝďŝƚŽƌǇƉĂƌĂŵĞƚĞƌƐĚĞƚĞƌŵŝŶĞĚŝŶ,K ?ɴ1-CS
ĂŶĚ ,K ?ɴ1YFPN clonal cell lines in the total [3H]cAMP accumulation assay in the
absence and presence of 100 nM cimaterol. The pIC50 values represent the inhibition
of 100 nM cimaterol by 10 nM CGP 12177.
  ,K ?ɴ1 ?^ ,K ?ɴ1YFPN n
absence of 100 nM cimaterol
pEC50 7.27 ± 0.12 7.31 ± 0.08 3
EMAX (% of 100 nM cimaterol) 55.5 ± 10.7 60.7 ± 11.0 3
presence of 100 nM cimaterol
pEC50 7.24 ± 0.04 7.42 ± 0.07 3
EMAX (% of 100 nM cimaterol) 55.9 ± 10.6 61.0 ± 11.1 3
pIC50 8.56 ± 0.05 8.47 ± 0.09 3
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Following this, we obtained preliminary data in the [3H]cAMP accumulation
ĂƐƐĂǇƵƐŝŶŐ,K ?ɴ1YFPN ?ɴ1YFPCĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPCĐĞůůƐ ?ŝŶǁŚŝĐŚɴ1-
adrenoceptors that formed homodimers were constrained through
irreversible reconstitution of the full length YFP from the two YFP fragments
(YFPN and YFPC ? ĨƵƐĞĚ ƚŽ ƚŚĞ ?ƚĞƌŵŝŶƵƐŽĨɴ1-adrenoceptors. Both cell lines
ǁĞƌĞŐĞŶĞƌĂƚĞĚĨƌŽŵƚŚĞƐĂŵĞĐůŽŶĂů,K ?ɴ1YFPN cell line, suggesting similar
expression levels of the YFPN ?ƚĂŐŐĞĚ ɴ1-adrenoceptor in these cell lines.
However, we did not investigate the expression levels of YFPC ?ƚĂŐŐĞĚ ɴ1AR
ĂŶĚ ɴ1D138AAR. In the [3H]cAMP accumulation assay, the antagonist and
agonist properties of CGP 12177 were retained in both cell lines. The obtained
data revealed a reduced EMAX ŝŶ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells compared to
,K ?ɴ1YFPN ?ɴ1YFPC cells, whilst the CGP 12177 EC50 and IC50 values derived
from the CGP 12177 concentration-response curves in the absence and
presence of 100 nM cimaterol, respectively, were comparable between the
two cell lines (Figure 7.16, Table 7.3). An increased agonist response may be
due to increased receptor expression which can lead to a partial agonist
response becoming a full(er) agonist response without affecting the EC50 of
that agonist response. To investigate potential differences in levels of
receptor expression in these two cell lines, cimaterol concentration-response
ĐƵƌǀĞƐǁĞƌĞŽďƚĂŝŶĞĚŝŶ,K ?ɴ1YFPN ?ɴ1YFPCĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells
ĂŶĚ ĐŽŵƉĂƌĞĚ ƚŽ ƚŚĞ ĐŝŵĂƚĞƌŽů ƌĞƐƉŽŶƐĞ ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1-CS and CHO-
ɴ1YFPN cells (Figure 7.17). The concentration-response curve of a full agonist
will be left-shifted in a system with a greater receptor reserve (i.e. greater
receptor expression) which is reflected in a lower EC50 value. However, the
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EC50 values derived for cimaterol were similar in all four cell lines (P > 0.05,
one-way ANOVA analysis followed by Tukeys post hoc test). This may suggest
ƐŝŵŝůĂƌ ůĞǀĞůƐ ŽĨ ɴ1-adrenoceptor expression in all cell lines, but it is
noteworthy that we do not know what percentage of receptors dimerised in
the different cell lines and what potential effect these dimers may have had
on the functional responses measured. Interestingly, upon closer inspection
ŽĨ ƚŚĞ 'W  ? ? ? ? ? ĚĂƚĂ ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN-
ɴ1D138AYFPC cells, the response to 10 µM CGP 12177 (EMAX) was greater than
that to 100 nM cimaterol in the first experiment, but smaller in subsequent
experiments (Table 7.3). These data were obtained in cells of increasing
ƉĂƐƐĂŐĞƐ  ?W ? ? ? ? ĂŶĚ ŵĂǇ ƐƵŐŐĞƐƚ ƚŚĂƚ ƚŚĞ ĞǆƉƌĞƐƐŝŽŶ Ĩ ɴ1YFPC and
ɴ1D138AYFPC was lost over time in their respective cell lines. Both cell lines
ǁĞƌĞ ŐĞŶĞƌĂƚĞĚ ĨƌŽŵ ƚŚĞ ƐĂŵĞ ɴ1YFPN ĐĞůů ůŝŶĞ ? ƚŚƵƐ Ă ůŽƐƐ ŽĨ ɴ1YFPC and
ɴ1D138AYFPC expression over time may be one explanation for the similar
cimaterol EC50ǀĂůƵĞƐĚĞƚĞƌŵŝŶĞĚŝŶ,K ?ɴ1YFPN ?,K ?ɴ1YFPN ?ɴ1YFPC (P5) and
,K ?ɴ1YFPN ?ɴ1D138AYFPC (P5) cell lines.
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Figure 7.16 CGP 12177 concentration-response curves in the absence and presence
of 100 nM cimaterol on A ?,K ?ɴ1YFPN ?ɴ1YFPC (P4) and B ?,K ?ɴ1YFPN ?ɴ1D138AYFPC (P4)
cells determined in a total [3H]cAMP accumulation assay. Bar graphs show basal level
of total [3H]cAMP accumulation in unstimulated cells and [3H]cAMP accumulation
following stimulation with 100 nM cimaterol. Bar graph and 0.01 nM (log M -11) CGP
12177 data are mean ± range of error of duplicate determinations, whereas all other
data are mean ± s.e.m. of triplicate determinations from one single experiment
which is representative of a total of three separate experiments.
B
A
[CGP 12177] Log (M)
[3 H
]c
A
M
P
a
c
c
u
m
u
la
tio
n
(d
pm
)
0
2000
4000
6000
8000
-11 -10 -9 -8 -7 -6 -5
basal
100 nM cimaterol
CGP 12177
CGP 12177 + 100 nM cimaterol
[CGP 12177] Log (M)
[3 H
]c
A
M
P
a
c
c
u
m
u
la
tio
n
(d
pm
)
0
1000
2000
3000
4000
5000
-11 -10 -9 -8 -7 -6 -5
Table 7.3 ^ƵŵŵĂƌǇ ŽĨ 'W  ? ? ? ? ? ĂŶƚĂŐŽŶŝƐƚ ĂŶĚ ĂŐŽŶŝƐƚ ƉƌŽƉĞƌƚŝĞƐ ĚĞƚĞƌŵŝŶĞĚ ŝŶ ƐƚĂďůĞ ,K ?ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell lines (at
passages 2, 3 and 4).
pIC50 pEC50 EMAX (% of 100 nM cimaterol) n
CHO-ɴ1YFPN-ɴ1YFPC 8.14; 8.51; 8.44 7.46; 7.75; 7.58 224.7; 83.6; 72.2 3
CHO-ɴ1YFPN-ɴ1D138AYFPC 7.98; 8.77; 8.52 7.49; 7.75; 7.70 205.4; 62.4; 52.2 3
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Figure 7.17 Cimaterol concentration-response curves on A ? ,K ?ɴ1-CS, B, CHO-
ɴ1YFPN, C ? ,K ?ɴ1YFPN ?ɴ1YFPC (P5) and D ? ,K ?ɴ1YFPN ?ɴ1D138AYFPC (P5) cells
determined in a total [3H]cAMP accumulation assay. Bar graphs show basal level of
total [3H]cAMP accumulation of unstimulated cells and total [3H]cAMP accumulation
level following stimulation with 10 µM CGP 12177. Data are mean ± s.e.m. of
triplicate determinations from a single experiment which is representative of two
additional separate experiments.
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dŽĨƵƌƚŚĞƌŝŶǀĞƐƚŝŐĂƚĞƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐŝŶƚŚĞ,K ?ɴ1YFPN,
,K ?ɴ1YFPN ?ɴ1YFPC  ?W ? ? ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells (P5), the
fluorescence of reconstituted YFP and of 20 nM BY-CGP binding to cell surface
ɴ1-adrenoceptors was determined using confocal microscopy (Figure 7.18). As
ĞǆƉĞĐƚĞĚ ?ŶŽz&WĨůƵŽƌĞƐĐĞŶĐĞǁĂƐĚĞƚĞĐƚĞĚŝŶ,K ?ɴ1YFPN cells. Interestingly,
ǁĞĂůƐŽƐĂǁŶŽz&WĨůƵŽƌĞƐĐĞŶĐĞŝŶ,K ?ɴ1YFPN ?ɴ1YFPC cells and only one cell
ŽĨƚŚĞ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell line was found to exhibit YFP fluorescence
ŽŶƚŚĞ ĐĞůů ŵĞŵďƌĂŶĞƚŽ ŝŶĚŝĐĂƚĞ ƚŚĂƚ ɴ1YFPN ?ɴ1D138AYFPC homodimerisation
and YFP reconstitution had taken place. In contrast, good membrane labelling
of 20 nM BY-CGP was seen in all three cell lines (Figure 7.18). This suggests
ƚŚĂƚ ƚŚĞ ŶƵŵďĞƌƐ ĞǆƉƌĞƐƐĞĚ ŽĨ ɴ1YFPC ĂŶĚ ɴ1D138AYFPC were insufficient to
ĨŽƌŵ ɴ1AR homodimers (yellow pixels in merged image in Figure 7.18), and
ƚŚĂƚ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ  ? ? ŶD z ?'W ŽĐĐƵƌƌĞĚ ƉƌĞĚŽŵŝŶĂƚůǇ ƚŽ ɴ1YFPN
ŵŽŶŽŵĞƌƐ ? dŚĞ ďŝŶĚŝŶŐ ŽĨ z ?'W ƚŽ ,K ?ɴ1YFPN cells also highlighted the
ŚĞƚĞƌŽŐĞŶĞŝƚǇŽĨɴ1YFPN expression in this cell line as some cells appeared to
ĞǆƉƌĞƐƐ ɴ1YFPN not at all or at levels too low to detect BY-CGP binding, and
thus may also be too low to detect any BiFC YFP fluorescence. It is unlikely
that the lack of YFP fluorescence is due to impaired YFP reconstitution upon
ɴ1AR homodimerisation based on the data we have already shown in this
chapter, although previous binding and imaging data were collected in
transient cells and not stable cell lines. Unfortunately, earlier passages (P2) of
the stable cell lines were not imaged to demonstrate initial YFP fluorescence
ĂƐĂƌĞƐƵůƚŽĨz&WƌĞĐŽŶƐƚŝƚƵƚŝŽŶƵƉŽŶɴ1AR homodimerisation in these cells.
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Figure 7.18 WŚĂƐĞ ĂŶĚ ĨůƵŽƌĞƐĐĞŶƚ ĐŽŶĨŽĐĂů ŝŵĂŐĞƐ ŽĨ ,K ?ɴ1YFPN ? ,K ?ɴ1YFPN-
ɴ1YFPC ?W ? ?ĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPC (P5) cells. The fluorescence of reconstituted
YFP was measured using 488 nm excitation and the fluorescence of 20 nM BY-CGP
binding to the cells was measured using 543 nm excitation. The merged images show
 ? ? ŶD z ?'W ďŝŶĚŝŶŐ ƚŽ ƌĞĐŽŶƐƚŝƚƵƚĞĚ z&W  ?ŝ ?Ğ ? ĐŽŶƐƚƌĂŝ ĞĚ ɴ1AR homodimers) in
ǇĞůůŽǁ ƉŝǆĞůƐ ĂŶĚ ƚŽ ɴ1Z ŵŽŶŽŵĞƌƐ  ?ɴ1YFPN Žƌ ɴ1YFPC ? Žƌ ƵŶĐŽŶƐƚƌĂŝŶĞĚ ɴ1AR
ŚŽŵŽĚŝŵĞƌƐ ?ɴ1YFPN ?ɴ1YFPNŽƌɴ1YFPC ?ɴ1YFPC) in red pixels. Scale bar = 50 µm.
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Previous imaging data shown in this chapter suggested good efficiency of
ƚƌĂŶƐŝĞŶƚ ƚƌĂŶƐĨĞĐƚŝŽŶ ŽĨ z&W ĨƌĂŐŵĞŶƚ ?ƚĂŐŐĞĚ ɴ1-adrenoceptor in CHO cells.
Thus, we transiently transfected the YFPC ?ƚĂŐŐĞĚ ɴ1Z ĂŶĚ ɴ1D138AAR
ĐŽŶƐƚƌƵĐƚƐ ŝŶƚŽ ƚŚĞ ĐůŽŶĂů ,K ?ɴ1YFPN cell line. We were not able to
determine receptor expression levels, but we aimed to ensure comparable
ůĞǀĞůƐŽĨɴ1YFPNďǇƵƐŝŶŐƚŚĞ,K ?ɴ1YFPN cell line to transfect into. We then
examined the cimaterol response in these cells in the total [3H]cAMP
accumulation assay (Figure 7.19). The pEC50 of cimaterol was 7.66 ± 0.21 (n=3)
ŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐƚǁŽǁŝůĚ ?ƚǇƉĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌĐŽŶƐƚƌƵĐƚƐ ?ɴ1YFPN ?ɴ1YFPC),
which was not significantly different to the value derived in cells expressing
ŽŶĞŶĂƚŝǀĞĂŶĚŽŶĞŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐƌĞĐĞƉƚŽƌŵƵƚĂŶƚ  ?ɴ1YFPN ?ɴ1D138AYFPC;
pEC50  ? ? ? ? A?  ? ? ? ? ? ŶA? ? ? ĂŶĚ ƵŶƚƌĂŶƐĨĞĐƚĞĚ ,K ?ɴ1YFPN cells (P < 0.05, one-
way ANOVA followed by Bonferronis post hoc test). The maximum CGP
12177 response (EMAX ?ǁĂƐĚĞƚĞƌŵŝŶĞĚ ŝŶ,K ?ɴ1YFPN cells transfected with
ǁŝůĚ ?ƚǇƉĞ ɴ1YFPC ĂŶĚ ŵƵƚĂŶƚ ɴ1D138AYFPC receptor constructs by measuring
the [3H]cAMP accumulation in response to 10 µM CGP 12177 and comparing
it to the response measured to 10 µM cimaterol in the same cells (Table 7.4).
The derived EMAX ǀĂůƵĞƐ ĨŽƌ 'W  ? ? ? ? ? ǁĞƌĞ ƐŝŵŝůĂƌ ŝŶ ,K ?ɴ1YFPN cells
ƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚɴ1YFPCĂŶĚɴ1D138AYFPC (P > 0.05, one-way ANOVA followed
by Bonferronis post hoc test). These preliminary data may suggest that the
maximum response elicited by CGP 12177 is unaffected by the presence of a
ŶŽŶ ?ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƉƌŽƚŽŵĞƌ ŝŶ ɴ1AR homodimers. However, CGP 12177
concentration response curves would have to be obtained to determine
potential effects on its potency, and more importantly the receptor
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expression levels would have to be monitored in conjunction with these
functional studies. Using fluorescently labelled tags, for example, would allow
the detection of each receptor promoter. In conjunction with this, the
receptor population that form dimers may be measured by BiFC
homodimerisation to provide an insight into the percentage of dimers of the
overall receptor population in a given cell system. Only then could any
ŽďƐĞƌǀĞĚ ĨƵŶĐƚŝŽŶĂů ĐŚĂŶŐĞƐ  ?Žƌ ůĂĐŬ ŽĨ ŝƚ ? ďĞ ĂƚƚƌŝďƵƚĞĚ ƚŽ ɴ1-adrenoceptor
homodimerisation.
373
Figure 7.19 Normalised cimaterol concentration-response curves on CHO-K1 cells
ƚƌĂŶƐŝĞŶƚůǇĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1YFPN ?ɴ1YFPCĂŶĚɴ1YFPN ?ɴ1D138AYFPC constructs. Data
are mean ± s.e.m. of three separate experiments in which each data point was
determined in triplicates.
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Table 7.4dŚĞĨƵŶĐƚŝŽŶĂůƌĞƐƉŽŶƐĞƐŽĨĐŝŵĂƚĞƌŽůĂŶĚ'W ? ? ? ? ŽŶƚŚĞƵŶƚĂŐŐĞĚŶĂƚŝǀĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐƚĂďůǇĞǆƉƌĞƐƐĞĚŝŶ,K ?^ĐĞůůƐ ?ɴ1) and the YFPN-
ƚĂŐŐĞĚŶĂƚŝǀĞɴ1ZŝŶƚŚĞĂďƐĞŶĐĞ ?ɴ1YFPN) and presence of YFPC ?ƚĂŐŐĞĚŶĂƚŝǀĞ ?ɴ1YFPN ?ɴ1YFPC ?ĂŶĚŵƵƚĂŶƚɴ1D138AZ ?ɴ1YFPN ?ɴ1D138AYFPC ) stably expressed
in CHO-K1 cells were tested in the [3H]cAMP accumulation assay. *statistical significance (PAM ? ? ? ? ?ĨƌŽŵǀĂůƵĞĚĞƚĞƌŵŝŶĞĚĨŽƌƐƚĂďůǇĞǆƉƌĞƐƐĞĚɴ1YFPN as determined
by one-way ANOVA followed by Bonferronis post hoc test
cimaterol 10 µM CGP 12177
pEC50 n EMAX (% 10 µM cimaterol) n
stable expression
ɴ1 7.24 ± 0.16 3 35.7 ± 2.8 3
ɴ1YFPN 7.16 ± 0.14 3 34.0 ± 0.3 3
ɴ1YFPN ?ɴ1YFPC 7.25 ± 0.10 3 36.3 ± 1.3 3
ɴ1YFPN ?ɴ1D138AYFPC 7.33 ± 0.06 3 38.7 ± 0.7 3
transient expression
ɴ1YFPN ?ɴ1YFPC 7.66 ± 0.21 3 46.4 ± 3.2 3
ɴ1YFPN ?ɴ1D138AYFPC 7.28 ± 0.05 3 47.5 ± 3.5* 3
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7.4 Discussion
/ŶƚŚŝƐĐŚĂƉƚĞƌ ?ǁĞĂŝŵĞĚƚŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞƌŽůĞɴ1AR homodimerisation may
ƉůĂǇ ŝŶ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ŝŶƚĞƌĂĐƚŝŽŶƐ ĚĞĨŝŶĞĚ ĨŽƌ ƚŚĞ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌ ? ,ŽŵŽĚŝŵĞƌƐ ŽĨ ɴ1-adrenoceptors have been reported to be
transient (Calebiro et al., 2013; Dorsch et al., 2009) with dimeric interactions
reported to last circa four seconds (Calebiro et al., 2013). The short-lived
ŶĂƚƵƌĞ ŽĨ ɴ1AR homodimer interactions poses a major challenge in the
ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ Ă ƉŽƚĞŶƚŝĂů ƌŽůĞ ŽĨ ɴ1-adrenoceptor homodimerisation in
ƌĞĐĞƉƚŽƌ ĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇ ĂŶĚ ĨƵŶĐƚŝŽŶ ? ŶǇ ƉŚĂƌŵĂĐŽůŐŝĐĂů ĞĨĨĞĐƚ ŽĨ ɴ1AR
homodimerisation will be equally short-lived and thus difficult to detect.
However, bimolecular fluorescence complementation (BiFC) traps dimers that
have formed without affecting the rate of dimer formation (Hu et al., 2003a).
BiFC allows the detection of dimeric and/or higher order oligomeric receptor
complexes (Vidi et al., 2010) by measuring the reconstitution of two halves of
a fluorescent protein that were each attached to one receptor protomer
(Rose et al., 2010). The reconstitution of the fluorescent protein upon
receptor dimerisation is an irreversible reaction, thus trapping (or
constraining) formed dimers, but making it impossible to study the dynamics
of receptor oligomerisation using this technique. Here, we used the
ŝƌƌĞǀĞƌƐŝďŝůŝƚǇ ŽĨ ŝ& ƚŽŽƵƌ ĂĚǀĂŶƚĂŐĞ ? ůŽĐŬŝŶŐɴ1-adrenoceptors into stable
dimeric complexes to allow us to investigate ligand-receptor interactions at
the dimeric complex. Throughout this thesis, we have used CHO-CS cells
ĞǆƉƌĞƐƐŝŶŐ ǁŝůĚ ?ƚǇƉĞ ŚƵŵĂŶ ɴ1-adrenoceptors that form transient
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homodimers according to Dorsch et al. (2009) and Calebiro et al. (2013). If
ɴ1AR homodimers play a role in the ligand-binding interactions defined in this
ĐĞůů ůŝŶĞ ? ǁĞ ĞŶǀŝƐŝŽŶĞĚ ƚŽ ŚŝŐŚůŝŐŚƚ ƚŚŝƐ ƌŽůĞ ŝŶĂ ƐǇƐƚĞŵ ǁŚĞƌĞ ɴ1AR
homodimers are constrained (i.e. stable) after they have spontaneously
formed. This BiFC-mediated prevention of dimer dissociation will therefore
ŝŶĐƌĞĂƐĞ ƚŚĞ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1AR homodimers of the overall receptor
ƉŽƉƵůĂƚŝŽŶ ? ƚŚƵƐ ŝŶĐƌĞĂƐŝŶŐ ĂŶǇ ĚŝŵĞƌ ?ŵĞĚŝĂƚĞĚ ĞĨĨĞĐƚƐ ŽŶ ƚŚĞ ɴ1AR
pharmacology. Indeed, the dissociation rate of BODIPY-TMR-CGP was
enhanced 12-fold in the presence of 1 µM CGP 12177 and 1 µM propranolol
compared to the dissociation rate of the fluorescent ligand in the absence of
an unlabelled ligand in CHO-K1 cells that were transiently expressed with
ɴ1YFPNĂŶĚɴ1YFPC (i.e. stable constrained homodimers). In contrast, only a 3-
ĨŽůĚ ĚŝĨĨĞƌĞŶĐĞ ŝŶ ĚŝƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞ ǁĂƐ ŽďƐĞƌǀĞĚ ŝŶ ,K ?ɴ1-CS cells (i.e.
unconstrained dimers). Thus, a greater enhancement of the BODIPY-TMR-CGP
dissociation rate was observed in cells expressing constrained dimers
compared to unconstrained dimers, suggesting that the allosteric effect of
unlabelled ligands on the dissociation rate of BODIPY-TMR-CGP is mediated
ĂĐƌŽƐƐĂɴ1AR homodimer interface. However, this enhanced difference in the
BY-CGP dissociation rate was mainly due to the change in the BY-CGP
dissociation rate in the absence of unlabelled ligand as it was significantly
ƐůŽǁĞĚŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1YFPC homodimers compared to transient
ĚŝŵĞƌƐ ŝŶ ,K ?ɴ1 ?^ ĐĞůůƐ ? dŚŝƐ ƐƵŐŐĞƐƚƐ ƚŚĂƚ ƚŚĞ ĨŽƌŵĂƚŝŽŶ ŽĨ ɴ1-
adrenoceptor dimers results in a conformational change that affects the
dissociation kinetics of BY-CGP at the catecholamine site to which 3 nM BY-
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CGP predominantly binds. This therefore indicates distinct BY-CGP
ĚŝƐƐŽĐŝĂƚŝŽŶŬŝŶĞƚŝĐƐĂƚɴ1-adrenoceptor dimers and monomers. Unfortunately,
we were not able to accurately determine the BY-CGP association rate, and
ƚŚĞz ?'WĂĨĨŝŶŝƚǇ ?ƚŽĐŽŶƐƚƌĂŝŶĞĚɴ1YFPN ?ɴ1YFPC homodimers. It is important
to note that we could not establish the percentage of dimers of the overall
receptor population. Furthermore, the kinetic parameters determined were
ĂůǁĂǇƐ Ă ĐŽŵďŝŶĂƚŝŽŶ ŽĨ ĐŽŶƐƚƌĂŝŶĞĚ ƌĞĐĞƉƚŽƌ ĚŝŵĞƌƐ  ?ɴ1YFPN ?ɴ1YFPC),
ƚƌĂŶƐŝĞŶƚ ƌĞĐĞƉƚŽƌ ĚŝŵĞƌƐ  ?ɴ1YFPN ?ɴ1YFPN ĂŶĚ ɴ1YFPC ?ɴ1YFPC) and receptor
ŵŽŶŽŵĞƌƐ  ?ɴ1YFPN ĂŶĚ ɴ1YFPC). Even though we used BiFC to specifically
detect constrained receptor dimers and only analysed cells that showed clear
membrane YFP fluorescence intensity, the fluorescent ligand will still have
bound to transient dimers and monomers also expressed on the surface of
the cells analysed. An analysis of membrane BY-CGP fluorescence intensities
following a co-localisation analysis (of YFP and BY-CGP fluorescence) may
have reduced influences by non-BiFC receptor populations.
Interestingly, the dissociation rates of BY-CGP in the presence of unlabelled
ůŝŐĂŶĚƐ ĚĞƚĞƌŵŝŶĞĚ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1YFPC homodimers and CHO-
ɴ1-CS cells (i.e. transient dimers) were comparable. We have already shown
that the BODIPY-TMR-CGP dissociation rate in the presence of CGP 12177 and
propranolol appeared to reach a plateau beyond which the dissociation rate
could not be enhanced any further (Chapter 4). Thus, the concentration of 1
µM CGP 12177 and 1 µM propranolol may represent too high concentrations
ĂƚďŽƚŚƚƌĂŶƐŝĞŶƚĚŝŵĞƌƐĂŶĚĐŽŶƐƚƌĂŝŶĞĚǁŝůĚ ?ƚǇƉĞĚŝŵĞƌƐ ?ɴ1YFPN ?ɴ1YFPC) to
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detect a difference between the two dimeric complexes. To investigate this
further, a range of CGP 12177 and propranolol concentrations would have to
be tested at the constrained homodimer complexes. The concentration at the
midpoint of the resulting concentration-response curve represents the KB ?ɲ ?
ǁŚĞƌĞ ɲ ŝƐ Ă ŵĞĂƐƵƌĞ ŽĨ ĐŽ ?ŽƉĞƌĂƚŝǀŝƚǇ ďĞƚǁĞĞŶ ƚŚĞƚǁŽ ďŝŶĚŝŶŐ ƐŝƚĞƐ ?
ŝĨĨĞƌĞŶĐĞƐ ŝŶ ɲ ŵĂǇ ƉŽŝŶƚ ƚŽ ƉŽƚĞŶƚŝĂů ĞĨĨĞĐƚƐ ŽĨ ĐŽŶƐƚƌĂŝŶŝŶŐ ɴ1-
adrenoceptors into stable homodimers.
To further test whether the effects of unlabelled ligands are mediated across
Ă ɴ1-adrenoceptor homodimer interface, we performed the same kinetic
ƉĞƌĨƵƐŝŽŶ ĞǆƉĞƌŝŵĞŶƚƐ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ĐŽŶƐƚƌĂŝŶĞĚ ɴ1-adrenoceptor
homodimers where one protomer contained a point mutation that abolished
ďŝŶĚŝŶŐ ŽĨ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ ƚŽďŽƚŚ ? ƚŚĞŚŝŐŚ  ?ƐŝƚĞ  ? ? ĂŶĚ ůŽǁ  ?ƐŝƚĞ  ? ?
ĂĨĨŝŶŝƚǇɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌďŝŶĚŝŶŐƐŝƚĞƐ ?ɴ1D138AYFPC). Indeed, the effect seen in
ĐŽŶƐƚƌĂŝŶĞĚ ǁŝůĚ ?ƚǇƉĞ ɴ1AR homodimers was reduced in wild-type/mutant
ɴ1Z ŚŽŵŽĚŝŵĞƌƐ  ?ɴ1YFPN ?ɴ1D138AYFPC) and reflected more closely the
ƉŚĂƌŵĂĐŽůŽŐǇ ŽďƐĞƌǀĞĚ ŝŶ ,K ?ɴ1-CS cells. Interestingly, the BY-CGP
ĚŝƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞ ĚĞƚĞƌŵŝŶĞĚ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC
ŚŽŵŽĚŝŵĞƌƐ ǁĂƐ ƐůŽǁĞƌ ƚŚĂŶ ƚŚĂƚ ŵĞĂƐƵƌĞĚ ŝŶ ,K ?ɴ1-CS cells, but faster
ƚŚĂŶ ƚŚĂƚ ŽďƚĂŝŶĞĚ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ǁŝůĚ ?ƚǇƉĞ ɴ1YFPN ?ɴ1YFPC homodimers.
This may point to an effect of the introduced mutation on the conformation
ŽĨƚŚĞɴ1AR dimeric complex that resulted in a different BY-CGP dissociation
rate. Alternatively, this intermediate dissociation rate may reflect that of a
different percentage of dimers of the overall receptor population. As
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described above, constraining dimers using BiFC is expected to increase the
ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1AR dimers by preventing dissociation of normally transient
ɴ1Z ĚŝŵĞƌƐ ? ,ŽǁĞǀĞƌ ? ƚŚĞ z&W ĨƌĂŐŵĞŶƚ ?ƚĂŐŐĞĚ ɴ1AR constructs were
transiently transfected into CHO-K1 cells prior to each experiment and the
transfection efficiency of the different constructs may not be comparable,
ƚŚƵƐ ƌĞƐƵůƚŝŶŐ ŝŶ ĚŝĨĨĞƌĞŶƚ ƉĞƌĐĞŶƚĂŐĞƐ ŽĨ ƚƌĂƉƉĞĚ ɴ1YFPN ?ɴ1YFPC and
ɴ1YFPN ?ɴ1D138AYFPC dimers. Therefore, a less reduced BY-CGP dissociation rate
ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC homodimers may be due to a lower
ƉĞƌĐĞŶƚĂŐĞ ŽĨ ƚŚĞƐĞ ĚŝŵĞƌƐ ĐŽŵƉĂƌĞĚ ƚŽ ǁŝůĚ ?ƚǇƉĞ ɴ1YFPN ?ɴ1YFPC dimers
expressed in CHO-K1 cells. Because 3 nM BY-CGP predominantly binds to the
ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ  ?ƐŝƚĞ  ? ? ŽĨ ƚŚĞ ɴ1-adrenoceptor, the introduced mutation
ĂďŽůŝƐŚŝŶŐ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ƐĞĐŽŶĚ ɴ1AR site (i.e. second protomer)
would not be expected to affect its dissociation rate, whereas a different
percentage of dimers would do precisely that, if the dissociation kinetics of
z ?'W Ăƚ ɴ1AR homodimers and monomers were markedly different. To
further investigate this hypothesis, it would be interesting to perform the
ƐĂŵĞŬŝŶĞƚŝĐĞǆƉĞƌŝŵĞŶƚƐŽŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐǁŝůĚ ?ƚǇƉĞɴ1-adrenoceptors that
cannot dimerise, for example, if key residues that formed part of the
structural dimer interface were mutated. Computational modelling and
mutagenesis studies performed on a variety of GPCRs provide new structural
insights into dimeric interfaces (Hu et al., 2012; Johnston et al., 2011; Wang et
al. ? ? ? ? ? ? ?ĂŶĚŵŽƐƚƌĞĐĞŶƚůǇƚŚĞĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞŽĨɴ1-adrenoceptor dimers
has been reported (Huang et al., 2013).
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It is worth noting that there are limitations to comparing the association and
dissociation kinetics of 3 nM BY-CGP determined in CHO-K1 cells transiently
transfected with YFPN/YFPC ?ƚĂŐŐĞĚɴ1-adrenoceptor constructs to stable CHO-
ɴ1-CS cells. Apart from the transient transfection, the cells expressing the BiFC
constructs undergo a 24 hour 30 °C incubation to allow the correct folding
ĂŶĚŵĂƚƵƌĂƚŝŽŶŽĨƚŚĞƌĞĐŽŶƐƚŝƚƵƚĞĚĨůƵŽƌĞƐĐĞŶƚƉƌŽƚĞŝŶ ?dŚĞƐƚĂďůĞ,K ?ɴ1-
CS cells were not treated the same way. Furthermore, the C-terminal
ĨůƵŽƌĞƐĐĞŶƚ ƉƌŽƚĞŝŶ ƚĂŐƐ ƵƐĞĚ ƚŽ ĂĐŚŝĞǀĞ ŝ& ŵĂǇ ĂĨĨĞĐƚ ɴ1-adrenoceptor
conformations in such a way that they affect allosteric interactions. Therefore,
future experiments investigating the differences of BY-CGP kinetics at
transient and constrained dimers should use transiently transfected YFP-
ƚĂŐŐĞĚɴ1-adrenoceptors as a control.
The presence of unlabelled ligands also had a reduced effect on the
ĚŝƐƐŽĐŝĂƚŝŽŶ ŽĨ  ? ŶD z ?'W ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC
ŚŽŵŽĚŝŵĞƌƐĐŽŵƉĂƌĞĚƚŽĐĞůůƐĞǆƉƌĞƐƐŝŶŐɴ1YFPN ?ɴ1YFPC homodimers. Again,
a lower percentage of constrained dimers may have resulted in a reduced
effect on the BY-CGP dissociation rate. Unfortunately, we do not know the
percentage of dimers expressed in CHO-K1 cells, and since different
percentages of dimers may influence the results as described above, it is
difficult to conclusively attribute changes in BY-CGP dissociation rates to a
ŵƵƚĂƚŝŽŶ ŝŶƚƌŽĚƵĐĞĚ ŝŶƚŽ ŽŶĞ ɴ1-adrenoceptor protomer. However, upon
close inspection of the BY-CGP dissociation rates in the presence of unlabelled
ůŝŐĂŶĚƐ ŝŶ Ăůů ƚŚƌĞĞ ĐĞůů ƐǇƐƚĞŵƐ  ?,K ?ɴ1-CS cells, CHO-K1 cells expressing
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ɴ1YFPN ?ɴ1YFPC ĂŶĚ ɴ1YFPN ?ɴ1D138AYFPC dimers), it becomes evident that the
BY-CGP dissociation rates in the presence of unlabelled ligands in cells
ĞǆƉƌĞƐƐŝŶŐƚŚĞǁŝůĚ ?ƚǇƉĞ ?ŵƵƚĂŶƚɴ1AR homodimers were even slower than in
,K ?ɴ1-CS cells, i.e. in cells where dimers were not constrained, but were
ƚƌĂŶƐŝĞŶƚ ?KŶĞĞǆƉůĂŶĂƚŝŽŶŽĨƚŚŝƐŵĂǇďĞƚŚĂƚƚŚĞɴ1YFPN ?ɴ1D138AYFPC dimers
detected by BiFC do not contribute to the enhanced BY-CGP dissociation rate,
ĂƐ ƚŚĞ ƵŶůĂďĞůůĞĚ ůŝŐĂŶĚ ĐĂŶŶŽƚ ďŝŶĚ ƚŽ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ƐŝƚĞ  ?ɴ1D138AYFPC
protomer) to cause an enhanced off rate of BY-CGP. Instead, the enhanced off
ƌĂƚĞ ŝƐ ĨĂĐŝůŝƚĂƚĞĚ ďǇ ƚƌĂŶƐŝĞŶƚ ĚŝŵĞƌƐ  ?ɴ1YFPN ?ɴ1YFPN). As mentioned above,
the trace of BY-CGP fluorescence was analysed for cells that showed clear YFP
fluorescence (i.e. BiFC), but these cells will also have expressed transient
ůŝŐĂŶĚďŝŶĚŝŶŐĚŝŵĞƌƐ ?ɴ1YFPN ?ɴ1YFPN ?ĂŶĚŵŽŶŽŵĞƌƐ ?ɴ1YFPN). The transient
ŶŽŶ ?ůŝŐĂŶĚ ďŝŶĚŝŶŐ ĚŝŵĞƌƐ  ?ɴ1D138AYFPC ?ɴ1D138AYFPC) and monomers
 ?ɴ1D138AYFPC) will not have been picked up by the fluorescent ligand either. If
ƚŚĞ z ?'W ĚŝƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞ ƐĞĞŶ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC
ŚŽŵŽĚŝŵĞƌƐ ǁĂƐ ĚƵĞ ƚŽ ƚƌĂŶƐŝĞŶƚ ɴ1YFPN ?ɴ1YFPN homodimers, one might
ĞǆƉĞĐƚ ĐŽŵƉĂƌĂďůĞ ŽĨĨ ƌĂƚĞƐ ƚŽ ƚŚŽƐĞ ƐĞĞŶ ŝŶ ,K ?ɴ1-CS cells. However, the
ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1YFPN monomers available to form transient dimers in cells
ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1D138AYFPC ĚŝŵĞƌƐ ǁŝůů ďĞ ƌĞĚƵĐĞĚ ĐŽŵƉĂƌĞĚ ƚŽ ɴ1AR
ŵŽŶŽŵĞƌƐ ĂǀĂŝůĂďůĞ ŝŶ ,K ?ɴ1-CS cells (unconstrained dimers). Since BiFC
traps transient dimers into stable dimers, thereby increasing the percentage
of dimers of the overall receptor population, it also effectively depletes ligand
ďŝŶĚŝŶŐ ɴ1YFPN monomers, thus reducing the percentage of monomers
available to form transient dimers, which results in a reduced effect of
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unlabelled ligands on the BY-CGP dissociation rate. This explanation suggests
ƚŚĂƚ ĂŶ ŝŶĐƌĞĂƐĞĚ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ɴ1D138AYFPC ƚŽ ɴ1YFPN co-transfected into
CHO-K1 would further reduce the effects of unlabelled ligands on the
dissociation rate of BY-CGP as increasing amounts of non-ligand binding
ɴ1D138AYFPC ǁŽƵůĚ ŝŶĐƌĞĂƐŝŶŐůǇ ƚƌĂƉ ŵŽƌĞ ĂŶĚ ŵŽƌĞ ɴ1YFPN into stable
homodimers to which unlabelled ligands cannot bind to enhance the BY-CGP
ŽĨĨ ƌĂƚĞ ? ĂŶĚ ůĞĂǀŝŶŐ ĨĞǁĞƌ ĂŶĚ ĨĞǁĞƌ ɴ1YFPN monomers available to form
transient dimers to cause any effects on the BY-CGP dissociation rate. A
similar observation of reduced effects of unlabelled ligands on the
dissociation rate of a fluorescent ligand in the presence of increasing amounts
of a non-ligand binding receptor was made for A3 homodimers (May et al.,
2011). It is also noteworthy that 1 µM CGP 12177 enhanced the BY-CGP
dissociation rate to a greater extent than 1 µM propranolol in cells expressing
ɴ1YFPN ?ɴ1D138AYFPC dimers. This is in line with previous data from this thesis
that determined a higher KB ?ɲ ?ĂĨĨŝŶŝƚǇŽĨĂůŝŐĂŶĚĨŽƌƚŚĞƐĞĐŽŶĚĂƌǇƐŝƚĞǁŝƚŚ
a ligand bound to the first site) for CGP 12177 than for propranolol (Chapter 6,
Table 6.4).
dŚĞ ŚǇƉŽƚŚĞƐŝƐ ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site is
ĨĂĐŝůŝƚĂƚĞĚďǇĂƐĞĐŽŶĚɴ1AR in a homodimer formation is also consistent with
the conclusion drawn by Baker et al. (2008) following a mutagenesis study to
ŝĚĞŶƚŝĨǇŬĞǇƌĞƐŝĚƵĞƐŽĨƐŝƚĞ ?ĂŶĚƐŝƚĞ ?ŽĨƚŚĞɴ1-adrenoceptor. The results of
ƚŚĂƚƐƚƵĚǇƐƵŐŐĞƐƚĞĚƚŚĂƚƚŚĞƚǁŽɴ1-adrenoceptor sites must be overlapping
as introduced single point mutations affected ligand binding to both sites
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equally (Baker et al., 2008). In the dimerisation model, the two sites do not
overlap, but instead they are the same binding site with the second
ŽƌƚŚŽƐƚĞƌŝĐƐŝƚĞďĞĐŽŵŝŶŐƚŚĞĂůůŽƐƚĞƌŝĐƐŝƚĞ ŝŶĂɴ1AR homodimer formation.
Furthermore, the kinetic data shown in this chapter do not suggest two
ƐĞƉĂƌĂƚĞďŝŶĚŝŶŐƐŝƚĞƐŝŶĂɴ1-adrenoceptor monomer. If this was the case, the
same effect of unlabelled ligands on the dissociation rate of the fluorescent
ligand would have been expected to be observed in dimers with a ligand
ďŝŶĚŝŶŐĂŶĚŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐƐĞĐŽŶĚɴ1-adrenoceptor protomer. However,
we observed a clear difference in the effect of unlabelled ligands on the
K/Wz ?dDZ ?'W ĚŝƐƐŽĐŝĂƚŝŽŶ ƌĂƚĞ ? ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ ƚŚĞ ĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ɴ1-
adrenoceptors plays an important role in the ligand-receptor interactions.
dŚĞďŝŶĚŝŶŐƐƚƵĚŝĞƐƐƚƌŽŶŐůǇƐƵŐŐĞƐƚĂƌŽůĞŽĨɴ1AR homodimers in the ligand-
ďŝŶĚŝŶŐ ŝŶƚĞƌĂĐƚŝŽŶƐ ŽĨ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ Ăƚ ƚŚŝƐ ƌĞĐĞƉƚŽƌ ? dŽ ĨƵƌƚŚĞƌ
ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƚŚĞƌ ŚŽŵŽĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ƚŚĞ ɴ1-adrenoceptor also plays a
ƌŽůĞ ŝŶ ƚŚĞ ĨƵŶĐƚŝŽŶĂů ƌĞƐƉŽŶƐĞƐ ŽďƐĞƌǀĞĚ ĨŽƌ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ ? ǁĞ
performed [3, ?ĐDW ĂĐĐƵŵƵůĂƚŝŽŶ ĞǆƉĞƌŝŵĞŶƚƐ ŝŶ ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN/
ɴ1YFPC ĐŽŶƐƚƌƵĐƚƐ ĂŶĚ ɴ1YFPN ?ɴ1D138AYFPC constructs. The co-expression of
YFPN- and YFPC ?ƚĂŐŐĞĚ ɴ1AR constructs allowed reconstitution of full length
YFP when the two halves of the YFP were brought into close proximity of one
ĂŶŽƚŚĞƌ ƚŚƌŽƵŐŚ ɴ1AR homodimerisation. The kinetic binding studies
highlighted that trapping dimers in stable conformations using BiFC caused a
detectable change in dissociation rate of the fluorescent analogue of CGP
12177. Thus, we examined whether effects on the functional response of the
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parent compound could be detected using the same approach (BiFC) in
conjunction with the [3H]cAMP accumulation assay.
First, we established that the YFPN-tag did not appear to affect the CGP 12177
ƉŚĂƌŵĂĐŽůŽŐǇĂƚƚŚĞɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ?ĂƐĞǆƉĞƌŝŵĞŶƚƐĐĂƌƌŝĞĚŽƵƚŝŶ,K ?ɴ1-
^ ĂŶĚ ,K ?ɴ1YFPN (stable clonal cell lines; unconstrained dimers) revealed
similar CGP 12177 agonist and antagonist effects. In both cell lines CGP 12177
was a partial agonist compared to cimaterol, consistent with previous CGP
12177 data reported throughout this thesis and reports in the literature
(Baker et al., 2003a; Joseph et al., 2004; Konkar et al., 2000; Pak et al., 1996).
tĞ ƚŚĞŶ ŐĞŶĞƌĂƚĞĚ ƐƚĂďůĞ ĐĞůů ůŝŶĞƐ ĞǆƉƌĞƐƐŝŶŐ ɴ1YFPN ?ɴ1YFPC and
ɴ1YFPN ?ɴ1D138AYFPCƌĞĐĞƉƚŽƌƐ ?tĞĚŝĚŶŽƚŝŶǀĞƐƚŝŐĂƚĞƚŚĞůĞǀĞůŽĨɴ1YFPN in the
ĐůŽŶĂůƐƚĂďůĞ,K ?ɴ1YFPN cell line, but using the same cell line to transfect the
YFPC ?ƚĂŐŐĞĚ ɴ1AR construct into, we attempted to ensure that the level of
ɴ1YFPNǁĂƐĐŽŵƉĂƌĂďůĞŝŶĂůůƚŚƌĞĞĐĞůůůŝŶĞƐ ?ƉĂƌĞŶƚ,K ?ɴ1YFPN cell line and
,K ?ɴ1YFPN ?ɴ1YFPCĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPC cell lines). CGP 12177 agonist
and antagonist data obtained in the absence and presence of 100 nM
ĐŝŵĂƚĞƌŽůƌĞǀĞĂůĞĚĂƌĞĚƵĐĞĚŵĂǆŝŵĂůƌĞƐƉŽŶƐĞŽĨ'W ? ? ? ? ?ŝŶ,K ?ɴ1YFPN-
ɴ1YFPCĐĞůůƐĐŽŵƉĂƌĞĚƚŽ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells. This may be explained
by different levels of receptor expression as submaximal responses are
caused by partial agonists that occupy all available receptors to elicit their
functional response. Thus, an increased receptor expression will result in an
increased response to that agonist. However, the first CGP 12177 set of data
ŽďƚĂŝŶĞĚ ŝŶ ,K ?ɴ1YFPN ?ɴ1YFPC ĂŶĚ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells revealed
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CGP 12177 responses greater than those caused by 100 nM cimaterol, which
ǁĂƐ ĚŝĨĨĞƌĞŶƚ ƚŽ ƚŚĞ ƌĞƐƉŽŶƐĞ ƐĞĞŶ ŝŶ ,K ?ɴ1YFPN cells alone. A full
concentration-response curve of cimaterol was not obtained at the same time
as the initial CGP 12177 functional data, which made it impossible to
accurately define a maximal system response and to clearly describe the CGP
12177 response observed here. A greater receptor expression level could
ĞǆƉůĂŝŶ ƚŚĞ ŝŶĐƌĞĂƐĞĚ ƌĞƐƉŽŶƐĞ ŝŶ ,K ?ɴ1YFPN ?ɴ1YFPC cells, however, the
ƐĂŵĞ ĐĂŶŶŽƚ ďĞ ĚŽŶĞ ĨŽƌ ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells, as the introduced
ɴ1D138AYFPC receptor is non-ligand binding. Baker et al. (2008) observed no
specific binding of [3, ?'W  ? ? ? ? ? ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ƚŚĞ  ? ? ? ɴ1AR and also
reported no functional response to full agonists isoprenaline and cimaterol
(Baker et al., 2008). Whether this is due to impaired binding of these ligands
to the receptor or impaired functionality of the receptor, is unclear. If the
 ? ? ? ɴ1-adrenoceptor retained functionality, this may affect the
ƉŚĂƌŵĂĐŽůŽŐǇ ĂŶĚ ĨƵŶĐƚŝŽŶĂůŝƚǇ ŽĨ ƚŚĞ ɴ1AR dimer. The minimal functional
GPCR unit has been described as one receptor/one G protein (Whorton et al.,
2007; Whorton et al., 2008). Even for GPCR dimers the 2:1 stoichiometry of
two receptors to one G protein is generally accepted (Damian et al., 2006;
Hlavackova et al., 2005) although a 2:2 stoichiometry of GPCR protomers to G
proteins has been described for the neuropeptide Y2 receptor (Parker et al.,
2008), thus making possible an amplification of the signalling response.
Another explanation for the increased CGP 12177 response seen at both wild-
ƚǇƉĞ ?ǁŝůĚ ?ƚǇƉĞĂŶĚǁŝůĚ ?ƚǇƉĞ ?ŵƵƚĂŶƚɴ1AR homodimers may be higher-order
oligomers.
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Repeat experiments of the above described data did not confirm the initial
findings, with CGP 12177 being a partial agonist compared to cimaterol in
subsequent experiments. In fact, the CGP 12177 pharmacology was similar to
ƚŚĂƚ ŽďƐĞƌǀĞĚ ŝŶ ,K ?ɴ1 ?^ ĂŶĚ ,K ?ɴ1YFPN cells, suggesting that the
ĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞǁŝůĚ ?ƚǇƉĞĂŶĚŵƵƚĂŶƚɴ1YFPC receptor was lost over time as
cells were passaged between each experiment. Cimaterol concentration-
response curves that were obtained in the same cell lines in subsequent
experiments to address the question of receptor expression levels revealed
similar EC50 values, supporting the notion of unstable and reduced expression
ŽĨǁŝůĚ ?ƚǇƉĞĂŶĚŵƵƚĂŶƚɴ1YFPC receptor. Furthermore, imaging experiments
showed that little or no YFP fluorescence, but BY-CGP binding could be
ĚĞƚĞĐƚĞĚ ŝŶ,K ?ɴ1YFPN ?ɴ1YFPCĂŶĚ,K ?ɴ1YFPN ?ɴ1D138AYFPC cells, supporting
the hypothesis that the expression of YFPC ?ƚĂŐŐĞĚɴ1AR was very low.
The use of transiently transfected cells worked well in the kinetic binding
studies, so we aimed to use a similar approach for the functional studies.
hƐŝŶŐ,K ?ɴ1YFPNĐĞůůƐƚŚĂƚǁĞƌĞƚƌĂŶƐŝĞŶƚůǇƚƌĂŶƐĨĞĐƚĞĚǁŝƚŚƚŚĞɴ1YFPC and
ƚŚĞɴ1D138AYFPC construct. This appeared to work, as a small (but statistically
insignificant) difference in cimaterol EC50ǀĂůƵĞƐǁĂƐŽďƐĞƌǀĞĚŝŶ,K ?ɴ1YFPN
ĐĞůůƐ ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ɴ1YFPC construct, reflecting an increased receptor
ĞǆƉƌĞƐƐŝŽŶ ĨŽůůŽǁŝŶŐ ƚŚĞ ŝŶƚƌŽĚƵĐƚŝŽŶ ŽĨ ĂĚĚŝƚŝŽŶĂů ɴ1-adrenoceptors. In
contrast, cimaterol EC50 ǀĂůƵĞƐ ŽďƚĂŝŶĞĚ ŝŶ ɴ1D138AYFPC transfected and
ƵŶƚƌĂŶƐĨĞĐƚĞĚ,K ?ɴ1YFPN cells were similar. Whether the lack of a change in
the cimaterol EC50 between these two cell populations was due to cell surface
387
non-ligand binding receptors or unsuccessful transfection and/or expression
of the receptor construct in these cells, is unclear. It will be difficult to
determine accurate expression levels, using for example a traditional
ƌĂĚŝŽůŝŐĂŶĚďŝŶĚŝŶŐĂƉƉƌŽĂĐŚĂƐƚŚĞĞǆƉƌĞƐƐĞĚŶŽŶ ?ůŝŐĂŶĚďŝŶĚŝŶŐɴ1D138AYFPC
receptor will not be picked up using this technique. However, the YFP
ĨƌĂŐŵĞŶƚ ?ƚĂŐŐĞĚ ɴ1-adrenoceptors could be fused to an additional
fluorescent tag at the N-terminus (e.g. SNAP-tag) that would allow the
expression of each receptor protomer to be measured, in addition to
monitoring their dimerisation using BiFC. This approach, in conjunction with
[3H]cAMP accumulation experiments should be used to examine a potential
ƌŽůĞŽĨĚŝŵĞƌŝƐĂƚŝŽŶ ŝŶ ƚŚĞ ĨƵŶĐƚŝŽŶĂůɴ1-adrenoceptor responses, and would
have been the main focus of further studies if time had allowed. Furthermore,
ligand-binding interaction of the fluorescently labelled CGP 12177 ligand with
^EW ?ƚĂŐŐĞĚ ɴ1-adrenoceptors could be investigated at the single molecule
level using fluorescence correlation spectroscopy (FCS). FCS allows the
distinction of free and bound receptor complexes based on their diffusion
speed, i.e. a small low molecular weight molecule passes quicker through the
0.25 fL FCS detection volume than a membrane bound receptor (Briddon et
al., 2007). Using FCS in conjunction with photon counting histogram (PCH)
analysis, monomeric and dimeric complexes of fluorescently labelled receptor
can also be distinguished based on the detected molecular brightness per
receptor species (Herrick-Davis et al., 2012; Patel et al., 2002). Furthermore,
two-colour fluorescence cross-correlation spectroscopy (FCCS) allows the
investigation of the binding of a fluorescent ligand to a receptor species that
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is labelled with a different wavelength-separated fluorophore (Neugart et al.,
2009; Weidemann et al., 2011). Thus, BODIPY-TMR-CGP binding to
ĐŽŶƐƚƌĂŝŶĞĚ ɴ1-adrenoceptor BiFC dimers could be examined at the single
molecule level. The advantage of using this technique is that high expression
of the receptor is not needed due to the inverse relationship between the
particle (e.g. receptor) number and the detected FCS signal (Briddon et al.,
2007), making it feasible to use a stable (or inducible) mixed population cell
line. Alternatively, the dissociation kinetic experiments performed here on
ĐŽŶƐƚƌĂŝŶĞĚ ĚŝŵĞƌƐ ĐŽƵůĚ ĂůƐŽ ďĞ ĚŽŶĞ ŽŶ ɴ1-adrenoceptors that cannot
dimerise, in order to investigate CGP 12177 ligand-binding and functional
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐĂƚƚŚĞɴ1-adrenoceptor monomer.
389
7.5 Conclusion
Bimolecular fluorescence complementation was successfully used to detect
ĂŶĚ ĐŽŶƐƚƌĂŝŶ ɴ1AR homodimers that contained a wild-type or non-ligand
ďŝŶĚŝŶŐ  ? ? ? ŵƵƚĂŶƚ ɴ1-adrenoceptor second protomer. Kinetic binding
experiments revealed that unlabelled ligands enhanced the BODIPY-TMR-CGP
ĚŝƐƐŽĐŝĂƚŝŽŶƌĂƚĞŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐǁŝůĚ ?ƚǇƉĞɴ1AR homodimers compared to
cells expressing unconstrained (i.e. transient) dimers. Furthermore, these
ĞĨĨĞĐƚƐǁĞƌĞƌĞĚƵĐĞĚŝŶĐĞůůƐĞǆƉƌĞƐƐŝŶŐǁŝůĚ ?ƚǇƉĞ ?ŵƵƚĂŶƚɴ1AR homodimers,
ƚŚƵƐŚŝŐŚůŝŐŚƚŝŶŐĂƌŽůĞŽĨɴ1ZĚŝŵĞƌƐŝŶƚŚĞůŝŐĂŶĚ ?ďŝŶĚŝŶŐŝŶƚĞƌĂĐƚŝŽŶƐŽĨɴ ?
ĂĚƌĞŶŽĐĞƉƚŽƌůŝŐĂŶĚƐƚŽƚŚĞɴ1-adrenoceptor.
We were unable to obtain reproducible functional data in stable cell lines
ĞǆƉƌĞƐƐŝŶŐ ɴ1AR homodimers, but preliminary data obtained in cells
ƚƌĂŶƐŝĞŶƚůǇĞǆƉƌĞƐƐŝŶŐɴ1AR homodimers revealed differences in EC50 values of
full agonist cimaterol. Future experiments will need to investigate whether
this is due to differences in receptor expression levels, or in fact the
ŝŶƚƌŽĚƵĐĞĚ ŵƵƚĂƚŝŽŶ ? ĂŶĚ ƚŚƵƐ ƚŽ ĞƐƚĂďůŝƐŚ Ă ƉŽƚĞŶƚŝĂů ƌŽůĞ ŽĨ ƚŚĞ ɴ1AR
ŚŽŵŽĚŝŵĞƌ ŝŶ ƚŚĞ ɴ1AR-mediated cellular responses and also to potentially
ŝĚĞŶƚŝĨǇƚŚĞɴ1ZƐĞĐŽŶĚƉƌŽƚŽŵĞƌĂƐƚŚĞƐĞĐŽŶĚƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor.
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Chapter 8
General discussion and conclusion
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8.1 General discussion
dŚĞĞŶĚŽŐĞŶŽƵƐɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŐŽŶŝƐƚƐĂĚƌĞŶĂůŝŶĞĂŶĚŶŽƌĂĚƌĞŶĂůŝŶĞďŝŶĚ
ƚŽƚŚĞĞŶĚŽŐĞŶŽƵƐ ?ŽƌƚŚŽƐƚĞƌŝĐ ?ďŝŶĚŝŶŐƐŝƚĞŽĨƚŚĞɴ1-adrenoceptor to cause
cardiostimulation (Mutlu et al., 2008). Blocking these stimulatory effects with
ɴ ?ďůŽĐŬĞƌƐ ŝƐ Ă ǀŝƚĂů ůŝŶĞ ŽĨ ƚƌĞĂƚŵĞŶƚ ŝŶ Ă ǀĂƌŝĞƚǇ ŽĨ ŚĞĂƌƚ ĚŝƐĞĂƐĞƐ ƐƵĐŚ ĂƐ
hypertension and myocardial infarction (Baker et al., 2011b; Poirier et al.,
2012; Sanz-Rosa et al. ? ? ? ? ? ? ?ɴ ?ďůŽĐŬĞƌƐƐƵĐŚĂƐƉƌŽƉƌĂŶŽůŽůĂƌĞĂŶƚĂŐŽŶŝƐƚƐ
that bind to the same site as the endogenous agonists, thereby preventing
receptor activation. Antagonists are described to have no efficacy of their
ŽǁŶ  ?ŝ ?Ğ ? ĚŽ ŶŽƚ ĂĐƚŝǀĂƚĞ ƚŚĞ ƌĞĐĞƉƚŽƌ ? ? ,ŽǁĞǀĞƌ ? Ăƚ ƚŚĞ ɴ2-adrenoceptor
ƐŽŵĞ ɴ ?ďůŽĐŬĞƌƐ ǁĞƌĞ ĨŽƵŶĚ ƚŽ ĞǆŚŝďŝƚ ƐŵĂůů ĂŐŽŶŝƐƚ ĂĐƚŝŽŶƐ  ?ĂŬĞƌet al.,
2003b). Interestingly, propranolol was found to decrease basal cAMP levels
but increase SPAP levels in the CRE-mediated SPAP gene reporter assay,
highlighting biased agonism of propranolol at this receptor (Baker et al.,
2003b). Similarly, CGP 12177 was initially described as an antagonist, but was
also found to exert partial agonist effects. Interestingly, these agonist effects
were elicited at much higher concentrations than those needed to inhibited
catecholamine-induced receptor activation (Kaumann et al., 1983; Staehelin
et al., 1983). Kaumann et al.  ? ? ? ? ? ?ĞǆĂŵŝŶĞĚƚŚĞĂĨĨŝŶŝƚŝĞƐŽĨĂǀĂƌŝĞƚǇŽĨɴ ?
adrenoceptor partial agonists from their inhibitory and stimulatory effects
measured in isolated feline heart tissues. The affinity values determined using
the two different approaches compared well for conventional agonists (e.g.
practolol), whereas a defined difference in affinity values was observed for
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non-conventional agonists, such as CGP 12177 (Kaumann et al., 1980;
Kaumann et al., 1983). A radiolabelled version of CGP 12177 was used to
further investigate its pharmacology. Initial studies used isolated tissues,
ǁŚŝĐŚ ĞǆƉƌĞƐƐ ŵĂŝŶůǇ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ďƵƚ ĂůƐŽ ɴ2 ? ĂŶĚ ɴ3-adrenoceptors
(Kaumann et al., 2008). The observed pharmacology of non-conventional
agonists could not be attributed conclusively to either receptor, which led to
ƚŚĞ ƉƌŽƉŽƐĂů ŽĨ ƚŚĞ ĞǆŝƐƚĞŶĐĞ ŽĨ Ă ĨŽƵƌƚŚ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?<ĂƵŵĂŶŶ ?  ? ? ? ? ? ?
,ŽǁĞǀĞƌ ? ƐƚƵĚŝĞƐ ƉĞƌĨŽƌŵĞĚ ŝŶ ,K ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐƌĞĐŽŵďŝŶĂŶƚ ɴ1-
ĂĚƌĞŶŽĐĞƉƚŽƌƐ ĐůĞĂƌůǇ ƐŚŽǁĞĚ ƚŚĞ ɴ1AR alone was responsible for the
pharmacology of CGP 12177 (Pak et al., 1996). The high and low affinity
binding sites or receptor conformations were defined, although the nature of
the secondary site is still unknown. A site-directed mutagenesis study by
Baker et al.  ? ? ? ? ? ? ĂŝŵĞĚ ƚŽ ŝĚĞŶƚŝĨǇ ŬĞǇ ƌĞƐŝĚƵĞƐ ŽĨ ĞĂĐŚ ŽĨ ƚŚĞ ǁŽ ɴ1-
adrenoceptor sites, but instead found that the mutations tested affected both
sites to similar extents (Baker et al., 2008). Here we used a fluorescently
labelled version of CGP 12177 and fluorescence confocal microscopy in a
kinetic binding approach to investigate ligand-receptor interactions at the
ŚƵŵĂŶɴ1-adrenoceptor in single living cells. Using this approach, an allosteric
mode of action of CGP 12177 was revealed at this receptor.
First, we confirmed the CGP 12177 pharmacology using CHO cells expressing
ƚŚĞ ŚƵŵĂŶ ɴ1-adrenoceptor and the CRE-SPAP reporter gene construct
(Chapter 3). In the SPAP transcription assay, we determined that CGP 12177
inhibited cimaterol-induced responses with high affinity (circa 0.2 nM) at the
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ĐĂƚĞĐŚŽůĂŵŝŶĞ ɴ1-adrenoceptor site (site 1), and exhibited partial agonist
ĞĨĨĞĐƚƐ ƚŚƌŽƵŐŚ Ă ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site (site 2) with much lower
affinity (circa 26 nM). This difference in affinity values is circa 100-fold, which
is consistent with reports in the literature (Baker et al., 2003a; Konkar et al.,
2000; Pak et al., 1996). A similar pharmacology was observed for the
fluorescent analogue of CGP 12177, BODIPY-TMR-CGP 12177 (BY-CGP), which
inhibited cimaterol-induced responses with high affinity (circa 0.6 nM) and
exerted partial agonist effects with low affinity (circa 87 nM), thus also
ĚŝƐƉůĂǇŝŶŐ Ă ĐŝƌĐĂ  ? ? ? ?ĨŽůĚ ĚŝĨĨĞƌĞŶĐĞ ŝŶ ĂĨĨŝŶŝƚǇĨŽƌ ƚŚĞ ƚǁŽ ƉƌŽƉŽƐĞĚ ɴ1-
adrenoceptor sites (Chapter 4).
dŚĞ ƐĂŵĞ ƚƌĞŶĚ ǁĂƐ ŽďƐĞƌǀĞĚ ĨŽƌ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶƚĂŐŽŶŝƐƚƐ ƉƌŽƉƌĂŶŽůŽů
and CGP 20712A, as high affinity values of antagonists were determined for
ƚŚĞ ĐĂƚĞĐŚŽůĂŵŝŶĞ ɴ1-adrenoceptor site from parallel rightward shifted
cimaterol concentration-response curves, and lower affinity values were
derived from parallel rightward shifted CGP 12177 concentration-response
curves. The low antagonist affinity values for the secondary site have caused
ƚŚĞ 'W  ? ? ? ? ? ĂŐŽŶŝƐƚ ĞĨĨĞĐƚ ƚŽ ďĞ ĚĞĞŵĞĚ  SƌĞƐŝƐƚĂŶ ? ƚŽ ɴ ?ďůŽĐŬĞƌ ĂĐƚŝŽŶ ?
ǁŚŝĐŚ ŚŽůĚƐ ƚƌƵĞ ŽŶůǇ ĨŽƌ ƚŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ ɴ ?ďůŽĐŬĞƌƐ ƵƐĞĚ ƚŽ ŝŶŚŝďŝƚ
agonist effects through the catecholamine site. Interestingly, the cimaterol
concentration-response curves were shifted in manner consistent with
competitive mechanism of action of the antagonists used, and no co-
operative interactions between two binding sites were detected. This may be
due to the concentrations of antagonists used to shift the cimaterol
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concentration-response curves, which were all lower than the affinity of these
ůŝŐĂŶĚƐ ĨŽƌ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site. Higher antagonist
concentrations (KDsite2 concentrations and higher) may have revealed
allosteric mechanisms of actions of the ligands used, by not shifting the
cimaterol concentration-response curve any further right. Alternatively, a
different agonist could be used to induce a response through the
catecholamine site, as allosteric effects of ligands are probe-dependent, i.e.
they act as an allosteric modulator for one ligand, but not another, or to a
different extent (Christopoulos et al., 2002). Interestingly, 10 and 30 nM CGP
 ? ? ? ? ? ǁĞƌĞ ŶŽƚ ĂďůĞ ƚŽ ƐŚŝĨƚ ƚŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ƌĞƐƉŽŶƐĞ ĐƵƌǀĞ ƚŽ ƚŚĞ ɴ ?
adrenoceptor agonist isoprenaline any further than 3 nM CGP 12177, but
increased the basal response in a concentration-dependent manner
consistent with these CGP 12177 concentrations eliciting an agonist response
ƚŚƌŽƵŐŚ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site (Baker et al., 2002). This
bunching up of the concentration-response curve was not seen when using
cimaterol in this thesis, suggesting a probe-dependency of the CGP 12177
ĂůůŽƐƚĞƌŝĐĞĨĨĞĐƚƐĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor.
The affinity of the fluorescently labelled CGP 12177 (BY-CGP) was circa 3-fold
lower at both sites compared to the affinities determined for the parent
compound. With an affinity of circa 0.6 nM, BY-CGP was used in fluorescence
microscopy studies to further investigate ligand-receptor interaction at the
ƐĞĐŽŶĚĂƌǇ ɴ1-adrenoceptor site. We demonstrated in confocal microscopy
ƐƚƵĚŝĞƐ ƚŚĂƚ z ?'W ĂůůŽǁĞĚ ǀŝƐƵĂůŝƐĂƚŝŽŶ ŽĨ ɴ1-adrenoceptors expressed in
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,KĐĞůůƐ ?dŚĞƐƉĞĐŝĨŝĐďŝŶĚŝŶŐŽĨz ?'WƚŽɴ1-adrenoceptors was highlighted
by co-localising BY-CGP fluorescence with fluorescently labelled SNAP-tagged
ɴ1Z ĞǆƉƌĞƐƐĞĚ ŝŶ ,K ĐĞůůƐ ? /Ŷ ĂĚĚŝƚŝŽŶ ? z ?'W ďŝŶĚŝ Ő ƚŽ ŶĂƚŝǀĞ ɴ1-
adrenoceptors was concentration-dependent, and could be displaced in a
concentration-dependent manner by CGP 20712A (Chapter 4). Interestingly,
the CGP 20712A displacement binding curve was shallower when displacing
20 nM BY-CGP compared to displacing 2 nM BY-CGP. Using the IX Ultra
confocal plate reader in an automated higher throughput live cell
fluorescence-based ligand binding assay, we further investigated this, and
revealed two-phase antagonist displacement binding curves in the presence
ŽĨ  ? ? ?  ? ? ĂŶĚ  ? ? ? ŶD z ?'W ŝŶ ,K ?ɴ1-CS cells, yielding high and low IC50
values (Chapter 5). In addition, the proportion of the secondary phase of the
displacement binding curves increased with increasing BY-CGP concentrations,
ǁŚŝĐŚ ǁĂƐ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ z ?'W ďŝŶĚŝŶŐ ƚŽ ƚŚĞ ƐĞĐŽŶĚĂƌǇ ůŽǁ ĂĨĨŝŶŝƚǇ ɴ1-
adrenoceptor site. Crucially, two-phase displacement binding curves were not
ŽďƚĂŝŶĞĚ ŝŶ,K ?ɴ2-CS cells, as only one binding site has been described for
ƚŚĞ ɴ2-adrenoceptor (Rasmussen et al., 2007). The displacement binding
curves were shifted rightwards with increasing BY-CGP concentrations, and
when log IC50 ǀĂůƵĞƐ ĚĞƚĞƌŵŝŶĞĚ ĨŽƌ ĞĂĐŚ ŽĨ ƚŚĞ ƚǁŽ ɴ1-adrenoceptor sites
were plotted against the log of the BY-CGP concentrations used, the obtained
slopes were shallow (i.e. not slopes of 1.0), which has been described as a
characteristic of allosteric modulators (Christopoulos et al., 2002; Hulme et al.,
2010). However, shallow slopes were also seen when correlating antagonist
IC50ǀĂůƵĞƐŽďƚĂŝŶĞĚŝŶ,K ?ɴ2-CS cells with BY-CGP concentrations. This was
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likely due to non-equilibrium conditions in the competition binding assay. BY-
'W ŚĂƐ ďĞĞŶ ĚĞƐĐƌŝďĞĚ ĂƐ Ă ůŽŶŐ ĂĐƚŝŶŐ ƉĂƌƚŝĂů ĂŐŽŶŝƐƚ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ2-
adrenoceptor (Baker et al., 2003d), and subsequent BY-CGP kinetic
ĞǆƉĞƌŝŵĞŶƚƐƉĞƌĨŽƌŵĞĚŝŶ,K ?ɴ1-CS cells revealed a slow dissociation rate of
z ?'WĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor (Chapter 6), indicating that equilibrium
conditions could not have been achieved within a 1 hour incubation time for
BY-CGP.
dŽ ĨƵƌƚŚĞƌ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ůŝŐĂŶĚ ?ƌĞĐĞƉƚŽƌ ŝŶƚĞƌĂĐƚŝŽŶƐ Ăƚ ƚŚĞ ŚƵŵĂŶ ɴ1-
adrenoceptor, we performed kinetic binding experiments using BY-CGP and
,K ?ɴ1-CS cells. The confocal perfusion system allowed visualisation of BY-
'W ďŝŶĚŝŶŐ ƚŽ ,K ?ɴ1-CS cells in real time, and uniquely, allowed the
determination of BY-CGP dissociation rates under infinite dilution conditions
(May et al., 2010a). This allowed the comparison of BY-CGP dissociation rates
in the absence and presence of unlabelled ligands. The dissociation rate of 3
nM BY-CGP was enhanced in the presence of increasing concentrations of
unlabelled CGP 12177 and propranolol, and these effects of CGP 12177 and
propranolol on the BY-CGP dissociation rate were saturable, suggesting an
ĂůůŽƐƚĞƌŝĐŵĞĐŚĂŶŝƐŵŽĨĂĐƚŝŽŶĂƚƚŚĞɴ1-adrenoceptor. Using a kinetic binding
approach is a very sensitive way to detect allosteric modulators, as allosteric
effects may not be apparent in equilibrium binding assays (Christopoulos et
al., 2002). The BY-CGP dissociation rates in the presence of increasing
concentrations of CGP 12177 and propranolol were plotted against the CGP
12177 and propranolol concentrations used, and the fitted curve revealed the
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< ?ɲĂƚƚŚĞŵŝĚƉŽŝŶƚŽĨƚŚĞƐĞĐƵƌǀĞƐ ?dŚĞ< ?ɲƌĞƉƌĞƐĞŶƚƐƚŚĞĂĨĨŝŶŝƚǇŽĨƚŚĞ
unlabelled ligand for the allosteric site (site 2) with a ligand bound to the
orthosteric site (site 1), and this value determined for CGP 12177 and
propranolol compared well to the affinity value of both ligands determined in
the SPAP transcription assay. This is not altogether unexpected, as ligand-
receptor interactions at the secondary site were always determined with a
ligand bound to site 1, due to the ligands displaying higher affinity for the
orthosteric site than the allosteric site. This suggests that the affinity for the
secondary site may be quite different in the absence of a ligand bound to site
1. The co-operativity factor describing the co-operative interaction between
the two receptor sites cannot be determined without knowing the affinity for
the secondary site at the unoccupied receptor. The effects of unlabelled
ligands on the BY-CGP dissociation rates clearly demonstrated allosteric
interactions; however, these may not necessarily lead to altered affinities of
ligands at equilibrium. This is the case if the affinity of unlabelled ligands for
the occupied receptor is the same as for the unoccupied receptor, thus
resulting in a co-operativity factor of 1 (Christopoulos et al., 2002).
Our preliminary data indicated that the allosteric interactions were mediated
ĂĐƌŽƐƐ Ă ɴ1-adrenoceptor homodimer interface (Chapter 7), where the
ƐĞĐŽŶĚĂƌǇďŝŶĚŝŶŐƐŝƚĞ ŝƐ ĨĂĐŝůŝƚĂƚĞĚďǇĂƐĞĐŽŶĚɴ1-adrenoceptor orthosteric
site that becomes the allosteric site upon dimerisation. Thus, the secondary
site becomes a low affinity site either as a result of conformational changes
ƚŚĂƚ ŽĐĐƵƌ ĚƵƌŝŶŐ ĚŝŵĞƌŝƐĂƚŝŽŶ ? Žƌ ĂƐ Ă ƌĞƐƵůƚ ŽĨ Ă ůŝŐĂŶĚ ďŝŶĚŝŶŐ ƚŽ ŽŶĞ ɴ1-
398
adrenoceptor site in the dimer (i.e. through allosteric interactions). In order to
better understand the interactions between the protomers of the dimer and
ůŝŐĂŶĚƐďŝŶĚŝŶŐƚŽƚŚĞɴ1-adrenoceptor, we would need to determine affinity
ǀĂůƵĞƐ ŽĨ ůŝŐĂŶĚƐ ĨŽƌ ƚŚĞ ŵŽŶŽŵĞƌŝĐ ɴ1-adrenoceptor as well as the dimer.
dŚĞ ɴ1-adrenoceptor is reported to form transient homodimers (Calebiro et
al., 2013; Dorsch et al., 2009), which means that affinity values of ligands
determined in this thesis reflect a combination of the affinity to the dimeric
ĂŶĚƚŚĞŵŽŶŽŵĞƌŝĐɴ1-adrenoceptor. That the affinities are likely different for
these two receptor conformations was suggested by the BY-CGP dissociation
ƌĂƚĞ ŽďƚĂŝŶĞĚ ŝŶ ĐĞůůƐ ŝŶ ǁŚŝĐŚ ɴ1-adrenoceptor dimers that spontaneously
formed were trapped in stable dimers by bimolecular fluorescence
complementation (BiFC). In these cells the BY-CGP dissociation rate was
ƐŝŐŶŝĨŝĐĂŶƚůǇƐůŽǁĞƌĐŽŵƉĂƌĞĚƚŽŽĨĨƌĂƚĞĚĞƚĞƌŵŝŶĞĚŝŶ,K ?ɴ1-CS cells (were
receptors form transient dimers). This also highlights that the formation of
homodimers induces conformational changes within the receptor complex
that affect the BY-CGP affinity at the receptor.
The reciprocal nature of allosteric interactions between two ligands means
that kinetic binding experiments using a fluorescently labelled propranolol
ligand to measure dissociation rates in the absence and presence of
unlabelled CGP 12177 should confirm the data presented here. We have in
fact tested a fluorescent propranolol derivative in this thesis, but were unable
to use it in kinetic binding experiments due to high non-specific binding levels
(Chapter 6). As such, using a different fluorescent propranolol derivative
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would be an important next experiment to validate the allosteric interactions
reported in this thesis. Furthermore, the next experiments should address the
concentration-dependency of the effect observed when cotransfecting wild-
ƚǇƉĞ ĂŶĚ ŵƵƚĂŶƚ ŶŽŶ ?ůŝŐĂŶĚ ďŝŶĚŝŶŐ ɴ1-adrenoceptor constructs. Increasing
concentrations of the non-ligand binding protomer would be expected to
ŝŶĐƌĞĂƐŝŶŐůǇ ĚŝƐƉůĂĐĞ ǁŝůĚ ?ƚǇƉĞ ɴ1-adrenoceptors as the second protomer in
ɴ1-adrenoceptor homodimers, as was observed for the adenosine A3 receptor
(May et al. ?  ? ? ? ? ? ? dŚŝƐ ǁŽƵůĚ ĚĞŵŽŶƐƚƌĂƚĞ Ă ĐůĞĂƌ ƌŽůĞ ŽĨ ɴ1-adrenoceptor
homodimers in the receptor-ligand interactions, where homodimerisation
affects the dissociation rate of the ligand bound to the high affinity
ĐĂƚĞĐŚŽůĂŵŝŶĞ ƐŝƚĞ ŽĨ ƚŚĞ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ? tĞ ŽďƐĞƌǀĞĚ ƚŚĂƚ ɴ1-
adrenoceptor homodimerisation slowed the dissociation of fluorescently
labeled CGP 12177, thus increasing its duration of action at the receptor. It
ǁŽƵůĚďĞŝŶƚĞƌĞƐƚŝŶŐƚŽƐĞĞǁŚĞƚŚĞƌƚŚĞƐĂŵĞǁĂƐƚƌƵĞĨŽƌƚŚĞĞŶĚŽŐĞŶŽƵƐɴ ?
adrenoceptor ligands in recombinant cell systems as well as primary
ĐĂƌĚŝŽŵǇŽĐǇƚĞƐ ? ĂƐ ƚŚŝƐ ŵŝŐŚƚ ŚŝŐŚůŝŐŚƚ ƚŚĂƚ ɴ1-adrenoceptor
homodimerisation contributes to prolonged receptor-ligand interactions, and
ƚŚƵƐ Ă ŵŽƌĞ ƐƵƐƚĂŝŶĞĚ ĐĞůůƵůĂƌ ƌĞƐƉŽŶƐĞ ? dŚĞ ƚƌĂŶƐŝĞŶƚ ŶĂƚƵƌĞ ŽĨ ɴ1-
adrenoceptor homodimers may therefore represent a means of fine-tuning
cardiomyocyte contraction responses upon agonist stimulation. Agonist
treatment alone was reported not to affect the oligomerisation state of the
ɴ1-adrenoceptor, although this was so far only investigated for isoprenaline
and using a recombinant cell line (Calebiro et al., 2013). Nevertheless, the
ƉŽƚĞŶƚŝĂů ŽĨ ŝŶĐƌĞĂƐŝŶŐ ƚŚĞ ɴ1-adrenoceptor homodimerisation state in
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cardiomyocytes may present an interesting future therapeutic target in the
treatment of cardiac conditions in which the cardiac output is too low, such as
bradycardia or hypotension.
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8.2 General conclusion
The investigation of dissociation rates of a labelled ligand under infinite
dilution in the absence of excess concentrations of an unlabelled competitor
ligand is a very powerful and sensitive tool to detect allosteric modulators
that affect the dissociation rate of the labelled ligand. Using this approach in
conjunction with a fluorescently labelled CGP 12177 and confocal microscopy,
we have shown for the first time an allosteric mechanism of action for CGP
 ? ? ? ? ?ĂƚƚŚĞŚƵŵĂŶɴ1-adrenoceptor. This clearly distinguishes two separate
ɴ1-adrenoceptor binding sites, which preliminary data suggest are facilitated
ďǇ ƚǁŽ ŽƌƚŚŽƐƚĞƌŝĐ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌ ƐŝƚĞƐ ŝŶ Ă ɴ1-adrenoceptor homodimer.
We have also shown that the dissociation rate of the fluorescent CGP 12177
analogue was slower when measured in a receptor population that contains a
ŚŝŐŚĞƌ ƉĞƌĐĞŶƚĂŐĞ ŽĨ ɴ1-adrenoceptor homodimers, suggesting a role of ȕ1-
adrenoceptor homodimers in the ligand-binding interactions at this receptor.
The co-operativity between the two receptor sites in cellular responses will
now have to be investigated, which may reveal the nature of the agonist
effect observed for non-conventional ȕ-adrenoceptor agonists at the human
ȕ1-adrenoceptor.
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Appendix I  supplementary data
S1 Comparison of signal DNA sequence to 5-HT3A DNA sequence
The query sequence was used in the NCBI BLAST program with the settings such to
find a match against any nucleotide sequence. The best match was found against the
5-HT3A sequence.
Query sequence signal DNA sequence from above (S2) sequence
Subject sequence 5-HT3A DNA sequence (accession number AY605711)
gb|AY605711.1| Mus musculus serotonin-gated ion channel subunit
A short splice
variant (Htr3a) mRNA, complete cds, alternatively spliced
Length=1452
GENE ID: 15561 Htr3a | 5-hydroxytryptamine (serotonin) receptor
3A
[Mus musculus]
Score = 139 bits (75), Expect = 2e-30
Identities = 75/75 (100%), Gaps = 0/75 (0%)
Strand=Plus/Plus
Query 1 ATGCGGCTCTGCATCCCGCAGGTGCTGTTGGCCTTGTTCCTTTCCATGCTGACAGGGCCG 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 1 ATGCGGCTCTGCATCCCGCAGGTGCTGTTGGCCTTGTTCCTTTCCATGCTGACAGGGCCG 60
Query 61 GGAGAAGGCAGCCGG 75
|||||||||||||||
Sbjct 61 GGAGAAGGCAGCCGG 75
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^ ? E ĂŶĚ ƉƌŽƚĞŝŶ ƐĞƋƵĞŶĐĞ ŽĨ ƚŚĞ ĐŽŵƉůĞƚĞ ^EW ?ƚĂŐŐĞĚ ɴ1AR fusion
protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
Protein sequence
length (residues)
signal sequence 22  105 84 28
SNAP-tag sequence 106  654 549 183
ɴ1AR sequence 655  2085 1431 477
fusion protein sequence 22  2085 2064 688
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein DNA sequence
1 CTTAAGCTTGGTACCGCCACCATGCGGCTCTGCATCCCGCAGGTGCTGTTGGCCTTGTTC
61 CTTTCCATGCTGACAGGGCCGGGAGAAGGCAGCCGGAAGCTTACCCTGGACAAAGACTGC
121 GAAATGAAGCGCACCACCCTGGATAGCCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGAA
181 CAGGGCCTGCACGAGATCAAGCTGCTGGGCAAAGGAACATCTGCCGCCGACGCCGTGGAA
241 GTGCCTGCCCCAGCCGCCGTGCTGGGCGGACCAGAGCCACTGATGCAGGCCACCGCCTGG
301 CTCAACGCCTACTTTCACCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCCCTGCAC
361 CACCCAGTGTTCCAGCAGGAGAGCTTTACCCGCCAGGTGCTGTGGAAACTGCTGAAAGTG
421 GTGAAGTTCGGAGAGGTCATCAGCTACCAGCAGCTGGCCGCCCTGGCCGGCAATCCCGCC
481 GCCACCGCCGCCGTGAAAACCGCCCTGAGCGGAAATCCCGTGCCCATTCTGATCCCCTGC
541 CACCGGGTGGTGTCTAGCTCTGGCGCCGTGGGGGGCTACGAGGGCGGGCTCGCCGTGAAA
601 GAGTGGCTGCTGGCCCACGAGGGCCACAGACTGGGCAAGCCTGGGCTGGGATCCCTGGGC
661 GCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCACCGCTC
721 CCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCCTCGTTG
781 CTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGCATGGGT
841 CTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATCGTGGCC
901 ATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTGGCCAGC
961 GCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTGTGGGGC
1021 CGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTGTGCGTG
1081 ACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATCACCTCG
1141 CCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGCACCGTG
1201 TGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGGGCGGAG
1261 AGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACCAACCGG
1321 GCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATGGCCTTC
1381 GTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGCTGCGAG
1441 CGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTCCCCGCG
1501 CCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCGCTGGCC
1561 AACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAGAAGGCG
1621 CTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTG
1681 GCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTCTTCTTC
1741 AACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGCCCCGAC
1801 TTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGGCGCCAC
1861 GCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCCCCGCCA
1921 TCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCGCCCGCG
1981 CGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGACTCGAGC
2041 CTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAGGAATTCTGCAGA
The start codons of the three separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚ ŝŶ ŐƌĞǇ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ ŵƵƚĂƚĞĚ ƐƚĂƌƚ ĐŽĚŽŶƐ  ?d' AP d' ? ǁŚŝĐŚ ĂůůŽǁ
continuous transcription of the fusion protein. The stop codon is also highlighted in
grey and marks the end of the fusion protein. Underlined sequences are restriction
enzyme sites recognised by KpnI (GGTACC), BamHI (GGATCC)and EcoRI (GAATTC).
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The sequence before (<22bp) and after (>2088bp) is the sequence of the
pcDNA3.1(Neo+) plasmid vector.
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein amino acid sequence
L K L G T A T M R L C I P Q V L L A L F L S M L T G P G E G S R K L T L D K D C E M K R T T L D S P L G K L E L S
G C E Q G L H E I K L L G K G T S A A D A V E V P A P A A V L G G P E P L M Q A T A W L N A Y F H Q P E A I E
E F P V P A L H H P V F Q Q E S F T R Q V L W K L L K V V K F G E V I S Y Q Q L A A L A G N P A A T A A V K T
A L S G N P V P I L I P C H R V V S S S G A V G G Y E G G L A V K E W L L A H E G H R L G K P G L G S L G A G
V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q QW T A G
M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V P F G A T
I V V W G R W E Y G S F F C E L W T S V D V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L L T R A R
A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y A I A S S
V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P A P A P
P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C W L P F F
L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C C A R R A
A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E P W A G C
N G G A A A D S D S S L D E P C R P G F A S E S K V Stop E F C R
The start codons of the three separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein.
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^ ?,K ?ƐƐɴ1 ?^ĐůŽŶĂůĐĞůůůŝŶĞƐƚŚĂƚƐŚŽǁŶŽĞǆƉƌĞƐƐŝŽŶŽĨ^EW ?ƚĂŐŐĞĚɴ1-
adrenoceptors following BG-488 labelling Transmitted light and confocal
images of CHO-ssȕ1-CS clones are shown. Fluorescence of BG-488 (1 µM)
labelled SNAP-tagged ȕ1-adrenoceptors was measured using 488 nm
excitation and a 505 nm long-pass emission filter using the Zeiss LSM710
confocal microscope. Scale bars = 50 µm.
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^ ? ǆƉƌĞƐƐŝŽŶ ŽĨ ^EW ?ƚĂŐŐĞĚ ɴ1 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ŝŶ ,K ?ƐƐɴ1-CS clonal cell
lines following BG-488 labelling Transmitted light and confocal images of
CHO-ssȕ1-CS clones are shown. Fluorescence of BG-488 (1 µM) labelled SNAP-
tagged ȕ1-adrenoceptors was measured using 488 nm excitation and a 505
nm long-pass emission filter using the Zeiss LSM710 confocal microscope.
Scale bars = 50 µm.
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S5 Comparison of SNAP-tag amino acid sequence to human methylated-
DNA-protein-cysteine methyltransferase (MGMT) amino acid sequence
The NCBI BLAST program was used for this alignment.
Query sequence SNAP-tag amino acid sequence from above (S2) sequence
Subject sequence MGMT amino acid sequence (accession number NP_002403)
Score = 340 bits (873), Expect = 8e-124, Method:
Compositional matrix adjust.
Identities = 167/179 (93%), Positives = 169/179 (94%), Gaps =
0/179 (0%)
Query 1 LDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLM 60
+DKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLM
Sbjct 32 MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLM 91
Query 61 QATAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAAL 120
Q TAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAAL
Sbjct 92 QCTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAAL 151
Query 121 AGNPAATAAVKTALSGNPVPILIPCHRVVSSSGAVGGYEGGLAVKEWLLAHEGHRLGKP 179
AGNP A AV A+ GNPVPILIPCHRVV SSGAVG Y GGLAVKEWLLAHEGHRLGKP
Sbjct 152 AGNPKAARAVGGAMRGNPVPILIPCHRVVCSSGAVGNYSGGLAVKEWLLAHEGHRLGKP 210
The active site of the human alkylguanine alkyltransferase (hAGT) is highlighted in
grey (Pegg, 2011) and is unaltered in the SNAP-tag. The hAGT protein was truncated
to reduce the size of the engineered SNAP-tag. The mutations were introduced to
increase enzyme activity compare to wild-type hAGT and to decrease affinity
towards double-stranded DNA (Juillerat et al., 2003, 2005), thus enhancing specificity
of protein labelling.
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S6 Affinity of BODIPY-TMR-CGP 12177 (BY-CGP) at the SNAP-tagged ȕ1-
adrenceptor
A, SPAP secretion of cimaterol in the absence and presence of increasing
concentrations of BY-CGP. Bars show basal SPAP secretion from unstimulated cells
and that in response to 10, 30 and 100 nM BY-CGP. B, SPAP secretion of increasing
concentrations of cimaterol and BY-CGP alone. Bar shows basal SPAP secretion from
unstimulated cells. Data points are mean ± s.e.m. of triplicate determinations from a
single experiments and are representative of a total of A, five and B, five separate
experiments. From these data the log affinity values of BY-CGP were determined to
ďĞ ? ? ? ?A? ? ? ? ? ?ŶA? ? ?ĂƚƐŝƚĞ ?ĂŶĚ ? ? ? ?A? ? ? ? ? ?ŶA? ? ?ĂƚƐŝƚĞ ?ŽĨƚŚĞ^EW ?ƚĂŐŐĞĚɴ1-
adrenoceptor.
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^EW ?ƚĂŐŐĞĚ ɴ1AR
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S7 Affinity of BODIPY630/650-S-PEG8-propranolol (BY-PROP) at the SNAP-
tagged ȕ1-adrenceptor
SPAP secretion of A, cimaterol and C, CGP 12177 in the absence and presence of
increasing concentrations of BY-PROP. Bars show basal SPAP secretion from
unstimulated cells and that in response to A, 30, 100 and 300 nM and C, 1 µM BY-
PROP. Data points are mean ± s.e.m. of triplicate determinations from a single
experiments and are representative of a total of A, six and C, four separate
experiments. B, Schild plot of data shown in A (slope 1.43, R2 1.00). From these data
the log affinity values of BY-PROP were determined to be 7.45 ± 0.06 (n=6) with a
Schild slope of 1.43 ± 0.05 (n=6), and 6.44 ± 0.10 (n=4) at site 2 of the SNAP-tagged
ɴ1-adrenoceptor.
^EW ?ƚĂŐŐĞĚ ɴ1AR
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S8 Comparison of perfusion data obtained using the Zeiss LSM710 and the
Zeiss LSM510 confocal microscope
Data shows association and dissociation of 10, 30 and 100 nM ABA-X-630 at CHO-A3-
CS and CHO-CS cells using the Zeiss A, LSM710 and B, LSM510 confocal perfusion
system. Regions of interest were drawn around the membranes of ten cells for each
perfusion slide and the ABA-X-630 fluorescence intensities plotted against time. Data
are mean ± s.e.m of 4-6 separate perfusion slides obtained on three separate
experimental days. The kinetic parameters of ABA-X-630 binding to these cells are
summarised and compared in the table below.
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ABA-X-BY630 konobs koff(fast) koff(slow) kon pKD n
min
-1
min
-1
min
-1
x10
7
M
-1
min
-1
M
-1
LSM710 system
CHO-CS
10 nM N/A N/A
30 nM 2.20 ± 0.39 2.20 ± 0.28 4
100 nM 3.16 ± 0.42 2.18 ± 0.19 6
CHO-A3-CS
10 nM 1.14 ± 0.20 2.19 0.65 ± 0.05 4.92 ± 1.61 7.81 ± 0.09 5
30 nM 1.45 ± 0.25 2.19 0.38 ± 0.06 3.58 ± 0.94 7.96 ± 0.17 6
100 nM 2.53 ± 0.33 2.19 0.34 ± 0.06 2.19 ± 0.29 7.82 ± 0.06 4
LSM510 system
CHO-CS
10 nM N/A N/A
30 nM 2.66 ± 0.49 2.34 ± 0.32 4
100 nM 3.63 ± 0.57 2.25 ± 0.22 4
CHO-A3-CS
10 nM 1.53 ± 0.16 2.30 0.53 ± 0.06 10.04 ± 1.74 8.27 ± 0.10 4
30 nM 2.25 ± 0.33 2.30 0.54 ± 0.06 5.71 ± 0.95 8.01 ± 0.07 4
100 nM 2.51 ± 0.34 2.30 0.38 ± 0.04 2.14 ± 0.36 7.74 ± 0.10 4
May et al. (2010)
CHO-K1
10 nM - -
30 nM 3.84 3.68
100 nM 4.65 3.95
CHO-A3
10 nM 0.89 - 0.51 3.79 7.83
30 nM 1.82 3.81 0.40 4.74 7.94
100 nM 2.53 3.81 0.43 2.10 7.73
Summary of association and dissociation data obtained in CHO cells either expressing
the A3 receptor and in untransfected CHO cells. Data are mean ± s.e.m of (n) number
of separate perfusion slide preparations and are compared to data in the literature
(May et al., 2010).
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^ ? E ĂŶĚ ƉƌŽƚĞŝŶ ƐĞƋƵĞŶĐĞ ŽĨ ƚŚĞ ĐŽŵƉůĞƚĞ z&W ?ƚĂŐŐĞĚ ŶĂƚŝǀĞ ɴ1AR
fusion protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
Protein sequence
length (residues)
ɴ1AR sequence 1-1431 1431 477
linker sequence 1432-1458 27 9
eYFP sequence 1459-2175 717 239
fusion protein sequence 1-2175 2175 725
z&W ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein DNA sequence
1 ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
61 CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
121 TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
181 ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
241 GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
301 GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
361 TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
421 TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
481 ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
541 ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
601 GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
661 AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
721 GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
781 TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
841 CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
901 CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
961 AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
1021 TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
1081 TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
1141 CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
1201 CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
1261 CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
1321 CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
1381 TCCAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGGGCTCGAGG
1441 GATCCACCGGTCGCCACCCTGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCC
1501 ATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC
1561 GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTG
1621 CCCGTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGCCTGCAGTGCTTCGCCCGC
1681 TACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
1741 CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAG
1801 TTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC
1861 GGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATG
1921 GCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGAC
1981 GGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG
2041 CTGCTGCCCGACAACCACTACCTGAGCTACCAGTCCGCCCTGAGCAAAGACCCCAACGAG
2101 AAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATG
2161 GACGAGCTGTACAAGTAA
The start codons of the two separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚ ŝŶ ŐƌĞǇ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ ŵƵƚĂƚĞĚ z&W ƐƚĂƌƚ ĐŽĚŽŶ  ?d' AP d' ? ? ǁŚŝĐŚ
allows continuous transcription of the fusion protein. The stop codon (TAA) is also
ŚŝŐŚůŝŐŚƚĞĚŝŶŐƌĞǇĂŶĚŵĂƌŬƐƚŚĞĞŶĚŽĨƚŚĞĨƵƐŝŽŶƉƌŽƚĞŝŶ ?dŚĞɴ1AR sequence is the
414
ƐĂŵĞĂƐƚŚĞɴ1AR sequence used in previous experiments, apart from a change of the
base 1383 (guanine to cytosine) which was silent and did not cause an amino acid
change (TCG -> TCC, encoding the amino acid serine at position 461). The linker
sequence is double underlined.
z&W ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein amino acid sequence
M G A G V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q Q
W T A G M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V
P F G A T I V V W G R W E Y G S F F C E L W T S V D V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L
L T R A R A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y
A I A S S V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P
A P A P P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C
W L P F F L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C
C A R R A A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E
P W A G C N G G A A A D S D S S L D E P C R P G F A S E S K V G S R D P P V A T L V S K G E E L F T G V V P I
L V E L D G D V N G H K F S V S G E G E G D A T Y G K L T L K F I C T T G K L P V P W P T L V T T F G Y G L Q C
F A R Y P D H M K Q H D F F K S A M P E G Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L V N R I E L
K G I D F K E D G N I L G H K L E Y N Y N S H N V Y I M A D K Q K N G I K V N F K I R H N I E D G S V Q L A D
H Y Q Q N T P I G D G P V L L P D N H Y L S Y Q S A L S K D P N E K R D H M V L L E F V T A A G I T L G M D E
L Y K Stop
The start codons of the two separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein. The linker
sequence is double underlined.
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S10 DNA and protein sequence of the complete YFPN ?ƚĂŐŐĞĚ ŶĂƚŝǀĞ ɴ1AR
fusion protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
Protein sequence
length (residues)
ɴ1AR sequence 1-1431 1431 477
linker sequence 1432-1458 27 9
eYFPN sequence 1459-1923 465 155
fusion protein sequence 1-1923 1923 641
YFPN ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein DNA sequence
1 ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
61 CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
121 TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
181 ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
241 GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
301 GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
361 TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
421 TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
481 ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
541 ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
601 GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
661 AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
721 GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
781 TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
841 CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
901 CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
961 AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
1021 TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
1081 TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
1141 CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
1201 CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
1261 CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
1321 CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
1381 TCCAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGGGCTCGAGG
1441 GATCCACCGGTCGCCACCCTGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCC
1501 ATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGC
1561 GAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTG
1621 CCCGTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGCCTGCAGTGCTTCGCCCGC
1681 TACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
1741 CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAG
1801 TTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGAC
1861 GGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATG
1921 GTCTAGAGGGCCCGTTTAAACCCGCTG
The start codons of the two separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚŝŶŐƌĞǇ ?ŝŶĐůƵĚŝŶŐƚŚĞŵƵƚĂƚĞĚƐƚĂƌƚz&WĐŽĚŽŶ ?d'APd' ?ǁŚŝĐŚĂůůŽǁƐ
continuous transcription of the fusion protein. The stop codon (TAG) is also
highlighted in grey and marks the end of the fusion protein. The ȕ1AR sequence
matches that of the ȕ1YFP sequence (i.e. includes the silent mutation at position
1383). The linker sequence is double underlined. The YFPN sequence matches the
first part (base 1459-1923) of the YFP sequence used in the ȕ1YFP construct (YFP
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amino acids 1-155), apart from a change of base 1922, where the cytosine was
mutated to a thymine and caused an amino acid residue change from alanine to
valine (GCC -> GTC) at position 641 of the fusion protein (position 155 of the YFPN
fragment). This introduced the XbaI restriction enzyme site (underlined sequence) at
the end of the fusing protein sequence. The sequence after (>1926 bases) is the
sequence of the pcDNA3.1(Neo+) plasmid vector.
YFPN ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein amino acid sequence
M G A G V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q Q
W T A G M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V
P F G A T I V V W G R W E Y G S F F C E L W T S V D V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L
L T R A R A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y
A I A S S V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P
A P A P P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C
W L P F F L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C
C A R R A A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E
P W A G C N G G A A A D S D S S L D E P C R P G F A S E S K V G S R D P P V A T L V S K G E E L F T G V V P I
L V E L D G D V N G H K F S V S G E G E G D A T Y G K L T L K F I C T T G K L P V P W P T L V T T F G Y G L Q C
F A R Y P D H M K Q H D F F K S A M P E G Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L V N R I E L
K G I D F K E D G N I L G H K L E Y N Y N S H N V Y I M V Stop R A R L N P L
The start codons of the two separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein. The linker
sequence is double underlined. The sequence after the stop codon is the sequence of
the pcDNA3.1(Neo+) plasmid vector.
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S11 DNA and protein sequence of the complete YFPC ?ƚĂŐŐĞĚ ŶĂƚŝǀĞ ɴ1AR
fusion protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
Protein sequence
length (residues)
ɴ1AR sequence 1-1431 1431 477
linker sequence 1432-1455 24 8
eYFPC sequence 1456-1713 258 86
fusion protein sequence 1-1713 1713 571
YFPC ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein DNA sequence
1 ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
61 CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
121 TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
181 ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
241 GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
301 GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
361 TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
421 TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
481 ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
541 ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
601 GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
661 AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
721 GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
781 TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
841 CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
901 CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
961 AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
1021 TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
1081 TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
1141 CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
1201 CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
1261 CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
1321 CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
1381 TCCAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGGGCTCGAGC
1441 CACAACGTCTATATCCTGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATC
1501 CGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
1561 ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTCCGCCCTG
1621 AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
1681 GGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA
The start codons of the two separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚ ŝŶ ŐƌĞǇ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ ŵƵƚĂƚĞĚ ƐƚĂƌƚ z&W ĐŽĚŽŶ  ?d' AP d' ? ? ǁŚŝĐŚ
allows continuous transcription of the fusion protein. The stop codon (TAA) is also
highlighted in grey and marks the end of the fusion protein. The ȕ1AR sequence
matches that of the ȕ1YFP sequence (i.e. includes the silent mutation at position
1383). The linker sequence is double underlined. The last 18 bases (6 amino acids) of
ƚŚĞ ůŝŶŬĞƌ ƐĞƋƵĞŶĐĞŵĂƚĐŚ ƚŚŽƐĞ ĨƌŽŵďĂƐĞ  ? ? ? ? W ? ? ? ?ŽĨ ƚŚĞɴ1YFP sequence and
the ȕ1YFPN sequence (YFPN amino acids 148-153), thus creating a sequence overlap
of the two separate YFP fragments. The YFPC sequence matches the last part (bases
1918-2178) of the YFP sequence used in the ȕ1YFP construct (YFP amino acids 154-
418
 ? ? ? ? ? ĂƉĂƌƚ ĨƌŽŵ ƚŚĞ ĐŚĂŶŐĞ ŽĨ ďĂƐĞ  ? ? ? ? ĨƌŽŵ ĂĚĞŶŝŶĞ ƚŽ ĐǇƚŽƐŝŶĞ  ?d' AP d' ?
start codon methionine to leucine).
YFPC ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein amino acid sequence
M G A G V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q Q
W T A G M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V
P F G A T I V V W G R W E Y G S F F C E L W T S V D V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L
L T R A R A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y
A I A S S V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P
A P A P P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C
W L P F F L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C
C A R R A A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E
P W A G C N G G A A A D S D S S L D E P C R P G F A S E S K V G S S H N V Y I L A D K Q K N G I K V N F K I R
H N I E D G S V Q L A D H Y Q Q N T P I G D G P V L L P D N H Y L S Y Q S A L S K D P N E K R D H M V L L E F
V T A A G I T L G M D E L Y K Stop
The start codons of the two separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein. The linker
sequence is double underlined.
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^ ? ? E ĂŶĚ ƉƌŽƚĞŝŶ ƐĞƋƵĞŶĐĞ ŽĨ ƚŚĞ ĐŽŵƉůĞƚĞ ^EW ?ƚĂŐŐĞĚ ɴ1D138AAR
fusion protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
protein sequence
length (residues)
signal sequence 22  105 84 28
SNAP-tag sequence 106  654 549 183
ɴ1D138AAR sequence 655  2085 1431 477
fusion protein sequence 22  2085 2064 688
^EW ?ƚĂŐŐĞĚɴ1-adrenoceptor fusion protein DNA sequence
1 CTTAAGCTTGGTACCGCCACCATGCGGCTCTGCATCCCGCAGGTGCTGTTGGCCTTGTTC
61 CTTTCCATGCTGACAGGGCCGGGAGAAGGCAGCCGGAAGCTTACCCTGGACAAAGACTGC
121 GAAATGAAGCGCACCACCCTGGATAGCCCTCTGGGCAAGCTGGAACTGTCTGGGTGCGAA
181 CAGGGCCTGCACGAGATCAAGCTGCTGGGCAAAGGAACATCTGCCGCCGACGCCGTGGAA
241 GTGCCTGCCCCAGCCGCCGTGCTGGGCGGACCAGAGCCACTGATGCAGGCCACCGCCTGG
301 CTCAACGCCTACTTTCACCAGCCTGAGGCCATCGAGGAGTTCCCTGTGCCAGCCCTGCAC
361 CACCCAGTGTTCCAGCAGGAGAGCTTTACCCGCCAGGTGCTGTGGAAACTGCTGAAAGTG
421 GTGAAGTTCGGAGAGGTCATCAGCTACCAGCAGCTGGCCGCCCTGGCCGGCAATCCCGCC
481 GCCACCGCCGCCGTGAAAACCGCCCTGAGCGGAAATCCCGTGCCCATTCTGATCCCCTGC
541 CACCGGGTGGTGTCTAGCTCTGGCGCCGTGGGGGGCTACGAGGGCGGGCTCGCCGTGAAA
601 GAGTGGCTGCTGGCCCACGAGGGCCACAGACTGGGCAAGCCTGGGCTGGGATCCCTGGGC
661 GCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCACCGCTC
721 CCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCCTCGTTG
781 CTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGCATGGGT
841 CTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATCGTGGCC
901 ATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTGGCCAGC
961 GCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTGTGGGGC
1021 CGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGCCGTGCTGTGCGTG
1081 ACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATCACCTCG
1141 CCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGCACCGTG
1201 TGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGGGCGGAG
1261 AGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACCAACCGG
1321 GCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATGGCCTTC
1381 GTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGCTGCGAG
1441 CGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTCCCCGCG
1501 CCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCGCTGGCC
1561 AACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAGAAGGCG
1621 CTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTG
1681 GCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTCTTCTTC
1741 AACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGCCCCGAC
1801 TTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGGCGCCAC
1861 GCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCCCCGCCA
1921 TCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCGCCCGCG
1981 CGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGACTCGAGC
2041 CTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAGGAATTCTGCAGA
The start codons of the three separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚ ŝŶ ŐƌĞǇ ? ŝŶĐůƵĚŝŶŐ ƚŚĞ ŵƵƚĂƚĞĚ ƐƚĂƌƚ ĐŽĚŽŶƐ  ?d' AP d' ? ƚŚĂƚ ĂůůŽǁ
continuous transcription of the fusion protein. The stop codon is also highlighted in
ŐƌĞǇ ĂŶĚ ŵĂƌŬƐ ƚŚĞ ĞŶĚ ŽĨ ƚŚĞ ĨƵƐŝŽŶ ƉƌŽƚĞŝŶ ? dŚĞ ĞŶƚŝƌĞ ƐƐɴ1D138AAR sequence
ŵĂƚĐŚĞƐ ƚŚĂƚ ŽĨ ƚŚĞ ƐƐɴ1AR sequence described earlier, apart from the change of
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base 413 (boxed in; base 1067 in the fusion protein sequence) from adenine to
ĐǇƚŽƐŝŶĞƚŚĂƚĐĂƵƐĞĚƚŚĞĚĞƐŝƌĞĚĂŵŝŶŽĂĐŝĚĐŚĂŶŐĞĂƚƉŽƐŝƚŝŽŶ ? ? ?ŽĨƚŚĞɴ1AR from
an aspartic acid (D) to an alanine (A) residue. The sequence before (<22bp) and after
(>2088bp) the fusion protein DNA sequence is the sequence of the pcDNA3.1(Neo+)
plasmid vector.
^EW ?ƚĂŐŐĞĚɴ1D138A-adrenoceptor fusion protein amino acid sequence
L K L G T A T M R L C I P Q V L L A L F L S M L T G P G E G S R K L T L D K D C E M K R T T L D S P L G K L E L S
G C E Q G L H E I K L L G K G T S A A D A V E V P A P A A V L G G P E P L M Q A T A W L N A Y F H Q P E A I E
E F P V P A L H H P V F Q Q E S F T R Q V L W K L L K V V K F G E V I S Y Q Q L A A L A G N P A A T A A V K T
A L S G N P V P I L I P C H R V V S S S G A V G G Y E G G L A V K E W L L A H E G H R L G K P G L G S L G A G
V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q QW T A G
M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V P F G A T
I V V W G R W E Y G S F F C E L W T S V A V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L L T R A R
A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y A I A S S
V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P A P A P
P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C W L P F F
L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C C A R R A
A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E P W A G C
N G G A A A D S D S S L D E P C R P G F A S E S K V Stop E F C R
The start codons of the three separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein. The boxed in
ĂŵŝŶŽĂĐŝĚƌĞƐŝĚƵĞŝƐƚŚĞĚĞƐŝƌĞĚ ? ? ?ŵƵƚĂƚŝŽŶŝŶƚŚĞɴ1AR sequence.
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S13 DNA and protein sequence of the complete YFPC ?ƚĂŐŐĞĚ ɴ1D138AAR
fusion protein
start and end position of
DNA sequence (bases)
DNA sequence
length (bases)
Protein sequence
length (residues)
ɴ1D138AAR sequence 1-1431 1431 477
linker sequence 1432-1455 24 8
eYFPC sequence 1456-1713 258 86
fusion protein sequence 1-1713 1713 571
YFPC ?ƚĂŐŐĞĚɴ1D138A-adrenoceptor fusion protein DNA sequence
1 ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
61 CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
121 TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
181 ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
241 GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
301 GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
361 TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGCCGTGCTG
421 TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
481 ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
541 ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
601 GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
661 AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
721 GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
781 TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
841 CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
901 CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
961 AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
1021 TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
1081 TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
1141 CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
1201 CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
1261 CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
1321 CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
1381 TCCAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGGGCTCGAGC
1441 CACAACGTCTATATCCTGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATC
1501 CGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
1561 ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTCCGCCCTG
1621 AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
1681 GGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA
The start codons of the two separate components of the fusion protein are
ŚŝŐŚůŝŐŚƚĞĚŝŶŐƌĞǇ ?ŝŶĐůƵĚŝŶŐƚŚĞŵƵƚĂƚĞĚƐƚĂƌƚz&WĐŽĚŽŶ ?d'APd' ?ǁŚŝĐŚĂůůŽǁƐ
continuous transcription of the fusion protein. The stop codon (TAA) is also
ŚŝŐŚůŝŐŚƚĞĚ ŝŶŐƌĞǇĂŶĚŵĂƌŬƐ ƚŚĞĞŶĚŽĨ ƚŚĞ ĨƵƐŝŽŶƉƌŽƚĞŝŶ ?dŚĞĞŶƚŝƌĞɴ1D138AYFPC
ƐĞƋƵĞŶĐĞŵĂƚĐŚĞƐƚŚĂƚŽĨƚŚĞɴ1YFPC sequence, apart from the change of base 413
(boxed in) from adenine to cytosine that caused the desired amino acid change at
position 138 from an aspartic acid (D) to an alanine (A) residue. The linker sequence
is double underlined.
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YFPC ?ƚĂŐŐĞĚɴ1D138A-adrenoceptor fusion protein amino acid sequence
M G A G V L V L G A S E P G N L S S A A P L P D G A A T A A R L L V P A S P P A S L L P P A S E S P E P L S Q Q
W T A G M G L L M A L I V L L I V A G N V L V I V A I A K T P R L Q T L T N L F I M S L A S A D L V M G L L V V
P F G A T I V V W G R W E Y G S F F C E L W T S V A V L C V T A S I E T L C V I A L D R Y L A I T S P F R Y Q S L
L T R A R A R G L V C T V W A I S A L V S F L P I L M H WW R A E S D E A R R C Y N D P K C C D F V T N R A Y
A I A S S V V S F Y V P L C I M A F V Y L R V F R E A Q K Q V K K I D S C E R R F L G G P A R P P S P S P S P V P
A P A P P P G P P R P A A A A A T A P L A N G R A G K R R P S R L V A L R E Q K A L K T L G I I M G V F T L C
W L P F F L A N V V K A F H R E L V P D R L F V F F N W L G Y A N S A F N P I I Y C R S P D F R K A F Q G L L C
C A R R A A R R R H A T H G D R P R A S G C L A R P G P P P S P G A A S D D D D D D V V G A T P P A R L L E
P W A G C N G G A A A D S D S S L D E P C R P G F A S E S K V G S S H N V Y I L A D K Q K N G I K V N F K I R
H N I E D G S V Q L A D H Y Q Q N T P I G D G P V L L P D N H Y L S Y Q S A L S K D P N E K R D H M V L L E F
V T A A G I T L G M D E L Y K Stop
The start codons of the two separate components of the fusion protein are
highlighted in grey as well as the stop codon of the fusion protein. The linker
sequence is double underlined. The boxed in amino acid residue is the desired D138A
mutation.
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Appendix II  buffer compositions
DEA buffer
used to measure SPAP activity
100 mM (100 mL) Diethanolamine
280 mM (16.36 g) NaCl
0.5 mM (0.102 g) MgCl2.6H2O
made up to 1 litre with double distilled water
used HCl to achieve pH 9.85
autoclaved to sterilise
stored at 4 °C
PNPP was dissolved in DEA buffer at a concentration of 100 mM. 500 µL PNPP
added to 10 mL DEA buffer was used to assess the SPAP content of one 96-
well plate.
TBE buffer
Used in gel electrophoresis experiments
90 mM (10.9 g) Tris-Base
90 mM (5.56 g) Boric acid
2 mM (0.58 g) EDTA
made up to 1 litre in double distilled water
autoclaved to sterilise
stored at room temperature
HBSS  HEPES buffered saline solution
used in all confocal imaging experiments
10 mM (2.38 g) HEPES
147 mM (8.46 g) NaCl
424
24 mM (0.37 g) KCl
1 mM (0.24 g) MgSO4.7H20
2 mM (0.22 g) Sodium Pyruvate
1.3 mM (0.19 g) CaCl2
1.43 mM (0.12 g) NaHCO3
made up to 1 litre in double distilled water
used NaOH to achieve pH 7.45
autoclaved to sterilise
stored at 4 °C
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